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1.1  Research Problem 
Type 2 diabetes mellitus (T2DM) is one of the most prevalent chronic metabolic 
diseases of the 21st century (1, 2). In 2011, 366 million people were diagnosed with 
diabetes globally, and by the year 2040 it is predicted that 642 million adults will 
have diabetes (3). The human and economic burden of illness associated with T2DM 
contributes significantly to ill health, disability and premature death, and is further 
exacerbated by the onset of micro- and macrovascular complications, which appear 
to be driven in part by the presence of an underlying chronic low-level of systemic 
inflammation in adults with this condition (4). Thus, there is a need to develop safe, 
effective and sustainable population-based prevention and management strategies 
that collectively improve glycaemic control, insulin sensitivity and the multiple risk 
factors associated with this disease. 
 
Lifestyle modification combining energy restriction, weight loss and physical 
activity remains the cornerstone of T2DM management (5, 6). While a reduction in 
body weight and improvements in glycaemic control have been observed following 
energy restriction, weight loss and aerobic or endurance activity, a concomitant loss 
in lean mass also tends to occur (7, 8). Lean mass is critical for people with T2DM, 
as it is the largest mass of insulin-sensitive tissue and the predominant reservoir for 
glucose disposal (9). Losses in muscle mass can negatively impact metabolic rate, 
compound the problems of insulin resistance and lead to reduced physical function 
and quality of life (10, 11). As a result, current international consensus exercise 
guidelines recommend that progressive resistance training (PRT) be incorporated 
into the overall physical activity plan for people with T2DM (6).  
 
Previous research has demonstrated that high-intensity PRT conducted within a 
controlled setting is safe and effective for improving glycated haemoglobin (HbA1c) 
levels and lean mass in older adults with T2DM (12-14). Furthermore, exercise and 
to a lesser extent PRT has also been shown to play a role in lowering chronic low-
grade inflammation, particularly in people who are overweight or obese and/or have 
a diagnosed chronic disease (15-18). Chronic low-grade inflammation has been 
linked to accelerated muscle loss and has emerged as the common denominator 
linking T2DM, metabolic syndrome and cardiovascular disease (19-22). This chronic 
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state of inflammation has also been associated with a decrease in beta-cell insulin 
secretion and a subsequent deterioration in insulin resistance (19-22). However, 
whether improvements in markers of inflammation are associated with improvements 
in glycaemic control remain to be observed. 
 
Whilst there has been considerable research into the effects of PRT on body 
composition, HbA1c, insulin sensitivity and to a lesser degree inflammation, many of 
the randomised controlled trials (RCTs) have commonly occurred under tightly 
controlled and structured clinical laboratory settings. The translation of this research 
into practice and whether similar benefits can be achieved from participation in 
community based-programs, where there is often less supervision and more 
independence in performing the training, remains uncertain. Improvements in health 
outcomes following community-based exercise programs, even if modest, are still 
important from a public health perspective given small improvements at an 
individual level can translate to substantial changes within the population (23). 
Further, community-based physical activity programs are a key avenue for assessing 
the relevance and real-world applicability of research-to-practice programs. Previous 
research measuring the economic value of research-to-practice programs in 
community-settings has also found participation in such programs may reduce total 
healthcare costs for older adults, society and the national healthcare system (24).  
 
Since nutritional management is also an important component in the treatment of 
T2DM, combining PRT with dietary modification may offer an incremental effect on 
glycaemic control, insulin sensitivity as well as body composition and cardiovascular 
risk factors. Traditionally, caloric restriction has been prescribed to adults with 
T2DM largely due to the well-documented benefits on glycaemic control, blood 
pressure and serum lipid levels as well as fat mass and overall weight loss (25-27). 
However, weight reduction remains a difficult-to-reach goal for many and long-term 
maintenance of caloric restricted diets and the resultant weight loss often fails to be 
maintained (28-30). Aerobic or endurance training is also often combined with 
caloric restriction but this approach does not appear to attenuate the muscle loss 
arising from weight loss. However, a limited number of studies in overweight and 
obese adults (31, 32) and those with T2DM (33-35) have reported that exercise, 
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primarily aerobic training, combined with weight loss/caloric restriction is more 
effective at improving glycaemic control and various inflammatory markers than 
either exercise or diet alone. A study which combined calorie restriction with PRT 
compared to calorie restriction alone also found that the combination was effective at 
improving glycaemic control, fat mass, lean mass and upper body strength to a 
greater degree than weight loss alone (12). However, the effects of PRT combined 
with caloric restriction on circulating inflammatory markers has not been examined 
in adults with T2DM. This is an important question given the role that systemic 
inflammation plays in the pathogenesis of T2DM and related co-morbidities 
including cardiovascular disease.  
 
While the optimal macronutrient composition of the diet for the management of 
T2DM remains uncertain, emerging evidence suggests that there are health benefits 
associated with high-protein diets in overweight and obese adults and those with 
T2DM (36, 37). For instance, a meta-analysis of nine RCTs ranging from four to 24-
weeks reported that high-protein diets had beneficial effects on weight loss and 
HbA1c levels and tended to reduce blood pressure in people with T2DM, with no 
adverse effects on blood lipids (38). Despite these positive findings, dietary studies 
controlling for macronutrient composition are often difficult to implement in the 
‘real-world’ as they require an individual to follow a prescribed meal plan. 
Therefore, the addition of a protein supplement might be a more practical and 
effective approach, as it does not require individuals to make marked changes in their 
usual dietary habits.  
 
Acute studies have shown that both whey protein and PRT stimulate muscle protein 
synthesis (MPS) (39). A number of long-term (>10 weeks) human intervention trials 
in healthy older adults have also reported that ingestion of high-quality protein can 
enhance the effects of PRT on muscle mass and strength (40-42), although these 
findings are not consistent (34, 43). The inconsistent findings may be due to a 
number of factors, including the type of protein, the dose, timing of intake and the 
distribution throughout the day (44, 45). In terms of the type of protein, there is 
considerable evidence showing that whey protein is particularly effective for 
stimulating an acute increase in MPS, which is likely due to the fact that it contains 
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all the essential amino acids, particularly leucine, which is crucial for triggering the 
initial MPS response (46-48). While there is still ongoing research into defining 
whether there is an optimal dose of protein, particularly in older adults or those with 
chronic disease, to elicit a synergistic anabolic muscle response with PRT, several 
recent studies and reviews have recommended that 20 to 40g of high-quality, rapidly 
digested, leucine-rich protein, such as whey protein, be consumed soon after each 
bout of PRT to maximally stimulate MPS and promote muscle hypertrophy whilst 
concomitantly reducing muscle protein breakdown (MPB) (49-51). Furthermore, 
previous studies have demonstrated that whey protein and its bioactive components 
may offer insulinotropic (52-56), muscle-sparing (57) and cholesterol-lowering 
effects (58) in adults with T2DM. Presently, however, the long-term effects of whey 
protein supplementation in combination with PRT on body composition, glycaemic 
control, insulin sensitivity and inflammation along with serum lipid levels and blood 
pressure in older adults with T2DM remains unknown.  
 
There are also other lifestyle factors that might have beneficial effects on skeletal 
muscle. For instance, there is mounting evidence that vitamin D may act as a 
modifier of diabetes risk and that deficiency in serum 25(OH)D, the circulating 
marker of vitamin D, is associated with impaired beta-cell function, glucose 
intolerance and insulin resistance and reduced muscle function, strength and size (22, 
59-62). Whilst an inverse association exists between serum 25(OH)D levels and 
T2DM (22, 63, 64), the role that vitamin D exerts on insulin resistance and 
glycaemic control remains controversial with mixed findings from a limited number 
of RCTs conducted in older adults with T2DM (65-68). Nevertheless, there is some 
evidence that vitamin D supplementation can improve glycaemic control and insulin 
sensitivity in adults with or at high risk of this disease, including those with 
prediabetes and T2DM (69-71).  
 
In summary, there is overwhelming evidence to support a positive role for supervised 
and structured PRT in older adults with T2DM, however, whether the addition of 
certain nutritional factors, particularly whey protein and vitamin D, can act 
synergistically to enhance the health benefits of a community-based PRT program 
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remains unknown. One of the key aims of this thesis is to conduct a high quality 
RCT to address this question.  
 
1.2  Thesis Aims 
The primary aim of this thesis is to investigate if lifestyle strategies such as caloric 
restriction to promote weight loss or nutritional supplementation with protein and 
vitamin D, in combination with PRT, can promote greater improvements in 
glycaemic and insulinaemic outcomes, body composition, cardiovascular risk factors 
and systemic inflammation in older overweight adults with T2DM compared to PRT 
alone.  
 
The specific aims are:  
1. To compare the effect of PRT plus a moderate weight loss program versus 
weight loss alone on systemic and endothelial markers of inflammation in older 
overweight adults with T2DM (Chapter 3). 
2. To describe the challenges related to recruiting older adults with T2DM into a 6-
month community-based exercise and nutrition research intervention, and to 
assess the costs associated with the recruitment methods used (Chapter 5). 
3. To investigate whether ingestion of a daily whey-protein drink in combination 
with vitamin D supplementation can enhance the effects of a community-based 
PRT program on glycaemic control and insulin sensitivity in older adults with 
T2DM (Chapter 6). 
4. To examine whether a community-based PRT program combined with a whey-
protein drink and vitamin D supplementation is more effective for enhancing 
total body and regional lean mass, muscle cross-sectional area (CSA), muscle 
strength and reducing inter-/intra-muscular fat infiltration, than PRT alone in 
older adults with T2DM (Chapter 6). 
5. To compare the effects of a community-based PRT program combined with 
whey-protein and vitamin D supplementation versus PRT alone, on 
cardiovascular risk factors, including blood pressure and blood lipid levels, and 
pro-inflammatory and anti-inflammatory cytokines. (Chapter 6). 
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1.3  Thesis Hypotheses 
It is hypothesised that in older adults with T2DM:  
1. Supervised high-intensity PRT combined with weight loss will lead to greater 
improvements in various inflammatory and endothelial markers than weight loss 
alone. 
2. A community-based PRT program combined with a daily whey-protein drink 
and vitamin D supplements will lead to greater improvements in glycaemic 
control and insulin sensitivity compared to PRT alone. 
3. A community-based PRT program combined with a whey-protein drink and 
vitamin D supplementation will augment the anabolic effects of PRT alone on 
total body and regional lean mass, muscle cross-sectional area, muscle strength 
and reduce inter-/intra-muscular fat infiltration. 
4. A community-based PRT program combined with a whey-protein drink and 
vitamin D supplementation will be associated with greater improvements in 
cardiovascular risk factors, including circulating total, high-density lipoprotein 
(HDL) and low-density lipoprotein (LDL) cholesterol levels, triglycerides and 
blood pressure and a reduction in the catabolic milieu as reflected by a decrease 
in pro-inflammatory cytokines and an increase in anti-inflammatory markers 
compared to PRT alone. 
 
1.4  Significance of this Research 
The International Diabetes Federation (IDF) estimates 415 million adults currently 
suffer a form of diabetes (3). The most recent predictions, which are based on the 
present growth of this disease, suggest that by the year 2040 642 million adults will 
have diabetes (3). The rapid rise and predicted continued increase in the prevalence 
of this condition is largely due to T2DM (3), which accounts for up to 91% of all 
total cases of this condition in high-income countries (72, 73). The human and 
economic burden of illness associated with T2DM is further exacerbated with the 
onset of micro- and macro-vascular complications, highlighting the need for 
sustainable population-based prevention and management approaches that can 
improve multiple risk factors for T2DM and its associated micro- and macrovascular 
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complications. In older adults with T2DM the most effective combined exercise and 
nutrition strategy to improve glycaemic control, body composition and 
cardiovascular outcomes, and concomitantly reduce the risk for micro- and 
macrovascular complications, remains unknown. If successful, the findings from this 
thesis will make an important contribution to the development of evidence-based and 
accepted community-based exercise and nutrition treatment approaches effective for 
improving multiple health outcomes implicated in the development and progression 
of this disease. Of note, an increase in circulating levels of pro-inflammatory 
cytokines with concomitant lower levels of anti-inflammatory markers is a common 
finding in older adults with T2DM. Such an inflammatory profile can have 
particularly deleterious consequences for older adults with T2DM given that it has 
been associated with an increased risk of cardiovascular disease and various 
diabetes-related micro- and macro-vascular complications. This thesis will provide 
an insight into whether combining calorie restriction (for weight loss) with PRT may 
result in an additive effect on augmenting markers of inflammation in older adults 
with T2DM than either strategy alone. As an extension of this work, this thesis will 
also investigate whether a community-based PRT program combined with whey 
protein and vitamin D supplementation can enhance the effects of PRT alone on 
body composition, glycaemic control, insulin sensitivity and cardiovascular health 
outcomes including systemic inflammation, lipids and blood pressure in older adults 
with T2DM. The results of the studies that make up this thesis will assist in 
answering many important questions about the most appropriate lifestyle strategy for 
the management of T2DM in older adults. Further, the results of the studies in this 
thesis will provide critical insight into the effectiveness of community-based PRT 
programs for older adults with T2DM on a range of important health outcomes. More 
specifically, this thesis will identify whether nutritional factors in combination with a 
community-based PRT program can enhance the recognised and established health 
benefits of PRT alone in older overweight and obese adults with T2DM.  
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2.1  Type 2 Diabetes – A Global Health Problem  
Globally, type 2 diabetes mellitus (T2DM) currently represents one of the largest and 
most prevalent chronic, non-communicable diseases of the 21st century (3). The 
International Diabetes Federation (IDF) estimates 415 million adults currently suffer 
a form of diabetes (3). There has been an unrelenting increase in the global 
prevalence of this chronic condition in recent decades, due largely to the rise in 
prevalence of T2DM (3). It is believed that T2DM accounts for up to 91% of the 
total cases of this condition in high-income countries (72, 73). In addition, the most 
recent predictions, based on the current growth of this condition, project by the year 
2040 approximately 642 million adults will have diabetes (3). A further 318 million 
adults are currently estimated to suffer the pre-diabetic conditions of impaired 
glucose tolerance (IGT) or impaired fasting glucose (IFG), both intermediary points 
between normoglycaemia and T2DM (74-77).  
 
Advancing age is associated with increased rates of diabetes prevalence across all 
regions of the world (78). At present the highest observed age-specific prevalence of 
T2DM is in people aged 60-79 years, however, the largest total number of 
individuals with T2DM are those aged 40-59 years where 184 million people 
globally have been diagnosed (78). It is expected that this prevalence pattern will 
persist and by the year 2035 the largest total number of individuals will be those aged 
60-79 years as people transition into old age (78).  
 
In Australia, statistics from the 2010-11 follow-up investigation of the population-
based, prospective Australian Diabetes, Obesity and Lifestyle (AusDiab) study 
revealed that the prevalence of T2DM was 12% in adults aged 25 years and over 
(79). Recent figures published by the Australian Institute for Health and Welfare 
(AIHW) reported the prevalence of T2DM in Australian adults aged 18 years and 
over to be 4.7% (849,000 people) (80). This disagreement and underestimate in the 
AIHW figures is likely due to the fact this data was self-reported data (80). Like 
global figures, the prevalence of this chronic condition has been steadily increasing 
for decades, and currently in Australia 280 new cases of diabetes are diagnosed every 
day (79). More men compared to women are affected by T2DM (14.8% versus 
9.8%), with yearly incidence rates also higher in men (0.8% compared to 0.6%) (79). 
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Paralleling global figures, the incidence of T2DM in Australia also increases with 
advancing age as shown in Figure 2.1 (79, 81). By 2031, it is projected that 3.3 
million Australians will be diagnosed with this condition (82, 83). The 2010-11 
AusDiab follow-up survey found that a further 2 million Australians suffer from a 
pre-diabetic condition (79). Finally, it is also important to highlight the high rate of 
missed or undiagnosed (and thus underreported) cases of T2DM; for every five-
people diagnosed with T2DM, four cases remain undiagnosed (84). Collectively, 
these findings highlight that T2DM is currently a major public health problem that is 
projected to increase substantially in coming decades, unless effective strategies are 
identified and implemented to treat and prevent this condition.  
 
 
 
Figure 2.1 Percentage of Australian adults with or at risk of developing T2DM as 
assessed by fasting plasma glucose in 2011-12. Sourced from Australian Bureau of 
Statistics (85). 
 
Type 2 diabetes that is not appropriately managed can lead to numerous 
complications, increased morbidity and premature mortality (86). For instance, 
poorly controlled T2DM is associated with an increased risk of micro-vascular 
(retinopathy, nephropathy and neuropathy) and macro-vascular complications 
[cardiovascular disease (CVD) and associated conditions including hypertension, 
hypertriglyceridaemia, coronary heart disease and stroke] (87, 88). In almost all 
high-income countries including Australia, the most predominant diabetes-
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complications are CVD, retinopathy, kidney disease and lower limb amputations 
(89). To further compound this issue, many of these conditions do not exist 
exclusively; the presence of one comorbid condition is frequently associated with 
one or more other co-morbidities or additional complications. 
 
The most predominant cause of morbidity and mortality in people with T2DM is 
CVD (90-92). Mortality from CVD is more than double in those with T2DM 
compared with age-matched healthy adults (93). The risk of CVD is strongly 
associated with and rises with increases in fasting plasma glucose (FPG) levels, even 
prior to reaching levels sufficient for a diagnosis of diabetes (94). In Australia in 
2011-12, over two-thirds of people with diabetes (68%) reported suffering a form of 
CVD; the most common and serious types including coronary heart disease, stroke 
and heart failure (95). The reasons and exact mechanisms which contribute to the 
high prevalence of CVD in people with T2DM have not been fully elucidated, but 
have been postulated to be due to conventional risk factors which contribute 
similarly to both conditions, such as obesity, hyperglycaemia, a sedentary lifestyle 
and chronic systemic inflammation (4, 96).  
 
2.2  The Economic Burden of Type 2 Diabetes 
The continual and rapid growth of T2DM prevalence and related complications and 
the associated increased risk of premature mortality associated with this disease is 
imposing a substantial burden on national health care budgets globally. In 2015, 
healthcare expenditure associated with the treatment and management of this 
condition was estimated to be $673 million or 12% of total global health expenditure 
(3). By 2040, universal expenditure is estimated to exceed $US802 billion for the 
prevention and treatment of diabetes and its complications (3). In Australia, the 
Australian Institute of Health and Welfare (AIHW) reported that the total national 
healthcare expenditure on diabetes alone in 2008-09 was approximately $1,507 
million or 2.3% of total health-care expenditure, placing diabetes 14th out of 200 
diseases (97). This value was an increase of 86% from the year 2001-02, with the 
largest increase in diabetes health-care expenditure being for hospital admitted 
patient services, where diabetes expenditure more than doubled from $300 million to 
$647 million (97). By 2051, health care costs are predicted to increase 2.5-fold, due 
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predominantly to our ageing population. When including both obesity and physical 
inactivity, both risk factors for T2DM discussed in section 2.5, the financial burden 
accompanied with treating this disease is set to quadruple over this period (98). 
Consequently, there is an urgent need to both prevent and develop better strategies to 
manage this condition in Australia and globally.  
 
It is important to note these aforementioned cost estimates are based on calculations 
involving direct and non-direct health care costs which are both quantifiable. A 
limitation of these estimates is the inability to estimate the indirect or intangible costs 
associated with T2DM. This includes pain, anxiety, inconvenience, losses in 
productivity in the work force and a reduced quality of life, all of which can have a 
significant impact on the lives of people with this disease and their families and 
contribute further to the overall economic burden associated with this condition. 
Thus, the estimates do not provide a complete picture of diabetes related health 
expenditure but do capture approximately 70% of health dollars spent on diabetes as 
a disease (97). 
 
2.3  Pathophysiology of Type 2 Diabetes 
The pathophysiology of T2DM is complex and typically involves three basic 
metabolic defects; insulin resistance, diminished beta-cell functioning and an 
increase in hepatic glucose production (99). While there is an ongoing debate 
regarding the contributions of each of these factors, and which precedes the other, 
there is a general consensus that insulin resistance is the primary defect in T2DM and 
is responsible for the impairment in insulin-stimulated glucose metabolism (100, 
101). Insulin is the key hormone for regulating plasma glucose levels and 
normoglycaemia is maintained by a complex and tightly regulated interplay between 
secretion and action of insulin at various target tissues, including skeletal muscle, 
liver and adipose tissue (102). In individuals with T2DM, hepatic glucose production 
is excessive and remains high when in a post-prandial state, even though 
concentrations of plasma insulin can be two to four-fold higher than normal (103, 
104). In addition, the ability of endogenously secreted insulin to enhance glucose 
uptake at the site of muscle is diminished in these individuals and causes plasma 
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glucose levels to remain chronically high with eventual weakened beta-cell 
functioning and reduced insulin secretion (103).  
 
Over more recent decades it has become apparent that low-grade systemic 
inflammation, closely associated with obesity and insulin resistance, precedes and is 
able to predict the development of T2DM (105). Adipocytes, or fat cells, particularly 
in those who are overweight/obese secrete a number of pro-inflammatory cytokines 
(105). Some of these cytokines are recognised to directly inhibit insulin signalling. 
Such an effect has several negative consequences in the human body including an 
augmentation and perpetuation of this already low-level of inflammation, a 
worsening of insulin sensitivity and can also alter the cardiovascular system with 
some cytokines established to result in vasoconstriction, potentially progressing the 
onset and development of CVD .  
 
2.4  Defining Pre-Diabetes and Type 2 Diabetes 
Type 2 diabetes is diagnosed based on the presentation of chronic hyperglycaemia 
resulting from impaired insulin secretion, insulin resistance or both (88). The 
intermediate condition between normal glucose tolerance and overt T2DM is termed 
pre-diabetes, which includes both IGT and IFG. Diagnosis of pre-diabetes and 
diabetes is made by an oral glucose tolerance test (OGTT) and/or fasting plasma 
glucose (FPG) assessment. Table 2.1 outlines the diagnostic cut-offs for T2DM and 
pre-diabetes as defined by the World Health Organization (WHO) report on the 
Diagnosis and Classification of Diabetes Mellitus and adopted by the National 
Health and Medical Research Council (NHMRC) of Australia (75, 106). Once 
diagnosis of a pre-diabetic condition is made, around 50% of those diagnosed will 
progress to develop T2DM within a 10-year period (77, 107). The cut-off values 
employed for the diagnosis of T2DM are based on associations with diabetes related 
microvascular and macrovascular complications (108-110). For instance, 
microvascular risk increases significantly with plasma glucose concentrations ≥7.0 
mmol and macrovascular disease risk increases with fasting values ≥7.0 mmol (108, 
109, 111). 
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Table 2.1: Diagnostic criteria for pre-diabetes and type 2 diabetes. Sourced from 
Stumvoll et al. (102). 
Diagnosis Plasma glucose (mmol/L)  
 Fasting glucose  OGTT  HbA1c% 
Pre-diabetes     
     IGT <7.0 and 7.8-11.0  
     IFG 6.1-6.9 and <7.8  
Type 2 diabetes ≥7.0 or ≥11.1 ≥6.5 
IGT, Impaired glucose tolerance; IFG, Impaired fasting glucose; OGTT, Oral glucose 
tolerance test. 
  
In recent years, the measurement of glycated haemoglobin (HbA1c), reflective of the 
average blood glucose concentration over the previous two to three-month period, 
has been recommended as an alternative test to diagnose T2DM. The use of HbA1c as 
a diagnostic test has been endorsed by WHO, the IDF and the American Diabetes 
Association (ADA) (106, 112, 113). An expert committee established by the 
Australian Diabetes Society has recommended that an HbA1c value ≥6.5% be used as 
the cut-point for diagnosis T2DM (113). While this cut-point has been derived based 
on data showing an association between HbA1c and prevalent retinopathy (114), there 
is also evidence that a 1% reduction in HbA1c is associated with a 21% relative risk 
reduction (RRR) for any clinical end point or death related to diabetes, 14% for 
myocardial infarction and 37% for microvascular complications (109, 115). 
However, a recent study that used HbA1c for the sole identification of individuals 
with T2DM in population based health surveys failed to identify a substantial 
proportion of previously undiagnosed individuals who would be considered as 
having diabetes using a glucose-based test (116). These findings highlight the 
importance of glucose-based tests for the detection of T2DM when calculating 
national and global prevalence of this disease (116).  
 
2.5  Risk Factors for the Development of Type 2 Diabetes 
Common risk factors for T2DM include a range of non-modifiable (genetics, age, 
gender, ethnicity) and modifiable (obesity, physical inactivity, poor diet quality) 
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factors, which can form a complex interaction with one another (Table 2.2) (117). A 
brief discussion of some of these risk factors is presented below. 
 
Non-modifiable risk factors 
Genetics / Family History  
While T2DM is often considered a lifestyle-related disease, twin and family studies 
estimate that disease risk is increased up to three-fold in those with first degree 
relatives with T2DM and five to six-fold in those with both maternal and paternal 
disease history (102, 118). A genetic predisposition to T2DM, if present, may be 
triggered in the presence of a “diabetogenic” environment such as high-calorie 
consumption and a sedentary lifestyle (119, 120). Others have suggested that specific 
genes may be implicated in the development of T2DM. At present, 88 genes have 
been identified to potentially play a role in the genetic or inbred component of 
T2DM risk (121). This genetic heritability remains poorly understood with limited 
evidence available on how the identified genes specifically interrelate with 
environmental factors that have been linked to T2DM. Thus, it presently remains 
impossible to estimate an individual’s risk for T2DM through genetics alone (121, 
122). 
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Table 2.2: Major risk factors for type 2 diabetes. Adapted from Chen et al. (1). 
Non-modifiable risk factors  
§ Age greater than 45 years 
§ Gender; males at higher risk 
§ Ethnicity; Hispanic, Native American, African American, Asian 
American, or Pacific Islander descent 
§ First degree relative or family history of T2DM (e.g. parent or sibling) 
§ History of gestational diabetes or delivering a baby with a birth weight of 
over 9 pounds 
§ Polycystic ovary syndrome 
Modifiable risk factors 
§ Body fat mass  
§ High BMI 
§ Reduction in lean mass  
§ Physical inactivity 
§ Poor diet  
§ Smoking 
§ Previously diagnosed IGT or IFG 
§ Low serum 25(OH)D 
§ Chronic low grade systemic inflammation  
§ Hypertension (>140/90 mmHg) or dyslipidaemia (HDL <1.0 mmol/L for 
men and <1.3 mmol/L in women or triglyceride level >2.0 mmol/L) 
BMI, Body mass index; IGT, Impaired glucose tolerance; IFG, Impaired fasting 
glucose; HDL, High-density lipoprotein cholesterol 
 
Age 
Age per se is not a risk factor for T2DM, however, the chances of being diagnosed 
increase with advancing age with incidence greatest after 45 years (79). However, 
over the last decade there has been a concerning trend for an increasing incidence in 
younger adults, and even adolescents, which is likely driven by rising obesity rates 
(123).  
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Gender  
The reason males have a greater risk for T2DM has been proposed to be related to 
differences in the anatomical distribution of fat relative to females (124-126). Males 
have a predisposition to distribute their fat centrally which is a recognised and 
independent risk factor for insulin resistance, glucose intolerance and several 
cardiovascular risk factors (127-129). In contrast, women tend to store fat 
peripherally which has not been found to be strongly associated with such metabolic 
defects (126). Other proposed reasons for the gender differences include the effects 
of the sex hormones oestrogen and testosterone (126). Oestrogen has been proposed 
to have beneficial effects on insulin sensitivity via several possible mechanisms, 
including directly effecting insulin and glucose homeostasis, involvement in adipose 
tissue metabolism and body composition and/or effects on pro-inflammatory markers 
(130-132).  
 
Ethnicity  
Ethnic differences in the prevalence of T2DM remain well documented (133, 134), 
with a higher prevalence (and incidence) observed in Asians, Hispanics and Blacks 
compared to Caucasians, even after adjusting for recognised lifestyle factors (133). 
In 2001 in Australia, approximately 35% of individuals who reported a diagnosis of 
diabetes were born overseas (135).  
 
Modifiable risk factors 
Overweight and Obesity  
There is consistent and compelling evidence demonstrating that excessive body 
weight is a major risk factors for the development of T2DM, with 60-90% cases 
worldwide directly related to obesity (136-138). In a meta-analysis of prospective 
cohort studies which included 18 trials in adults aged 18-80 years (total sample size 
of 590,251), it was established that the relative risk of diabetes diagnosis if 
overweight and obese was 2.92 (95% CI, 2.57 to 3.32) and 7.28 (95% CI, 6.47 to 
8.28), respectively (139), independent of age, family history of T2DM and physical 
activity. Additionally, the distribution of adipose tissue has been identified as an 
important risk factor for T2DM, with central visceral adipose tissue (VAT) carrying 
a greater degree of risk compared to subcutaneous fat distribution (140, 141). This 
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has been attributed in part to the fact that VAT releases several bioactive molecules 
and hormones, such as non-esterified free fatty acids and several pro-inflammatory 
factors, which possesses unique characteristics that negatively influence a range of 
metabolic complications and abnormalities, including insulin resistance, glucose and 
lipid metabolism, which can lead to endothelial dysfunction, all of which have been 
found to directly precede the development of T2DM (142, 143).  
 
Loss of Muscle / Sarcopenia 
Losses in skeletal muscle are particularly detrimental for people at risk or diagnosed 
with T2DM as skeletal muscle is the predominant (~80%) site of glucose disposal 
under insulin stimulated conditions and is the major reservoir for glucose storage 
(144, 145). It is well established that ageing is accompanied with a natural 
progressive decline in skeletal muscle mass, most adults with T2DM appear to 
experience this loss in muscle mass, strength and function, termed sarcopenia, at an 
accelerated rate in comparison to healthy peers (146-148). Originally, this was put 
down to a greater degree of type II muscle fibre atrophy (146, 147) however, others 
have shown no difference in muscular myotype between healthy older adults and 
those with T2DM (148). Instead, insulin resistance and reduced glycaemic control 
both of which are independently associated with muscle loss, are believed to be 
responsible (Figure 2.2) (149, 150). Further, several cross-sectional studies have 
demonstrated an association between low muscle mass and insulin resistance, 
impaired insulin secretion leading to a deterioration in glycaemic control and thus an 
increased risk for T2DM, independent of central and visceral adiposity (6, 151-154). 
This was confirmed in the third National Health and Nutrition Examination Survey 
(NHANES) which reported a 10% increase in skeletal muscle mass was associated 
with an 11% reduction in insulin resistance and a 12% decrease in the diagnosis of 
pre-diabetes (10).  
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Figure 2.2: Common aetiological pathways and the metabolic links shared between 
sarcopenia and type 2 diabetes. Adapted from Landi et al. (155). 
 
Physical Inactivity and Sedentary Behaviour  
Physical inactivity, defined as not meeting the current recommended level of 
physical activity, is a fundamental modifiable risk factor for T2DM (156). Physical 
inactivity results in reduced energy expenditure, facilitates weight gain and is 
associated with abnormal glucose tolerance (157). It can also lead to increased levels 
of pro-inflammatory cytokines and promote the development of an atherogenic lipid 
and cholesterol profile, termed dyslipidaemia (157-160). Whilst the role of exercise 
for the management of T2DM will be discussed in greater detail later in this thesis, a 
considerable body of evidence indicates that physically active or regularly exercising 
individuals have a 30-50% reduced risk for T2DM compared to their physically 
inactive counterparts (157, 161). Further, recent observational and epidemiological 
studies strongly suggest that irrespective of physical activity participation, sedentary 
behaviour, defined as any waking activity characterised by an energy expenditure ≤ 
1.5 metabolic equivalents and a sitting or reclining posture, may also be a direct and 
independent risk factor for T2DM (157, 162-164).  
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Poor Diet Quality  
A large degree of uncertainty remains concerning specific macronutrients which may 
modulate T2DM risk (165, 166), yet previous research reports indicate that Western 
type diets, characteristically reflective of heightened consumption of processed, 
energy dense foods (i.e. large amounts of red meat, processed meat, high fat dairy 
products, sugar-sweetened beverages, sweets and desserts) are associated with 
increased prevalence and incidence of T2DM, independent of age, BMI or physical 
activity (167-169). Chronic excess energy consumption and increased dietary 
saturated and trans fatty acid intake have all been associated with increased T2DM 
risk (170-172). As such, nutrition recommendations made by peak health bodies such 
as the NHMRC, Diabetes Australia and the ADA, advocate those at risk of T2DM to 
reduce total calorie and saturated fat intake, achieve the recommended daily intake 
for dietary fibre and consume foods containing wholegrains (166). More specific 
details about the role of nutrition for the management of T2DM is discussed in 
section 2.8.  
 
Low Serum 25(OH)D  
A review of longitudinal, prospective and small-scale intervention studies provide 
evidence that low levels of serum 25-hydroyxvitamin D (25(OH)D), the main 
circulating form of vitamin D, are associated with future T2DM development (173). 
In a recent meta-analysis which included 76,220 participants and had 4,996 incident 
T2DM, each 10 nmol/L increment in serum 25(OH)D was associated with a 4% 
reduced risk of T2DM (linear trend P<0.0001) (174). However, the findings from 
several randomised controlled trials (RCTs) have largely found no effect of vitamin 
D supplementation on glycaemia or T2DM incidence (22, 65, 175-180). As pointed 
out in a recent review, a concrete conclusion cannot be determined from these trials 
as the majority were designed for other primary outcomes with T2DM examined 
post-hoc (181). More detailed information about the role of vitamin D in the 
management of T2DM will be presented in section 2.9. 
 
Chronic Low-grade Systemic Inflammation  
There is accumulating evidence from both in vitro, in vivo and epidemiological 
studies suggesting that chronic low-grade systemic inflammation, defined as a two- 
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to four-fold age-related increase in circulating inflammatory cytokines and acute 
phase reactants, is implicated in a number of metabolic processes that contribute to 
the development and progression of insulin resistance which plays a crucial 
intermediary role in the pathogenesis of T2DM (16, 182-184). The quantifiable risk 
posed by the presence of inflammation has not yet been confirmed with further 
research in this area presently required. The effects of chronic inflammation in those 
with T2DM will be discussed in further detail below. 
 
2.6  Prevention of Type 2 Diabetes 
Since T2DM is considered to be a lifestyle related disorder, numerous RCTs have 
examined whether lifestyle interventions aimed at reducing weight, increasing 
physical activity and improving dietary habits can reduce the risk for this disease. 
Overall the findings from these studies indicate that T2DM is largely preventable, 
even in those at high risk for this condition (27, 86, 185-190). For instance, the 
Diabetes Prevention Study (DPP), the largest RCT conducted to date in this area, 
randomised 3,234 participants with IGT to one of three interventions: 1) standard 
lifestyle and metformin; 2) standard lifestyle plus placebo, or 3) an intensive lifestyle 
program for four-years, with re-assessments conducted annually (191). Those in the 
standard lifestyle intervention were provided written information on what constitutes 
a healthy lifestyle. The intensive lifestyle intervention was goal oriented, with 
participants encouraged to achieve at least 150 min/week of moderate-intensity 
physical activity and a 5-10% reduction in weight. Participants in this group were 
also advised to cease smoking, limit alcohol intake and reduce total and saturated fat 
intake. To enhance successful achievement of the above recommendations, 
participants were enrolled in a 16-session education program covering topics such as 
exercise, nutrition and behaviour modification (191). After a mean follow-up of 3.2 
years, there was a 58% relative risk reduction (RRR) in the incidence of T2DM in 
the intensive lifestyle compared to standard lifestyle group, which was greater than 
the 31% RRR in the metformin group (27, 192). Furthermore, the intensive lifestyle 
intervention induced a greater reduction in HbA1c compared to either metformin or 
control (27). A number of other RCTs have also reported favourable results with 
similar lifestyle interventions (186, 193, 194). Collectively, these findings suggest 
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that a lifestyle approach to prevent and manage this disease may be more effective 
than pharmacological strategies. 
 
In recent years, several systematic reviews and meta-analyses have examined the 
effects of the above lifestyle interventions for the prevention of T2DM. Gillies et al. 
(193) aimed to quantify the effectiveness of lifestyle and pharmacological 
interventions on the delay or prevention of T2DM in those with IGT. Of the 17 trials 
evaluated, seven focused on a combined lifestyle intervention (exercise and diet) 
with the remaining ten either focussing on the effects of diet or exercise alone or the 
combined effects of these with pharmaceutical agents. The lifestyle interventions 
utilised in these seven studies examined the individual and combined effects of diet 
and physical activity in comparison to a control group and were all implemented for 
greater than six-months. Type 2 diabetes incidence was the primary outcome 
measure in all studies included (193). The pooled effect for all types of lifestyle 
interventions provided a hazard ratio of 0.51 (P<0.001), indicative of a 49% 
reduction in risk of T2DM (193). When considering each intervention separately 
(diet, exercise and diet and exercise), there was a similar reduction in risk [hazard 
ratios 0.67 (95% CI, 0.49 to 0.92), P=0.013; 0.49 (95% CI, 0.32 to 0.74), P=0.001; 
and 0.49 (95% CI, 0.40 to 0.59), P<0.001, respectively] (193). Pharmacological 
interventions were also found to be as effective as lifestyle in reducing T2DM 
incidence [hazard ratios 0.70 (95% CI, 0.62 to 0.79), P<0.001] (193). However, there 
is evidence that the lifestyle interventions may offer a long-term risk reduction in that 
they may reduce the incidence of T2DM beyond the active intervention phase (189). 
For instance, in a 20-year follow-up of the Da Qing study population, a 43% reduced 
risk of developing T2DM was observed in those in the combined intervention 
compared to control group (189). In summary, the available evidence suggests that 
long-term interventions targeting lifestyle behaviours are safe, feasible, and effective 
at reducing the risk for developing T2DM, with the benefits extending beyond just 
the intervention period. 
 
The following sections of this literature review will discuss the results of human 
intervention studies, with a focus on RCTs, which have examined solely or in 
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combination the effects of exercise and/or nutrition modification on glycaemic 
control, insulin sensitivity, body composition and cardiovascular risk factors in older 
adults with T2DM.  
 
2.7  Exercise for the Management of Type 2 Diabetes 
Physical activity is central to the management of T2DM. The contractile muscle 
activity associated with regular exercise produces a multitude of physiological, 
biochemical and molecular changes within muscle cells which play an important role 
in regulating blood glucose levels (195). These metabolic responses associated with 
single bouts of exercise, which generally last 24-48 hours, can be translated to long-
term beneficial metabolic adaptations, which are largely ascribed to the accumulative 
effects of repeated single-bouts of exercise (196). While it is beyond the scope of this 
thesis to discuss in detail all the cellular responses to exercise, in people with T2DM 
acute bouts of exercise have been shown to increase glucose transport through the 
increase in number of glucose transporter type 4 (GLUT4) proteins and translocation 
of these proteins to the muscle cell surface, which results in enhanced regulation, 
utilisation and uptake of plasma glucose from the circulation into muscle, 
subsequently reducing plasma glucose levels (157). In response to regular exercise 
training, the flux through these muscle glucose uptake processes, which are 
controlled by several insulin-independent signals generated within working muscles 
and which are heavily dependent on levels of circulating insulin, are boosted in 
individuals with T2DM (157). Importantly, long-term exercise performance has been 
consistently shown to result in favourable effects on FPG, fasting insulin, HbA1c and 
low grade systemic inflammation as well as cholesterol, blood pressure and body 
composition, all important for the management of T2DM and the prevention or delay 
in development of chronic complications (6, 23, 185). Indeed, the current Australian 
exercise prescription guidelines for individuals with or at risk of T2DM recommend 
a combination of aerobic and resistance training (Table 2.3) (185, 197). These 
recommendations are consistent with the recent position statement from the 
American College of Sports Medicine (ACSM) (197) and are included in the most 
recent Standards of Care for Diabetes Patients published by ADA (198). Despite 
these recommendations and the well-established health benefits, there is still some 
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controversy surrounding the optimal dose (intensity, frequency, duration) that is most 
beneficial for people with T2DM.  
 
Table 2.3: Minimum exercise recommendations for patients with type 2 diabetes. 
Adapted from Hordern et al. (185). 
Type of Exercise Intensity Duration/week Frequency 
Aerobic Training 
(E.g. walking, 
running, cycling, 
swimming) 
Moderate 
40-59% VO2R or HRR 
55-69% HRmax 
RPE 12-13 
OR 
210-minutes No more 
than two 
consecutive 
days without 
exercising 
Vigorous 
60-84% VO2R or HRR 
70-89% HRmax 
RPE 14-16 
 
125-minutes 
Progressive 
Resistance 
Training 
 
Moderate to vigorous 
8-10 exercises 
2-4 sets 
8-10 repetitions 
1—2 min rest intervals 
60-minutes 
(included in 
totals above) 
2 or more 
times/week 
VO2R= VO2 reserve, HRR=Heart rate reserve, HRmax=Heart rate maximum, 
RPE=Ratings of perceived exertion 
 
2.7.1  Aerobic Training and Type 2 Diabetes 
Aerobic or endurance exercise (running, brisk walking, swimming and/or cycling) is 
recommended for the management of T2DM due largely to its positive effects on 
reducing weight and improving cardiovascular risk factors (8, 199, 200). However, 
such programs alone may not be the most efficacious to prescribe to individuals with 
T2DM given that as many as 80% are overweight or obese and may suffer from any 
number of long-term complications including CVD, impaired mobility or visual 
impairment, that may make it challenging for these individuals to reach the required 
volume and/or intensity of training to achieve health benefits (201). Additionally, 
such training has little effect on lean mass and strength. For instance, some studies 
have reported a loss in lean mass following participation in aerobic-type training, 
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particularly when combined with weight loss induced by caloric restriction (7, 8). 
Since skeletal muscle plays a critical role in glycaemic control and metabolic 
homeostasis and accounts for up to ~80% of glucose disposal under insulin 
stimulated conditions (145), losses in lean mass can negatively impact metabolic rate 
and further compound the problems of insulin resistance and glycaemic control (6, 
154). As a result, PRT is included in current exercise guidelines for people with 
T2DM because it is widely recognised as a safe and viable mode of training that can 
significantly improve lean mass, size and strength in older adults, including those 
with T2DM. The following section will provide an overview of the available 
evidence regarding the efficacy of PRT for improving glycaemic control, insulin 
sensitivity, body composition, inflammation and cardiovascular health in adults with 
T2DM. 
 
2.7.2  Progressive Resistance Training and Type 2 Diabetes 
2.7.2.1  Effects of PRT on Body Composition  
As summarised in Table 2.4, a number of RCTs conducted over a period of 12- to 
52-weeks have reported positive effects of PRT on lean mass and/or size, with gains 
of up to ~1-2 kg (absolute net differences) reported after some trials (202) and 
reductions in fat mass in the range of ~1 kg (12, 157, 202-208). It has been suggested 
that the intensity of PRT is one of the most important parameters determining clinical 
outcomes including change in weight and fat mass in those with T2DM (209, 210). 
Many early resistance training studies which focused on light- to moderate-intensity 
circuit type resistance training (50-59% of 1-repetition maximum (RM)) reported 
modest or no marked effects on measures of body composition (205, 211). In 
contrast, moderate- to high-intensity (≥ 60-80% 1-RM) PRT programs have typically 
observed beneficial effects on both fat mass and lean mass (203). For instance, a 16-
week RCT in 62 adults with T2DM (mean ± SD; age 66 ± 8 years) found that thrice 
weekly moderate to high-intensity (60-80% 1-RM) supervised PRT resulted in a 
mean gain of 1.2 kg (P=0.04) in whole-body lean mass and a reduction of 0.7 kg 
(P=0.01) in trunk fat mass in comparison to standard care (no exercise) (203). A 
meta-analysis in older adults with T2DM which included 626 adults involved in 12 
trials of eight to 12-week duration found that PRT was associated with a mean 1.5% 
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reduction in total body fat percentage when compared to baseline (212). Ten of the 
12 studies in this meta-analysis prescribed training intensity above 60% of 1-RM 
(212). Collectively, the available evidence indicates that PRT programs which are of 
moderate to high-intensity appear to be best for improving lean mass and reducing 
fat mass in older adults with T2DM. Indeed, most current exercise prescription 
guidelines for adults with T2DM recommend PRT programs consisting of 2 to 3 sets 
of 8 to 12 repetitions at 50-75% 1-RM and containing 8-10 exercises targeting major 
muscle groups of the body with training be performed 2 to 3 times per week (213).  
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Table 2.4: Summary of the main findings (between-group differences) in RCTs investigating the effects of PRT or the combination of PRT and 
aerobic training under supervised gymnasium-based settings in older adults with type 2 diabetes. 
Reference Subjects 
Intervention Period, 
Intervention and Training 
Frequency 
Training Volume and Intensity Main Results and Adverse Events 
PRT Training Alone  
Church et al. 
2010 (7) 
n=262   
Age (years) 
PRT: 56.9 ± 8.7 
COMB: 55.4 ± 8.3 
AE: 53.7 ± 9.1 
CON: 58.6 ± 8.2 
Men and women 
36-weeks 
PRT, AE and combination 
of PRT and AE compared to 
controls 
3 sessions per week 
PRT: n=73 
2- sets x 10-12 reps upper and lower body; 
2 sets x 10-12 reps of 2 core exercises 
AE: n=72 
Treadmill walking 150 min per week at 50-
80% VO2 max.  
COMB: n=76;  
AE and PRT: PRT 2 sessions per week 
with only one set of above PRT program 
completed. 
CON: n=41 
Non-exercise controls. 
Fat mass: PRT ↓ 1.4 kg vs CON 
(P<0.05) 
Lean mass: PRT ↑ 0.8 kg vs 
COMB and AE (P<0.05) 
21 adverse events with 
prevalence similar across groups 
(CON, 3 events; PRT, 8 events; 
AE, 6 events; and COMB, 4 
events).  
De Lade et al. 
2016 (214) 
n=23 
Age (years) 
PRT: 57 ± 12 
AE: 54 ± 9 
Men and women 
20-weeks 
Comparisons of PRT to AE 
 
PRT: n=11 
2-3 sets x 12-15 reps; moderate-intensity 
(established as 11-13 on the Borg scale of 
RPE) 
AT: n=12 
No between-group differences in 
any outcomes including HbA1c, 
FPG, lipid or cholesterol levels, 
body weight, height, waist 
circumference. Lean mass and fat 
mass not assessed. 
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40 minutes of cycling, walking or elliptical 
machine use. Intensity controlled within 
60-70% predicted HRmax or by utilising the 
Borg scale of RPE 
No adverse events reported 
Plotnikoff et 
al. 2010 (215) 
n=48  
Age (years) 
PRT: 55 ± 12 
CON: 54 ± 12 
Men and women 
16-weeks 
PRT compared to control. 
3 sessions per week 
PRT: n= 27;  
Weeks 1-9 70-85% of 1-RM 3 sets x 10-12 
reps 
Weeks 10-16 70-85% of 1-RM 3 sets x 8-
10 reps 
CON: n=21  
Non-exercise controls 
HDL cholesterol: PRT ↑ 0.1 
mmol/L vs CON (P=0.049) 
1-RM muscle strength: PRT ↑ 9.3 
kg bench press, ↑ 41.0 leg press, 
↑ 12.4 kg upright row vs CON 
(all P<0.01). 
Fasting insulin in PRT reduced 
significantly compared to 
baseline only. 
No adverse effects reported. 
Honkola et al. 
1997 (216) 
n=38  
Age (years) 
PRT: 62 ± 2 
CON: 67 ± 2 
Men and women 
20-weeks 
PRT compared to control. 
2 sessions per week 
PRT: n=18  
Moderate-intensity circuit style PRT 
(intensity NS) 
CON: n=20  
Non-exercise controls  
HbA1c: PRT ↓ 0.5% vs CON 
(P<0.05) 
No reported adverse events. 
Castaneda et 
al. 2002 (203) 
n=62 
Age (years) 
PRT: 66 ± 2 
CONT: 66 ± 1 
Men and women 
20-weeks 
PRT performed 3 sessions 
per week 
PRT: n=31  
Weeks 1–8; 60–80% of 1-RM 
Weeks 10–14; 70–80% 1-RM  
CON: n=31 
Lean mass: PRT ↑ 1.2 kg vs CON 
(P=0.04) 
HbA1c: PRT ↓ 1% (absolute 
reduction) vs CON (P=0.01) 
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Non-exercise controls  SBP: ↓ 17.4 mmHg PRT vs CON 
(P=0.05) 
No complications or injuries 
reported. 
Cauza et al. 
2005 (202) 
n=39  
Age (years) 
PRT: 56.2 ± 1.1 
AE: 57.9 ± 1.4 
Men and women 
16-weeks 
PRT performed 3 sessions 
per week  
PRT: n=22 
Moderate-intensity (No % of 1-RM 
supplied), training targeted towards 
muscle hypertrophy 
3 sets x 10-15 reps 
AE: n=17 
Cycle ergometer at 60% VO2max  
HbA1c: PRT ↓ 0.9% vs AE 
(P=0.04) 
Blood glucose: PRT ↓ 56 mg/dL 
vs AE (P=0.002),  
HOMA-IR: PRT ↓ 3.5 vs AE 
(P=0.009)  
TC: PRT ↓ of 78 mg/dL vs AE 
(P=0.002) 
Body composition was not 
assessed. 
No adverse effects reported. 
Dunstan et al. 
2002 (12) 
n=29 
Age (years) 
PRT: 66.9 ± 5 
PRT+WL: 67.6 ± 
5 
Men and women 
24-weeks 
PRT combined with a 
weight loss (WL) program 
compared to sham exercise 
and WL 
3 times per week 
PRT+WL: n=16 
75-85% 1-RM  
3 sets x 8-10 reps plus moderate WL diet 
WL: n=13 
Sham exercise (stretching) plus moderate 
WL  
HbA1c: PRT+WL ↓ 0.8% 
(absolute reduction) vs WL  
(P<0.05) 
Lean mass: PRT+WL ↑ 0.9 kg vs 
WL 
No adverse events 
Sigal et al. 
2007 (8) 
n=251 
Age (years) 
26-weeks PRT: n=64 HbA1c: PRT ↓ 0.38% vs CON 
(P=0.038)  
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PRT: 54.7 ± 7.5 
AE: 53.9 ± 6.6 
COMB: 53.5 ± 7.3 
CON: 54.8 ± 7.2 
Men and women 
PRT, AE and the 
combination were compared 
to controls 
3 times per week 
2-3 sets x 7-9 reps maximal weight that 
could be lifted (no % of 1-RM training rate 
supplied) 
AE: n=60 
60-75% HRmax on treadmills and bicycles 
COMB: n=64 
Both the PRT and AE programs completed 
CON: n=63 
Non-exercise controls 
Thigh muscle CSA: PRT ↑ 8.0 
cm2 vs CON (P<0.001) 
Four individuals, all in the AE 
group, withdrew because of 
adverse events; 38% of exercise 
group participants and 14% of 
control reported an adverse event. 
Mavros et al. 
(217) 
n=103 
Age (years) 
PRT: 67.1 ± 4.8 
CON: 68.9 ± 6.0 
Men and women 
48-weeks 
PRT program compared to 
sham exercise  
3 sessions per week 
PRT: n=47 
80% of 1-RM with concentric explosive 
force. 3 sets x 8 reps 
CON: n=53 
Sham exercises (no load and no 
progression) 
Mid-thigh muscle CSA: PRT ↑ 
5.6 cm2 vs CON (P<0.01) 
No adverse effects reported 
Kwon et al. 
2010 (208) 
n=28 
Age (years) 
PRT: 55.7 ± 6.2 
CONT: 57.0 ± 8.0 
Women only 
12-weeks 
PRT compared to controls 
 3 sessions per week 
PRT: n=13 
Light resistance building to 40-50% 1-RM 
(Thera-bands) by week 12 
CON: n=15 
Non-exercise control group 
Lean mass: PRT ↑ ~2 kg vs CON 
(P=0.007) 
Fat mass: PRT ↓ ~1 kg vs CON 
mass (P=0.039) 
No adverse effects reported. 
Jorge et al. 
2011 (218)  
n=48 
Age (years) 
PRT: 54.1 ± 8.9  
12-weeks 
Comparisons of PRT, AE 
and combination to controls 
PRT: n=12 
Whole body program (no intensity or rep 
information provided) 
No differences between the 
groups for insulinaemic or 
glycaemic outcomes, blood 
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AE: 52.1 ± 8.7 
COMB: 57.9 ± 9.8 
CON:53.4 ± 9.8 
Men and women 
3 sessions per week AE:  n=12 
Cycling at a heart rate corresponding to 
lactate threshold 
COMB: n=12 
PRT interchanged with AE performed at 
same intensity and half the volume of the 
AE and PRT groups. 
CON: n=12 
Sham (Light stretching) 
pressure or lipid profile. Body 
composition not assessed. 
No adverse events reported. 
Combination Training 
Balducci et al. 
2012 (219) 
n=606  
Age (years) 
COMB: 59.0 ± 8.9 
CON: 61.9 ± 8.0 
Men and women 
52-weeks 
Combination of PRT and 
AE compared to a usual care 
program. 
2 sessions per week 
COMB: n=303 
AE: 55–70 % of VO2max using a treadmill, 
step, elliptical, arm, or cycle-ergometer. 
PRT: 60–80% of 1-RM (no sets or reps 
information was provided) 
CON: n=303 
Non-exercise (received usual care)  
HbA1c: COMB ↓ 0.3% vs CON 
(P<0.001)  
Fasting insulin: COMB ↓ 1.18 
pmol/L vs CON (P<0.001)  
HOMA-IR: COMB ↓ 0.36 vs 
CON (P=0.047)  
SBP and DBP: COMB ↓ 4.2 and 
1.7 mmHg vs CON (both P<0.01)  
LDL: COMB ↓ 9.6 mg/dL vs 
CON (P<0.003)  
HDL: COMB ↑ 3.7 mg/dL vs 
CON (P<0.001) 
BMI: COMB ↓ 0.78 kg/m2 vs 
CON (P<0.001) 
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Adverse effects related to training 
were more frequent (not 
significant) in COMB than in 
CON subjects. 
Cuff et al. 
2003 (220) 
n=28 
Age (years) 
COMB: 59.4 ± 1.9 
AE: 63.4 ± 2.2 
CON: 60.0 ± 2.9 
Women only 
16-weeks 
Combination of PRT and 
AE compared to AE and 
controls 
3 sessions per week 
COMB: n=10 
PRT: Light – moderate 2 sets x 10-12 reps 
AE: 60-75% heart rate reserve using 
mixed aerobic equipment (treadmills, 
bicycles etc.) 
AE: n=9 
60-75% heart rate reserve using mixed 
aerobic equipment (treadmills, bicycles 
etc.) 
CON: n=9 
Non-exercise control group 
Body weight: COMB ↓ 4.9 kg vs 
CON (P<0.05)  
No complications or adverse 
events reported 
Tan et al. 
2012 (221) 
n=25  
Age (years) 
COMB: 65.9 ± 4.2 
CON: 64.8 ± 6.8 
Men and women 
24-weeks 
Combination training versus 
control 
3 sessions per week 
 
COMB: n=15 
AE: 30 minutes of walking/running 
intensity controlled within the 
individualised 55-70% predicted HRmax  
PRT: 2 sets x 10-12 reps 50-70% of 1RM  
CON: n=10 
Maintenance of daily activities without 
commencing exercise 
HbA1c: COMB ↓ of 0.61% vs 
CON (P<0.05)  
% Body Fat: COMB ↓ 2.3% vs 
CON (P<0.05)  
Total cholesterol: COMB ↓ 1.35 
mmol/L in TC (P<0.001)  
TG: COMB ↓ 0.83 mmol/L vs 
CON (P<0.05) 
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No reported injuries or adverse 
effects of training 
Liu et al.  
2015 (222) 
n=48 
Age (years) 
COMB: 52.6 ± 
11.4 
CON: 51.2 ± 11.3 
Men and women 
12-weeks 
Combination of AE and 
PRT compared to controls 
3 sessions per week 
COMB: n=21 
AE: The exercise intensity for each patient 
set at 40–60% of VO2max.  
PRT: 50–60% 1-RM  
CON: n=17 
Conventional therapy 
HbA1c: COMB ↓ 0.52% vs CON 
(P<0.001)  
Postprandial blood glucose: 
COMB ↓ 1.9 mmol/L vs CON 
(P<0.01)  
Postprandial insulin: COMB ↓ 
22.6 mmol/L vs CON (P<0.05) 
TG: COMB ↓ 0.79 mmol/L vs 
CON (P<0.05) 
No adverse events reported. 
Note-Only significant changes relative to controls (between-group differences) are reported. Data reported as net differences. Age is mean ± SD.  
Abbreviations: PRT, Progressive resistance training; AE, Aerobic exercise; COMB, Combination of PRT and AE; CON, control; WL, weight loss; 
CSA, Cross-sectional area; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, total triglycerides; ↓ decrease; ↑ 
increase; HRmax, heart rate maximum; 1-RM, 1 repetition maximum; VO2max, maximal oxygen uptake, RPE, ratings of perceived exertion; NS, not 
stated
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2.7.2.2  Effects of PRT on Glycaemic and Insulinaemic Outcomes  
In those with T2DM there is consistent evidence from RCTs and meta-analyses of 
these trials demonstrating that structured and supervised PRT is effective at 
improving FPG, insulin sensitivity (HOMA-IR) and HbA1c as shown in Table 2.4 
(12, 203, 205, 212, 223-228). Similarly, there is evidence that PRT can improve 
glucose disposal rates, increase glycogen storage capacity and increase the number of 
GLUT4 receptors on muscle, which is important because glucose uptake by 
contracting skeletal muscle occurs by facilitated diffusion, dependent on the presence 
of GLUT4 in the surface membrane and an inward diffusion gradient for glucose 
(229). Despite these favourable findings, what remains less clear is the specific 
characteristics of a PRT program (intensity, frequency and duration) that are most 
effective. While it is beyond the scope of this thesis to review all the studies 
conducted in this area, the following section will focus on training intensity and its 
effects on glycaemic control and insulin sensitivity as as mentioned previously, 
training intensity is proposed to be a key influencing factor determining the success 
or failure of exercise programs to affect a range of clinically relevant health 
outcomes in those with T2DM. 
 
One of the first studies to examine the glycaemic and insulinaemic changes in adults 
with T2DM following participation in PRT utilised a supervised low to moderate-
intensity (~50-55% of 1-RM) circuit resistance training program (205). Fifteen 
previously sedentary adults (mean age, 51 years) performed supervised circuit 
resistance training three times per week for eight-weeks (205). Significant reductions 
were observed in both glucose and insulin area under the curve (AUC) in the training 
group compared to controls as assessed from OGTT (205). There was no change in 
HbA1c, which may be related to the relatively short intervention period of only 8-
weeks and/or the low-moderate training intensity (205). Assessment of HbA1c is best 
made at three-monthly intervals due to the long lifespan of red blood cells. In 
contrast to these findings, a five-month trial which included supervised modest 
intensity PRT (2 sets, 12-15 reps, intensity monitored with the Borg scale) performed 
twice per week in 18 adults with T2DM reported a significant net 0.5% absolute 
benefits to HbA1c in the training compared to control group (216). However, it is 
important to note that there was no change in HbA1c in the PRT group (7.5 ± 0.3% to 
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7.4 ± 0.2%), and so the net difference was largely driven by a deterioration in HbA1c 
levels in the control group (7.7 ± 0.3 to 8.1 ± 0.3%, P<0.01) (216). The lack of an 
improvement in the PRT group in this study may be related to the modest training 
dose (twice per week, 2 sets of 12-15 reps) and/or intensity (modest as assessed by 
the Borg scale). Based upon the findings presented here and the results of others 
(214), low- to moderate-intensity PRT programs appear to have little or no marked 
effects on improving HbA1c levels. In a meta-analysis of 23 studies comprising 954 
patients with T2DM which aimed to define the characteristics of PRT that might be 
most effective for improving glycaemic control, it was reported that there was no 
relationship between training intensity and HbA1c reduction (Table 2.5) (228). 
However, it should be noted that most of the included trials in this meta-analysis 
prescribed similar training programs and intensities (50-80% of 1-RM) and thus there 
was potentially not enough heterogeneity between the studies to detect differences. 
 
Several studies have found that high-intensity PRT in which the training load is 75-
85% of 1-RM is safe, well-tolerated and effective for improving HbA1c and insulin 
sensitivity in older adults with T2DM (12, 203, 230). For instance, a 16-week RCTs 
in 62 older adults with T2DM (mean age ± SE, 66 ± 2 years) compared the effects of 
supervised moderate- to high-intensity (60-80% 1-RM) PRT versus standard care on 
glycaemic control, FPG and insulin sensitivity (203). Participants allocated to the 
PRT program who completed three supervised 45-minute training sessions per week 
demonstrated a significant improvement in HbA1c (8.7 ± 0.3% to 7.6 ± 0.2%) when 
compared to control (8.4 ± 0.3% to 8.3 ± 0.5%, P = 0.01) (203). Additionally, in 
subsequent analysis of this same study insulin resistance (HOMA-IR) was found to 
improve in the PRT group (median reduction 0.7%, P=0.05) and deteriorate in the 
controls (mean increase 0.8%, P=0.05) (230). No significant change was observed in 
FPG or insulin for either group (203, 230). Importantly, of the 62 individuals who 
participated in this trial, all but two completed the PRT program with exercise 
compliance reported above 90% in the PRT group. This demonstrates that high-
intensity PRT was safe and well-tolerated by older adults with T2DM (203).  
 
In recent years several meta-analyses have investigated the effects of training dose 
on measures of glycaemic control and insulinaemic outcomes following PRT in 
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people with T2DM (212, 227, 228). While these meta-analyses have consistently 
reported beneficial effects of PRT on HbA1c (effects size -0.32 to -0.64), they have 
been unable to find any association between training intensity, frequency or number 
of exercises performed and an improvement in HbA1c. However, in the meta-analysis 
by Ishiguro et al. (228) they reported that completing ≥21 sets of PRT per session 
was associated with a greater improvement in HbA1c compared to <21 sets (Table 
2.5). While this suggests that the total dose of training may be more important than 
the intensity, it is important to note that many of the RCTs included in this meta-
analysis used a similar training frequency (3 sessions per week) and intensity (60-
80% 1-RM), which is what is commonly recommended for adults with T2DM. Thus, 
the effects of PRT programs greater than this volume on HbA1c remain inconclusive 
(228).  
 
In summary, the literature reviewed above and presented in Table 2.4 suggests that 
moderate to high-intensity supervised and structured PRT performed three times per 
week is safe, manageable and results in clinically meaningful improvements in 
glycaemic control in older adults with T2DM (12, 202, 203, 212, 227, 228). This 
aligns with the current physical activity guidelines for individuals with T2DM by 
bodies such as the ADA and Exercise Sports Science Australia (ESSA) who 
recommend PRT at a moderate- to high-intensity be incorporated into a physical 
activity plan and performed at least twice a week, including all major muscle groups 
(185, 231). 
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Table 2.5: Analysis of effect size for change in HbA1c stratified by characteristics of 
the PRT program. Adapted from Ishiguro et al. (228). 
Program 
Characteristic 
Number 
of RCTs 
Effect size (%) 
(95% CI)  
I2 P-valuea 
P-
valueb 
Intervention Period     
  ≥12-weeks 12 -0.33 (-0.60 to -0.06) 84.9 <0.001  
  <12-weeks 11 -0.39 (-0.62 to -0.17) 46.5 0.04 0.72 
Frequency     
  ≥3-weeks 17 -0.25 (-0.44 to -0.06) 77.8 <0.001  
  <3-weeks 6 -0.66 (-0.88 to -0.44) 11.7 0.34 0.09 
Number of Exercises     
  ≥9 items 10 -0.54 (-0.90 to -0.19) 49.7 0.04  
  <9 items 13 -0.25 (-0.47 to -0.04) 84.1 <0.001 0.24 
Intensity      
  ≥75% 1-RM 10 -0.41 (-0.72 to -0.09) 86.8 <0.001  
  <75% 1-RM 10 -0.30 (-0.51 to -0.09) 53.3 0.02 0.60 
Interval (time between exercises)    
  ≥1.5 min 8 -0.47 (-0.88 to -0.06) 91.3 <0.001  
  <1.5 min 5 -0.38 (-0.97 to -0.21) 0.0 0.95 0.85 
Total sets per session     
  ≥21 sets 10 -0.65 (-0.97 to -0.32) 62.7 0.004  
  <21 sets 13 -0.16 (-0.38 to 0.05) 79.8 <0.001 0.03 
Total sets per week     
  ≥60 sets 14 -0.32 (-0.58 to -0.06) 80.9 <0.001  
  <60 sets 9 -0.40 (-0.70 to -0.09) 72.6 <0.001 0.09 
a P-value for heterogeneity b P-value for difference between strata. 1-RM, 1 repetition 
maximum; CI, confidence interval; RCTs, Randomised controlled trials. 
 
2.7.2.3  Effects of PRT on Markers of Inflammation  
Some, but not all, cross-sectional and longitudinal studies have demonstrated that 
regular physical activity, with or without weight loss, can reduce circulating levels of 
inflammatory markers (232-235). While the vast majority of interventional research 
in this area has focused on the effects of aerobic training or general physical activity, 
there is some, albeit limited, evidence that participation in PRT can improve 
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circulating inflammatory markers in older healthy adults, with only limited 
favourable evidence in adults with T2DM (218, 222, 230, 236-240). For example, 26 
overweight/obese older adults (mean aged 61 years) with T2DM who performed 
moderate-to-high intensity (60-80% 1-RM) PRT three times per week (236) for 12-
weeks experienced a non-significant 0.52 mg/L reduction in hs-CRP in comparison 
to a control program (P=0.189) (236). The lack of significance observed was 
proposed to be due to either the lack of fat mass reduction or that the volume of 
training required to reduce inflammation is greater than what was prescribed in this 
trial. In another trial, the change in IL-6 and hs-CRP was assessed in 102 sedentary 
middle-aged and older adults (40-65 years of age) performing either; PRT (n=35, 70-
75% 1-RM) or aerobic training (n=41, 70-75% HRmax) or no exercise (controls, 
n=25) for 10-weeks (240). A 3.7% reduction in total body fat mass and a 32.7% 
reduction in hs-CRP in the PRT group compared to baseline (P<0.05) was observed 
in the PRT group (240). Post-hoc analyses demonstrated there was a trend towards a 
difference in hs-CRP in the PRT group compared to the post-intervention aerobic 
and control group (P=0.11 and P=0.08, respectively) which authors suggested to be 
due to the significant pre-post reduction in percentage fat mass, although a 
significant pre-post reduction in percentage fat mass was observed in the aerobic 
group without the same trend towards a significant reduction in hs-CRP (240). As 
this trial, and the previous study by Kadoglou et al. (236) prescribed similar training 
interventions the contrasting results suggest that improvements in inflammation are 
likely related to changes in fat mass.  
 
Mechanistically, it has been suggested that reductions in fat mass are required to 
reduce inflammatory gene expression in visceral adipose tissue (241, 242). Others 
have suggested that the improvements in inflammation following weight loss are due 
to a shift in the activity of lipolysis; adipocyte lipolysis is known to increase adipose 
tissue inflammation (243). Whilst the mechanism(s) remain undefined, evidence 
from some RCTs demonstrate an association between reductions in fat mass and/or 
increases in lean mass and improvements in inflammation. In a recent trial in which 
older (mean age 68 years) diabetic adults were randomised to 12-months of high-
intensity PRT (80% 1-RM) or a sham exercise program (low-intensity, non-
progressive exercise), performed three days per week (238), it was found that hs-
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CRP levels tended to decrease more in the PRT group when compared to sham 
(P=0.087) (238). Further analysis of these results revealed that reductions in hs-CRP 
were associated with both increases in muscle mass (r=-0.48, P=0.01) and reductions 
in total fat mass (r=0.45, P=0.02) in the PRT group, but not in the sham group (238). 
This suggests that the greatest benefits on inflammation may be achieved with 
exercise-induced fat loss combined with muscle gain. Despite these positive results, a 
limitation of this trial was that they only assessed one inflammatory marker and as 
such further studies are needed to not only confirm these results but to also examine 
the effects of PRT on other inflammatory markers. Recently, findings from a meta-
analysis of exercise interventions on inflammatory markers that included 14 RCTs in 
people with T2DM, three of which included PRT, found that mostly aerobic but 
some PRT programs of longer duration or which had a larger number of total training 
sessions were associated with the greatest benefits for circulating IL-6 levels (244). 
This suggests that the duration and dose of training may play an important role in 
improving systemic inflammation (244). 
 
In summary, epidemiologic studies demonstrate that exercise plays a role in reducing 
inflammation, and whilst the body of evidence is small from intervention studies in 
adults with T2DM, there are some studies which have observed an improvement 
which may be explained by the duration or dose of the training program or 
concomitant changes in body composition.  
 
2.7.2.4  Effects of PRT on Blood Pressure and Blood Lipids 
There is some evidence that PRT can also lower blood pressure in adults with T2DM 
(245, 246), although others have also observed no marked benefits (8). For example, 
6-months of high-intensity PRT (75-85% 1-RM, 3 sessions per week, 3 sets of 8-10 
repetitions) in 29 older (mean age, 67 years) obese (mean BMI, 31.5 kg/m2) adults 
with T2DM lowered systolic blood pressure (SBP) and diastolic blood pressure 
(DBP) by 6.7 and 4.4 mmHg, respectively (P<0.01) (12). However, since this 6-
month program also involved a moderate weight-loss diet the improvements in blood 
pressure may not have been the result of PRT alone. However, 12-weeks of PRT (3 
times per week, 60 minutes per session) in 48 older overweight adults (age ± SD 54.1 
± 8.9 years, BMI ± SD 30.9 ± 4.1 kg/m2) with T2DM significantly lowered both SBP 
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and DBP (10 and 2.5 mmHg, respectively P<0.05) compared to baseline but not 
when compared to controls or aerobic or combined aerobic and PRT (218). A recent 
meta-analysis of ten RCTs in 403 participants which aimed to determine the effects 
of structured PRT on blood pressure changes in adults with T2DM, Figueria et al. 
(247) reported that PRT performed on average three times per week ranging from 
eight to 26-weeks was associated with significant 4.44 mmHg (95% CI, -6.76, -2.11) 
and 2.84 mmHg (95% CI, -3.88, -1.81) (both P<0.05) reductions in SBP and DBP 
respectively, compared to controls (247). Sensitivity analysis also demonstrated that 
the greatest reductions in blood pressure occurred in those with hypertension at 
baseline (247). Analyses of data according to the weekly amount of exercise found 
the improvements in blood pressure were greatest when PRT was performed for 
more than a total of 150 minutes per week (247).  
 
Dyslipidaemia, like hypertension, is common among those diagnosed with T2DM 
and is significantly associated with CVD (93). While there is some evidence that 
PRT can have a positive effect on lowering lipids levels in adults with T2DM (218, 
248-251), some studies have observed no effect (12, 252, 253). Studies as short as 8-
weeks have demonstrated improvements in triglyceride and/or cholesterol levels 
(248) while others have observed long-standing improvements in serum lipids with 
training interventions up to 12-months (249). For instance, a study conducted in 236 
older men and women (mean age 74 years) who performed 12-weeks of PRT (3 
times per week; 3 sets, 6-8 repetitions at 75-80 % of the 1-RM) demonstrated 
significant reductions in LDL cholesterol (mean change 0.47 mmol/L), total 
cholesterol (mean change 0.67 mmol/L) and triglycerides (mean change 0.14 
mmol/L) (all P<0.05). The positive effects of PRT on cholesterol and lipid levels has 
been suggested to be due to reductions in cholesterol formation and/or increases in 
lipid oxidation via an increase in lipoprotein lipase, although this remains to be 
confirmed (249, 254). As stated above, not all studies have observed a favourable 
response of PRT on blood lipids. A 6-month trial of high-intensity PRT (3 days per 
week, 80% 1-RM) was found not to alter levels of triglycerides, total, LDL or HDL 
cholesterol in 16 older adults (mean age ± SD, 67.6 ± 5.2 years) with T2DM who 
were also on a moderate weight loss diet (-500 calories/day) in comparison to sham 
exercise and weight loss alone (n=13, mean age ± SD, 66.9 ± 5.3 years) or even 
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baseline (12). The lack of an effect may have been due to participants presenting 
with relative normal lipid levels at baseline and/or the fact that both groups in this 
study lost a similar amount of weight and fat mass (12). A recent meta-analysis 
which included 12 intervention trials ranging from 8- to 12-months and which 
compared aerobic and resistance exercise in adults with T2DM, provided important 
clinical insights into cardiovascular health outcomes following such training 
programs (212). A total of 422 participants from ten of the 12 trials examined 
provided within-group pre-post change data on serum triglycerides and HDL levels 
(212). Improvements in serum triglycerides were pooled from aerobic and PRT 
interventions and found to be significant [triglycerides −0.33 mmol/L (95% CI 
−0.47, −0.18), all P<0.05] (212). Within this meta-analysis pooled data from nine 
PRT trials found that this mode of training resulted in significant reductions in both 
LDL [mean change: -0.05 mmol/L (95% CI −0.09 to −0.01)] and total cholesterol 
[mean change -0.22 mmol/L (95% CI −0.30 to −0.14)] (212).  
 
In summary, there is a growing body of evidence from a number of RCTs and even a 
few meta-analyses in older adults with T2DM which report significant beneficial 
effects of structured and clinically controlled PRT programs PRT on serum lipids 
and blood pressure levels. While the findings from some studies may be confounded 
by the addition of weight loss via caloric restriction, these effects appear to be 
magnified in those with hypertension and dyslipidaemia at baseline.  
 
2.7.3  Efficacy of Community-Based Resistance Training Programs 
Most research examining the health benefits of PRT in people with T2DM have been 
conducted in tightly-regulated, structured and supervised clinical exercise 
laboratories where both participants and research conditions are highly controlled. 
The effectiveness of less controlled community-based training programs on body 
composition changes in older adults with T2DM is less clear, but from a public 
health perspective it is important to understand just how effective PRT programs are 
when undertaken in the community (255). Community settings provide an optimal 
avenue for assessing the relevance and applicability of research-to-practice 
programs. Intervention studies in older adult’s show that group-based community 
exercise programs can increase time spent exercising and frequency of exercise (256, 
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257). Furthermore, previous research measuring the economic value of research-to-
practice programs in community settings has found participation in such programs 
may reduce total healthcare costs for older adults (24). 
 
In a retrospective analysis of a 24-week community based research-to-practice PRT 
program called Lift for Life® (75-85% 1-RM, 3 sets of 8-10 reps performed 3 times 
per week), in which training was supervised but performed in small groups (not one-
on-one supervision) in a community setting, 86 adults with or at risk for T2DM 
demonstrated significantly lower central obesity following 8-weeks of training [mean 
reduction in waist circumference: -1.9cm (95% CI, -2.8 to -1.0)]. By 24-weeks, the 
mean reduction in waist circumference -4.9 cm (95% CI, -6.7 to -3.0; P<0.001 for a 
time effect) in those individuals (n=36) who completed the full training program 
(255). Although this study did not include assessment of other common clinically 
relevant outcomes (e.g. HbA1c, lean mass, blood pressure, lipids etc.) these results 
highlight that community-based PRT programs, with less supervision than a clinical 
exercise laboratory-based trial, may be effective in improving health and body 
composition measures in older adults with T2DM.  
 
A recent meta-analysis further supports community-based exercise programs as 
effective methods for managing T2DM (23). Pooling 11 studies examining 
community-based physical activity interventions, largely performed using exercise 
machines or group physical activity education programs, yoga classes, telephone 
counselling or motivational techniques with some interventions also based in social-
cognitive theories or interventions that were tailored based on such theories, 
demonstrated that such interventions were effective in reducing HbA1c levels (0.32% 
absolute reduction) which only approached statistical significance (P=0.06) possibly 
because four of the studies included in this meta-analysis reported no change in 
HbA1c (23). This meta-analysis further demonstrated that community-based physical 
activity programs were also effective in reducing weight and waist circumference 
and increasing habitual physical activity levels (23). Collectively, these findings 
indicate that community-based physical activity programs can provide important 
health improvements in adults with T2DM (23). Additionally, such programs have 
been found to be cost-effective for individuals with T2DM and there is also evidence 
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of lower health care utilisation in individuals with T2DM who attain minimum 
physical activity guidelines (258, 259). Despite this evidence, a number of 
unanswered questions still remain in relation to other outcomes of relevance to older 
adults with T2DM such as effects on insulin sensitivity, lipids and cholesterol, 
inflammation and the longer-term maintenance of such programs over periods of 
time greater than 2-months. Further, little is known about the enhanced effect 
nutrition may provide in addition community-based PRT interventions on these 
aforementioned outcomes. 
 
2.8  Nutrition for the Management of Type 2 Diabetes 
Traditionally, nutrition recommendations made by peak medical and/or nutrition 
authorities around the world for people with T2DM have recommended a percentage 
energy contribution from carbohydrate, fat and protein of 50-60%, ≤30% and 10-
20%, respectively (Table 2.6). In addition, these recommendations suggest 
consuming moderate amounts of polyunsaturated fat whilst restricting saturated fat 
intake due to the apparent adverse effects on CVD and related outcomes (260-262). 
The rationale for such a macronutrient distribution was based on preventing 
excessive spikes in chronic and post-prandial glycaemia and improving plasma lipid 
profiles to reduce CVD risk (263). While less attention has been given to dietary 
protein, there is emerging evidence to support an important physiological role of 
dietary proteins and constituent amino acids as part of an overall diet in the 
management of T2DM (264-267). However, questions remain as to what proportion 
of energy intake should be derived from dietary protein for adults with T2DM. The 
following sections will provide an overview that the role dietary protein may play in 
modulating important metabolic and physiological health outcomes in adults with 
T2DM. 
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Table 2.6: Macronutrient recommendations for the management for type 2 diabetes 
by the British and American Diabetes Association and the American Heart 
Foundation. Sourced from Ajala et al. (268). 
Variable Diabetes UK (262) ADA (260) AHA (261) 
Carbohydrate (%) 50-55 50-60 45-55 
Fat (%) 30-35 35-35 <30 
Protein (%) 10-15 15-20 12-20 
ADA, American Diabetes Association; AHA, American Heart Association 
 
2.8.1  High Protein Diets for the Management of Type 2 Diabetes 
The following section provides a brief overview of the effects of diets high in protein 
(i.e. 30% energy from protein) on glycaemic and insulinaemic outcomes, change in 
body composition, triglycerides, cholesterol, blood pressure and markers of 
inflammation in older overweight adults and those with T2DM. Subsequent to this 
section is a more in-depth discussion about the role and potential health benefits of 
protein supplementation (i.e. whey protein) for adults with T2DM. 
 
2.8.1.1  Effects of a High Protein Diet on Glycaemic and Insulinaemic Outcomes 
Previous research has shown that short-term diets higher in protein can have 
favourable influence on glycaemic measures in overweight adults (265, 269) as well 
as those with T2DM (263, 267, 270-272). For instance, in eight men with T2DM 
who were randomly assigned to consume a high (30% total energy) or low (15% 
total energy) protein diet for 5-weeks there was a 29% (P<0.003) reduction in FPG in 
the high protein group by week 5; HbA1c was significantly reduced by week 3 and 
22% lower than the low protein group by week 5 (P<0.05) (272). However, longer-
term (at least 12-months) dietary intervention trials examining the effects of 
increased dietary protein provide mixed evidence regarding the effects on glycaemic 
control in adults with T2DM (273, 274). For instance, a study of 419 adults with 
T2DM aged 30–75 years with a BMI >27 kg/m2 who were randomised to 
hypocaloric diets of either high protein (30% of energy) or lower protein (15% of 
energy) for 12-months found no significant differences in FPG or HbA1c (274). 
However, in this study only 6% of the high protein diet group attained the target 
protein intake (25% energy from protein) with the remainder consuming < 21% 
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energy from protein (274). The authors of this study suggested that the null findings 
were likely attributed to the difficulty participants had in achieving the prescribed 
protein intake over an extended period. Nevertheless, the findings from a meta-
analysis of nine RCTs ranging in duration from 4- to 24-weeks and including 418 
adults with T2DM (mean age 46–63 years and BMI 31–39 kg/m2) revealed that high 
protein (25-32% of total energy) compared to normal or low protein (15-20% of total 
energy) diets led to significant reductions in HbA1c [mean difference, 0.52% (95% 
CI, -0.90, -0.14)] (38). Based on these findings, increasing dietary protein intake may 
play a valuable role in optimising glycaemic control in adults with T2DM. Questions 
remain as to whether such an approach is feasible and sustainable in the long-term 
and, what the optimal dietary protein intake is to achieve clinically meaningful 
benefits in glycaemic control.  
 
Dietary protein and specific amino acids, particularly arginine, leucine and 
phenylalanine, have also been reported to offer acute insulinotropic effects, a 
phenomenon observed in several acute postprandial trials and which has been 
observed to occur in older adults with long-standing T2DM (275-277). Whilst the 
exact mechanism(s) behind this process have not yet been fully identified, it appears 
amino acids promote the secretion of insulin from the pancreatic beta-cell (278-280). 
For instance, one study in 60 older adult males with T2DM found that protein (0.3 
g/kg) or protein hydrolysate (0.3 g/kg) with co-ingestion of carbohydrate was 
associated with a 99 and 110% postprandial increase in insulin in comparison to 
carbohydrate ingestion alone, whilst attenuating the postprandial rise in glucose by 
22% (281) with other researchers reporting similar observations in acute settings 
observing similar in an acute setting (275-277). Despite these positive acute effects 
on insulin, the effects of longer-term (≥12-weeks) high protein diets on fasting 
insulin and insulin sensitivity in older overweight adults (282-285) and in older 
adults with T2DM (286-288) remain mixed. Indeed, several of the studies conducted 
to date in those with T2DM are confounded by the incorporation of caloric restriction 
which has led to weight loss. For example, in the study by Brinkworth et al. (288) 66 
obese adults with T2DM were randomised to a high protein (30% energy) or low 
protein (15% energy) diet plus energy restriction for 8-weeks followed by 4-weeks of 
energy balance. At the end of the 12-week period the high protein diet resulted in a 
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22% reduction in HOMA-IR and a 14% reduction in fasting insulin levels (both 
P<0.01) when compared to baseline (288). This reduction was no different to the low 
protein group likely explained by the fact both groups lost a similar amount of 
bodyweight (288). As there was no high protein diet group without energy restriction 
in this trial, the effects of a higher protein diet in the absence of weight loss remains 
uncertain in older adults with T2DM. However, recently an improvement in HOMA-
IR independent of weight loss in overweight and obese women without T2DM (mean 
age ± SD, 44.0 ± 9.1 years and BMI 37.7 ± 3.4 kg/m2) was observed when 
consuming a diet providing 27 and 35% energy as protein. The same improvement in 
HOMA-IR relative to baseline was not seen in those consuming only 20% energy 
from protein in the same trial (289). In summary, the effects of high protein diets on 
fasting insulin and insulin sensitivity/resistance appear to be favourable in older 
adults with T2DM yet the studies conducted to date are confounded by the 
prescription of caloric restriction to induce weight loss. Further trials are required 
which prescribe a high protein diet in the absence of caloric restriction to investigate 
whether a high protein diet without weight loss can improve insulinaemic outcomes 
in older adults with T2DM. 
 
2.8.1.2  Effects of a High Protein Diet on Body Composition 
Dietary protein and its constituent branched chain amino acids have been found to 
play an important role in stimulating muscle protein synthesis (MPS) and reducing 
muscle protein breakdown (MPB) in both young and older adults (290-292). In 
healthy or overweight/obese adults, long-term exposure to such stimuli (protein) has 
been shown to preserve and in some instances, increase muscle mass whilst 
concomitantly reducing weight and fat mass (293-296). Maintenance of skeletal mass 
is of relevance for older adults and those with T2DM because of the important role 
muscle plays in insulin-stimulated glucose uptake and storage, as discussed 
previously in this review.  
 
There are a number of mechanisms which have been proposed to explain how greater 
reductions in fat mass can be achieved on a high protein diet. Explaining at length 
many of these proposed mechanisms is beyond the scope of this review. Briefly 
however, proposed mechanisms include the thermic effect of feeding which is 
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greater in those with T2DM consuming high protein diets compared to low protein 
diets (297-299). Additionally, high protein diets have been found to blunt the 
reduction in resting energy expenditure commonly observed following weight loss 
from an energy restrictive diet in obese non-diabetic and lean populations (300, 301), 
but this remains unconfirmed in adults with T2DM and. Furthermore, protein 
increases secretion of satiety hormones gastric inhibitory polypeptide (GIP) and 
glucagon-like peptide-1 (GLP-1) and reduces secretion of the orexigenic hormone 
ghrelin (302-304).  
 
The effects of increased protein on fat mass and total weight reductions in the short 
and longer-term appear favourable with reductions from 2 to 9 kg observed 
depending on the length of the intervention (38, 264, 267, 305-307). However, the 
number of trials of longer duration are limited in older adults with T2DM. A meta-
analysis conducted by Dong et al. (38) comprising nine studies ranging in duration 
from 4- to 24-weeks, including 418 T2DM patients (mean age 46–63 years and mean 
BMI 31–39 kg/m2) revealed high protein diets (25-32% of total energy) compared to 
normal or lower protein (15-20% of total energy) diets lead to greater reductions in 
weight [mean difference -2.08 kg (95% CI, -3.25, -0.90)] (38). However, the authors 
highlighted the lack of evidence for longer term trials with most of the interventions 
examined being ≤ 6-months and thus the long-term efficacy of such diets is not yet 
known (38).  
 
Ingestion of protein has been shown in the young, elderly and those with T2DM to 
successfully stimulate a MPS response, which in the long-term may translate to 
maintenance or enhancement of muscle mass (308-312). However, it has been 
suggested that older adults with T2DM may be less responsive to such anabolic 
stimuli (313, 314), although recent data indicates that the MPS response to protein is 
not impaired in adults with T2DM (308). Ageing muscle also appears to be less 
sensitive to lower doses of protein/amino acids, with reductions in lean mass 
occurring rapidly with low protein intake, subsequently suggesting older adults with 
T2DM may require higher quantities of protein to acutely stimulate an equivalent 
MPS response above basal (310, 312). For instance, 17 obese men and women with 
T2DM (mean age ± SD, 46 ± 3 years) who followed a low protein diet (15% energy) 
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for 4-weeks were found to lose ~1 kg of lean mass (P=0.004) when measured with 
bioimpedance, whereas when these same adults (after a 3-week washout) consumed 
a high-protein (30% energy) diet there was no loss in lean mass (315). Trials of 
longer duration in older adults with T2DM generally corroborate the short-term 
findings although the maintenance of such diets appears to falter after a few months. 
For example, in a parallel clinical intervention conducted by Brinkworth et al. (306) 
58 older (mean age 50.2 years) adults who were hyperinsulinaemic but not diagnosed 
with T2DM followed a 12-week energy-restricted weight loss diet either high in 
protein (30% energy as protein) or low in protein (15% energy) following this the 
high and low protein diet was continued but energy intake was balanced without 
restriction (306). Protein intake was significantly greater in the high protein group 
during the initial 16 weeks (P<0.001), but decreased in the high protein and increased 
in low protein groups during 52-weeks of follow-up (306). Subsequently, there was 
no difference between the groups in protein intake at week 68, indicating poor long-
term dietary adherence behaviour to both dietary patterns. 
 
In summary, high protein diets appear to translate to relevant reductions in total body 
weight and fat mass in older adults with T2DM. Such diets show promise for 
maintaining or enhancing muscle mass, but long term maintenance of these diets 
appears to be difficult with marked deviations from prescribed diets evident in some 
studies. Long-term maintenance of such diets may be enhanced with the use of a 
protein supplement which will be discussed in section 2.8.2.  
 
2.8.1.3  Effects of High Protein Diets on Lipids, Blood Pressure and Markers of 
Inflammation  
Higher protein diets, with a low intake of fat, have been associated with 
improvements in blood lipids, blood pressure and to a smaller degree inflammation 
in overweight/obese adults with limited evidence in adults with T2DM (267, 306, 
316). Proposed mechanisms for improvements in serum lipids include increased 
hepatic bile acid synthesis (317, 318), enhanced faecal sterol excretion (319, 320), 
decreased hepatic de novo cholesterol biosynthesis (319, 321) or reduced uptake of 
cholesterol through reductions in LDL receptor activity (321-323). The interactions 
between protein-digested products (bioactive peptides) and gut hormones including 
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GLP-1 are thought to drive blood pressure improvements (324) with an attenuation 
in adipose tissue oxidation and inflammatory responses or suppression of 
inflammatory synthesis pathways to drive improvements in inflammatory factors 
(325). 
 
Studies in older adults with T2DM examining the effects of high protein diets on 
lipids, blood pressure and inflammatory cytokines remain limited. In the 64-week 
trial in obese older adults with T2DM conducted by Brinkworth et al. (306) 
discussed above, the high protein weight reduction diet led to a significant reduction 
in plasma level of hs-CRP (baseline vs 64-weeks; 5.0 ± 1.0 vs 3.8 ± 0.8 mg/L, 
P<0.05). Those in the higher protein group also had greater improvements in blood 
pressure plus total and LDL cholesterol however, like inflammation these 
improvements were not different to those on the low protein diet, possibly explained 
by the similar amount of weight lost in both groups (306). In the meta-analysis by 
Dong et al. (38) discussed in section 2.7.2.3 of this review, the pooled treatment 
effects found high protein diets did not alter triglycerides, total, HDL or LDL 
cholesterol, but there was a trend for an improvement in SBP (-3.13 mmHg (95 % CI 
-6.58, 0.32) P-value not reported) and DBP (-1.86 mmHg (95 % CI -4.26, 0.56) P-
value not reported) (38). Further, in another more recent systematic review and meta-
analysis of nine RCTs ranging from six to 36-weeks in duration with participant 
numbers from 20 to 190 obese, hypertensive adults largely with metabolic syndrome, 
no significant effect of higher protein diets on circulating levels of hs-CRP were 
observed. However, the authors noted that their results were limited by considerable 
heterogeneity across all included trials (326). Differences in trial duration and the 
level of professional (i.e. dietetic) support made available to participants as well as 
differences in the macronutrient composition of the diets make any conclusions about 
the effects of high protein diets on blood lipids, blood pressure and/or inflammation 
difficult with further research required. 
 
2.8.1.4  Potential Problems with Prescribing High Protein Diets  
Whilst many of the trials presented above provide support for a beneficial role of a 
high protein diet for the management of T2DM and improvement of cardiovascular 
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risk factors, there remains insufficient data to conclusively recommend such a diet. 
Conducting large scale RCTs which control for macronutrient content are habitually 
difficult to implement and adherence to dietary recommendations is rarely sustained 
(327). Such interventions typically require participants to follow prescribed meal 
plans which over an extended period of time can become tedious and burdensome, 
often leading to high dropout rates and poor adherence to the prescribed diet (286, 
307). In addition, adherence often relies on self-reported dietary intake, which in 
obese and T2DM populations may not be appropriate as under-reporting of food 
intake is widely acknowledged to occur in these groups (328). To account for these 
issues, the use of a protein supplement may be a more appropriate strategy to 
increase dietary protein intake and to encourage greater compliance, particularly over 
a longer period of time. 
 
2.8.2  Protein Supplements for the Management of Type 2 Diabetes 
Protein supplements can be broadly categorised according to their nutrient profile as 
providing protein as a single source protein or as a multi-ingredient supplement i.e. 
protein and carbohydrate. For example, whey protein derived from milk is one such 
example of a single source protein; others include casein, soy, pea or egg protein. Of 
all single source protein supplements available, whey protein has received the 
greatest amount of attention due to its high nutritional value as it contains all 
essential amino acids, it is rapidly absorbed compared to other sources of protein like 
casein, and has been shown to have positive effects on insulin secretion, lowering the 
postprandial glycaemic response and stimulating MPS (329, 330). The evidence 
available for these effects is discussed in greater detail below (329, 330). 
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Figure 2.3: Protein fractions and types of whey protein derived from whole milk. 
 
Whey proteins are derived from whole milk and are a by-product of cheese and curd 
manufacturing (Figure 2.3) (331). Several advancements in processing technology 
such as ultrafiltration, microfiltration, reverse osmosis and ion-exchange have 
resulted in development of several different whey products (331). These condensed 
products include whey concentrate, isolate and hydrolysate (332, 333). These 
condensed forms of whey protein preserve the favourable components such as the 
protein and amino acid content whilst reducing other components such as fat and 
lactose, Table 2.7 describes these various whey protein products (333, 334). Whey 
protein concentrate contains approximately 35-80% protein, with the remainder 
consisting of fat, lactose and minerals (331). Whey protein isolate contains 
approximately 85-90% protein and minimal fat or lactose (331). Both whey protein 
concentrate and isolate are manufactured from whey using ultrafiltration, spray 
drying and evaporation techniques (335). Whey protein hydrolysates are peptides 
derived from hydrolysing the proteins in whey in a process that includes their 
fermentation with proteolytic enzymes (336). Both whey protein isolate and 
hydrolysate are more expensive in comparison to whey protein concentrate, which is 
an important consideration should whey protein supplements be made commercially 
available as a nutritional approach for the management of T2DM.  
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Mortensen et al. (337) observed the first phase insulin response (assessed from AUC) 
to be greater after whey protein hydrolysate consumption in comparison to other 
types of whey protein including whey isolate and mixed whey products (whey 
protein plus alpha-lactalbumin and whey protein plus casein), when consumed with a 
high fat/carbohydrate meal. However, whey protein hydrolysates, have been found to 
be less palatable than whey concentrate or isolate, detracting from their potential 
therapeutic use (332). Further, the available data to date indicates that over the long-
term there is no convincing evidence that one form of whey protein can stimulate 
insulin secretion or has better glycaemia lowering effects than another (332). 
Therefore, whey protein concentrate which is more cost-effective for a consumer, 
combined with its enhanced palatability and beneficial health properties, is most 
commonly used. 
 
Table 2.7: Types of commercially available whey protein. Adapted from Marshall et 
al. (331). 
Product 
Description Protein Concentration 
Fat, Lactose and 
Mineral Content 
Whey Protein 
Concentrate 
Most commonly available as 80%. 
Can range from 25-89% 
Some fat, lactose, and 
minerals. As the protein 
concentration increases, 
fat, lactose, and mineral 
content decreases. 
Whey Protein 
Isolate 
90-95% Little if any 
Whey Protein 
Hydrolysate 
Variable hydrolysis used to cleave 
peptide bonds. Larger proteins 
become smaller peptide fractions. 
Reduces allergy potential of whey 
protein. 
Varies with protein 
concentration 
 
As mentioned above, whey protein supplements have received considerable attention 
largely because of their role in stimulating MPS which may help to preserve or 
increase muscle mass (338-340). Their use as a functional food in the management of 
chronic diseases including T2DM has also begun to receive considerable attention. A 
growing number of studies in adults with T2DM highlight that whey protein 
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supplementation can have insulinotropic and glycaemia lowering effects (341-343). 
Studies in healthy and/or overweight and obese adults have also demonstrated that 
whey protein can enhance thermogenesis, aid in satiety and reduce subsequent 
energy intake, which may be of value in supporting an energy deficit to facilitate 
weight loss (344-348). Whey protein is also a more robust stimulator of MPS and has 
been found to be more effective than other protein sources such as casein and soy 
(340, 349). Others have shown that whey protein can have beneficial effects on blood 
pressure, vascular function, inflammation, lipids and lipoproteins levels (333, 346, 
350). Collectively these findings indicate that whey protein may have an important 
role in managing weight, muscle mass and cardiovascular health in older adults and 
those with T2D, but the longer-term effects of whey protein in older adults with 
T2DM on these aforementioned outcomes has received less attention. The following 
section will provide an overview of the effects of whey protein on weight 
management, glycaemic control and insulin sensitivity, markers of inflammation, 
serum lipids and cholesterol and blood pressure in individuals with T2DM. Where 
possible this review only included studies or interventions that were conducted in 
older adults diagnosed with prediabetes or T2DM.  
 
2.8.2.1  Effect of Whey Protein on Weight and Fat Mass  
Long-term whey-protein supplementation in older overweight/obese adults has been 
associated with reductions in fat mass and total body weight (351-356). However, the 
findings from some of these studies are confounded as some included caloric 
restriction or included a low-fat dietary component (352). Nevertheless, in one 23-
week intervention trial in which 73 older overweight (mean BMI 31 kg/m2) adults 
followed an ad-libitum diet and were randomised to one of three supplements (whey 
protein or soy protein both containing 26 g/serve of protein or an isoenergetic 
carbohydrate supplement consumed twice daily – breakfast and lunch), Baer et al. 
(353) reported that those who consumed the whey protein supplement had a mean 
1.8 kg and 2.3 kg significantly lower total body weight and fat mass than the 
carbohydrate group at the completion of the study, respectively (both P<0.006) 
(353). Lean mass did not differ between groups (353). In contrast, a 12-week 
intervention in 45 middle-aged overweight (mean ± SD, BMI 32.1 ± 3.0 kg/m2) men 
who consumed either 65 g of whey protein (80% WPC) or 60 g of soy protein isolate 
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30-minutes prior to their largest meal of the day (midday-meal) found that there was 
also a greater reduction in total body weight (6.4 ± 1.1 kg versus 3.5 ± 0.3 kg, 
P=0.008) and percentage body fat (9.2 versus 3.1%, P<0.001) in the whey protein 
compared to soy group after 12-weeks (355). The differences in magnitude of 
reductions in weight and fat mass when comparing these two trials may have been 
due to the greater single bolus of protein consumed in the second study compared to 
the first or as will be discussed below the effects on satiety of the two different doses 
of protein. 
 
The mechanism(s) proposed for the greater reductions in body weight and fat mass 
from whey protein compared to soy protein (and other sources of protein) might be 
due to differential effects among protein sources on energy intake or body weight 
regulation (353). For instance, and drawing upon the two previous studies discussed 
above, the first study, unexpectedly observed a greater increase in serum grehlin 
levels, a hormone which serves as a hunger signal and has been found to strongly 
increase food intake (353, 357). This could explain the smaller reduction in body 
weight and fat mass compared to the second study where a significantly greater 
reduction in total calorie intake in the whey compared to soy protein groups was 
observed (355). Suggesting that the whey protein had a more profound effect on 
appetite suppression (355). Reductions in energy intake following whey protein 
supplementation have previously been observed (348, 358) and are believed to be 
associated with the ability of protein or amino acids to elevate peripheral 
concentrations of the anorexogenic hormones glucagon-like polypeptide-1 (GLP-1),  
and cholecystolinin (CCK), the satiety related gastrointestinal hormones (348, 354, 
359, 360). No studies have specifically examined the independent effects of whey 
protein on body composition in adults with T2DM. 
  
2.8.2.2  Effect of Whey Protein on Lean Mass  
With advancing age, rates of MPS in response to an anabolic stimulus such as 
physical activity and food consumption decline, which contribute to age-related 
losses in skeletal muscle mass (275, 361). It is well established that the balance 
between MPS and MPB largely determines any loss or gain in muscle mass. 
Maintenance or gains in muscle mass occur as a result of a net positive protein 
Chapter 2 
Page | 56 
	
balance, which is largely determined by consumption of an adequate dose of protein 
and/or exercise (361-363). There has been extensive research into determining the 
optimal type, dose, timing and distribution of protein intake for muscle health, and it 
appears that doses of whey protein <15 g are largely ineffective at stimulating MPS 
in older adults. In contrast, a number of acute studies have shown that doses of 20-40 
g of whey protein increases MPS compared to basal (51, 312, 339, 364). For 
instance, in a study of 33 healthy older men (mean age ± SD, 73 ± 2 years) who were 
randomised to receive either a 10, 20 or 35 g single bolus of whey protein, Pennings 
et al. (364) reported that consumption of a 20 and 35 g dose of whey protein resulted 
in the greatest increase in whole body MPS compared to the 10 g dose (P<0.01); 
there was no differences between the 20 and 35 g doses (364). Since a similar dose of 
whey protein has been found to provide an additive effect on the acute MPS response 
when older adults perform PRT, a dose of 20-40 g of high quality protein (e.g. whey) 
is likely to provide the greatest MPS benefits to older adults (51). The additive effect 
protein has on an acute MPS and over the longer-term on lean mass will be discussed 
in section 2.11. 
 
In addition to the dose of protein, the amino acid content of a protein bolus or 
supplement is integral to whether it is effective at eliciting an anabolic response (47, 
363). The MPS effects of whey protein are largely believed to be due to the high 
leucine (~10%) and other branched chain amino acid content along with its fast-
digestion rate (275, 365, 366). Leucine is reported to be the key regulator of muscle 
protein metabolism as it possesses the power to activate the mammalian target of 
rapamycin (mTOR) pathway which is necessary for cellular protein synthesis 
regulation (367, 368). Older adults appear to require a leucine dose of ~2-3 g to 
initiate MPS (361). This has been termed the ‘leucine threshold’ or ‘trigger’ point 
(39, 369). Importantly, leucine provided alone appears to be ineffective in promoting 
an anabolic muscle response whereas leucine co-ingested with other amino acids, as 
is the case in whey protein, enhances the postprandial MPS response (370). 
 
Randomised controlled trials which have investigated the long-term (>12-weeks) 
effects of whey protein supplementation alone on muscle outcomes in older adults 
have produced conflicting results (41, 371, 372). This may be explained by 
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differences in population groups (e.g. older adults, older obese middle-aged adults, 
elderly, sarcopenic) examined or differences in the methodological prescription of 
the whey supplement (as a pre-meal, pre-load or once or multiple times/day). For 
example, in a multi-centre 18-month RCT, 106 older adults (~70 years) were 
supplemented with 45 g/day of whey protein with another 102 older adults provided 
with a maltodextrin control supplement (41). Baseline protein intakes were self-
reported to be between 0.6 to 1.0 g/kg/day (41). Following the 18-month intervention 
a significant between-group difference was observed for the change in total body 
lean mass in favour of the whey protein supplemented group (0.33 kg, P<0.05) as 
assessed via DXA (41). However, two other studies investigating the effects of whey 
protein supplementation alone on muscle mass have failed to observe any beneficial 
effects (371, 372). In a two-year randomised, double-blind, placebo controlled trial, 
elderly post-menopausal women aged 70-80 years (mean 74.3 ± 2.7 years) were 
randomly assigned to either a daily high protein drink containing 30 g of whey 
protein (n=109) or a placebo drink containing only 2.1 g of whey protein (n=110) 
daily (371). At both 1- and 2-years follow-up there were no differences between the 
groups and no within-groups changes for total body or appendicular lean mass 
(ALM) (371). The authors proposed that the null effect was due to participants 
baseline protein intakes being quite high at 1.2 g/kg/day. This theory is supported by 
the results of another RCT where protein replete well-nourished older individuals 
(mean baseline protein intake >0.8 g/kg/day) experienced no gain in total body lean 
mass following whey protein supplementation (28 g) twice/day for 23-weeks (353). 
Based on this limited evidence, it appears that the effectiveness of a daily whey 
protein supplement to improve muscle mass or prevent loss in healthy older adults is 
limited and may depend on the existing habitual protein intake (371).  
 
The timing or spread of whey supplementation throughout the day combined with the 
habitual protein intake are also important considerations for maximising gains in lean 
mass in older adults. Indeed, there is emerging research that a more uniform pattern 
of protein consumption throughout the day (i.e. doses of ~20-30 g protein consumed 
at breakfast, lunch and dinner) may allow for greater optimisation of the postprandial 
MPS response translating to positive effects on lean mass (373-376). While the 
current evidence from long-term human intervention trials is limited, a study in 80 
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mobility-limited older adults (aged 70 to 85 years) randomised to consume two 
serves of 20 g of whey protein/day or an isocaloric control supplement whilst 
performing high-intensity PRT three times per week for 6-months found whey plus 
PRT increased lean mass by 1.3% and muscle cross-sectional area (CSA) by 4.6% 
compared to baseline (377). Whilst the magnitude of change in these muscle 
measures was greater than that observed in the control group (0.6% and 2.9%, 
respectively) there was no significant difference observed between the groups (377). 
Which was suggested to be due to changes in dietary protein intake from ad-libitum 
foods during the 6-months, as when taking into consideration the compliance with 
the supplement the increase in protein intake averaged only 18 g/day (377).  
 
In summary, there is consistent evidence showing that acute ingestion of whey 
protein and the essential amino acid leucine, particularly at a dose of 20-40 g (2-3 g 
leucine) are key factors in stimulating MPS in older adults. However, the findings 
from trials investigating the long-term effects of daily whey protein supplementation 
on lean mass remains mixed. Furthermore, there is little or no research into the long-
term effects of whey protein on body composition in older adults with T2DM.  
 
2.8.2.3  Effect of Whey Protein on Glycaemic and Insulinaemic Outcomes  
Nutritional strategies which effectively stimulate early phase and long-term insulin 
secretion in those with T2DM may serve to improve daily and long-term glycaemic 
control. Several acute studies and to a lesser extent longer-term intervention trials 
have shown that consumption of whey protein has a positive effect on improving 
insulin secretion, insulin sensitivity and postprandial glucose levels (52, 337, 341-
343, 351, 378, 379), but questions remain with regard to the optimal type and dose 
required. Further, the degree of improvement in these outcomes from the available 
literature is inconsistent, largely explained by methodological differences between 
the studies. For instance, of the studies conducted some have used different delivery 
methods (as a pre-load to a meal or as a stand-alone supplement), a wide range of 
whey protein doses (4.5 to 50g) and different forms of whey protein (concentrate, 
isolate, hydrolysate).  
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Whey protein consumed as a pre-load to a meal or consumed in conjunction with a 
meal is established to have an insulinotropic effect (52, 337, 343, 379). Whey protein 
has also been found to confer glucose-lowering effects in those with T2DM (379). 
For example, 15 individuals with well-controlled T2DM, consumed on two separate 
days either a whey protein drink (50 g mixed with 250mls of water) or placebo 
(250ml of water), followed by a standardised high glycaemic-index breakfast (379). 
The AUC in serum glucose immediately following breakfast (0-30 minutes) was 
significantly lower in the whey than placebo group (Figure 2.4) (379). Similarly 
spikes in plasma glucose levels were significantly lower during the 60- to 120-
minute period and for the overall measured period (154 ± 8.5 vs 213.6 ± 13.8 
mmol/L x min P=0.001) (379). Conversely, insulin levels were significantly higher 
during the postprandial early insulin release phase (0-30 minutes), remained higher 
and increased more rapidly in the whey group compared to the placebo pre-load for 
the entire post meal intervention as shown in Figure 2.4 (379). This study 
successfully demonstrated that a whey protein pre-load reduces both the peak and 
AUC for post meal glucose which was associated with a rapid and significantly 
enhanced early and late postprandial insulin response in adults with T2DM (379). 
Doses of whey protein ranging from 17 g to as high as 55 g have also been found to 
offer similar effects on glucose and insulin levels (52, 337, 343). Collectively these 
studies highlight that a pre-meal dose of protein may be optimal for those with 
T2DM to improve daily insulin and glucose parameters.  
 
 
Figure 2.4: The serum glucose and insulin responses to a high-glycaemic index 
breakfast meal following a whey protein (white circles) or placebo (black circles) 
pre-load in 15 participants with type 2 diabetes. Sourced from Jakubowicz et al. 
(379). Values are means ± SEM. *p<0.05 vs placebo for the same time point.  
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The acute insulinotropic properties of whey protein are believed to be due to the 
branched chain amino acids present in whey which exert direct effects on stimulating 
pancreatic beta-cells to produce insulin (53, 275). In addition, the amino acids and 
bioactive peptides present in whey may facilitate the rise of the incretin hormones 
gastric inhibitory peptide (GIP) and GLP-1, which both exert strong insulinotropic 
effects (380).  In fact, following a bolus of oral glucose, approximately two thirds of 
the plasma insulin response can be attributed to the effects of GIP and GLP-1 (332). 
The incretin hormone GLP-1 is also recognised to play a role in the management of 
postprandial glycaemia in adults with T2DM largely through its effects on slowing 
gastric emptying (380, 381). Delayed gastric emptying reduces postprandial 
glycaemic increases whereas rapid gastric emptying has the opposite effect (381). 
The results of acute studies demonstrating beneficial effects on both insulinaemic 
and glycaemic outcomes has led some researchers to propose that whey protein 
supplements should be considered as a long-term management strategy in adults with 
T2DM.  
 
At present, there is limited data from intervention trials with regard to the long-term 
effects of whey protein on insulin sensitivity and HbA1c in adults with T2DM (341). 
Seven older overweight/obese adults (mean age and BMI ± SEM, 60 ± 2 years and 
31 ± 2 kg/m2) were randomly assigned to consume a chocolate-flavoured whey 
protein pre-load (100 ml water with 25 g whey protein) or placebo (25 g chocolate-
flavoured ‘diet’ sauce), 30-minutes before each main meal for 4-weeks, followed by 
a 2-week washout, and then the alternative pre-load for 4-weeks (341). At the start 
and end of each treatment period participants were provided the meal pre-load 
following by a high glycaemic index breakfast meal with the glucose response 
measured for next 240 minutes (341). Following the 4-weeks of whey protein pre-
load, postprandial blood glucose was lower after whey compared to placebo (P<0.05) 
(341). However, HbA1c was not changed from baseline or different between the 
groups likely explained by the short intervention period. In overweight and obese 
adults, the effects of longer-term whey protein supplementation on insulin outcomes 
show some promise. For example, Pal et al. (351) investigated the effects of a twice 
daily whey protein supplement (27g of protein per drink) on insulin and glucose 
parameters in 89 overweight and obese women (BMI ± SEM, 31.3 ± 0.8 kg/m2) in 
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comparison to a supplement containing either casein (27g of protein per drink) or 
glucose control (27g of glucose per drink) over a period of 12-weeks (351). 
Participants were asked to consume these drinks 30-minutes prior to a breakfast and 
an evening meal (351). At the end of the 12-week period fasting plasma insulin 
levels and HOMA-IR were decreased by 11% and 10%, respectively, in the whey 
protein group compared with baseline (P=0.012 and P=0.046, respectively) which 
was significantly different from the change in the controls (between-group difference 
P=0.049 and P=0.034, respectively) (351). Fasting plasma glucose and HbA1c were 
not assessed. Importantly, the benefits were independent of changes in body 
composition (including visceral fat). However, further studies are required to 
determine why acute consumption of whey protein, as a pre-meal supplement, can 
have insulinotropic effects but in the long term can decrease plasma insulin levels yet 
improve insulin sensitivity (351). 
 
Despite the overwhelming evidence for the positive effects of whey protein on 
insulin and glucose levels in adults with T2DM in an acute setting, and some 
evidence for beneficial effects in the longer-term in overweight/obese adults, there 
remains no long-term intervention trials which have examined if these same benefits 
can be observed in adults with T2DM, with a clear need for these interventions to be 
performed. 
 
2.8.2.4  Effect of Whey Protein on Markers of Inflammation 
According to Hayes et al. (382) bioactive peptides from milk and present in whey 
protein which have an impact on the human body can be categorised into anti-
hypertensive, anti-thrombotic, anti-microbial and even immunomodulatory Further, 
whey has been identified to have anti-oxidant and potentially anti-inflammatory 
properties (383). Whilst limited evidence exists, a mechanism by which whey protein 
may positively alter anti-oxidant or anti-inflammatory levels includes inhibiting 
angiotensin-converting-enzyme activity (329, 384, 385). It has also been suggested 
that the peptides in whey along with specific proteins including α-lactalbumin may 
inhibit the production of several inflammatory cytokines including TNF-α and IL-6 
(386, 387).  
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To the best of my knowledge there are no studies which have examined whether 
whey protein is able to modify levels of circulating inflammatory markers in adults 
with T2DM. Of the studies conducted in healthy adults, only a few small studies 
have demonstrated an improvement in levels of inflammation (as assessed from hs-
CRP) following whey supplementation in an acute (388, 389) or chronic (one month) 
setting (390). For example, in a randomised, crossover trial, 11 obese non-diabetic 
subjects (aged: 40-68 years, BMI: 30.3-42.0 kg/m2) were provided a fat-rich mixed 
meal supplemented with 45 g of one of four proteins (cod, whey isolate, gluten or 
casein) with blood samples collected for 4-hours during the postprandial phase (388). 
Notably, a significant reduction in AUC of the inflammatory marker chemokine 
ligand 5 was observed following the whey protein supplemented meal when 
compared to the casein and the cod supplemented meal, but not the gluten meal 
(P<0.05 for both) (388). The inflammatory marker chemokine ligand 5 has been 
observed to be positively related to the development of T2DM, and has also been 
implicated in the onset and progression of atherosclerotic heart disease (388, 391). 
No significant differences between meals were observed for other inflammatory 
cytokines including adiponectin, macrophage inflammatory protein-1β, platelet-
derived growth factor and IL-1ra (388). Whilst providing some positive evidence for 
an anti-inflammatory effect of whey protein, this study was acute and only small in 
design and whilst participants were obese they were otherwise healthy.  
Studies which have used older adult populations or population groups with metabolic 
conditions also provide mixed evidence for the effects of whey protein on 
inflammation. Only four small RCTs have examined the effects of whey protein on 
inflammation in older adults, with considerable variation among the populations 
studied making conclusions difficult (one in healthy active older adults, two with 
stable chronic obstructive disorder and one recruited hospitalised stroke patients) 
(386, 392-394). Of these four studies, two demonstrated a favourable effect of whey 
protein on various markers of inflammation (e.g. hs-CRP, IL-6, IL-8, and TNF-α) 
(386, 392), whereas the other two observed no benefit (393, 394). Studies among 
adults with obesity or other metabolic conditions have mostly reached the same 
conclusion, that is, whey protein intake was not associated with a decrease in serum 
hs-CRP levels in individuals with obesity (285, 384), hypertension (395) and even 
metabolic syndrome (396). The reasons for this lack of effect may have related to a 
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range of factors, including limited follow-up periods, small sample sizes or even the 
composition of the whey supplements provided to the intervention groups (397).  
 
A recent meta-analysis including nine RCTs in adults aged 48 to 77 years ranging 
from four to 36-weeks and sample sizes of 20 to 190 investigated the inflammatory 
mediating effects of whey protein (326). Of these nine trials, six were conducted in 
adults with prehypertension, mild hypertension, chronic obstructive pulmonary 
disease or metabolic syndrome (326). Whilst there was considerable heterogeneity in 
the design of these trials and the dose of whey protein prescribed (doses ranged from 
0.7 to 60 g/day), the meta-analysis concluded that there was not enough evidence to 
support the hypothesis of an active modulation of inflammation by whey protein in 
adults (326). However, sub-group analysis in those who presented at baseline with 
serum levels of hs-CRP ≥ 3 mg/L, which is often reported in adults with T2DM 
(398), found that whey protein had a small yet non-significant effect in reducing hs-
CRP (326). Whether long-term whey protein supplementation can reduce markers of 
inflammation in older adults with T2DM, particularly in the presence of increased 
inflammation, remains to be determined.  
 
2.8.2.5  Effect of Whey Protein on Serum Lipids and Blood Pressure 
Human and animal models suggest that whey protein may favourably alter serum 
lipids and cholesterol and improve blood pressure (319, 384, 399-402). Biologically 
plausible mechanisms by which whey protein may improve these measures include 
the promotion of hepatic lipid metabolism, inhibiting the absorption of fatty acids 
and cholesterol in the intestine and increasing the excretion of faecal sterol (403). 
Evidence from in vitro studies demonstrates the bioactive peptides found in whey 
protein are effectively able to inhibit enzymatic angiotensin converting enzyme 
(ACE) activity (404), which is a rate limiting step in the conversion of angiotensin I 
to angiotensin II and is responsible for vasoconstriction therefore playing a role in 
hypertension (405).  
 
There is limited evidence for the independent effects of acute or chronic whey 
protein supplementation on blood pressure with no studies conducted in adults with 
T2DM. However, studies in young normotensive and hypertensive overweight adults 
Chapter 2 
Page | 64 
	
have investigated such effects over acute (385) and chronic settings (351, 406) with 
conflicting results. For example, 12-weeks of whey protein supplementation (27 g 
twice/day) in 70 overweight (BMI ± SEM, 31.3 ± 0.8 kg/m2, mean age ± SEM 48 ± 
1.9 years), normal and hypertensive men and women improved blood pressure when 
compared to a baseline (SBP; 119.3 ± 3.2 mmHg vs 114.5 ± 3.1 mmHg; P=0.020 and 
DBP; 64.1 ± 1.9 mmHg vs 62.0 ± 1.7 mm Hg; P = 0.038) (384). Compared to 
controls there was a greater reduction in DBP at 12-weeks (384). In contrast, in 
young (~20 years of age) men and women 28 g/day of either hydrolysed or non-
hydrolysed whey protein over 6-weeks had no effect on SBP or DBP (406). 
However, when subgroup analyses were performed in those with elevated SBP (≥120 
mmHg) and DBP (≥ 80 mmHg) it was found that whey protein supplementation 
significantly reduced SBP and DBP by 8.0 and 8.6 mmHg respectively in 
comparison to baseline (P<0.001) (406). In summary, the current body of evidence, 
although limited, suggests that whey protein supplementation may have a positive 
effect on blood pressure in non-diabetic adults, but further trials are needed in adults 
with T2DM and there is a need to determine if there is an optimal type and dose of 
whey protein that is most effective.  
 
The health benefits of acute and longer-term whey protein ingestion may also extend 
to lowering blood lipids levels yet few studies in overweight/obese older adults or 
those with T2DM have investigated this with inconsistent results (351, 378). To my 
knowledge, only one acute study has been conducted in adults with T2DM (378). In 
this study, 12 men and women with T2DM (mean ± SD, age 64.6 ± 3.3 years and 
BMI 28.9 ± 3.7 kg/m2) were randomised to receive a high-fat meal supplemented 
with either 45g of whey, casein, cod or gluten protein (378). For 6-hours following 
the ingestion of the meals it was observed that the AUC of plasma triglycerides were 
significantly lower in the whey supplemented meal when compared to the three other 
meals (mean ± SD, whey, 205 ± 86 mmol/L vs casein, 282 ± 132 mmol/L; cod, 296 
± 11 mmol/L; gluten, 299 ± 75 mmol/L all P<0.05) (378). There are several factors 
which control the circulating concentrations of triglycerides including intestinal 
chylomicron secretion, hepatic very low density cholesterol secretion, conversion of 
triglyceride-rich lipoproteins to triglyceride-depleted lipoproteins, and tissue uptake 
of triglyceride-depleted lipoproteins, all of which may have influenced the 
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postprandial triglyceride response (407). Whilst this study was only conducted in a 
very small number of adults (n=12) with T2DM, importantly, the findings align with 
the results observed in a study of 89 overweight and obese individuals (385). In this 
other study, 89 overweight and obese adults (mean BMI 31.3 kg/m2) to 12-weeks of 
whey, casein or glucose supplementation (351). Following the 12-week intervention 
fasting triacylglycerol levels were significantly lower in those receiving the whey 
compared with the control supplement (P=0.035) (351). There was also a 
significantly greater reduction in total cholesterol in the whey group when compared 
to both the casein and control groups (P<0.05 for both) (351). Whilst chronic effects 
of whey protein supplementation in adults with T2DM remain unexamined, the 
authors of this study highlighted that most participants displayed at least one or two 
metabolic syndrome risk factors at baseline (351).  
 
In summary, the effects of whey protein supplementation on blood pressure in 
normotensive and overweight/obese adults appears favourable, however, no studies 
have been conducted in adults with T2DM. Acute studies also support improved 
triglyceride levels in adults with T2DM following whey supplementation, although 
no chronic studies have been conducted. Given these findings and the proposed 
mechanisms by which whey protein may improve blood pressure, serum lipids and 
cholesterol, further long-term trials with different types and doses of whey protein 
supplementation in adults with T2DM are warranted to determine the efficacy of 
such a nutritional approach.  
  
2.9  Vitamin D 
While vitamin D is widely recognised for its importance in bone and mineral 
metabolism, over the past two decades there has been considerable interest in the role 
that vitamin D may play in several extra-skeletal health outcomes, including T2DM 
(408). The renewed interest stems from the discovery that most body tissues and 
cells possess vitamin D receptors (VDR) and the required enzymes to convert the 
primary circulating form of vitamin D [25-hydroxyvitamin D (25(OH)D)], to the 
active form 1,25-dihydroxy vitamin D (408). Vitamin D is a fat-soluble vitamin that 
exists in two major forms. Vitamin D2 or ergocalciferol, which is available from 
plant based foods such as mushrooms, and vitamin D3, or cholecalciferol, which is 
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produced endogenously following exposure of the skin to ultraviolet light (sun 
exposure) and is present in small amounts in certain foods (salmon, tuna, mackerel 
and fish liver oils) and in some fortified products and supplements (409). Previously 
it was thought there was an age-related decline in some of steps of vitamin D 
metabolism (410, 411). However, it has been subsequently shown that intestinal 
absorption of vitamin D does not decrease with advancing age (412, 413). 
Nevertheless, vitamin D obtained from the sun or consumed through food must 
undergo two hydroxylation reactions to become active as discussed below and shown 
in Figure 2.5. Below is a discussion of the most recent evidence investigating the 
potential health benefits of vitamin D supplementation on glycaemic control, insulin 
sensitivity, muscle health, serum lipids and blood pressure in adults with T2DM. 
Prior to that a brief overview of the metabolism of vitamin D and the current 
recommended serum targets is provided.  
 
2.9.1  Metabolism of Vitamin D 
Vitamin D3 (cholecalciferol) is synthesised in the skin from 7-dehydrocholesterol by 
ultraviolet irradiation, the subsequent production of vitamin D is dependent on the 
intensity of UV irradiation which varies with season and latitude (414). 
Cholecalciferol obtained from the sun or directly from food is then metabolised in 
the liver to 25(OH)D by the enzyme vitamin D-25-hydroxylase to produce 25-
hydroxyvitamin D, the major circulating concentrations of vitamin D that serve as 
the primary biomarker of vitamin D status (408). This metabolising step is not 
enough to produce the biologically active vitamin D, and thus in the kidneys 
25(OH)D undergoes further metabolism by the enzyme 1,25-dihydroxyvitamin D-
1α-hydroxylase also called 1-OHase (CYP27B1) producing 1,25-dihydroxyvitamin 
D (1,25(OH)2D), which is the biologically active hormone (also called calcitriol) 
(408). Even though the kidney is the primary site of CYP27B1 expression, several 
other tissues also express this enzyme including the epithelial cells in the skin, lungs, 
breast, intestine, prostate and endocrine glands including the parathyroid gland, 
pancreatic islet cells, thyroid, ovary, placenta and some cells of the immune system 
including macrophages. However, the contribution of these tissues to calcitriol 
formation is yet unknown (415). The renal production of 1,25(OH)2D is tightly 
controlled primarily by two hormones, one which up-regulates calcitriol production 
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(parathyroid hormone (PTH)), and another which down regulates production via 
fibroblast-like growth factor (FGF23). Calcitriol, following synthesis in the kidneys, 
binds to vitamin D binding protein where it is transported to target organs and exerts 
its actions (408). Calcitriol increases the expression of the enzyme 25-
hydroxyvitamin D-24- hydroxylase (24-OHase) to catabolise 1,25(OH)2D to 
calcitroic acid, a biologically inactive water soluble compound which is excreted in 
bile (408). A summary of this process is provided below in Figure 2.5. 
 
 
Figure 2.5: Metabolism of vitamin D from the sun and dietary sources. Adapted 
from Holick. (408). Enzymes for the relevant metabolic conversions are written in 
italic text. The dotted arrow line reflects the two hormones which are responsible for 
controlling the renal production of 1,25(OH)2D. 
 
2.9.2  Recommended Serum 25(OH)D Levels  
Currently there is ongoing debate globally as to the optimal serum 25(OH)D 
concentrations for health benefits, particularly for older adults. Position statements 
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released by the Endocrine Society of Australia, Osteoporosis Australia and the 
Working Group of the Australian and New Zealand Bone and Mineral Society and 
the Institute of Medicine (IOM) proposed that serum 25(OH)D concentrations >50 to 
60 nmol/L year-round should be considered adequate/sufficient (Table 2.8) (416, 
417). In contrast, the International Osteoporosis Foundation (IOF) and the 
Endocrine Society Guidelines suggest a proposed a cut-off of >75 nmol/L be used to 
define vitamin D sufficiency (418, 419). The main difference between these 
guidelines relates to the population groups of reference; the IOM guidelines relate to 
the general population whereas the Endocrine Society guidelines are targeted 
towards a clinical population (420). While it is beyond the scope of this thesis to 
debate the relative merits of whether 50 or 75 nmol/L should be considered 
sufficient, for this thesis the Australian/IOM criteria will be adopted. It is important 
to note however, that such reference guidelines are recommended based on 
effectiveness of calcium absorption and bone metabolism and that such levels may or 
may not also translate to beneficial effects on non-skeletal outcomes.  
 
Table 2.8: Recommended serum vitamin D targets and classes of deficiency as 
recommended by the IOM (416). 
Serum Vitamin D Classification Serum Vitamin D Target Range 
Adequate/Sufficient ≥ 50-60 nmol/L at the end of winter 
Mild Deficiency 30–49 nmol/L 
Moderate Deficiency 12.5–29 nmol/L 
Severe Deficiency < 12.5 nmol/L 
1 nmol/L = 0.4 ng/mL 
 
2.9.3  Vitamin D and Type 2 Diabetes: Proposed Mechanisms of Action 
Whilst poorly understood, low serum 25(OH)D status is thought to play a role in the 
diminishment of normal glucose metabolism due to the presence of the vitamin D 
receptor (VDR) in all tissues receptive to insulin, including skeletal muscle, adipose 
tissue and pancreatic beta-cells (Figure 2.6) (421). Mechanistically, the active form 
of vitamin D (1,25(OH)2D) can bind directly to VDR in beta-cells, and stimulates the 
expression of insulin receptors and promotes insulin-mediated glucose transport via 
the translocation of GLUT4 proteins to the cell surface of insulin receptive tissues 
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(Figure 2.6) (422). It has also been shown that 1a-hydroxylase, the key enzyme 
regulating the conversion of 25(OH)D to 1,25(OH)2D, is expressed in pancreatic 
beta-cells which further supports a role for vitamin D in regulating blood glucose 
levels (423). Several other potential mechanisms may also explain the link between 
vitamin D and T2DM, including regulation of calcium homeostasis and inflammation 
(22). Vitamin D deficiency can alter circulating calcium levels and affect calcium 
influx to beta-cells (22). Calcium is a crucial ion in insulin secretion and action, with 
large deviations in calcium concentration (hypo- or hypercalcemia) known to impair 
the proper function of pancreatic beta-cells and alter insulin sensitivity of target 
tissues (22, 421). Further, vitamin D may regulate inflammation as 1,25(OH)2D 
decreases the production of inflammatory cytokines, which is important as increased 
inflammation can impair both beta-cell function and insulin sensitivity (22, 421, 422, 
424). However, the role of vitamin D and its ability to modulate inflammation related 
to T2DM or other chronic diseases remains to be confirmed with some studies 
observing effects to the contrary (425). 
 
 
 
Figure 2.6: Proposed role of vitamin D in the pathophysiology of type 2 diabetes  
Type 2 diabetes is characterised by increased insulin resistance followed by beta-cell 
dysfunction. Consequential to this, insulin is no longer able to block lipolysis in fat 
tissue, glucose production in the liver or able to stimulate glucose absorption in the 
muscle. Biologically active vitamin D, 1,25(OH)2D (shown as Vitamin D) may reduce 
beta-cell dysfunction by restoring insulin production/secretion, thereby reducing insulin 
resistance and improve glucose uptake in the muscle. Additionally, vitamin D may also 
lessen inflammation in the pancreas by reducing inflammatory cytokine production. The 
negative effects of vitamin D deficiency are depicted with the red arrows. 
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2.10   Vitamin D Supplementation for the Management of Type 2 Diabetes 
2.10.1  Effect of Vitamin D on Glycaemic and Insulinaemic Outcomes  
Several prospective epidemiological studies have demonstrated an association 
between serum 25(OH)D concentrations and the incidence of T2DM (22, 61, 174, 
426, 427). For example, data from the 5-year prospective AusDiab study involving 
>5,000 adults aged ~51 years (199 incident cases of diabetes were diagnosed) 
showed that a median 25(OH)D level of 70 nmol/L at baseline was associated with a 
57% reduced risk of developing T2DM (61). Low serum 25(OH)D levels have also 
been associated with impaired insulin sensitivity and reduced beta-cell function 
(428). Direct evidence from RCTs examining the effects of vitamin D 
supplementation on insulin sensitivity and glycaemic control in those with T2DM is 
continuing to expand yet the studies completed to date remain inconclusive (71, 429-
433). Much of this heterogeneity is likely due to the methodological differences in 
terms of the dose of vitamin D prescribed, the baseline serum 25(OH)D level and the 
population group examined (e.g. normoglycaemic, IGT or diagnosed with T2DM).  
 
While it is beyond the scope of this review to examine all the intervention studies 
conducted on this topic, data from the most recent systematic review and meta-
analysis is provided. This systematic review and meta-analysis included 23 RCTs 
representing 1,797 adults with T2DM with interventions ranging from 4-weeks to 
12-months and doses of vitamin D from 400 IU/day to 300,000 IU as a single dose 
over 3-months (434). The overall finding from this systematic review was that 
supplemental vitamin D had no significant effect on any parameters of glycaemic 
control or insulin outcomes (HbA1c, fasting glucose or HOMA-IR) in patients with 
T2DM (434). Furthermore, they found that the results remained unchanged when 
separating the studies into those sufficient or deficient in vitamin D at baseline (434). 
A number of reasons may explain the findings, including the short duration of some 
of the interventions, the lack of an appropriate vitamin D dosage or change in serum 
25(OH)D levels, the lack of a control comparison group and baseline 25(OH)D 
levels (434, 435). Interestingly, one 12-week RCT in adults with T2DM reported 
small but significant beneficial effects of high dose (50,000 IU weekly) vitamin D 
supplementation on glycaemic parameters, even in those with sufficient (>50 
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nmol/L) baseline serum 25(OH)D levels (436). Similarly, another 6-month trial in 54 
adults with T2DM found that treatment with 300,000 IU vitamin D3 intramuscularly 
improved insulin sensitivity and HbA1c (437). Despite these positive finding, others 
have reported no benefits of high dose supplementation on glycaemic control (438). 
It is evident from the available data that further work in this area is required to 
elucidate whether supplementation with vitamin D in adults with T2DM serves as an 
appropriate strategy to improve glycaemic and/or insulinaemic outcomes.  
 
2.10.2  Effect of Vitamin D on Body Composition  
There is some evidence that low serum vitamin D concentrations (<50 nmol/L) are 
associated with increased adiposity (439, 440) and reduced lean mass in older adults 
and those with T2DM (441, 442). Numerous hypotheses have been proposed to 
explain how inadequate vitamin D status may influence fat mass or vice versa, and 
include sequestration of vitamin D to adipose tissue, and/or that overweight/obese 
adults are inactive and thus less likely to perform outdoor activities (443). Another 
proposed mechanism is that higher intakes of vitamin D can repress fatty acid 
synthase enzyme activity by decreasing intracellular Ca2+ in adipocytes (444, 445). 
Proposed mechanisms which explain the relationship of vitamin D supplementation 
with improvements in skeletal muscle mass, strength and function may be through 
calcium handling and signalling and accumulation in the sarcoplasmic reticulum 
(influencing the involvement of calcium in muscle contraction) or through the 
activation of vitamin D receptors found in the cell nuclei of muscle cells (446-450).  
 
At present, the available evidence from RCTs investigating the effects of vitamin D 
supplementation on change in fat mass in middle-aged to older adults have largely 
been equivocal (177, 451-453). For example, Salehpour et al. (452) successfully 
demonstrated that 42 middle-aged overweight/obese women (mean ± SD, age 38 ± 
8.1 years, BMI 29.8 ± 4.1 kg/m2) with low serum 25(OH)D levels (<40 nmol/L) 
supplemented with 1,000 IU/day of vitamin D for 12-weeks experienced a greater 
reduction in fat mass compared a placebo control group (mean change -2.7±2.1 vs -
0.5 ± 2.1 kg; P<0.001). In contrast, a study in overweight men and women (mean age 
49 years) with 25(OH)D levels <30 nmol/L who were randomised to receive 3,320 
IU/day of vitamin D3 (n=82) or a placebo (n=83) and participated in a healthy 
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weight-reduction program for 12-months showed that there was no difference for the 
change in weight between the groups (mean ± SD change: vitamin D -5.7 ± 5.8 kg vs 
placebo -6.4 ± 5.6 kg)] (177). The authors suggested that the lack of an effect of 
vitamin D treatment in this study may have been confounded by a greater reduction 
and subsequent lower intake in total energy, carbohydrate, protein and fat intake in 
the placebo group as opposed to the vitamin D group (177). Nevertheless, these 
findings are in accordance with a recent systematic review and meta-analysis which 
found that supplementation with vitamin D had no effect on adiposity measures, 
including fat mass and BMI, in adults aged 60 years from 26 RCTs including 42,430 
participants with vitamin D doses ranging from 400 IU to 12,695 IU/day and with a 
mean follow-up of 12-months (454).  
 
In older adults with T2DM, there are also mixed findings from intervention trials 
with regard to the effect of vitamin D supplementation (or vitamin D plus calcium) 
on fat mass (455, 456). In one 12-week RCT, 118 older adults with serum 25(OH)D 
levels <75 nmol/L and diagnosed with T2DM were randomly assigned to one of four 
groups (1) 50,000 IU per week of vitamin D plus a calcium placebo; (2) 1000 mg per 
day calcium plus vitamin D placebo; (3) 50,000 IU per week vitamin D plus 1,000 
mg of calcium/day; or (4) vitamin D placebo plus calcium placebo (456). Participants 
in the vitamin D plus calcium group had a greater reduction in BMI (mean ± SD -
0.17 ± 0.12 kg/m2) when compared to all other groups (P=0.03), which was 
attributed to reductions in waist circumference (mean ± SD, -0.83 ± 0.44 cm) (456). 
These same improvements were not observed in the vitamin D and placebo group, 
suggesting improvements in these outcomes may have been related to the additional 
calcium (456). Few other studies have examined if vitamin D can alter measures of 
fat mass in older adults with T2DM, and largely these studies fail to corroborate the 
positive findings reported above (457, 458). In summary, given the limited studies 
available, the marked heterogeneity in populations studied (ethnicity, age, 
geographical location), differences in the duration of interventions and the dose of 
supplemental vitamin D prescribed, it remains uncertain as to whether vitamin D 
supplementation can improve fat mass in older adults with T2DM.  
Several recent trials have investigated the effects of vitamin D supplementation on 
lean mass with doses of vitamin D ranging from 800 IU/day to a mega-dose of 
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50,000 IU in healthy older adults or those with T2DM (453, 459-461). These recent 
trials found there was no effect found of vitamin D supplementation on lean mass 
outcomes (453, 459-461). Consistent with these trials a systematic review and meta-
analysis of 30 RCTs with 5,615 participants (mean aged 61 years) and 
supplementation periods ranging from 1-month to 5.5 years with vitamin D doses 
ranging from 400 IU/day up to ~3,500 IU/day, found no evidence for a beneficial 
effect on lean mass (462). 
 
In summary, intervention trials which have examined the effects of vitamin D 
supplementation on measures of fat and lean mass in older adults with T2DM or 
overweight/obese adults show very little support for any improvement on such 
outcomes. It is possible that the results of these trials are confounded by aspects of 
trial designs including the dose of vitamin D provided, the baseline serum 25(OH)D 
level of participants plus differences in the length of interventions and other 
micronutrients provided at the same time (i.e. calcium). It is also possible that the 
paucity of trials in this area, the great degree of heterogeneity in studies conducted to 
date and participants changes in energy intake during these interventions explains the 
lack of effect observed. It is evident that further research in this area is required.  
 
2.10.3  Effect of Vitamin D on Markers of Inflammation 
There is some evidence that supplementation with vitamin D may mediate and 
attenuate inflammation as seen in in vivo, in vitro and in animal studies (463-465). 
Indeed, the findings from predominantly in vitro studies, has expanded our 
understanding of the mechanisms by which vitamin D may alter cytokine production 
and although not conclusive, there is some suggestion that the coupling of 
1,25(OH)2D to vitamin D receptors located in several immune cells including 
monocytes, macrophages, T-cells and beta-cells, reduces the production of 
inflammatory cytokines including TNF-α, IL-6, IL-12 and IL-23 while increasing the 
production of various anti-inflammatory cytokine such as IL-1 and IL-4 (466). As a 
result, considerable interest exists in investigating if treatment with vitamin D exerts 
anti-inflammatory effects in humans.  
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In adults without T2DM, a recent systematic review and meta-analysis found no 
association between vitamin D supplementation and improved inflammatory 
biomarkers (467), however, evidence from prospective studies suggests there may be 
a role for vitamin D in ameliorating systemic inflammation in high risk groups with 
various chronic diseases, including T2DM (468). However, intervention studies 
which have investigated the effects of vitamin D supplementation on various 
circulating inflammatory markers in those with T2DM remain largely negative (463, 
464, 469, 470). One 16-week trial which randomised 64 older adults (mean age 
53.5 ± 9.5 years) with T2DM who had 25(OH)D levels <50 nmol/L to 4,000 or 2,000 
IU of vitamin D (depending on baseline serum 25(OH)D status) or placebo found 
that there were no changes in hs-CRP (463). Similarly, the findings from another 12-
week RCT in 100 adults with T2DM observed no change in hs-CRP following 12-
weeks of 5,000 IU of vitamin D compared to placebo (471). A limitation of both 
studies was the measurement of only a single inflammatory marker (463, 471). In 
another 12-week trial in older adults (mean age >55 years) with T2DM who were 
supplemented with vitamin D (11,200 IU daily for 2-weeks followed by 5,600 IU 
daily for 10-weeks), Kampmann et al. (469) failed to observe any significant within 
group changes or between group differences in hs-CRP, IL-6, IL-10 or TNF-α in 
comparison to placebo (469). Collectively, these findings indicate that vitamin D 
supplementation has little effect on various inflammatory biomarkers, but it is 
important to note that from the available studies there is considerable heterogeneity 
in the dose of vitamin D provided, the starting level and change in serum 25(OH)D 
concentrations.  
 
There is some evidence that the combination of vitamin D and calcium 
supplementation may be associated with improvements in inflammation (472). In an 
8-week RCT in 118 adults (mean age 51.2 years) with T2DM who were randomised 
to receive placebo, calcium (1,000 mg calcium carbonate), vitamin D (50,000 
IU/week) or calcium plus vitamin D supplements (50,000 IU vitamin D per week 
plus 1,000 mg calcium carbonate/day) for 8-weeks, Tabesh et al. (472) found that 
those who received both vitamin D and calcium plus vitamin D supplements 
experienced significant reductions in serum IL-6, TNF-α and leptin, compared to 
placebo (472). Whilst significant reductions in markers of inflammation were also 
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seen with calcium supplementation alone, all observed reductions in the vitamin D 
alone group were of greater magnitude, except for leptin, where no difference 
between-groups was observed (472). The reason for the positive finding in this study 
compared to previous trials is difficult to explain, but the authors noted that this 
study was conducted during summer where endogenous production of vitamin D 
may have increased the total amount of vitamin D received during this period. 
Furthermore, compliance with the supplements was excellent (almost 100%) (472). 
Studies in adults with T2DM which have used vitamin D fortified food products such 
as milk and yogurt have also observed improvements in various inflammatory 
markers, including hs-CRP, IL-6, IL-1 and adiponectin (473, 474). Despite these 
positive findings, it remains unknown whether it is the vitamin D alone or the 
combination of vitamin D with other ingredients in the food which is responsible for 
the beneficial effect.  
 
In summary, there are mixed findings regarding the sole effects of vitamin D 
treatment on markers of inflammation in adults with T2DM. To date, most studies 
have typically been of short duration with considerable heterogeneity in the 
population groups examined as well as the dose of vitamin D used. Of the studies 
which have found a favourable effect most have co-supplemented with calcium or 
used fortified-food products making it difficult to determine the independent benefits 
of vitamin D. As such, high-quality RCTs with large numbers of participants over an 
extended period are still required to investigate if vitamin D supplementation confers 
a positive effect on markers of systemic inflammation in this population group. 
 
2.10.4  Effect of Vitamin D on Serum Lipids and Blood Pressure 
Several cross-sectional and prospective studies propose an association between 
serum 25(OH)D, hypertension and dyslipidaemia (408, 475-477). For example, in a 
meta-analysis of 18 studies (4 prospective and 14 cross-sectional), every 40 nmol/L 
increase in serum 25(OH)D levels was associated with a 16% reduced risk of 
hypertension, However, most studies included in this meta-analysis had a cross-
sectional design, which cannot exclude the possibility of reverse causality (477). 
Nevertheless, these observations are supported by the potential biological 
mechanisms by which vitamin D may affect blood pressure and the suppressive 
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effects it can exert on the renin-angiotensin-aldosterone system (RAAS) (478). The 
RAAS is a key regulator of blood pressure via its regulation of renin activity (478). 
Renin cleaves angiotensin I to angiotensin II and once bound to the receptor it exerts 
regulatory effects on blood pressure (478). Activation or stimulation of RAAS is 
established to proceed the development of hypertension, therefore the suppression of 
RAAS by vitamin D may lower blood pressure (478). Others suggest the presence of 
vitamin D receptors on the endothelium may be play a role in the anti-hypertensive 
effects of vitamin D (479). Improvements in serum lipid profiles with vitamin D may 
be due to increases in calcium absorption which reduces triglyceride formation or 
secretion (480-482). Other potential mechanisms include mediation of parathyroid 
hormone levels which are known to suppress lipolysis (482). Despite these proposed 
yet unconfirmed mechanisms, results of intervention trials examining the effects of 
vitamin D supplementation on lipid profiles and blood pressure are contradicting in 
those with T2DM which will be discussed below.  
 
At present, there are mixed findings with regard to the effects of vitamin D 
supplementation on blood lipids in adults with T2DM. A recent meta-analysis which 
included 17 RCTs ranging from eight to 48-weeks and a total 1,365 participants 
aimed to assess the effects of supplemental vitamin D on serum triglyceride and 
cholesterol levels in adults with T2DM (483). While there was trend towards vitamin 
D treatment reducing triglyceride levels in those with serum 25(OH)D levels <50 
nmol/L at baseline (P=0.089), there was no effect in those with basal serum 
25(OH)D levels between 50 and 75 nmol/L (P=0.631) (483). Other factors which 
may influence the effects of vitamin D supplementation on lipid outcomes is the dose 
prescribed and the duration of the intervention. In the meta-analysis above, it was 
found that doses less than 2,000 IU/day for a minimum of 12-weeks were 
significantly associated with improvements in triglycerides and total cholesterol, but 
not HDL or LDL cholesterol (483). Interestingly, doses greater than 2,000 IU/day of 
vitamin D were not associated with any such improvements (483). The reason for 
these contrasting results remains uncertain, but could relate to differences in 
dyslipidaemia management and the delivery of vitamin D in such studies i.e. fortified 
food products or tablet forms (483). In terms of the duration of the intervention, the 
same meta-analysis reported that only interventions less than 12-weeks were 
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associated with significant improvements in LDL cholesterol; there were no 
significant effects of duration on triglycerides or total cholesterol (483). In contrast, 
it was found that interventions less than 12-weeks had a negative effect on HDL 
cholesterol, although interventions longer than 12-weeks were not significantly 
associated with improvements in HDL cholesterol either (483). While the findings 
from this meta-analysis suggest that vitamin D treatment may help to improve the 
lipid profile of adults with T2DM, it is clear that further long-term trials are needed 
to confirm such an effect. 
 
A recent systematic review and meta-analysis which evaluated the effects of 
micronutrients, specifically vitamin D supplementation, on blood pressure in adults 
with T2DM found vitamin D to be effective at reducing both SBP and DBP (484). 
Pooling data from seven interventions in 542 older adults with T2DM aged 50 to 66 
years led to a significant reduction of 4.6 mmHg in SBP (95% CI, −7.65, −1.47, 
P=0.004) and a reduction in DBP of 2.44 mmHg (95% CI, −3.49, −1.39, P < 0.001) 
(484). The authors of this systematic review and meta-analysis however, pointed out 
that these findings should be interpreted with caution given the small number of trials 
included and that another recent systematic review found no effect of vitamin D 
supplementation on SBP in older adults with T2DM when including 15 studies and 
1,134 participants with T2DM. As such, the evidence of vitamin D supplementation 
on blood pressure in older adults with T2DM appears to be mixed depending on the 
trials examined and the differences in population groups and study design (e.g. 
baseline serum 25(OH)D level variation, varying sun exposure and different dosing 
regimens) with further trials required.  
 
In summary, there are biologically plausible mechanisms by which vitamin D 
supplementation may improve plasma lipids and blood pressure, and along with an 
expanding body of evidence from RCTs and meta-analyses vitamin D 
supplementation may be important for improving SBP and DBP, triglycerides, total 
and LDL cholesterol in older adults with T2DM. Whether there is an optimal dose 
and/or achieved serum 25(OH)D level to improve these measures remains unknown. 
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2.11  Exercise, Protein and Vitamin D for the Management of Type 2 Diabetes 
As discussed above, there is evidence that PRT, whey protein and vitamin D each 
may have a beneficial effect on glycaemic control, body composition and 
cardiovascular risk factors in older adults with T2DM. In recent years, there has been 
interest in whether combining PRT with various nutritional factors may provide 
additive or synergistic health benefits in older adults and those with T2DM. The 
following section will provide an overview of the evidence regarding the combined 
effects of exercise and nutritional supplementation, with a focus on protein and/or 
vitamin D supplementation, on body composition, glycaemic control, insulin 
sensitivity/resistance, and cardiovascular risk factors including serum lipids, 
inflammation and blood pressure, in older adults and/or those with chronic diseases, 
including T2DM. 
 
2.11.1  Effects of Exercise and Protein or Exercise and Vitamin D on Lean Mass 
Over the past two decades, there has been a growing number of RCTs which have 
investigated whether PRT or multi-modal exercise programs combined with 
additional protein can produce added benefits on muscle compared to PRT alone in 
healthy older adults. As a result, there have been at least three meta-analyses and 
systematic reviews on this topic (485-487). These three meta-analyses and systematic 
reviews demonstrate the literature in this area is currently inconclusive with 
inconsistent findings, which could be due to different trial inclusion criteria used in 
these meta-analyses. For example, Cermak et al. (486) classified older adults as >50 
years and included 22 RCTs and 680 participants, whereas Finger et al. (485) 
selected a cut point of >60 years and included six RCTs with 334 adults. In the most 
recent meta-analysis, Thomas et al. (487) chose >70 years to reflect an elderly 
population and included 15 RCTs and 917 participants. The first two listed 
systematic reviews reported that increased dietary protein or protein supplementation 
enhanced the effects of PRT on fat-free mass [(0.69 kg (95% CI, 0.47, 0.91), 
P=0.00001) and (0.23 kg (95% CI, 0.05, 0.42)], respectively; there was no significant 
effect on muscle CSA or muscle mass (485, 486). In contrast, the most recent meta-
analysis by Thomas et al. (487) failed to detect any added benefits of protein or 
essential amino acid supplementation combined with PRT on muscle mass in the 
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elderly (487). These contrasting results may have been due to the fact, as touched 
upon above, there was considerable variability in the characteristics of the trials 
included in each of these meta-analyses, including differences in the source/quality 
of protein, the quantity of protein provided, the baseline dietary protein intake, the 
inclusion of other ingredients such as vitamin D, leucine and other essential amino 
acids plus the timing of supplementation relative to the PRT programs. Nevertheless, 
in healthy older adults aged 50 to 80 years, long-term participation in PRT (> 6-
weeks) combined with increased dietary protein, predominantly dairy derived such as 
whey protein, appears to provide a small (~0.5 kg) but significant additive effect on 
fat-free mass (485, 486).  
 
To date, little consideration has been given to whether increased dietary protein 
concomitant to PRT in older adults with T2DM can offer an additive effect on 
muscle mass. In the only study to date, Wycherley et al. (286) conducted a 2x2 
factorial design RCT that compared isocaloric energy-restricted diets of either 
standard control (19% energy from protein) or high protein (33% energy as protein) 
with or without supervised PRT (3 days/week, 70-85% 1-RM) for a period of 16-
weeks in 83 overweight/obese men and women (mean age ± SD, 56.1 ± 7.5 years, 
BMI ± SD, 35.4 ± 4.6 kg/m2). To facilitate good dietary compliance, a combination 
of dietary advice and some food products and recipes were provided by a qualified 
dietitian (286). Protein intake averaged 1.12 g/kg/day in the high protein groups and 
participants demonstrated good compliance with their intervention diets (mean 
percent energy from protein: control and control plus PRT ~18% vs high protein and 
high protein plus PRT ~32%, P<0.001 diet and treatment effect) (286). There were 
no improvements in total body lean mass in any of the groups and in fact an overall 
non-significant reduction in total body lean mass was observed across groups, which 
is likely explained by the calorie restricted diet (Figure 2.7) (286). Total body weight 
loss was greater in the high protein plus PRT groups compared to the control and 
high protein diet (P<0.05) but statistical significance was not reached when 
compared to the control diet plus PRT (286). Similarly, fat mass reduced in all 
groups yet was greatest in the high protein plus PRT compared to both the control 
and high protein diet groups (P<0.05) yet again was not different to the control plus 
PRT group (Figure 2.7) (286). The lack of an effect of the high protein diet 
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concomitant to PRT on total body lean mass could be related to a number of factors, 
including the level of protein intake achieved (dose in g/kg/day), the quality of the 
protein used, the timing of consumption relative to participation in the PRT program, 
the change in protein intake from baseline and/or the PRT load prescribed. The 
following section will review the available evidence with regard to the influence of 
the dose, distribution and timing of protein intake regarding PRT or multi-modal 
exercise programs in older adults or those with T2DM.  
 
 
Figure 2.7: Mean ± SD absolute changes (in kg) in total body weight, fat mass and 
lean mass after 16-weeks on a hypocaloric high protein (33% energy from protein) or 
hypocaloric control diet (19% energy from protein) with and without PRT. Taken 
from Wycherley et al. (286). * P<0.05, # P<0.01 vs high protein plus PRT 
 
While there is considerable evidence from acute studies indicating that the dose of 
whey protein and leucine are important factors that can influence the MPS response 
to exercise, there are mixed findings from long-term human intervention trials. 
Several longer-term human intervention trials have shown that there is little or no 
added benefits when PRT is combined with doses of whey protein < 20 g (and < 2 g 
of leucine) (284, 488-493), but there also mixed findings from a number of trials that 
used higher doses of protein (285, 377, 494). In one study, it was observed that when 
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327 middle to older aged overweight participants (age ± SD 48.0 ± 7.9 years) 
consumed whey protein supplements at a dose of either 0, 10, 20 or 30 g per serve 
twice per day and participated in a 9-month resistance and aerobic exercise program 
(3 days/week) there was no additive effect of whey protein on exercise induced gains 
in DXA-measured lean muscle (285). In a secondary analysis of this same study, 
when participants were stratified by total protein intake (<1.0, ≥1.0-<1.2 and ≥1.2 
g/kg/day) rather than dose of supplement there was still no difference between the 
groups for the change in total body lean mass (494). While another 6-month trial in 
80 70- to 85-year-old adults found that 40 g/day of whey protein (20 g at breakfast 
and dinner) increased total body lean mass by 1.3%, this change was not significantly 
different to the 0.6% increase observed in the isocaloric placebo group (377). The 
lack of enhanced effect of whey protein on PRT induced improvements in lean mass 
in these two studies was likely due to the baseline protein intakes of the participants, 
which exceeded 1.0 g/kg/day.  
 
As summarised in Table 2.10, there are few long-term human intervention trials in 
older adults which have shown that the combination of PRT with additional dietary 
or supplemental protein enhance the effects of PRT on muscle mass or size. As 
already indicated, many of the studies where protein intake at baseline has been ~1.0 
g/kg/day or higher did not observed an enhanced effect of additional protein in 
conjunction with PRT or exercise on lean mass or size (284, 377, 492). This is 
perhaps not unexpected given that most current international guidelines recommend 
that older adults (65+ years) have a daily protein intake of at least 1.0 to 1.2 g/kg/day 
of protein for the maintenance of physical function and optimal health. However, it is 
also recommended that higher levels (>1.2 g/kg/day) are needed for those that 
regularly participate in exercise (495). In part support of the above recommendation, 
there is some evidence for an additive effect of protein with PRT on lean mass in 
those with initial protein intakes <1.0 g/kg/day and those who have poor health for 
example are sarcopenic (284).  
 
The terms ‘protein spread’ and ‘protein change’ were proposed several years ago and 
have subsequently been suggested other potential factors that may explain the 
discrepant findings amongst some studies investigating effects of PRT with protein 
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on muscle (373). Protein spread refers to the magnitude of difference in protein 
intake between the groups during an intervention, whereas protein change refers to 
whether there is a sufficient change in total protein intake from baseline during the 
intervention (373). Signifying the importance of these factors was a review of 17 
intervention trials which examined the effects of additional protein intakes combined 
with PRT in both young and older adults (373). Interestingly it was found that in the 
studies which did observe an added benefit of protein with PRT on lean mass the 
average percent increase (change) in habitual protein intake (g/kg/day) was 59.5% as 
opposed to only 6.5% in the studies which saw no added benefit (373). Additionally, 
in those studies which concluded that higher protein interventions were effective 
there was an average 66% g/kg/day between group difference (spread) compared to 
only a 10% g/kg/day spread in the studies which were unsuccessful in observing an 
additive effect (373).  
 
The timing of protein intake relative to participation in a PRT program and the 
distribution of protein intake, that is, dispersing protein more evenly throughout the 
day, may be important factors influencing the effects of additional protein in 
combination with exercise on lean mass (49). For instance, a 12-week study in 13 
men (mean age ± SEM, 74 ± 1 years, mean baseline protein intake 1.1g/kg/day) 
found 10 g of protein consumed immediately (within 5-minutes) of PRT completion 
amounted to greater gains in total body lean mass compared to the men consuming 
the protein supplement 2-hours following PRT (496). However, others have failed to 
detect any added benefits of protein consumed either before or after PRT on muscle 
hypertrophy (282, 497), and thus questions remain as to whether there is an optimal 
time for protein intake relative to exercise. More recently however, there is some 
evidence indicating that studies which have dispersed protein intake more evenly 
throughout the day alongside a PRT program may provide some added benefits to 
lean mass (0.5 to 1 kg) (refer to Table 2.9) (42, 283). It has been suggested that PRT 
(exercise) may sensitise skeletal muscle to the anabolic effects of amino acids for up 
to 24-hours, and thus this even protein distribution (at a sufficient dose) throughout 
the day could enhance gains in skeletal muscle mass (498-501). However, others 
following a similar protocol have not observed a favourable effect (377), which may 
be related to the fact that repeated intake of supplements could act as a partial meal 
Chapter 2 
Page | 83 
	
replacement as the study by Chalé and colleagues found that habitual dietary protein 
intake reduced throughout the intervention (377). In summary, there is some 
evidence that dispersing protein intake throughout the day may enhance the effects of 
PRT on muscle, but further studies are still needed to address this question.  
 
Few studies have examined whether combining PRT or exercise with vitamin D 
supplementation can have an additive effect on muscle mass in older adults or those 
with T2DM. Previously, 52 older women (mean age >68 years) with T2DM who had 
insufficient serum 25(OH)D levels (<40 nmol/L) were randomised to either circuit 
training (3-4 times per week comprising PRT and aerobic exercise), circuit training 
plus 1,200 IU of vitamin D/day, vitamin D alone (1,200 IU/day) or control (502). 
Significant improvements were observed in total body weight (-2.1%), fat mass (-
4.9%), percent body fat (-2.1%), total abdominal fat area (-9.1%) and subcutaneous 
fat area (-9.2%) in those who completed the circuit training program with vitamin D 
supplementation compared to vitamin D and control yet these results were not 
different to those who performed circuit training alone (502). Additionally, there was 
a 1.5% improvement in lean mass resulting from the vitamin D plus circuit training 
program however, this improvement was no different to any of the other arms of the 
study (502). In another 16-week RCT, 20 older men (aged 60-75 years) with serum 
25(OH)D levels >50 nmol/L consumed ~2,000 IU/day of vitamin D with PRT 
performed three days per week (70-75% 1-RM) in the final 12-weeks of the 
intervention (503). Again, no significant additive effect of vitamin D with PRT on 
changes in DXA-derived total body lean mass and magnetic resonance imaging-
derived muscle size was observed in comparison to control (503). It is unclear to 
what extent baseline and target vitamin D concentrations, vitamin D dose and 
treatment duration may influence the outcomes of such intervention trials, however, 
any one or a combination of these factors could explain the lack of an enhanced 
effect. For instance, the precise serum 25(OH)D level which may be associated with 
improved muscle health or body composition outcomes remain unknown, but we do 
know that vitamin D deficiency [serum 25(OH)D <25-30 nmol/L] is associated with 
muscle weakness (504, 505). Thus, in older adults with serum levels >25-30 nmol/L 
there may be little impact on muscle mass Additional, well-designed RCTs 
supplementing vitamin D to older adults with a range of baseline serum 25(OH)D 
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levels are required to fully elucidate if there is any additive effect on total body lean 
mass or other body composition benefits when combined with exercise/PRT. 
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Table 2.9: Summary of randomised controlled trials which have examined the interactive effects of various protein supplements with PRT/ 
exercise and those which have examined the additive effects of protein and vitamin D supplements with PRT/exercise on lean mass in older and 
elderly adults. Adapted from (370).  
Reference Study Characteristics 
Baseline 
Protein 
(g/kg/day) 
Supplement Details 
(Dose, ∆ Protein 
Intake and Timing of 
Intake) 
Comparison 
Group 
Outcome and Method of 
Assessment 
Milk and Dairy-based protein supplements    
Campbell et 
al. 1995 (506) 
n=12 healthy sedentary 
adults aged ~64 years. 
2 days/week, 3 sets, 8-12 
reps, 80% 1-RM for 12-
weeks. 
 
0.6 
 
Dose: 1.6 g/kg 
∆ Protein: 1.0 g/kg/day 
Timing: NS 
Low-protein 
(0.8 g/kg) 
Lean mass: Significant increase (~1 
kg) compared to baseline but no 
difference between groups as assessed 
by total body weighing using the three 
compartment model of Siri.  
Rosendahl et 
al. 2006 (507) 
plus Carlsson 
et al. 2011 
(508). 
n=191 living in residential 
care adults aged 85 years. 
Multi-modal program 5 
times per fortnight for 12- 
weeks. 
NS 
Dose: 7.4 g/day 
∆ Protein 6.1 g/day 
Timing: After exercise 
Ex + placebo, 
milk or control 
plus placebo 
No difference between groups as 
measured using a bioelectrical 
impedance spectrometer. 
Iglay et al. 
2009 (492) 
n=36 healthy untrained 
adults aged 61 years. 
3 days/week, 3 sets, 8 reps, 
80 % 1-RM for 12-weeks. 
1.1 
Dose: 1.6 g/kg 
∆ Protein 0.1 g/kg/day 
Timing: At meal times  
  
Low protein 
(0.9 g/kg) 
Lean mass: Significant increase of 
~1kg compared to baseline. No 
difference between groups as 
measured by DXA. 
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Kukuljan et 
al. 2009 (493) 
n=180 healthy untrained 
males aged ~60 years 
3 days/week, 2–3 sets, 8–
20 reps, 60–85 % 1-RM 
72-weeks. 
~1.3  
Dose: 13 g/day 
∆ Protein: 11.9 g/day 
Timing: Morning and 
afternoon/evening 
Ex, fortified 
milk or usual 
care 
Lean mass: Significant within-group 
increase of ~1 kg as assessed by 
DXA. No difference between-groups. 
Tieland et al. 
2012 (283) 
n=62 frail elderly adults 
aged 78 years. 2 
days/week, 3–4 sets, 8–15 
reps, 75 % 1-RM for 24-
weeks. 
1.0 
Dose: 30 g/day 
∆ Protein: 0.3 g/kg/day 
Timing: After breakfast 
and lunch 
Flavoured 
CHO drink 
Lean mass: 1.3kg significant within 
group increase in the intervention 
group. Significant net difference of 
1.6 kg as measured by DXA. 
Leenders et 
al. 2013 (284) 
n=60 healthy untrained 
adults age=d 70 years. 
3 days/week, 3–4 sets, 8–
15 reps, 75–80 % 1-RM 
for 24-weeks. 
~1.1 
Dose: 15 g/day 
∆ Protein: 0.18-0.24 
g/kg/day 
Timing: After breakfast 
  
Lactose and 
calcium drink 
Lean mass: Similar significant ~1 kg 
increase but no differences between 
the groups as assessed by DXA. 
Buhl et al. 
2016 (509) 
n=29 acutely ill adults 
aged 72-73years. 
3 days/week, 3 sets, 8–12 
reps (intensity NS) for 12-
weeks. 
0.74 
Dose: 18.8 g/day 
∆ Protein 14.1 g/day 
Timing: After exercise 
Standard care 
Lean mass: Significant ~0.5 kg 
reduction compared to baseline. No 
difference between the groups in as 
measured by DXA. 
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Whey Protein     
Candow et al. 
2006 (497) 
n=29 mobility limited 
adults aged 63-66 years. 
3 days/week, 3 sets, 10 
reps, 70 % 1-RM for 12-
weeks. 
NS 
Dose: 0.3 g/kg 
∆ Protein: 0.3 g/kg/day 
Timing: Before or after 
exercise 
Chocolate 
CHO drink 
Lean mass: Similar significant 
increase in lean mass in all groups 
compared to baseline with no 
differences between-groups as 
measured by air-displacement 
plethysmography. 
Chale et al. 
2013 (377) 
n=80 healthy untrained 
adults aged 77-78, M/F     
3 days/week, 2–3 sets, 10–
12 reps, 80 % 1-RM for 
24-weeks. 
~0.9 
Dose: 40 g/day  
∆ Protein: 18 g/day 
Timing: After breakfast 
and evening meal 
Maltodextrin 
Lean mass: No between-group 
differences in lean mass as assessed 
by DXA.  
Arnarson et 
al. 2013 (510) 
n=161 obese untrained 
adults aged 73-74 years. 
3 days/week, 3 sets, 6–8 
reps, 75–80 % 1-RM for 
12-weeks. 
1.1 
Dose: 20 g/day (7 g 
EAA) 
∆ Protein: 0.06 
g/kg/day 
Timing: Immediately 
after exercise 
Carbohydrate 
control 
beverage 
Lean mass: No change in lean mass as 
assessed by DXA. No between-group 
differences. 
Soy-based protein     
Fiatarone et 
al. 1994 (511) 
n=100 frail elderly adults 
aged 87 years. 3 
days/week, 3 sets, 8 reps, 
80 % 1-RM for 10-weeks. 
NS 
Dose: 15 g/day,  
∆ Protein: 15 g/day 
Timing: Evening 
Ex, low energy 
beverage or 
control 
No within-group changes in lean mass 
and no between-group differences 
measured by whole body potassium as 
an index of body cell mass.  
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Casein      
Verdijk et al. 
2009 (282) 
n= 26 healthy untrained 
males aged 72 years. 
3 days/week, 4 sets, 8-15 
reps, 75-80% 1-RM for 
12-weeks. 
1.1 
Dose: 20 g/day  
∆ Protein: 20 g/day 
Timing: Prior to and 
following exercise 
Flavoured 
water 
Significant similar (~0.6 kg) increases 
in lean mass in both groups, no group 
by time interactions as measured by 
DXA. 
Leucine      
Trabal et al. 
2015 (490) 
n= 30 adults living in 
residential care, aged 84-
85. Three days/week, 2 
sets, 15 reps, 65% 1-RM 
for 12-weeks. 
1.2 
Dose: 5 g/day (twice) 
∆ Protein: 0.03 
g/kg/day 
Timing: After lunch 
and dinner 
Maltodextrin 
No differences within or between-
groups for calf circumference and 
triceps skin-folds (assessment of lean 
mass). 
Essential amino acids     
Godard et al. 
2002 (488) 
n= 17 healthy untrained 
males aged 71-72 years. 
3 days/week, 3 sets, 10 
reps 80% 1-RM or fatigue 
for 12-weeks. 
1.1 
Dose: 12 g/day 
∆ Protein: 2% increase 
in energy from protein 
Timing: After exercise 
or at same time each 
day 
Usual care 
Similar (7 and 6%) increases in 
muscle CSA in intervention and 
control groups. No differences 
between the groups from CT 
measured thigh cross-sectional area. 
Kim et al. 
2012 (489) 
n= 155 sarcopenic women 
aged 79 years. 2 
days/week, 1 set, up to 8 
NS 
Dose: 3 g/day (twice) 
∆ Protein: 6 g/day 
Exercise, EAA 
only or health 
education 
No within-group changes or between-
group differences in ALM. Protein 
plus PRT was significantly better than 
health education for improving leg 
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reps, 14-16 RPE for 12-
weeks. 
Timing: Twice a day 
(no statement on time) 
lean mass (P<0.010). 2 and 3% 
increases in leg lean mass in protein 
plus PRT and PRT alone vs baseline 
(P<0.05). Measurements conducted 
with BIA. 
 
Multi-nutrient supplements (Protein plus Vitamin D)   
Verreijen et 
al. 2015 (512) 
n= 80 obese older adults 
aged 63 years. PRT 3 
times/week, 3 sets, 10 reps 
(intensity NS) for 13-
weeks. All followed a 
hypocaloric diet (-600 
calories/day). 
NS 
Dose: 21 g whey, 3 g 
leucine, 800 IU vitamin 
D per supplement 
∆ Protein: 1.11 
g/kg/day of protein was 
consumed during the 
intervention by the 
intervention group 
Timing: Every morning 
and immediately 
following training on 
training days 
Isocaloric 
control plus 
exercise 
Significant interaction (P=0.03) 
between the groups. Driven by a 0.4 
kg gain in the PRT plus protein group 
with a 0.5 kg reduction in the control 
group. 
Rondanelli et 
al. 2016 (513) 
n= 130 sarcopenic elderly 
adults aged 80 years. 
Multi-modal exercise 
program of moderate-
intensity 5 times/week for 
12-weeks. 
0.9 
Dose: 1 x 32 g (22 g 
whey, 4 g leucine, 100 
IU vitamin D) 
∆ Protein: 1 g/day 
Timing: NS 
Maltodextrin 
plus exercise 
1.4 kg increase in lean mass in the 
intervention group, (P<0.001) 
compared to baseline as measured by 
DXA. This change led to a significant 
between-group difference (P<0.001). 
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Holm et al. 
2008 (514)  
n= 38 healthy untrained 
women aged 55 years. 
PRT 2-3 times/week, 3 x 
15 reps at 20-RM weeks 1-
2, 3 x 10 reps at 10-RM 3-
12 and 5 x 8 reps at 8-RM 
weeks 13-24.  
1.0 
Dose: 10 g of whey 
protein 200 IU of 
vitamin D 
∆ Protein: 
Timing: One/day 
immediately after 
training on training 
days 
Placebo plus 
PRT 
No between-group difference for 
change in lean mass. A 0.8 kg 
increase in lean mass was observed in 
the intervention group compared to 
baseline. Body composition measured 
with DXA. 
NS, Not stated; DXA, Dual energy X-ray absorptiometry; CT, computed tomography; IU, International units; EAA, essential amino acids; BIA, Bioelectrical 
impedance analysis; RPE, ratings of perceived exertion 
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2.11.2  Effects of Exercise Combined with Protein and Vitamin D on Lean Mass 
Several recent interventions have investigated whether multi-nutrient supplements 
including protein and vitamin D, when combined with exercise can enhance the 
effects of exercise on muscle mass and strength in older adults (Table 2.9) (512-515). 
In one trial, 80 obese older adults (mean age ± SD, 63.0 ± 5.6 years) performed PRT 
(3 times per week), followed a hypocaloric diet (-600 calories) and were randomised 
to either a high whey protein, leucine and vitamin D rich supplement (150 calories, 
21 g of protein, 2.8 g leucine, 800 IU of vitamin D) or an isocaloric control for 13-
weeks (512). All supplements were consumed prior to breakfast and after training 
sessions on training days (512). During the intervention period and inclusive of the 
supplement, protein intake was 1.1 g/kg/day in the intervention group. Baseline 
protein intake was not reported. Baseline serum 25(OH)D status was not reported nor 
was the change in serum 25(OH)D level. After 13-weeks, similar reductions in total 
body weight and fat mass in the intervention and control groups were observed (total 
body weight; 3.4 ± 3.6 kg vs 2.8 ± 2.8 kg; fat mass 3.2 ± 3.1 kg vs 2.5 ± 2.4 kg, all 
P<0.001, respectively) which was likely due to the hypocaloric diets followed by all 
participants (512). Following the 13-week weight loss intervention, the change in 
ALM and leg muscle mass was significantly different between the intervention and 
control group [mean change in ALM ± SD; intervention, +0.4 ± 1.2 kg and control, -
0.5 ± 2.1 kg, P=0.03 and mean change in leg muscle mass ± SD; intervention, +0.3 ± 
1.2 kg and control -0.6 ± 1.8 kg, P=0.01] (512). This suggests that a multi-nutrient 
supplement containing whey protein, leucine and vitamin D concurrent with PRT can 
enhance the effects of PRT on muscle mass in older adults (512). In another study, 
Rondanelli et al. (513) examined the effects of a 12-week multi-nutrient supplement 
(22 g of whey protein, 4 g of leucine and 100 IU of vitamin D) or placebo combined 
with a moderate-intensity physical activity program (aerobic and strength based 
training) performed 5 days per week on muscle mass in 130 sarcopenic elderly men 
and women (513). The combination of the multi-nutrient supplement and exercise 
program increased total body lean mass compared to placebo plus exercise [mean net 
difference 1.7 kg (95% CI, 0.9, 2.5), P<0.001 for the between-group interaction] 
(513). The greater magnitude improvement in this trial may be due to the differences 
in population groups examined (e.g. sarcopenic elderly adults compared to obese 
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older adults). Nevertheless, the findings from these two trials demonstrate an 
integrated intervention combining a multi-nutrient supplement containing protein and 
vitamin D in addition to a PRT or a multi-modal exercise program can lead to greater 
improvements in muscle mass in older adults when compared exercise alone (512, 
513).  
 
Despite the positive findings from two trials, not all interventions have observed an 
enhanced effect of PRT combined with a multi-nutrient supplement containing 
vitamin D and protein on muscle mass in older adults. For instance, the findings from 
a 24-week RCT in which early postmenopausal women (mean age 55 years) were 
provided a multi-nutrient supplement (n=16) containing 10 g of protein (no report of 
leucine content), 31 g of carbohydrate, 250 mg of calcium and 200 IU of vitamin D 
or a placebo product (n=13) consumed immediately following PRT (five 20 minute 
sessions per week of moderate-intensity) showed there were no additive benefits on 
DXA assessed lean or fat mass (514). The only significant result was a small increase 
in lean mass compared to baseline in the multi-nutrient intervention group (514). As 
baseline protein intake were on average >1.0 g/kg/day, it is likely that the additional 
10g of protein was not sufficient to enhance the anabolic effects of the exercise 
program. Another possible reason for the lack of an additive effect is that the 
participants in this trial were middle aged women, a time around which reductions in 
muscle mass due to ageing are just beginning to commence (516, 517), greater 
improvements may have been observed had participants been sarcopenic as seen 
previously (513). The authors of this study also posited that the lack of an interactive 
effect on gains in muscle may have been related to the moderate-intensity and 
moderate volume of the PRT program (514).  
 
Drawing conclusions from the studies conducted to date is difficult as the design of 
the trials, prescription of exercise/PRT programs, the doses of protein and vitmain D 
prescribed, the starting levels of vitamin D, protein status (deficient or replete), 
intervention protein prescribed (large dose or modest dose) and the age/gender 
characteristics of these trials were all different. Despite these factors, there is some 
positive evidence that PRT/exercise combined with increased protein intake and 
vitamin D supplementation may enhance the improvement in lean mass offered from 
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PRT/exercise alone. Whether the same benefits would also be observed in older 
adults with T2DM is not known. 
 
2.11.3  Effects of Exercise, Protein or Vitamin D on Glycaemic and Insulinaemic 
Outcomes 
Whether the combination of PRT and increased protein enhances the glycaemic and 
insulinaemic improvements typically associated with PRT in older adults and those 
with T2DM remains unknown. Studies which prescribe weight loss/energy 
restriction alongside increased dietary protein and PRT have been associated with 
improvements in glycaemic control and insulin sensitivity as summarised in Table 
2.10 yet the inclusion of energy restriction/weight loss may confound the findings as 
weight loss/energy restriction is commonly associated with improvements in these 
outcomes. For instance, the only study to examine the effects of increased dietary 
protein in conjunction with PRT on glycaemic and insulinaemic outcomes in older 
adults with T2DM also prescribed a hypocaloric diet to induce weight loss, as 
described previously (Table 2.10) (286). Briefly, in this 16-week RCT, 83 
overweight/obese men and women (mean age 56.1 ± 7.5 years) with T2DM were 
randomly assigned to a hypocaloric high (33% energy from protein) or low protein 
(19% energy from protein) diet with or without PRT (3 days/week, 70-85% 1-RM) 
(286). After 16-weeks all groups experienced a similar significant reduction in 
plasma glucose (reductions ranged from 1.9 to 2.5 mmol/L) and HbA1c (reductions 
ranged from 1.1 to 1.8%) (286). Interestingly, there was a significant reduction in 
insulin in the high protein plus PRT group compared to baseline (P<0.001), which 
was two-fold greater than the other groups, but again no interaction was observed 
(P=0.11) (Figure 2.8) (286). Secondary analysis and pooling of the groups in this 
study found the change in insulin was significantly correlated with changes in both 
total body weight (r=0.35, P<0.01) and fat mass (r=0.36, P=0.005), which is perhaps 
not surprising as body fat has been found to predict insulin sensitivity in older people 
(518). This may explain the greater reduction in insulin in the PRT plus high protein 
group as this group experienced the greatest reduction in fat mass (mean reduction -
11.4 kg, P>0.01) (286). Other studies have also failed to demonstrate the 
combination of increased dietary protein with PRT is more effective than PRT alone 
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on improving glycaemic and insulinaemic outcomes (285, 519), this is believed to be 
attributed to the fact that all participants experienced similar reductions in weight. 
 
 
 
Figure 2.8: Mean (± SD) absolute changes in fasting insulin (pmol/L), glucose 
(mmol/L) and HbA1c (%) following a 16-week high protein (33% energy from 
protein) or control diet (19% energy from protein) with or without participation in 
PRT (3 days/week 70-85% 1-RM). Taken from Wycherley et al. (286).  
 
Several studies examining the effectiveness of increased dietary protein alongside 
PRT, independent of a hypocaloric or weight loss diet, have failed to clearly 
demonstrate the value of such an approach on improving glycaemic control, insulin 
sensitivity and insulin levels (283-285, 519-521). For instance, 16-weeks of whey 
protein supplementation (21 g, three times per day) combined with high-intensity 
PRT performed four times per week in 27 healthy middle-aged adults (mean age 47 
years) resulted in significant reductions in glucose (21%), insulin (14%) and HOMA-
IR (31%) when compared to baseline (all P<0.05), but these improvements were no 
different to the protein only intervention without exercise (520). Potentially this was 
because both groups experienced similar significant mean reductions in body weight 
(1.4 kg), percent body fat (0.7%) and abdominal fat (0.3 kg) respectively, compared 
to baseline. Only the protein plus PRT group experienced a significant increase in 
percent total body lean mass (mean ± SD, 0.9 ± 0.3%, P<0.05) yet this increase was 
no different to those in the protein only group (520). Several possible reasons for the 
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lack of effect were proposed and include participants at baseline were consuming 
upwards of 1.1 g/kg/day of protein, the supplements were prescribed to provide an 
extra 60 g of protein per day on top of habitual protein intake yet the mean increase 
was only 34 g, suggesting displacement of habitual protein intake (520). The 
proposed displacement of protein intake following the addition of the protein 
supplements may have been both a consequence and a limitation of the study design 
where supplements were prescribed to be consumed in-line with the three daily main 
meals. Had the protein supplements successfully been consumed in addition to the 
habitual diet of participants (rather than replacing) this would have raised daily 
protein intakes to ~1.8 g/kg and percentage energy to well above 30%. Indeed, the 
findings from another study in middle-aged (mean age 48.4 years) overweight and 
obese adults showed that increasing total protein intake from ~20% to 35%, with the 
use of whey protein supplements, significantly improved insulinaemic outcomes, 
independent of PRT, weight loss or gains in total body lean mass (351). While a few 
other intervention trials in older adults have also used a protein supplement to 
investigate glycaemic outcomes, again these findings remain inconclusive which 
may be related to a number of factors, including the type and dose of protein. Table 
2.10 provides an overview of these interventions (283-285, 519, 521).  
 
Whether there is an optimal dose of protein to enhance the effects of PRT on 
glycaemic and insulinaemic outcomes remains uncertain. The closest study to 
investigate a dose response relationship was conducted in 220 healthy adults (mean 
age 48 years) who all performed 36-weeks of high-intensity combined resistance and 
aerobic training and were randomly assigned to one of four twice daily doses of 
whey protein (0g (placebo), 10g, 20g or 30 g of whey protein) (285). Whilst the 
primary outcome of this study was to examine change in body composition, changes 
in glucose, HOMA-IR and insulin sensitivity were also assessed. At the end of the 
intervention no differences were observed between the groups in terms of the gains 
in total body lean mass or any glycaemic or insulinaemic measures (285). However, 
pooling of the data found an overall reduction in insulin AUC of 2.6 ± 32% (-7.5 ± 
29 nmol/L × 3 h, P = 0.01), which coincided with an overall 1.9 ± 2.8% (P<0.001) 
increase in total body lean mass (285). The lack of a greater magnitude gain in lean 
mass was likely due to participants in this trial being relatively healthy (albeit 
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overweight) with sufficient intakes of protein at baseline (~1.0-1.1 g/kg/day). 
Another study also observed no beneficial effect of PRT combined with a twice daily 
milk protein concentrate supplement on glycaemic or insulinaemic outcomes in 62 
older frail but metabolically healthy adults (mean age ~78 years) who had intakes of 
protein at baseline of ~1.0 g/kg/day. Participants in this study also presented with 
FPG and insulin levels in the healthy normal range (mean glucose 5.3 ± 0.5 mmol/L 
and mean insulin 130.6 ± 47 pmol/L) which did not change following twice daily 
(breakfast and lunch, 15 g per serve) milk protein concentrate supplementation with 
PRT (twice per week) (283). Other possible reasons for the lack of an additive effect 
may have been due to the type of protein used (e.g. milk protein) or the level of total 
protein intake not being significantly different from the control group (supplement 
83.5 g/day vs control 77.7 g/day, P=0.61), combined with the lack of a marked 
change in protein intake from baseline (mean increase of only 6 g/day) (283).  
 
In summary, studies investigating the combined effects of PRT with increased 
protein on insulinaemic and glycaemic outcomes remain inconclusive, largely 
confounded by the incorporation of energy restriction/weight loss in these trials 
which is well established to be a potent method to improve glycaemic control and 
insulin sensitivity. Nevertheless, several studies have demonstrated the importance of 
independent participation in PRT for improving glycaemic control and to a lesser 
extent levels of insulin as discussed in section 2.7.2.2 of this literature review.  
 
It is possible that other nutrients such as vitamin D in addition to PRT and increased 
protein consumption may interact to improve glycaemic control and insulin 
sensitivity in older adults with T2DM. However, no studies appear to have 
specifically addressed this question. The closest study to do so randomised 52 elderly 
(mean age 70 years) women deficient in vitamin D with T2DM to vitamin D 
treatment (1,200 IU/day) or placebo with and without circuit training (moderate-
intensity PRT and aerobic training) for 12-weeks (502). Following the intervention, 
no significant differences were observed between the groups for the change in FPG, 
insulin or HOMA-IR, but greater non-significant improvements in the combined 
group relative to controls was observed (-10.7% vs 4.1% fasting insulin; -35.8% vs 
29.2% and HOMA-IR; -42.8% vs 28.9%) (502). The lack of a significant interaction 
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may have been due to the intervention period not being long enough, the lack of 
change in lean mass, the insufficient training intensity and/or the dose of vitamin D 
being low. Whilst the dose of vitamin D and serum 25(OH)D level which may offer 
glycaemic and insulinaemic improvement remains unknown, a study which did find 
a significant positive effect of vitamin D supplementation on insulin outcomes in 
middle-aged women with T2DM, yet without exercise or PRT, provided a dose four 
times as high (4,000 IU/day) (65). Clearly further research is need to determine if 
there is in fact an optimal serum level of 25(OH)D and/or dose of vitamin D that may 
produce an additive effect with PRT on glycaemic and insulinaemic outcomes. 
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Table 2.10: Summary of RCTs which have examined the interactive effects of increased dietary protein or protein supplements with PRT or exercise 
on glycaemic and/or insulinaemic outcomes in older and elderly adults. 
Reference 
Study Characteristics  
 
Baseline 
Protein 
Intake 
(g/kg/day) 
Supplement/Diet 
Details 
(Dose/Intake, ∆ Protein 
Intake, Type) 
Comparison 
Group 
Change in insulin or glycaemic 
parameters 
Adults with Type 2 Diabetes      
Wycherley et al. 
2010 (286) 
n= 83 adults aged 56 ± 7.5 
years.  
PRT 3 days per week, 3 
sets 8-12 reps 70-85% 1-
RM 
NS 
Dose: 1.12 g/kg 
∆ Protein Intake: 
Unknown 
Type: High protein food 
sources (not specified) 
Control diet, 
high protein 
diet and control 
diet plus PRT 
Glucose and HbA1c similarly and 
significantly reduced in all groups 
no difference between groups. 
Insulin reduced to a greater degree 
in the high protein plus PRT group 
(two-fold) but was not significant 
compared to other groups. 
Healthy Older or Elderly Adults     
Tieland et al. 2012 
(283) 
n= 62 adults aged 78 ± 7 
years 
PRT completed 2 
days/week for 24-weeks 3-
4 sets, 8-10 reps 75% 1-
RM for 24-weeks 
~1.0  
Dose: 15 g twice/day 
(breakfast and lunch) 
∆ Protein Intake: 0.3 
g/kg/day 
Type: Milk protein 
concentrate 80 
Placebo plus 
PRT 
Plasma glucose and insulin did not 
change in either group. 
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Layman et al. 2005 
(305) 
n= 48 women aged ~47 
years 
2 d/week 30 min of 
stretching and PRT. PRT 
program, 7 exercises, 
minimum one 12-rep set 
on each machine with 
weight set to fatigue by 
final rep. Plus 5 days/week 
30 min walking for 16-
weeks. 
~0.8-0.9 
Dose: 1.6 g/kg/day (30% 
energy) 
∆ Protein Intake: ~30 
g/day in both higher 
protein groups 
Type: Greater intake of 
high protein food sources 
(meat, eggs, dairy and 
nuts) 
Lower protein 
diet of 0.8 
g/kg/day with 
exercise or 
lower protein 
only or higher 
protein with no 
PRT. 
Insulin fell by ~50 pmol/L in both 
exercising groups (higher and lower 
protein) compared to baseline with 
no differences between the groups.  
Meckling et al. 
2007 (519) 
n= 60 women aged 43 
years performed 
3 days/week of PRT 
(within a circuit training 
program), 80% max heart 
rate for 12-weeks. 
~0.8 
Protein intake: 1g:1g of 
protein:carbohydrate. 
 
∆ Protein Intake: 15g in 
higher protein only and 
50g/day in higher protein 
plus PRT  
Type: Greater intake of 
high protein food sources 
(meat, eggs, dairy and 
nuts) 
Higher protein 
alone or control 
diet plus PRT 
or control diet 
only. Control 
diet protein: 
carbohydrate 
ratio 1g:3g. 
* All 
participants 
randomised to 
No within group changes or 
between group differences observed 
in fasting plasma glucose or insulin. 
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hypocaloric (-
500 calories) 
Iglay et al. 2007 
(521 ) 
n=36 adults aged ~61 
years performed PRT 3 
days/week 3 sets 8 reps 
80% 1-RM for 12-weeks.  
~1.0 
Dose: 1.2 g/kg/day 
higher protein diet. 
∆ Protein Intake: ~6 g or 
0.1 g/kg/day 
Type: Higher intake of 
egg and dairy proteins 
0.9 g/kg/day 
lower protein 
diet plus PRT. 
Insulin AUC reduced in the control 
group but did not change in the 
higher protein group (group by time 
interaction P<0.05). No changes or 
between group differences observed 
for FPG, glucose AUC, HOMA or 
HbA1c. 
Leenders et al. 
2013 (284) 
n= 60 adults mean age ~70 
years. PRT 3 days/week, 
3–4 sets, 8–15 reps, 75–80 
% 1-RM for 24-weeks. 
~1.1 
Dose: 15 g/day 
∆ Protein Intake: 0.18-
0.24 g/kg/day 
Type: Milk protein 
concentrate 80 
Lactose and 
calcium drink 
No change in fasting glucose or 
insulin, HbA1c, HOMA-IR. 
Arciero et al. 2014 
(520) 
n= 51 adults mean age ~50 
years. PRT performed 4 
days/week, 2-3 sets 7-9 
reps 80% 1-RM for 16-
weeks. Multi-modal 
exercise: 4 days/week 
PRT+aerobic and 
functional training, 
~1.0-1.1 
Dose: All whey protein 
was consumed 20 g 3 
times/day (upon waking, 
mid-afternoon/following 
exercise and within 2 
hours of bed) 
∆ Protein Intake: 25-35 
g/day for all groups 
Whey protein 
alone or whey 
protein plus 
multi-modal 
exercise. 
No change from baseline in fasting 
glucose or insulin or HOMA-IR and 
no difference between the groups. 
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yoga/pilates and stretching 
exercises. 
Type: Whey protein (no 
further details provided)  
Weinheimer et al. 
2012 (285) 
n=220 adults aged 48 ± 7.9 
years performed PRT 2 
days/week, 3 sets of 8-10 
reps ~80% 1-RM plus 1 
day per week a 60-minute 
aerobic training, ~70% 
maximum heart rate for 
36-weeks. 
Range 0.97-
1.12 
Dose: 10, 20 or 30 g 
whey protein 
∆ Protein Intake: 0.16-
0.72 g/kg/day 
Timing: Breakfast and 
lunch 
Type: Whey protein 
concentrate 80  
Placebo 
beverage 
Insulin AUC fell by 2.6 ± 32%, P 
=0.01 when all participants were 
pooled. No between group 
interactions observed. 
Fasting glucose, glucose AUC and 
HOMA-IR no change. 
 
Data is presented as mean ± SD. NS, Not stated; PRT, Progressive resistance training; 1-RM, one repetition maximum; AUC, area under the curve.
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2.11.4  Effects of Exercise, Protein and Vitamin D on Cardiovascular Health  
The interactive effect of PRT with high protein diets or protein supplementation on 
cardiovascular health outcomes in older adults with T2DM has not been thoroughly 
examined. In the only intervention trial conducted to date in older adults with T2DM 
by Wycherley and colleagues which has been discussed extensively above in section 
2.11.1 page 78, they found increased dietary protein alone and in combination with 
PRT was associated with significant improvements in blood pressure, lipids and hs-
CRP, but there were no between group differences for any of these outcomes (286). 
This may be explained by the fact that participants in this intervention did not present 
with elevated levels of lipids, cholesterol or blood pressure (286). Indeed, more 
favourable changes in serum lipid and cholesterol levels in response to greater 
protein intake or increased protein intake plus PRT in those with adverse levels at 
baseline have been found in other studies (522, 523). Secondly, although participants 
in the high protein diet groups (with or without PRT) were reported to be consuming 
approximately 118 g/day or 1.3 g/kg of protein during the intervention the baseline 
protein intake was not reported and thus the change in protein intake may not have 
not been sufficiently large enough (286). As previously discussed, the change in 
protein intake from baseline is an important factor which could explain why no effect 
was observed as another study found raising protein intake (via the prescription of a 
high protein diet) by 50 g/day for 10-weeks from 0.9 g/kg to 1.6 g/kg resulted in 
significant improvements in total cholesterol (5.80 ± 0.16 to 5.38 ± 0.21 mmol/L, 
P<0.05), LDL (3.81 ± 0.17 to 3.45 ± 0.19 mmol/L, P<0.05) and triacylglycerol levels 
(1.31 ± 0.21 to 0.98 ± 0.16 mmol/L, P<0.05) compared to baseline (305). These 
improvements were likely due to the significant reductions in total fat and saturated 
fat that were observed to occur in those receiving protein supplements with or 
without PRT, suggesting that the increased intake of protein was associated with 
displacement of fat intake in the habitual diet of these participants (305). 
 
Studies using a protein supplement (as opposed to a high protein diet) in combination 
with PRT in middle-aged and older adults have observed mixed effects on 
cardiovascular risk factors. In a 24-week RCT, 60 healthy elderly men and women 
(mean age ± SEM, 70 ± 1 year) were randomly assigned to a PRT program combined 
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with 15 g/day of milk protein concentrate or placebo (284). Triglyceride levels were 
within normal ranges at baseline (<1.7 mmol/L) and did not change during the 
intervention in any group (284). In contrast, total and LDL cholesterol levels were 
elevated (<5.2 and <2.6 mmol/L, respectively) at baseline in all participants and by 
12-weeks both placebo plus PRT and protein plus PRT groups experienced similar 
significant reductions in total cholesterol [(range 0.13 to 0.26 mmol/L, P<0.001)] and 
reductions in LDL cholesterol by 12-weeks (range, 0.16 to 0.32 mmol/L, P<0.001) 
and 24-weeks (range 0.7 to 0.16 mmol/L P<0.05)] (284). Significant (~6 mmHg) 
reductions in SBP and DBP were also observed with no differences between the 
groups (284). The findings from this study indicate that PRT was effective at 
lowering cholesterol, lipid and blood pressure levels, but the additional milk based 
protein did not provide any enhanced benefits (284). Several other studies using PRT 
or exercise in combination with protein supplementation have observed mostly a null 
effect on blood pressure, lipids or cholesterol and markers of inflammation in 
comparison to placebo (285, 393, 524). For example, the findings from a study in 26 
older (mean age ± SD, 65 ± 5 years) overweight, sarcopenic men who were 
randomised to 4-months of PRT (three times per week, 80% 1-RM) with post 
exercise consumption of a either a dairy based protein supplement (13.5 g protein 
and 3.5 g of leucine), soy based protein supplement (12 g of protein and 3.5 g of 
leucine) or a placebo product (0.6 g of protein) found no within group changes (in 
any groups) or between-groups differences in triglycerides, LDL and HDL 
cholesterol or inflammatory markers (TNF-α, IL-6 or hs-CRP) (524). This was 
despite above 90% compliance with the supplements in each of the groups. There 
were no marked changes in weight or fat mass which has been associated with 
improvements in triglycerides and cholesterol levels along with blood pressure and 
likely explains the null findings.  
 
Further research is still required to ascertain if increased dietary protein/protein 
supplements can enhance the cardiovascular benefits of PRT in older adults and/or 
those with T2DM. Given the studies conducted to date have prescribed relatively low 
doses of protein that have resulted in only modest increases in dietary protein along 
with the discrepancies in trial designs and population groups studied, there is a clear 
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need for further large scale RCTs investigating the cardiovascular health benefits of 
PRT combined increased protein/protein supplements in older adults with T2DM.   
 
The effects of combining PRT (and aerobic exercise) with vitamin D (and protein 
supplements) on cardiovascular risk factors may provide a greater beneficial effect 
than either alone. However, the available evidence in this area is limited with only 
one study conducted in older women with T2DM assessing cardiovascular risk 
factors as discussed extensively in section 2.11.1 (502). In comparison to controls, 
women allocated to the PRT and vitamin D supplemented group experienced 
significantly greater reductions in serum triglyceride (-17.2 vs 20.3%, P<0.05), total 
cholesterol (-12.5 vs 3.5%, P<0.001) and LDL cholesterol levels (-9.7 vs 6.4%, 
P<0.001) whilst improving HDL cholesterol levels (8.5 vs -16.5%, P<0.001) (502). 
Significant improvements in these same parameters were not observed in those 
receiving only the vitamin D supplements (502). Whilst only small in sample size 
and failing to report important information, including baseline and follow-up serum 
25(OH)D levels, this study demonstrated the combination of PRT plus vitamin D 
supplementation may have a positive effect on cardiovascular health outcomes not 
seen with vitamin D treatment alone. It is possible these benefits were due largely to 
the PRT program as opposed to the additive effect of vitamin D supplements. PRT 
alone only significantly improved total cholesterol (-7.4%), LDL (-8.7%) and HDL 
(6.7%) cholesterol levels, but not triglycerides (502). These improvements were also 
of a lower magnitude than the PRT and vitamin D group (Figure 2.9).  
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Figure 2.9: Absolute percentage change in total cholesterol, HDL cholesterol, LDL 
cholesterol and triglycerides following a 12-week intervention of multi-modal 
exercise, multi-modal exercise plus 1,200 IU/day of vitamin D, 1,200 IU/day of 
vitamin D alone or control. Taken from Kim et al. (502). *P<0.05 †P<0.01 
significantly different from baseline. Values without a common letter are 
significantly different. 
 
Excess adiposity has a negative effect on blood pressure, inflammation and other 
cardiovascular health risk factors, including serum lipid and cholesterol levels (525). 
Conversely, reductions in fat mass resulting from participation in exercise can 
improve these outcomes (526). All participants in the previous study by Kim et al. 
(502) performing the PRT and aerobic training, irrespective of receiving vitamin D 
or a placebo, experienced similar significant reductions in total abdominal fat area 
compared to baseline. It is thus possible that the improvements in serum lipids and 
cholesterol levels observed in this study were influenced by the reductions in fat 
mass resulting from the exercise program as opposed to the combined effect of 
exercise and vitamin D. The limited evidence in this area makes conclusions about 
the effects of exercise/PRT and vitamin D on serum lipid and cholesterol levels 
difficult and thus it is evident that further studies prescribing a range of vitamin D 
doses to participants with varying baseline serum 25(OH)D status with or without 
PRT remain warranted due to the limited evidence available, some confounding in 
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the available evidence and limited reporting in the studies conducted (i.e. baseline 
serum 25(OH)D status and final serum level) to decisively establish if greater 
improvements in lipid, cholesterol, blood pressure and/or inflammation can occur 
from the combined effects of PRT and vitamin D. 
 
In recent years, there has been some interest into whether multi-nutrient supplements 
such as protein and vitamin D combined with PRT can improve various health 
outcomes of older adults. However, few studies have included cardiovascular health 
measures in their trial design (42, 513, 527). In one of the only studies to include 
such measures, Abizanda et al. (527) examined the effects of a multi-nutrient 
supplement (2x200 ml bottles containing 500 IU of vitamin D, 20 g of protein and 
480 mg of calcium/day) plus resistance, function and balance training (performed 5 
days per week) on inflammation and cholesterol in 91 elderly adults (>70 years). No 
changes were detected following the 12-week intervention on total cholesterol or hs-
CRP, which may have been due to factors such as participants presenting with 
normal total cholesterol levels at baseline, the relatively low dose of vitamin D used 
(possibly not altering serum 25(OH)D status), the short duration of the intervention 
or that the training program/intensity was insufficient to illicit a change in 
cardiovascular health outcomes in these frail older adults. A limitation of this trial 
and the reporting of the results was that the source/type of protein used in the 
supplement was not identified thus its quality is unknown, the baseline and change in 
habitual protein intake was also not reported. Further, baseline serum 25(OH)D 
status (or the magnitude of the change in 25(OH)D levels) was not reported 
numerically although we were informed most of the participants were deficient in 
vitamin D. One or a combination of these factors could have influenced the findings 
of this trial. Additionally, this study was not a RCT so the results were not compared 
to a control or exercise alone group. Another trial, provided a once daily nutritional 
supplement containing 22 g of whey protein and 100 IU of vitamin D to frail older 
(mean age 80.3 years) adults whilst participating in a supervised multi-modal 
exercise program (20 minutes per session, 5 times per week, moderate-intensity of 12 
to 14 on the Borg scale) for 12-weeks and reported a non-significant reduction in hs-
CRP [−0.19 mg/dL (95% CI, −0.57, 0.19) P=0.329] and a non-significant increase 
[0.44 mg/dL (95% CI, −0.02, 0.90) P=0.06] in the control group (placebo plus 
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exercise) such that there was a significant between-group difference (P=0.038) (513). 
Unfortunately, other parameters such as triglyceride, cholesterol and blood pressure 
levels were not assessed in this study.  
 
Whilst only scarce, and far from compelling, there is some promising evidence of an 
additive effect of PRT or multi-modal exercise, protein and vitamin D supplements 
on improving some cardiovascular risk factors in older adults. Yet given the paucity 
of this data, there is a pronounced need for trials to examine the additive effects of 
protein and vitamin D supplements in addition to PRT to ascertain if this novel 
combination provides a more pronounced effect on a combination of these risk 
factors in older adults with T2DM. Should the combination of these strategies prove 
to be beneficial for a range of cardiovascular outcomes, such a strategy could play a 
significant role in reducing risk for CVD morbidity and mortality experienced by 
many older adults with T2DM.  
 
2.12  Summary 
Skeletal muscle mass is of critical importance to those with T2DM as it is the largest 
mass of insulin sensitive tissue and the primary site for glucose disposal. Losses in 
muscle mass can negatively impact metabolic rate further compounding the problems 
of insulin resistance and glycaemic control as well as exacerbate cardiovascular risk 
factors. PRT is one of the few approaches that can simultaneously have beneficial 
effects on almost all the above factors, but most trials to date have been conducted in 
a tightly-controlled clinical exercise laboratory environments with little examination 
of the ‘real-world’ effectiveness of such an exercise program. Nutritional 
modification and/or caloric restriction are also recognised as primary elements in the 
ongoing management of T2DM. Combining PRT with dietary modification may 
offer an additive effect on glycaemic and insulinaemic outcomes, body composition 
and cardiovascular risk factors compared to either strategy alone. Historically, 
caloric restriction has been recommended to adults with T2DM with the goal to 
reduce weight and fat mass, but such an approach has been associated with a loss in 
skeletal muscle mass. However, few long-term trials have examined the effects of 
PRT combined with calorie restriction on glycaemic control, muscle mass and 
markers of systemic inflammatory in adults with T2DM.  
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Over the past two decades, there has been a growing body of evidence indicating that 
an increase in dietary protein, particularly rapidly digested proteins rich in leucine, 
such as whey protein, can enhance the anabolic effects of PRT on muscle. 
Favourable acute effects of whey protein alone on insulin and glucose have also been 
observed in those with T2DM. However, no studies have examined the long-term 
benefits of PRT combined with daily whey protein supplementation on lean mass, 
size and strength, glycaemic control, insulin resistance or cardiovascular risk factors 
in older adults with T2DM. Additionally, there is mounting evidence that vitamin D 
supplementation may offer several skeletal and non-skeletal health benefits of 
relevance to those with T2DM, including improvements in glucose tolerance and 
insulin resistance. However, the findings from intervention trials to date have been 
mixed with little consistency in the dose of vitamin D provided or the population 
groups examined.  
Given that the prevalence of T2DM is projected to reach ~ 584 million by the year 
2040, there is an urgent need to develop evidence-based management programs for 
older adults with T2DM that can simultaneously improve skeletal muscle mass, 
glycaemic control and cardiovascular risk factors whilst being safe, practical and 
widely accessible for people with this disease. Evaluating the efficacy of a lifestyle 
approach that incorporates PRT in combination with a protein enriched supplement 
and vitamin D has the potential to underpin more precise exercise and nutrition 
guidelines for the management of glycaemic control, insulin sensitivity, body 
composition and cardiovascular risk factors along with the ongoing refinement of 
community-based initiatives for the management of this condition.
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Chapter 3 
 
Effects of Progressive Resistance Training and Weight Loss versus 
Weight Loss alone on Inflammatory and Endothelial Biomarkers in 
Older Adults with Type 2 Diabetes:  
A 12-month Randomised Controlled Trial 
 
Chapter 3	
Page | 110 
	
3.1  Declaration Statement 
The findings from this chapter represent secondary analysis of a previous 12-month 
RCT in which the primary aim was to investigate the effects of high-intensity 
progressive resistance training with moderate weight loss compared to weight loss 
alone on glycaemic control, body composition and blood lipids in older overweight 
and obese adults with type 2 diabetes (T2DM). As a result, some findings presented 
within this chapter have previously been published, however, these have been 
appropriately cited. The aim of this study (and the analysis retrospectively performed 
as part of my thesis)) is to investigate the effects of the 6-month supervised PRT plus 
weight loss intervention compared to weight loss alone and the subsequent 6-month 
home-based training on systemic and endothelial markers of inflammation, including 
serum IL-6, TNF-α, ICAM-1, resistin, IL-10 and adiponectin in older overweight 
adults with T2DM.  
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3.2  Abstract 
Circulating markers of inflammation and endothelial function are often increased in 
people with type 2 diabetes mellitus (T2DM), and have been associated with 
increased risk of cardiovascular disease and diabetes-related complications. Aerobic 
exercise has been shown to improve these biomarkers in adults with T2DM, but 
whether high-intensity progressive resistance training (PRT) with weight loss (WL) 
is effective remains uncertain. In this 12-month randomised controlled trial (RCT) 
we investigated the effects of PRT+WL versus WL alone on systemic and 
endothelial markers of inflammation, including serum interleukin-10 (IL-10), IL-6, 
tumour necrosis factor (TNF)-α, adiponectin, intercellular adhesion molecule-1 
(ICAM-1) and resistin, in older overweight adults with T2DM. Sedentary, 
overweight adults aged 60-80 years with poorly controlled T2DM were randomised 
to 6-months of supervised PRT+WL (n=19) or a supervised stretching (sham) 
program plus WL (n=17) followed by 6-months of home-training without dietary 
modification. DXA was used to assess total body fat mass and lean mass. Fasted 
blood samples were collected at baseline and subsequent 3-month intervals. Markers 
of inflammation were measured using a Milliplex immunoassay assay kit. Exercise 
compliance was similar between groups (phase 1, 86%; phase 2, 75%). Both groups 
lost similar amounts of weight and fat mass (P<0.01) during the supervised training, 
but PRT+WL had a net 0.9 kg gain in lean mass compared to WL (P<0.05) over the 
initial 6-months. These results were not maintained during the home-based training 
with similar significant increases in both groups for weight and fat mass (P range 
<0.05-0.01) compared to the 6-month mark. There were no significant within-group 
changes or between-group differences detected for any inflammatory or endothelial 
biomarker following the 6-month supervised exercise and WL phase. There was a 
greater reduction in IL-10 at 9-months in the PRT+WL relative to WL group 
(P=0.033). There was also a greater reduction in TNF-α at 9- and 12-months in the 
PRT+WL relative to WL group (P=0.026 and P=0.024, respectively). Serum 
adiponectin increased in the PRT+WL relative to WL group after 12-months 
(P=0.036). All results were adjusted for baseline values, age, weight, sex, diabetes 
duration, medication use and any change in medication. In conclusion, the main 
finding from this 12-month trial was that a 6-month moderate weight loss program 
with and without high-intensity gymnasium-based PRT did not change any markers 
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of systemic inflammation or endothelial function in older overweight adults with 
T2DM during weight loss. However, a further 6-months of continued home-based 
PRT independent of change in weight can result in some improvements in certain 
inflammatory markers in older overweight adults with type 2 diabetes compared to 
sham-exercise. 
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3.3  Introduction 
Type 2 diabetes is a common chronic disease that is currently estimated to affect 373 
million people globally (528). Although type 2 diabetes is considered a multifactorial 
disease caused by a combination of genetic and lifestyle-related factors, it has also 
been associated with an increase in circulating levels of pro-inflammatory cytokines 
including tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6) and high sensitive 
C-reactive protein (hs-CRP) with concomitant lower levels of anti-inflammatory 
markers such as interleukin-10 (IL-10) and adiponectin (529, 530). Clinically these 
changes in inflammatory cytokines are important as they have been associated with a 
decrease in beta-cell insulin secretion and an increase in insulin resistance (19, 20), 
along with the development and progression of various micro- and macro-vascular 
complications (16, 531). Thus, there has been considerable interest in identifying 
strategies that can improve the inflammatory profile of adults with type 2 diabetes. 
 
It is widely recognised that adipose tissue is an endocrine organ that can secrete a 
variety of inflammatory proteins (adipokines). As such, obesity has been associated 
with subclinical systemic inflammation, which may explain in part its link to insulin 
resistance and the development of T2DM (532, 533). To counter this increase in 
chronic systemic inflammation, weight loss or dietary modification are often 
recommended. In obese adults without diabetes and to a lesser extent people with 
T2DM, there is some evidence that diet induced weight loss can positively affect 
circulating pro-inflammatory cytokines and increase anti-inflammatory markers such 
as adiponectin (17, 33, 534, 535), but the findings remain mixed likely related to the 
magnitude of the weight loss (536, 537). Indeed, two studies have suggested the most 
consistent improvements in inflammatory markers are observed with at least a 10% 
reduction in weight (538, 539). 
Exercise training has also been shown to have a role in lowering chronic low-grade 
inflammation, particularly in people who are overweight or obese and/or have been 
diagnosed with a chronic disease (15). In a meta-analysis that included 14 RCTs in 
people with T2DM, Hayashino et al. (244) reported that exercise was associated with 
a significant decrease in circulating levels of hs-CRP and IL-6, but not adiponectin or 
resistin. It was also observed the greatest benefits were apparent following aerobic 
training, but only three resistance training trials were included and all were short-
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term (12- to 16-weeks). A recent 12-month intervention in older adults with T2DM 
found that progressive resistance training (PRT) alone was associated with a 
significant reduction in hs-CRP levels compared to sham exercise (238). 
Interestingly, the exercise-induced improvements in hs-CRP in this study were found 
to be mediated by both a reduction in fat mass and an improvement muscle mass 
(238). This suggests that the greatest benefits on inflammation may be achieved with 
fat loss combined with muscle gain. Recently, a limited number of studies in 
overweight and obese adults and those with T2DM have reported that exercise, 
primarily aerobic training, combined with weight loss arising from caloric restriction, 
is more effective at improving various inflammatory markers than either exercise or 
caloric restriction alone (31, 33, 34, 523, 540). However, the effects of PRT 
combined with weight loss on circulating inflammatory markers has not been 
examined in adults with type 2 diabetes. 
 
This study is a secondary analysis using archived blood samples and existing data 
from a 12-month RCT that was originally designed to examine the effects of PRT 
plus weight loss on glycaemic control and body composition compared to weight 
loss alone in older adults diagnosed with T2DM (12, 14). As previously reported, 6-
months of high-intensity PRT performed within a controlled and supervised research 
setting (gymnasium) in combination with weight loss was found to be effective for 
improving glycated haemoglobin (HbA1c), total body lean mass and muscle strength 
compared to weight loss alone in older adults with poorly controlled T2DM; both 
groups lost a similar amount of weight and fat mass. In addition, following a further 
6-months of home-based training with no further recommendations for weight loss, 
PRT performed at home was effective for maintaining the benefits on muscle mass 
and strength, but both groups experienced similar significant increases in weight, fat 
mass and HbA1c although overall body weight remained significantly lower than 
baseline levels in both groups (14). Building on these findings, the aim of this study 
is to investigate the effects of the 6-month supervised PRT plus weight loss 
intervention compared to weight loss alone and the subsequent 6-month home-based 
training on systemic and endothelial markers of inflammation, including serum IL-6, 
TNF-α, ICAM-1, resistin, IL-10 and adiponectin in older overweight adults with 
T2DM. It was hypothesised that PRT combined with weight loss would lead to 
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greater improvements in various inflammatory and endothelial markers than weight 
loss alone in older adults with T2DM. 
 
3.4  Methods 
3.4.1  Participants 
As previously described (12, 14), men and women aged between 60-80 years, with 
treated (diet and/or oral hypoglycaemic medications) T2DM, were recruited from the 
International Diabetes Institute clinics and a local media campaign. Detailed 
information on the recruitment methods and screening procedures have been 
previously published (12, 14). Participants were eligible for the study if they were: 
(1) overweight or obese (BMI>27 kg/m2 and ≤40 kg/m2); (2) not engaged in regular 
PRT and undertaking less than 150-minutes of brisk walking or moderate exercise 
per week or undertaking > 60-minutes of vigorous exercise per week in the preceding 
6-months; (3) had established but not optimally controlled T2DM (HbA1c range 7-
10%); (4) were not prescribed insulin and were non-smokers. Any prescribed anti-
diabetic and anti-hypertensive medications were continued during the study period.  
 
3.4.2  Study Design 
This study was a two arm, 12-month RCT that was separated into two distinct phases 
as previously reported and discussed in greater detail below (12, 14). Phase 1 
consisted of 6-months of supervised and structured gymnasium-based training (PRT 
or sham exercise) with moderate weight loss (WL). Phase 2 consisted of a further 6-
months of home-based PRT or sham-exercise training without specific dietary 
advice. Participants were randomised to one of the two groups by an independent 
staff member not involved in the study using a computer generated random numbers 
table (Microsoft Excel, Office 97). As shown in Figure 3.1, of the 36 participants 
initially randomised to either PRT+WL (n=19) or WL (n=17), 20 had a history of 
hypertension, three had a history of neuropathy, one had a history of retinopathy, and 
seven reported a history of arthritis. During phase 1, two participants from the 
PRT+WL group and four participants from the WL group withdrew from the study 
during the first 8-weeks. The reasons for withdrawal included health problems not 
related to the intervention (n=2) or other commitments that precluded ongoing 
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participation (n=4). One participant from the PRT+WL group was placed on insulin 
treatment within the first 6-weeks of the trial and was not included in any analysis. 
Thus, 29 participants [16 PRT+ WL (84%) and 13 WL (76%)] successfully 
completed phase 1 of the intervention (12, 14). During the home-based training, a 
further three participants withdrew from the study (PRT+WL, n=2; WL, n=1). All 
withdrawals occurred within the first 2-weeks of the home-based training. Reasons 
for withdrawals included overseas travel, continued pain associated with 
osteoarthritis of the knee and personal problems unrelated to the study. Thus, 72% of 
the participants [PRT+WL, n=14 (74%); WL, n=12 (71%)] completed the 12-month 
intervention. Outcome assessments for all participants were performed by the same 
research staff, but not all staff were blinded to the group allocation. 
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Figure 3.1: CONSORT flow diagram of participants through the trial. 
Progressive resistance training plus weight loss (PRT+WL); weight loss (WL). 
 
3.4.3  Ethics 
The study was approved by the International Diabetes Institute and Deakin 
University Human Research Ethics Committees. Written informed consent was 
obtained from all participants prior to their participation in the research program.  
 
3.4.4  Intervention 
This study was a 12-month RCT with measurements performed at baseline and 
subsequent 3-month intervals. As reported above, the intervention was divided into 
two distinct phases (supervised gymnasium based and home-based) which are 
described in detail below. 
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Phase 1: Supervised gymnasium-based training plus weight loss program 
Participants were randomly assigned to either PRT+WL (n=19) or a moderate weight 
loss group plus ‘sham’ exercise program (flexibility exercise) (WL, n=17). All 
training was conducted within a controlled exercise laboratory and participants were 
asked to train on three non-consecutive days per week. Those in the PRT+WL group 
performed a 5-minute warm up and 5-minute cool-down period of low-intensity 
stationary cycling and approximately 45-minutes of high-intensity PRT (dynamic 
exercise involving concentric and eccentric contractions). During the first and second 
weeks of training, the resistance was set at 50-60% of an individual’s 1-repetition 
maximum (RM). The 1-RM was defined as the maximum amount of resistance that 
could be moved through the full range of motion of an exercise for no more than one 
repetition. Thereafter, the goal for each training session was to lift a weight 
consistently between 75 and 85% of 1-RM. Participants followed an individually 
supervised PRT program using free weights and a multiple station weight machine. 
Nine exercises were used for training which included bench press, leg extension, 
upright row, lateral pull-down, standing leg curl (ankle weights), dumbbell seated 
shoulder press, dumbbell seated bicep curl, dumbbell triceps kickback and abdominal 
curls. All participants were instructed to perform each repetition in a slow, controlled 
manner, with a rest of 90- to 120-seconds between sets. Three sets of 8 to 10 
repetitions were performed for all exercises with the exception of abdominal curls at 
each training session. All sessions were supervised to ensure correct technique and to 
monitor the appropriate amount of exercise and rest intervals. The training work load 
was increased regularly as tolerated for each muscle group after participants had 
successfully achieved three sets of 10 repetitions with appropriate technique. Every 
12-weeks the 1-RM testing was repeated to establish a new baseline to maintain 
training intensity between 75-85% of 1-RM. Exercise compliance was computed 
from the exercise cards completed by the participants at each gym visit and checked 
by the research staff after each session. During the supervised gymnasium-based 
training phase compliance with the exercise program was 88% and 85% for the PRT 
+ WL and WL groups respectively.  
 
The ‘sham’ exercise program with WL was designed to only provide participative 
involvement but not elicit change in muscle strength, mass or cardiovascular fitness. 
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Each session involved stationary cycling with no workload for 5-minutes, followed 
by a series of static stretching exercises for approximately 30-minutes. Participants 
were not blinded to the treatments and were informed that improved flexibility was 
an expected outcome of the study.  
 
Weight loss/Healthy eating plan 
A healthy eating program was implemented under the supervision of a qualified 
dietitian four weeks prior to the commencement of phase 1. All participants were 
placed on a healthy eating plan supplying 30% or less of the total energy intake from 
fat (<10% from saturated fat), with the remainder distributed between carbohydrates 
and protein (12, 14). The healthy eating component of the study was designed to 
elicit a moderate weight loss of approximately 0.25 to 0.50 kg per week over the 
course of phase 1. All eating plans were individually prescribed by a dietitian 
calculated by utilising two separate 3-day food records performed during the initial 
4-week baseline period. The macronutrient breakdown of the diets was as follows: 
carbohydrate 55-60%, protein at least 0.8 g/kg, fat < 30%, cholesterol < 300 mg/day 
and fibre 40 g/day. Compliance with the healthy eating program was assessed via 
dietitian lead interviews every 2-weeks thereafter and by completion of a weekly 
food checklist. A 3-day food record was obtained at all subsequent assessments in 
order to evaluate changes in nutrient intake. Nutritional information obtained from 
food records was analysed by a dietitian using nutrient analysis software (Foodworks 
V2.10, Xyris Software, Queensland, Australia). 
 
Phase 2: Home-based Training 
At the completion of the gymnasium-based training, all participants were provided 
with individualised instructions and equipment (dumbbells/ankle weights or a 
flexibility wall chart) to continue the training at home or a commercial/community 
facility 3-days per week. No participants in the PRT+WL group continued their 
training programs within commercial or community facilities during this phase. To 
accommodate the transition from supervised gymnasium-based to home-based 
training, participants in the PRT+WL group completed their home-based exercise 
programs within the supervised gymnasium-based training phase for the final 4-
weeks of phase 1. The home-based exercises were similar to those used in the 
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gymnasium-based program, with the exception that dumbbells and ankle weights 
replaced the exercises performed on the multi-station weight machines. As reported 
previously in (14), the dumbbells provided for the home-based training provided 
capacity for workloads between 2.5 and 30 kg, and the ankle weights provided 
workloads between 0.5 and 20 kg. Additional weights were provided periodically to 
facilitate progression. The nine-home-based exercises included lying dumbbell flies, 
seated single leg-extension (ankle weighted), dumbbell shoulder press, dumbbell 
bent-over row, standing leg curl (ankle weights), dumbbell upright row, dumbbell 
triceps kickback and abdominal curls. Participants were also provided with detailed 
instruction booklets containing detailed descriptions on each resistance training 
exercise and how to safely perform these exercises, and were asked to follow an 
individually prescribed training program (3 sets of 8-10 repetitions) with the goal to 
exercise at an intensity corresponding to approximately 60-80% of the current 1-RM. 
However, it was estimated previously (14) that the volume of training reduced by 
~52% from the gymnasium-based program to the home-based program largely 
explained by the reduction in the amount of weight lifted. During the home-based 
training program, it was impossible to retain the absolute workload of the gym-based 
program as various exercises performed using machine weights had a total workload 
capacity much larger than that provided or available from hand or leg weights. 
During the first week of the home-based training, home visits were conducted to 
ensure the training environment was appropriate and safe. Participants were 
telephoned weekly for the first 4-weeks and every fortnight thereafter to monitor 
compliance, answer any questions and provide program feedback. In addition, 
participants recorded their training in training diaries each week and were asked to 
attend the gymnasium monthly to perform the home-based training program so that 
technique and progression could be monitored. During phase 2, participants were not 
required to follow a healthy eating plan, the monitoring and compliance with 
dietitians was ceased and participants were free to consume food ad-libitum. 
 
The sham exercise group was provided with a stretching wall chart and was asked to 
continue with the stretching program at home. Participants were telephoned weekly 
for the first 4-weeks and every 2-weeks thereafter to monitor compliance, answer 
questions and provide individualised feedback. All participants also completed 
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weekly training diaries and were required to attend Deakin University monthly to 
perform the home-based training so that technique and progression could be 
monitored. During the home-based training phase, exercise compliance was similarly 
reported at 73% and 78% in the PRT + WL and WL groups respectively. 
 
3.4.5  Measurements 
Detailed information about the methodology related to the key outcomes, including 
glycated haemoglobin, fasting plasma glucose (FPG), fasting insulin, insulin 
sensitivity, body composition and muscle strength, as well as height, weight, habitual 
physical activity and medication use, have previously been reported (12, 14).  
 
3.4.5.1  Cytokine and Endothelial Inflammatory Markers Measurements 
In order to measure cytokine and endothelial markers of inflammation morning blood 
samples were obtained from each participant following an overnight fast at baseline, 
3-, 6-, 9- and 12-months. All samples were collected at least 48-hours post-exercise. 
Of the 29 participants at baseline, two participants had insufficient serum available 
for analysis at baseline and 3-months with a further seven at 6-months. During the 
home-based training, five participants at 9-months and six participants at 12-months 
had insufficient serum available for analysis. The following parameters were 
measured by Cardinal Bio-research Pty Ltd (Australia) approximately 10-years after 
the trial was completed with the serum samples stored at -80º C during this time. 
Serum concentrations of IL-6, IL-10 and TNF-ɑ were measured in duplicate using a 
Millipore high sensitive cytokine immunoassay assay kit (Millipore Corp, Billerica, 
Massachusetts, USA) as per the manufacturer’s instructions. The mean intra and 
inter-assay CVs for IL-6, IL-10 and TNF-ɑ were <12%. The mean intra and inter-
assay CVs for adiponectin, ICAM-1 and resistin were <8%. Adiponectin, ICAM-1 
and resistin were assayed using an in-house multiplex immunoassay. Reagents were 
prepared as per previously described (541). Capture and detection antibodies were 
obtained from R&D Systems (Minneapolis, MN USA). The mean intra- and inter- 
assay CV was <8%. Samples with results below the lowest detectable limits of the 
assay were allocated the minimum detectable concentration: IL-6 = 0.1 pg/mL; IL-10 
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= 0.1 pg/mL; TNF-ɑ = 0.8 pg/mL; adiponectin = 0.01 µg/mL; ICAM-1 = 0.3 ng/mL 
and resistin = 0.05 ng/mL.  
 
3.4.6  Statistical Analysis 
Statistical analysis was conducted using Stata statistical software release 14 (College 
Station, TX: StataCorp LP.). All data was checked for normality and the cytokines 
IL-10, IL-6 and TNF-α, and the endothelial marker ICAM-1 were log-transformed 
prior to analysis to improve normality. The data was analysed on a modified 
intention-to-treat basis, including all randomly assigned participants with at least one 
follow-up observation. Linear mixed models with random intercepts were fitted for 
each outcome including fixed effects for time, group, and an interaction between 
group and time. The models were adjusted for baseline values (model 1) and 
baseline, age, weight, sex, diabetes duration, medication use and any change in 
medication during the intervention (model 2). Between-group differences were 
calculated by subtracting within-group changes from baseline for the PRT+WL 
group from within-group changes for the WL group after 3-, 6-, 9- and 12-months. 
Results from all models are reported as marginal means with 95% confidence 
intervals, back-transformed for any log transformed variables. No data imputation 
was used for missing data as one of the strengths of the linear mixed model is that it 
can handle missing data points without excluding participants. The percentage of 
change in results Figures 3.1 and 3.2 represents the absolute difference from baseline 
in the log transformed data multiplied by 100. P<0.05 was used to determine 
statistical significance. Data presented as mean ± SD unless otherwise specified. 
 
3.5  Results  
Baseline characteristics for the 29 participants included in the 12-month intervention 
have previously been reported and are shown in Table 3.1 (12, 14). There were no 
group differences in age, weight, BMI, diabetes duration, use of oral hypoglycaemic 
medication, energy intake or physical activity. Similarly, the groups were well 
matched for total body fat and lean mass (Table 3.1).  
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Table 3.1 Baseline descriptive characteristics of the PRT+WL and WL group. 
Reported previously in (12). 
 PRT + WL WL 
n 16 13 
Age (years) 67.6 ± 5.2 66.9 ± 5.3 
Sex (M/F) 10/6 6/7 
Duration of diabetes (years) 7.6 ± 5.4 8.8 ± 7.9 
Oral hypoglycaemic medication use (n) 15 10 
Weight (kg) 88.7 ± 10.9 89.5 ± 12.1 
Total body lean mass (kg) 33.1 ± 7.4 35.6 ± 6.8 
Total body fat mass (kg) 51.8 ± 8.1 49.7 ± 9.5 
BMI (kg/m2) 31.5 ± 3.4 32.5 ± 3.8 
HbA1c (%) 8.1 ± 1.0 7.5 ± 1.1 
Total energy intake (kcal/day) 1,783 ± 349 1,815 ± 431 
Estimated energy expenditure (kcal/day)1 3,022 ± 413 3,109 ± 428 
Values represent mean ± SD or number. 1 Calculated from 7-day recall.    
 
As already stated, the primary outcomes of the original trial have previously been 
published (12, 14). A brief summary of these published results is provided below for 
the reviewer’s benefit. Following the 6-month supervised training program, both the 
PRT+WL and WL groups experienced a similar significant reduction in weight 
(mean change ± SD; PRT+WL -2.5 ± 2.9 kg; WL -3.1 ± 2.1 kg) and total body fat 
mass (PRT+WL -2.4 ± 2.7 kg; WL -2.7 ± 2.5 kg) (12). In contrast, there was a net 
benefit of 0.9 kg (95% CI, 0.05–1.8) in total body lean mass to the PRT+WL group 
(group-by-time interaction, P<0.05). This was due to an increase in lean mass in the 
PRT+WL group (mean change, 0.5 kg (0.3, 0.7)) and decreased in the WL group 
(mean change, -0.4.kg (-0.7, -0.1)) (12). The PRT+WL program was also associated 
with a significant reduction in HbA1c [mean absolute change; -1.2% (95% CI, -1.7, -
0.7)] following supervised training relative to the WL group [-0.4% (95% CI, -0.9, 
0.1)] (group-by-time interaction, P<0.05) (12). As expected, the PRT+WL group 
experienced a significantly greater increase in both upper and lower body strength 
throughout the supervised training intervention compared to the WL group 
(interaction terms P<0.01) (12). Following home-based training, both groups 
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experienced similar significant increases in body weight compared to the end of the 
supervised-training [mean change (kg): PRT+WL, 1.4 kg (95% CI, 0.5, 2.3), WL, 
1.5 kg (95% CI, 0.4, 2.6)] and fat mass [PRT+WL, 1.8 kg (95% CI, 0.7, 2.7); WL, 
2.0 kg (95% CI, 0.8, 3.0)]. However, weight remained significantly lower than 
baseline in both groups (14). Lean mass did not change significantly in either group 
during the home-based training (6- to 12-months), but a significant 0.6 kg (95% CI, -
0.9, -0.4) reduction was observed in the WL group from baseline to 12-months 
(P<0.05). HbA1c levels increased significantly in both groups during the home-based 
training (both P<0.05), and the net benefit observed in the PRT+WL after the 
supervised training was not maintained following the 6-month home-based training. 
However, the improvements in upper and lower-body strength observed following 
supervised training in the PRT+WL group were maintained at the completion of the 
home-based training (14). 
 
3.5.1  Changes in Inflammatory Cytokines 
The baseline values and the percentage change from baseline in serum IL-10, IL-6 
and TNF-α for both groups across the supervised and home-based training are 
presented Table 3.2 and Figure 3.2. At baseline, serum IL-6 was higher in the 
PRT+WL compared WL group at baseline (P=0.05).  
 
Overall, there were no within-group changes or between-group differences for the 
change over time in serum IL-6, TNF-α or IL-10 after 3-, 6-, 9- or 12-months, with 
the exception of the following: 1) there was a significant decrease relative to baseline 
in TNF-α in the PRT+WL group at both 9-months [mean change, -1.26 pg/ml (95% 
CI, -2.37, -0.15); P=0.026] and 12-months [2.09 pg/ml (95% CI, -3.13, -1.06); 
P=0.001], which resulted in a significant difference for the change over time relative 
to the WL group [mean difference: 9-months, 2.37 pg/ml (95% CI, -4.37, -0.37); 
P=0.020; 12-months, 2.22 pg/ml (95% CI, -4.06, -0.38); P=0.018)] which remained 
unchanged after adjustment for age, sex, weight, duration of diabetes, use of oral 
hypoglycaemic medication and any change in medication 2) there was a meaningful 
between-group difference for the change in IL-10 after 9-months [mean difference, -
2.20 pg/ml (95% CI, -5.12, -0.71); P=0.138], which became significant after 
adjusting for confounders (P=0.033) including age, sex, weight, duration of diabetes, 
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use of oral hypoglycaemic medication and any change in medication. This was 
driven by a non-significant reduction in the PRT+WL group [mean change, 0.94 
pg/ml (95% CI, -2.23, 0.34); P=0.150] and non-significant increase in the WL group 
[1.26 pg/ml (95% CI, -1.32, 3.84); P=0.337]. 
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Table 3.2 Mean baseline values and the percentage change relative to baseline for serum IL-10, IL-6 and TNF-α for the PRT+WL and WL groups 
after 3-, 6-, 9- and 12-months.  
  Baseline Values and Within Group Changes  
 PRT+WL WL Intervention Effects 
 Mean ± SD or (95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P- values 
Model 1  |  Model 2 
IL-10       
  Baseline (pg/ml) 14.12 ± 19.17 ‡  4.20 ± 5.67    
  ∆ 3-month -0.80 (-2.10, 0.50) 0.227 -0.60 (-2.06, 0.87) 0.424 -0.20 (-2.20, 1.79) 0.840  |  0.524 
  ∆ 6-month -0.89 (-2.18, 0.40) 0.172 0.54 (-1.63, 2.70) 0.628 -1.43(-3.98, 1.12) 0.272  |  0.081 
  ∆ 9-month -0.94 (-2.23, 0.34) 0.150 1.26 (-1.32, 3.84) 0.337 -2.20 (-5.12, 0.71) 0.138  |  0.033 
  ∆ 12-month 0.13 (-1.82, 2.09) 0.894 -0.12 (-1.98, 1.74) 0.896 0.25 (-2.47, 2.99) 0.854  |  0.651 
IL-6       
  Baseline (pg/ml) 3.65 ± 3.06 ‡  1.61 ± 1.78    
  ∆ 3-month -0.41 (-0.94, 0.12) 0.126 0.24 (-0.58, 1.05) 0.571 -0.65 (-1.67, 0.37) 0.213  |  0.750 
  ∆ 6-month -0.17 (-0.80, 0.47) 0.605 0.33 (-0.57, 1.22) 0.472 -0.50 (-1.64, 0.65) 0.395  |  0.885 
  ∆ 9-month -0.48 (-1.02, 0.06) 0.084 0.99 (-0.19, 2.18) 0.101 -1.47 (-2.83, -0.12) 0.033  |  0.127 
  ∆ 12-month  -0.07 (-0.80, 0.66) 0.853 0.79 (-0.33, 1.91) 0.168 -0.86 (-2.25, 0.53) 0.227  |  0.624 
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TNF-α       
  Baseline (pg/ml) 8.23 ± 3.64  7.10 ± 5.02    
  ∆ 3-month -0.30 (-1.50, 0.91) 0.629 -0.04 (-1.37, 1.28) 0.947 -0.26 (-2.05, 1.55) 0.784  |  0.820 
  ∆ 6-month 0.14 (-1.19, 1.47) 0.834 0.84 (-0.75, 2.43) 0.299 -0.70 (-2.78, 1.38) 0.508  |  0.552 
  ∆ 9-month -1.26 (-2.37, -0.15) 0.026 1.11 (-0.54, 2.77) 0.188 -2.37 (-4.37, -0.37) 0.020  |  0.026 
  ∆ 12-month -2.09 (-3.13, -1.06) 0.001 0.13 (-1.39, 1.64) 0.871 -2.22 (-4.06, -0.38) 0.018  |  0.024 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). 
Intervention effect refers to the within group change from baseline in the intervention group minus the within group change from baseline in the 
control group. All change values and net differences were derived from model 1 – adjusting for baseline values. Significant differences are 
highlighted in bold. a P<0.05 vs WL at baseline. Model 1 represents the P-values after adjusting for baseline values. Model 2 represents the P-value 
after adjusting for baseline values, age, weight, sex, diabetes duration, medication use and any change in medication.   
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3.5.2  Change in Adiponectin 
At baseline adiponectin was lower in the PRT+WL compared WL group (P=0.004). 
Adiponectin levels remained unchanged in the both the PRT+WL and WL group 
across the supervised-gymnasium-based training program (Table 3.3 and Figure 3.2). 
During the home-based phase, levels of adiponectin in the PRT+WL group increased 
by an average of 0.49 µg/ml [(95% CI, 0.03, 0.96); P=0.036] relative to baseline after 
12-months, such that there was a significant group-by-time interaction when 
adjusting for potential confounders (Model 2, P=0.036). 
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Table 3.3 Mean baseline values and the percentage change from baseline for serum adiponectin in the PRT+WL and WL groups after 3, 6, 9 and 
12-months. 
  Baseline Values and Within Group Changes  
 PRT+WL WL Intervention Effects 
 
Mean ± SD or 
(95% CI) 
P-value 
Mean ± SD or 
(95% CI) 
P-value 
Net Difference  
(95% CI) 
P- values 
Model 1  |  Model 2 
Adiponectin       
  Baseline (µg/ml) 1.68 ± 0.66 ‡  2.67 ± 0.95    
  ∆ 3-month 0.08 (-0.32, 0.48) 0.700 0.27 (-0.15, 0.70) 0.206 -0.19 (-0.80, 0.42) 0.534  |  0.722 
  ∆ 6-month 0.23 (-0.19, 0.64) 0.278 0.25 (-0.21, 0.70) 0.287 -0.02 (-0.66, 0.62) 0.958  |  0.813 
  ∆ 9-month 0.47 (0.03, 0.90) 0.034 0.49 (0.05, 0.94) 0.030 -0.02 (-0.67, 0.61) 0.933  |  0.789 
  ∆ 12-month 0.49 (0.03, 0.96) 0.036 -0.10 (-0.57, 0.36) 0.661 0.59 (-0.07, 1.27) 0.081  |  0.036 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). 
Intervention effect refers to the within group change from baseline in the intervention group minus the within group change from baseline in the 
control group. All change values and net differences were derived from model 1 – adjusting for baseline values. Significant differences are 
highlighted in bold. a P<0.05 vs WL at baseline. Model 1 represents the P-values after adjusting for baseline values. Model 2 represents the P-value 
after adjusting for baseline values, age, weight, sex, diabetes duration, medication use and any change in medication.  
 Page | 130 
	
 
Figure 3.2: Mean percentage change with 95% CI from baseline for serum A) IL-10, B) TNF-α, C) IL-6 and D) Adiponectin following the 
gymnasium-based (3 and 6-months) and home-based (9 and 12-months) training for the PRT+WL (●) and WL (○) groups. The percentage changes 
in log transformed IL-6, IL-10 and TNF-ɑ represent the absolute differences from baseline multiplied by 100. * P<0.05, † P<0.01 for within-group 
change from baseline; # P<0.05 for between-group difference for the change from baseline. All P-values are based upon results adjusted for 
covariates. 
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3.5.3  Changes in Endothelial Markers 
In both the PRT+WL and WL group, there were no significant within or between-
group differences (group-by-time interactions) in either resistin or ICAM-1 at any 
time during the study (Table 3.4 and Figure 3.3), with the exception that resistin 
decreased significantly in the WL group relative to baseline at 12-months [mean 
change -20% (95% CI, -40, 1), P= 0.01]. All results remained unchanged following 
adjustment for age, sex, duration of diabetes, use of oral hypoglycaemic medication 
and any change in medication.
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Table 3.4 Mean baseline values and the percentage change from baseline for serum ICAM-1 and resistin for the PRT+WL and WL groups after 3, 6, 9 
and 12-months. 
  Baseline Values and Within Group Changes  
 PRT+WL WL Intervention Effects 
 Mean ± SD or (95% CI) P-value 
Mean ± SD or 
(95% CI) P-value 
Net Difference  
(95% CI) 
P- values 
Model 1  |  Model 2 
ICAM-1         
  Baseline (ng/ml) 134.86 ± 59.58  142.38 ± 69.44    
  ∆ 3-month 2.37 (-9.36, 14.10) 0.692 1.78 (-10.34,13.90) 0.773 0.59 (-16.25, 17.44) 0.945  |  0.970 
  ∆ 6-month  0.18 (-11.71, 12.06) 0.977 -8.76 (-20.72, 3.19) 0.151 8.94 (-7.90, 25.79) 0.298  |  0.355 
  ∆ 9-month -7.81 (-19.29, 3.66) 0.182 -0.80 (-13.61, 12.02) 0.903 -7.02 (-24.22, 10.18) 0.424  |  0.462 
  ∆ 12-month -12.64 (-24.58, -0.70) 0.038 -10.03 (-22.37, 2.31) 0.111 -2.61 (-19.79, 14.56) 0.766  |  0.797 
Resistin       
  Baseline (ng/ml) 10.54 ± 5.64  10.99 ± 3.86    
  ∆ 3-month 1.16 (-0.14, 2.46) 0.080 0.59 (-0.71, 1.89) 0.373 0.57 (-1.27, 2.41) 0.542  |  0.417 
  ∆ 6-month 0.53 (-0.82, 1.87) 0.441 -0.02 (-1.42, 1.38) 0.979 0.55 (-1.40, 2.49) 0.581  |  0.267 
  ∆ 9-month -0.23 (-1.57, 1.11) 0.736 0.39 (-1.01, 1.80) 0.584 -0.62 (-2.57, 1.32) 0.530  |  0.921 
  ∆ 12-month -1.97 (-3.44, -0.50) 0.008 -0.84 (-2.31, 0.63) 0.263 -1.13 (-3.21, 0.95) 0.286  |  0.618 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention 
effect refers to the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All 
change values and net differences were derived from model 1 – adjusting for baseline values. Significant differences are highlighted in bold. Model 1 
represents the P-values after adjusting for baseline values. Model 2 represents the P-value after adjusting for baseline values, age, weight, sex, diabetes 
duration, medication use and any change in medication.   
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Figure 3.3: Mean percentage change with 95% CI from baseline for serum A) 
ICAM-1 and B) Resistin following the gymnasium-based (3- and 6-months) and 
home-based (9- and 12-months) training for the PRT+WL (●) and WL (○) group. 
The percentage changes in log transformed ICAM-1 represent the absolute 
differences from baseline multiplied by 100. All P-values are based upon results 
adjusted for covariates. 
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3.6  Discussion 
It is well established that obesity is associated with subclinical systemic 
inflammation (542) and that dietary-induced weight loss can lower circulating 
inflammatory cytokines (543, 544) including in people with T2DM (545). There is 
also evidence that regular exercise training including aerobic training, PRT and the 
combination, can lower pro-inflammatory cytokines and increase anti-inflammatory 
markers in overweight and obese adults (15) and those with T2DM (33, 34, 244). On 
this basis, we hypothesised that combining PRT with weight loss would lead to more 
favourable changes in circulating markers of inflammation compared to weight loss 
alone. However, we found no evidence that moderate diet-induced weight loss alone 
or in combination with supervised high-intensity PRT influenced any marker of 
inflammation in older overweight and obese adults with T2DM, despite significant 
reductions in weight and fat mass (12). Whilst there is some evidence to suggest 
inflammatory cytokines undergo some degradation when stored for longer than three 
years (546), all inflammatory markers in this study were analysed at the same time 
and thus were all under storage for a similar length of time. 
 
Previous studies examining the combined effects of weight loss and exercise training 
on inflammatory markers in older obese adults with T2DM are scarce. Nevertheless, 
the findings from a 16-week intervention in 34 obese women aged 40-60 years 
revealed neither diet alone nor diet plus PRT performed twice per week led to any 
changes in circulating levels of IL-6 or CRP and the soluble receptors of TNF-α, 
despite a 6 to 8% reduction in total body weight (523). It is difficult to explain our 
results and these findings given that a number of interventions in overweight and 
obese adults (31, 534, 547, 548) and a larger intervention in adults with T2DM (34) 
reported that diet-induced weight loss, alone or in combination with exercise, was 
associated with a significant reduction in various inflammatory cytokines. For 
instance, the findings from a 12-month multi-centre RCT in 593 individuals with 
newly diagnosed T2DM revealed that diet-induced weight loss alone or in 
combination with regular physical activity (30 minutes of brisk walking) was 
associated with a significant 21-22% reduction in hs-CRP levels (and an 
improvement in adiponectin) after 6-months compared to usual care (34). However, 
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there was no differences in the magnitude of the change in hs-CRP between the 
weight loss alone and weight loss plus exercise group. Subsequent analysis found 
that the change in weight mediated around 40% of the total effect on hs-CRP (34). 
Although there is evidence that regular exercise can lower systemic inflammation, 
independent of changes in body composition (534), this finding is consistent with a 
number of previous trials which found that changes in circulating inflammatory 
cytokines in response to lifestyle interventions were largely related to weight loss 
and not exercise (31, 549).  
 
In our study, the moderate weight loss diet resulted in similar significant reductions 
in body weight of 2.8% and 3.5% in the PRT+WL and WL alone groups 
respectively. While it has been previously suggested that at least a 10% reduction in 
body weight is required to induce a reduction in various inflammatory markers (538), 
others have demonstrated that a 5% decrease in body weight can improve the 
inflammatory profile in obese adults or those with T2DM (17, 544). The healthy 
eating plan was expected to reduce body weight by almost double the amount 
observed in our trial, as such it is plausible the lack of significant change in any of 
the inflammatory markers in either group in our study during the initial 6-month 
period is explained, at least in part, by the smaller reduction in body weight . 
Secondary to this, another possible explanation may be the absence of change in 
visceral fat. Visceral fat is widely recognised to be a key secretory source for various 
systemic inflammatory markers or adipokines, and thus is it possible that the 
magnitude of the change in visceral fat in our participants was not enough to improve 
inflammation. This is only speculative given that visceral fat was not directly 
quantified in our study, however, both groups experienced a similar and significant 
6.7 to 7.0 cm reduction in waist circumference after 6-months, which is often used as 
surrogate estimate of visceral adiposity (550, 551). A more likely explanation for the 
lack of any changes in any of the inflammatory markers in our study is the relatively 
modest (mean 2.5 to 3.0 kg) reductions in overall weight (and fat mass). 
Interestingly, another study in obese adults with T2DM reported no improvements in 
inflammation (hs-CRP) following a 5-6 kg diet-induced weight loss over an 8-week 
period, but improvements were observed after 12-months (288). Similarly, a 4-month 
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trial in 27 obese adults with T2DM failed to detect any changes in any markers of 
inflammation (CRP, IL-1, IL-2, IL-6, IL-8, IL-10, TNF-a) following a very low 
caloric diet (VLCD) or VLCD plus exercise, with the exception of a reduction in hs-
CRP in the combination group (35). However, in this study the mean reduction in 
weight was 25 kg, and at subsequent follow-ups (6- and 18-months) whereby 
participants were in a eucaloric state, significant beneficial effects were observed for 
nearly all inflammatory markers. These findings suggest that the duration of the 
study or follow-up period may be an important factor in determining the 
inflammatory response to lifestyle-related interventions.  
 
Following the 6-month supervised gymnasium-based training plus weight loss 
program, we found that 6-months of continued home-based resistance training 
resulted in modest improvements in the inflammatory markers TNF-α and 
adiponectin, yet a reduction in the anti-inflammatory marker IL-10. This was 
somewhat unexpected given that this phase was eucaloric and associated with a 1.3 
to 1.5 kg weight regain in both groups. Nevertheless, the improvements in various 
inflammatory markers following the home-based maintenance phase supports the 
notion that there may be a delay in the inflammatory response to exercise and/or 
weight loss. Although there is evidence of acute or short-term changes 
(improvements) in markers of inflammation following exercise and/or weight loss, as 
discussed above the findings from our 12-month intervention are consistent with the 
results from several trials which observed a delayed improvement in inflammatory 
markers in both overweight and obese adults and those with T2DM (35, 539). While 
the underlying mechanism(s) explaining these findings remain unknown, several 
other studies observing a delay in inflammatory marker improvements following 
exercise and/or weight loss have proposed this to be due to the effects of such 
lifestyle interventions on adipose tissue lipolysis (35, 552). The components of total 
lipolysis are the sum of “basal lipolysis”, which appears elevated in the presence of 
adiposity and is greater in visceral adipose tissue compared to subcutaneous adipose 
tissue, plus “demand lipolysis”, which is a consequence of nutritional demand (35). 
It has been suggested that in the early stages of weight loss, adipocyte size does not 
change and therefore basal lipolysis remains high, yet following continued weight 
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loss (and during a eucaloric phase), demand lipolysis is reduced with lower local free 
fatty acid levels (35). This lower level of local free fatty acids is proposed to be 
associated with a reduced number of adipose tissue macrophages and a decrease in 
the free fatty acid-driven cytokine production, and consequentially a reduction in 
circulating cytokines (35). A study in mice found that this does occur (553), yet this 
hypothesis requires further investigation in humans but does provide a plausible 
explanation for the observations made during the second phase of our intervention. 
 
While there is some evidence that long-term exercise training, including PRT, can 
improve circulating levels of inflammatory markers (554-556), we found no 
evidence that our program of high-intensity PRT combined with weight loss 
improved any marker of inflammation in overweight and obese adults with T2DM. 
However, as reported above we found that during the less intense home-based 
training there were modest improvements in circulating levels of TNF-α and 
adiponectin, compared to sham-exercise. This is consistent with the findings from 
previous studies which have also reported mixed findings with regards to the effects 
of PRT on inflammatory cytokines in adults with T2DM (523, 540). Although 
factors such as age, fitness level, degree of adiposity, as well as the presence of other 
comorbid conditions are likely to have contributed to the mixed findings in various 
interventions, there is also evidence that differences in exercise duration, intensity 
and frequency can influence the inflammatory response to exercise. Indeed, the 
findings from a meta-analysis of exercise interventions on inflammatory markers in 
adults with T2DM found that mostly aerobic, but some PRT programs of longer 
duration or which had a larger number of total training sessions, were associated with 
the greatest benefits for circulating IL-6 levels (244). Similarly, it has been reported 
that interventions of 16-weeks or longer and/or with training intensities of at least 
80% of 1-RM may influence the inflammatory responses to PRT (557, 558). In light 
of these findings, it is somewhat surprising that our 6-month high-intensity PRT 
program, where training was prescribed three times per week at an intensity of 75-
85% 1-RM and compliance was high averaging 2.8 out of three sessions per week, 
did not have an effect on markers of inflammation assessed, particularly given the 
significant beneficial effects on HbA1c and the improvements in fat mass and lean 
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mass in the PRT+WL group. In part support of these findings, another meta-analysis 
of eight RCTs found that there were no differences between the PRT and control 
group for the change in serum concentrations of adiponectin, leptin, IL-6 and TNF-ɑ, 
but PRT was associated with a significant reduction in circulating CRP relative to 
controls (559). In addition, meta-regression revealed no dose-response relationship 
between PRT intensity and changes in inflammatory response. It is evident from the 
above findings that there is considerable heterogeneity across studies concerning the 
effects of PRT on inflammatory biomarkers, and thus further studies remains 
warranted.  
 
Like systemic inflammatory markers, endothelial markers such as ICAM-1 and 
resistin are also significantly elevated in adults with T2DM (560). In our study, we 
observed no changes in either ICAM-1 or resistin following the supervised 
gymnasium- or home-based resistance training. This is consistent with the findings 
from several previous trials which also examined the effects of resistance training on 
endothelial functioning in older adults with T2DM yet observed no effect (561, 562). 
For example, Kwon et al. (562), investigated the effects of aerobic or resistance 
training on endothelial function as assessed by flow-mediated dilation, in 40 older 
overweight women with T2DM compared to a control program (562). Participants 
randomised to aerobic or resistance training completed 60 minutes of training, 5 days 
per week for 12-weeks, whilst the control program did not exercise (562). At the 
completion of the intervention, endothelial function was improved in the resistance 
and aerobic training group, however, the improvement was only significant for the 
aerobic training group (2.2 ± 1.9%, P=0.002 compared to control) (562). Whilst the 
exact mechanisms by which exercise training can improve endothelial function 
remain unknown, it has been suggested that the mode of training is an important 
factor. For instance, there is evidence for a positive effect on various endothelial 
markers following aerobic training in adults with chronic disease such as chronic 
heart failure, which has been related to the more consistent increase in blood flow 
and laminar shear stress associated with this mode of training (563, 564). 
Furthermore, aerobic training also results in greater improvements in 
cardiorespiratory fitness which may translate into improved vascular endothelial 
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functioning and in turn reduce the endothelial expression of cellular adhesion 
molecules (561, 562, 565, 566). Therefore, the lack of any changes in any endothelial 
marker in either group in our study may be due to the absence of an aerobic 
component in the exercise program. As the precise mechanism(s) responsible for any 
improvements in endothelial function in older adults with T2DM remain unidentified 
and there is only limited evidence that PRT either with or without weight loss 
confers improvements in endothelial markers in older adults with T2DM (567), 
further research in this area is required.   
 
3.7  Limitations 
There are a number of limitations associated with this study which must be 
considered when interpreting the findings. First, although multiple cytokines 
reflective of systemic inflammation were assessed, hs-CRP, a more global and 
universal inflammatory marker for which there is clinical reference values, was not 
measured. Second, our study was limited to an assessment of circulating 
concentrations of various cytokines which have a short half-life, and a measure 
cytokine soluble receptors may be more representative of the inflammatory response 
(568). Third, a key goal of the healthy eating program was to reduce body weight by 
0.25-0.5 kg per week totalling approximately 6 kg over the duration of phase 1. The 
total amount of weight lost was only approximately half this which may in part 
explain the lack of significant improvement in levels of inflammatory markers 
assessed in this study. Further, our study was a secondary analysis and limited by a 
relatively small sample size, and given the known variability in inflammatory 
cytokines, it is likely that our study was underpowered to detect any potential 
between group differences. Finally, when interpreting our findings, it is important to 
acknowledge the long-time period (10-years) that the serum samples were stored 
prior to analysis. Thus, it is possible that there was degradation in the various 
cytokines during this time as there is some evidence that inflammatory markers 
degraded by up to 50% over a period of 2-3 years. Few studies have examined the 
stability of serum samples and the inflammatory markers measured in this trial, 
however, de Jager et al. (568) measured the effects of long time storage (up to 4 
years) on IL-6 and IL-10 and observed these inflammatory markers degraded by 50% 
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or less of the baseline value within 2-3 years of storage. A strength of our analysis 
though was that all samples were stored for the same amount of time and thawed and 
analysed simultaneously. It is also worth noting that a comparison of the mean 
baseline values of the participants in our study was similar to that previously 
published in our laboratory in healthy older men where samples were stored for only 
12- to 24-months using the same methodology (42, 569). 
 
3.8  Conclusion 
The main finding from this 12-month trial was that a 6-month moderate weight loss 
program with and without high-intensity gymnasium-based PRT did not change any 
markers of systemic inflammation or endothelial function in older overweight adults 
with T2DM. However, a further 6-months of continued home-based PRT 
independent of weight loss did result in modest improvements in the inflammatory 
markers TNF-α, IL-10 and adiponectin, compared to sham-exercise. These 
improvements may be beneficial to overweight older adults with T2DM given the 
close association of adverse CV health and systemic inflammation. Future trials 
remain necessary to optimise PRT prescription for the improvement of markers of 
inflammation in overweight older adults with T2DM. In addition, future trials with 
larger sample sizes are required to investigate if an improvement in inflammation as 
a result of participation in a PRT program is related to improvements in glycaemic 
control, insulin sensitivity and/or changes in body composition.  
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4.1  Declaration Statement 
The PhD student was responsible for developing the intervention testing and protocol 
booklet which outlined the specific methodology to be used for each of the outcome 
measures assessed. The student was also responsible for developing questionnaires, 
screening forms, trainer guide books/exercise cards, compliance calendars, monthly 
phone call forms and co-ordinating the 21-month recruitment campaign for the RCT 
outlined in this Chapter. The student was also responsible for co-ordinating several 
training sessions of qualified personal trainers/exercise physiologists who were not 
Lift for Life® accredited under Fitness Australia. The student commenced her PhD 
studies on a grant which had already been awarded funding and thus was not 
involved in the conceptualisation of this project thus was not first author on the 
methodology publication.  
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4.2  Abstract 
While physical activity, energy restriction and weight loss are the cornerstone of type 
2 diabetes mellitus (T2DM) management, less emphasis is placed on optimising lean 
mass. As muscle is the largest mass of insulin-sensitive tissue and the predominant 
reservoir for glucose disposal, there is a need to develop safe and effective evidence-
based lifestyle management strategies that optimise lean mass as well as improve 
glycaemic control and cardiovascular risk factors in people with this disease, 
particularly older adults who experience accelerated muscle loss. Using a two-arm 
randomised controlled trial (RCT), this 6-month study builds upon the community-
based progressive resistance training (PRT) programme Lift for Life® to evaluate 
whether ingestion of a whey-protein drink combined with vitamin D supplementation 
can enhance the effects of PRT on glycaemic control, body composition and 
cardiovascular health in older adults with T2DM. Approximately 200 adults aged 50 
to 75 years with T2DM, treated with either diet alone or oral hypoglycaemic agents 
(not insulin), were recruited. All participants were asked to participate in a 
structured, supervised PRT programme based on the Lift for Life® programme 
structure, and randomly allocated to receive a whey-protein drink (20 g daily of 
whey-protein plus 20 g after each PRT session) plus vitamin D supplements (2,000 
IU/day), or no additional powder and supplements. The primary outcome measures 
collected at baseline, 3- and 6-months were glycated haemoglobin (HbA1c) and 
insulin sensitivity (homeostatic model assessment). Secondary outcomes included 
changes in: muscle mass, size and intramuscular fat; fat mass; muscle strength; blood 
pressure; levels of lipids, adipokines and inflammatory markers, serum insulin-like 
growth factor-1 and 25-hydroxyvitamin D; renal function and change in diabetes 
medication. The findings from this study will provide new evidence as to whether 
increased dietary protein, achieved through the ingestion of a whey-protein drink, 
combined with vitamin D supplementation, can enhance the effects of PRT on 
glycaemic control, muscle mass and size, and cardiovascular risk factors in older 
adults with T2DM. 
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4.3  Methods 
4.3.1  Study Design  
The Resistance Exercise, Vitamin D and Muscle Protein Intervention Trial 
(REVAMP-IT) was a 24-week two-arm parallel, RCT. Participants with established 
T2DM who were suitable for the current community-based Lift for Life® resistance 
training program and met trial inclusion criteria (refer to section 4.2.6 Screening and 
Eligibility) were randomised to one of two groups: 1) the Lift for Life® program 
combined with a whey-protein drink and vitamin D supplementation or 2) the Lift for 
Life® program alone. The participants randomised to Lift for Life® alone did not 
receive placebo supplements. A placebo product was not used in this trial as it 
became evident through consultation with the manufacturer of the whey-protein 
drink that ingredients used to develop a placebo for use in this trial (e.g. using 
maltodextrin as a food additive) had the potential to alter blood glucose levels or 
influence muscle mass, which are two key outcomes for this trial. Thus, to avoid any 
potential adverse (or positive) effects on blood glucose levels of the participants 
assigned to this group, no placebo products were prescribed. We believed this would 
not compromise trial outcomes and that there was a strong justification for not 
including a matched placebo in this trial. It should also be noted that the selection of 
a two-arm design (e.g. lack of a true ‘non-exercise’ control arm) was consistent with 
our primary research objectives which sought to examine the effectiveness of the 
addition of whey-protein and vitamin D to an existing community-based PRT 
program (Lift for Life®). All research staff, except the project manager, were blinded 
to the intervention groups. The project manager was solely responsible for the 
distribution of whey-protein and vitamin D supplements to those in the Lift for Life® 
program plus protein and vitamin D arms. The study was coordinated from the 
Melbourne metropolitan campus of Deakin University (Melbourne, Victoria, 
Australia).  
 
4.3.2  Ethics  
Ethics was approved by the Deakin University Human Research Ethics Committee: 
Project number EC2013-050, Does a whey-protein enriched drink and vitamin D 
enhance the health benefits of the Lift for Life® resistance training program in older 
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adults with type 2 diabetes? (Appendix 4). This study was also registered with the 
Australian New Zealand Clinical Trials Registry, registration number 
ACTRN12613000592741.  
 
4.3.3  Funding 
This project was funded by a grant from the National Health and Medical 
Research Council Project (APP1046269). The whey-protein powder was provided by 
OmniBlend (Campbellfield, Victoria, Australia) and the vitamin D supplements 
(Ostelin) by Sanofi-Aventis Australia Pty Ltd (Macquarie Park, New South Wales, 
Australia).  
 
4.3.4  Participants 
Men and women aged 50 to 75-years with established T2DM, treated with diet alone 
or any oral hypoglycaemic agents (except insulin), were invited to participate in this 
study.  
 
4.3.5  Recruitment 
Recruitment methods used for this RCT are extensively discussed in Chapter 5 of 
this thesis. Briefly, recruitment occurred via targeted mail-outs to registrants of The 
National Diabetes Support Scheme (NDSS) database. Recruitment for this trial was 
further supplemented by a number of State and local media campaigns including 
newspaper advertisements, web-based media and notices at current Lift for Life® 
facilities, recruitment was also further supplemented by referrals from general 
practitioner (GP) and other allied health professionals including dieticians, 
endocrinologists, diabetes educators and local support groups.  
 
4.3.6  Screening and Eligibility  
A two-step screening process was employed in this study. Firstly, a telephone 
screening questionnaire (Appendix 5) was used to assess an individual’s eligibility. 
Participants were eligible if aged 50-75 years, had been diagnosed with established 
T2DM and were treating their condition with diet or oral hypoglycaemic medication 
only. Participants were excluded from the trial based on the criteria outlined in Table 
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4.1. Those who passed the telephone screening were then required to gain GP 
approval prior to randomisation and participation in the Lift for Life® program 
(second screening step). Medical clearance was deemed to have been approved by 
the participants GP upon completion of a Lift for Life® Recommendation to 
Participate Form based on guidelines published by the Australian College of Sports 
Medicine (ACSM) (refer to Appendix 6). All enrolled participants were encouraged 
and monitored to keep constant the use of lipid-lowering or anti-hypertensive 
medication throughout the trial and were additionally instructed to not modify their 
lifestyle habits other than necessary for the trial. In order to increase the external 
validity of this study and due to the lack of consensus regarding optimal serum 
vitamin D concentration, vitamin D status was not used as exclusion or inclusion 
criteria but was measured as part of the biochemical analysis post-randomisation.  
 
Table 4.1: Ineligibility criteria for the 24-week Lift for Life® RCT. 
Health-related 
  Not diagnosed with T2DM 
  Any medical condition contraindicated to PRT 
  BMI >40kg/m2 
  HbA1c >10% 
  Presence or indication of kidney disease 
  Current smoker 
Physical Activity Status 
  Meeting or exceeding National Physical Activity Guidelines   
Medication or Supplement Use 
  Prescribed insulin for management of T2DM 
  Taking vitamin D supplements >500IU/day 
  Taking dietary protein supplements 
Travel 
  Travel plans which impeded participation in the trial 
Other 
  Aged <50 or >75 years of age 
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4.3.7  Consent  
Following completion of the telephone screening questionnaire, eligible participants 
were provided with a Plain Language Statement (PLS) and Consent Form (refer to 
Appendix 7). Participants who wished to proceed with their involvement in this RCT 
were invited to complete baseline testing at Deakin University. Following baseline 
testing, participants were randomised to the Lift for Life® PRT program plus whey-
protein and vitamin D group or the Lift for Life® PRT program only group. 
 
4.3.8 Randomisation  
Randomisation occurred at the level of the individual participant, stratified by gender 
and diabetes treatment (diet or oral hypoglycaemic medication), in blocks of 4-8 
using a computer-generated random number sequence (Microsoft Excel 97) by an 
independent researcher. As mentioned previously, all research staff except the 
project manager were blinded to the intervention groups. The project manager was 
solely responsible for the distribution of protein and vitamin D supplements to those 
in the Lift for Life® program plus whey-protein and vitamin D arms. 
 
4.3.9  Intervention 
Lift for Life®: A community-based progressive resistance training program 
All participants involved in this trial were required to follow a training program 
modelled off the structure of the Lift for Life® PRT program. The Lift for Life® 
program is an evidence-based PRT program designed for people with diabetes or 
those at risk of developing T2DM. The program was developed based upon a series 
of previous laboratory and community-based exercise intervention trials (12, 204, 
205). Lift for Life® is a commercial program with a limited number of accredited 
training sites in Melbourne licensed and currently running the program which is 
overseen by Fitness Australia in collaboration with Baker IDI Heart and Diabetes 
Institute. The Lift for Life® program comprises moderate-intensity PRT (2-3 sets of 
8-12 repetitions at 60-75% of maximum strength of 8-10 exercises) involving 
dynamic concentric and eccentric contractions, focusing on the major muscle groups 
of the body. Some examples of the exercises used throughout the program include 
bench press, leg extension, upright row, lateral pull down, standing leg curl, 
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dumbbell seated shoulder press, dumbbell seated biceps curl, dumbbell triceps 
kickbacks and abdominal curls. Training was made incrementally more challenging 
at a rate of 2-10% per week to meet the principles of progressive overload with the 
Borg Rating of Perceived Exertion (RPE) scale used to validate training intensity. An 
appropriate training intensity level for this trial was established as 12 to 15 (moderate 
to high-intensity) on the RPE scale. The RPE scale has previously been validated for 
use in older adults with T2DM and found to appropriately measure exercise intensity 
(570). 
 
Due to the limited number of accredited Lift for Life® program providers in 
Melbourne Australia, the trial was expanded to include training locations such as 
commercial gymnasiums that were not accredited as a Lift for Life® program 
provider but which did allow participants to safely perform a PRT program under the 
guidance of qualified Certificate IV personal trainers. In such instances, the structure 
of the training programs for these participants replicated that of the Lift for Life® 
program. The same progressive overload and training principles were applied, 
consequently, all trial participants followed the same training program as discussed 
below. 
 
 
Figure 4.1: Flow diagram of the progress through the 24-week PRT program used in 
this trial modelled from the Lift for Life® program. 
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The 24-week Lift for Life® program is divided into three distinct phases (Bronze, 
Silver and Gold), each running for a period of eight weeks as shown above in Figure 
4.1. During the initial phase (Bronze), participants were asked to attend two PRT 
sessions per week. After eight weeks, participants commenced the second eight-week 
phase (Silver), but with the aim to participate in one additional PRT session to 
achieve the goal of three PRT sessions per week. The final phase (Gold) was a 
replication of the Silver phase. Throughout the program all completed exercises, sets 
and reps for each session were documented on Lift for Life® training cards. All 
training cards were collected and reviewed at the completion of the first four weeks 
of training with programs modified as required by the trainers. Subsequently, every 
eight weeks training programs, reported intensity and progressive overload were 
reviewed by Lift for Life® trainers or Certificate IV personal trainers and if required 
a new program was developed to maintain the training intensity at 12-15.  
 
To enhance participation in and retention of participants in this 24-week program 
participants received monthly follow-up phone calls from the research staff to 
enquire about their experiences at their respective training locations and discuss any 
issues or concerns they had experienced with the training program or with their 
trainers. Finally, to further promote adherence to the Lift for Life® PRT program all 
participants were eligible to receive up to AUD$240 by way of vouchers to cover the 
costs associated with their participation in the Lift for Life® program. The full 
reimbursement was provided to all participants who achieved 80% or above 
compliance with the exercise program, calculated from the Lift for Life® self-
completed exercise cards (see below section 4.2.11.9  Compliance Assessment for 
further information). Costs of the PRT program ranged from $3-$12 per session and 
were set by the training location.   
 
Whey-Protein and Vitamin D Supplementation 
Participants randomised to the Lift for Life® plus whey-protein and vitamin D 
supplementation group received a 12-week supply of a whey-protein enriched 
powder and vitamin D supplements at baseline testing and again after 12-weeks of 
training. Supplements were provided in single use sachet form with a number code 
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(OmniBlend, Campbellfield, Victoria, Australia) (Figure 4.2). Participants were 
instructed to mix one sachet containing 20 g of whey-protein concentrate 80% 
(WPC80), containing 2.4 g of leucine, with 150ml of water every morning of the trial 
and consume an additional supplement within two hours of each Lift for Life® PRT 
session on training days. This dosage raised the total supplemental protein dose on 
training days to ~40 g, providing ~32 g of whey-protein. Participants received a 
marked shaker cup with instructions on how to reconstitute the whey-protein powder 
in water (1 sachet per ~150 ml of cold water) along with appropriate storage 
instructions for the supplements. Participants were offered two flavours to select 
from either vanilla or mocha coffee. Each protein drink will provide approximately 
335 kJ of energy, 2 g of lactose, 1 g of fat and 5 g of fibre. 
 
 
Figure 4.2: Single use sachet of protein supplement and shaker cup used for protein 
supplement preparation. 
 
In addition to the whey-protein supplements, participants randomised to this 
treatment group were also asked to take two 1,000 IU capsules of vitamin D3 
(Ostelin, Melbourne, Victoria, Australia) each day for the duration of the study. The 
goal of vitamin D3 treatment was to raise serum 25(OH)D concentrations to at least 
75 nmol/L. Previously, in a 6-month RCT in 95 overweight and obese adults it has 
been shown that daily supplementation with 2,000IU was effective in raising serum 
25(OH)D levels to greater than 75nmol/L within 2-months of treatment and greater 
than 95nmol/L after 6-months in 91% of the trial population (571). Consistent with 
the double-masked design, the target goal of ≥75 nmol/L was not checked prior to 
randomisation. 
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4.3.10  Sample Size Calculations 
The calculated sample size for this trial was based on the following power 
calculations from previously published studies of PRT in older adults (including 
those with T2DM) (12-14, 204), and work of others that have assessed the 
independent or combined effects of protein, vitamin D and PRT on the outcome 
measures (351, 425, 572). It was estimated that 168 participants would provide 90% 
power (P<0.05 two-tailed) to detect a 0.5% difference for the change in HbA1c levels 
between the groups, assuming a conservative SD of 1.1%. For insulin sensitivity, a 
sample size of 140 would be required to detect an 0.7 difference for the change in 
HOMA-2 insulin resistance between the groups at a power of 90%, assuming a 
conservative SD of 1.2. To compensate for a projected 20% drop-out, a recruitment 
target of 202 participants for this trial was established. Participants were randomised 
1:1 to the two groups (101 per group). This recruitment target allowed for sufficient 
power (80-90%, P<0.05, two-tailed) to detect the following intervention effects on 
our secondary outcome measures: 0.6 kg for lean mass; 4 mmHg in SBP; 15% in 
serum IL-6 and IGF-1, and 12% in homocysteine levels. 
 
4.3.11  Outcome Measures 
Participants attended Deakin University a minimum of twice throughout the duration 
of the study for assessment (baseline and 24-weeks). All outcome measures were 
assessed within the School of Exercise and Nutrition Sciences at Deakin University, 
Burwood campus with the exception of fasted blood sample collections which 
occurred at local pathology clinics at baseline, 12- and 24-weeks. Research staff 
conducted on-site testing at each health and fitness centre after 12-weeks for a subset 
of the measures (weight, waist circumference, blood pressure, knee-extensor strength 
assessment and questionnaire collection).  
 
The primary outcome measures for this study were glycaemic control as measured by 
HbA1c and insulin sensitivity (estimated from the HOMA-2) which was assessed 
using FPG and insulin measured at ≥48-hours after the last Lift for Life® PRT 
session. Secondary outcome measures included: changes in body composition (total 
body and regional lean mass, 25% femur muscle cross-sectional area (CSA) and 
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intramuscular fat), blood pressure, blood lipids, adipokines, inflammatory markers, 
IGF-1, muscle strength, renal function and diabetes medication (purpose, variety and 
dosage). Other covariates and variables of interest assessed included: anthropometry, 
physical activity, diet, use of lipid-lowering and blood pressure medication and 
serum 25(OH)D. A summary of all the outcome measures and their assessment 
methods is shown below in Table 4.2.
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Table 4.2: Summary of the primary and secondary outcome measures collected and methods of collection. 
Variables Data Collection Method Data Collection Points 
Primary Outcome Measures Baseline 12-weeks 24-weeks 
  HbA1c  Overnight fasted serum sample x x x 
  HOMA-2 Insulin Sensitivity  Overnight fasted serum sample, HOMA-2 calculator x x x 
Secondary Outcome Measures  
  Anthropometry Height, weight and waist circumference x x x 
  Body Composition DXA total and regional lean and fat mass  x  x 
 pQCT scan at 25% femur site x  x 
  Biochemistry Measures Routine biochemistry x x x 
  HOMA-2 beta-cell function Overnight fasted serum sample, HOMA-2 calculator x x x 
  Serum 25(OH)D Levels Overnight fasted plasma collection x x x 
  Markers of Inflammation                           Overnight fasted plasma collection x x x 
  Blood Lipids Overnight fasted plasma collection x x x 
  Blood Pressure Automated measurement x x x 
  Muscle Strength  3-Repetition Maximum leg press and seated row x  x 
  Isometric knee extensor strength x x x 
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Table 4.2 continued     
  Physical Activity  CHAMPS questionnaire  x x x 
  Dietary Assessment  24-hour Food Recalls x x x 
  Diabetes and Other Medication  Monthly Phone Calls 
  Adverse Events  Monthly Phone Calls 
  Lift for Life® Program Adherence Calculated from exercise cards collected every 4-weeks 
  Supplement Compliance Calculated from supplement sachets and vitamin D capsules returned at 12 and 24-weeks 
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4.3.11.1  Anthropometry 
All participants’ height was measured to the nearest 0.1 cm with a wall-mounted 
stadiometer (Holton Limited. Crymmych, Pembs, U.K.). Body weight was measured 
to the nearest 0.1 kg using calibrated electronic digital scales (AND Personal 
Precision Scale UC-321). Waist circumference was measured on a horizontal plane, 
halfway between the lowest lateral portion of the ribcage and the iliac crest. 
 
4.3.11.2  Body Composition  
Dual Energy X-Ray Absorptiometry 
Total body and regional (arms and legs) lean mass, fat mass and percentage body fat 
was measured from total body scans performed using Dual X-ray Absorptiometry 
(DXA) (Lunar Prodigy, GE Lunar Corp., Madison WI), using software version 
12.30.008. To obtain total body scans all participants were instructed to wear loose 
fitting clothing free of any metal and to remove all metal objects (e.g. jewellery, bras 
and belts) for the scanning process. Patient positioning followed standardised 
procedures for whole body scanning (573). Briefly, participants were instructed to lie 
supine within the delineated boundaries of the scanning table, with their arms placed 
beside them and palms facing down, ensuring minimal contact was made between 
the upper limb and trunk soft tissue. The participant’s legs were positioned slightly 
apart and internally rotated. Participants were informed of the approximate length of 
the scan and were alerted of the mid-way point of the scan to assist with comfort. 
Participants were instructed to remain still for the duration of the scan with the image 
monitored for evidence of movement. If the image showed evidence of excessive 
movement the scan was aborted and repeated. For analysis, the total body scans were 
divided into sub-regions of interest to isolate the different body regions. The 
following standardised criteria, as provided in the manufacturer’s manual were used 
to define each body region (Figure 4.3).  
 
All scans and follow-up scans were performed by a sole researcher blinded to the 
randomisation. All follow-up measurements were analysed using the ‘comparison’ 
feature of the Lunar Prodigy program. Quality assurance (QA) using phantom 
scanning procedures were performed prior to each measurement as part of regular 
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clinical practice. The short-term co-efficient of variation (CV) for repeated 
measurements of total body lean mass and fat mass within the laboratory ranges from 
1.0% to 1.7%. 
 
Head: The cut line was placed just below the chin; 
Left and right ribs: The cut lines around the ribs were positioned lateral to the spine 
and superior to the pelvis; 
Left and right arm: The cut lines were placed on the most medial border of the 
humeral head and care was taken to make sure that no trunk or leg soft tissue was 
placed within the arm region; 
Left and right leg: The cut lines were angled mid-way through each femoral neck, 
and care was taken to include all leg soft tissue within the leg region border; 
Pelvic: The cut lines were just above the most superior point of the pelvis and 
through the mid-point of each femoral neck, creating a triangular pelvic region.  
 
 
 
Figure 4.3: Sub-regions within the whole body DXA scan. 
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Peripheral Quantitative Tomography 
A peripheral quantitative computed tomography (pQCT) scanner (XCT 3000, Stratec 
Medizintechnik GmbH, Pforzheim, Germany) was used to measure muscle CSA, 
subcutaneous fat CSA and muscle density, as a surrogate measure of intermuscular 
adiposity at the 25% femur site (Figure 4.4). The protocol used followed what has 
been previously reported (574). After performing a scout view of the distal end of the 
femur, the scanner reference line was placed midway over the most proximal aspect 
of the distal femur epicondyle. Images were acquired at 4% and 25% of the femur 
site proximal to the reference line. Slice thickness was set at 2.3 mm, and voxel size 
set at 0.3 mm with a scanning speed of 10 mm/s. Image quality was visually assessed 
following scan acquisition. Scans were rejected and repeated if the cortical shell was 
irregular due to movement artifacts. Subcutaneous fat CSA was determined by 
selecting the area with thresholds -40 to +40 mg/cm3 HA density (contour mode 3, 
peel mode 1), and muscle CSA was determined by subtracting the total bone CSA 
(threshold, 280 mg/cm3; contour mode 1, peel mode 2) and subcutaneous fat CSA 
from the total area of the distal femur (threshold, -40 mg/cm3, contour mode 3, peel 
mode 1) (574). Stratec XCT scanners are factory calibrated against the European 
Forearm Phantom for single energy which was performed prior to each scan. For 
consistency, all pQCT scans were performed and analysed by a single investigator 
blinded to the randomisation. The CV for femur muscle CSA within the laboratory is 
1.3%. 
 
 
 
Figure 4.4: Peripheral quantitative computed tomography (pQCT) scan at the 25% 
femur site. 
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4.3.11.3  Biochemical, Hormonal and Inflammatory Markers 
Following an overnight fast, a rested morning (8-10am) venous blood sample was 
collected from each participant’s antecubital vein at a National Association of 
Testing Authorities Royal College of Pathologists Australasia accredited pathology 
laboratory in each participant’s local area. The following series of parameters were 
all assessed by the pathology lab using standardised techniques: glycated 
haemoglobin (HbA1c), fasting plasma glucose (FPG), blood lipids (total cholesterol, 
high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) 
cholesterol and triglycerides), high-sensitive C-reactive protein (hs-CRP), estimated 
glomerular filtration rate (eGFR), creatinine, calcium. LDL cholesterol was 
calculated by using the Friedewald formula. eGFR, as a measure of kidney function, 
was calculated using the participants’ serum creatinine, age and gender according to 
the abbreviated Modification of Diet in Renal Disease (MDRD) formula, which is 
now used by most laboratories in Australia:  
 
eGFR (mL/min/1.73m2)=175 x [Serum Creatinine (umol/L) x 0.0113]-1.154 x 
Age(years)-0.203(x 0.742 if female) 
 
A series of serum aliquots (5 x 1.5 ml) were collected and stored at -80°C so that the 
following hormonal and inflammatory parameters could be assessed in a single batch 
at the completion of the study including serum 25(OH)D and insulin-like growth-
factor 1 (IGF-1), tumour necrosis factor α (TNF-α) and interleukins 6, 8 and 10 (IL-
6, IL-8 and IL-10). 
 
Measurement of Fasting Insulin and HOMA-IR  
Fasting insulin was assessed from stored serum using the ARCHITECT® insulin 
assay (Abbott Laboratories, Abbott Park, IL 60064 USA). This assay is a 1-step 
chemiluminescent microparticle immunoassay. Samples were prepared as instructed 
in the immunoassay kit. The 1-step immunoassay uses paramagnetic microparticles 
coated with an anti-insulin monoclonal antibody and acridinium-labelled insulin 
monoclonal antibody conjugate. Addition of the pre-trigger reagent leads to 
acridinium-produced chemiluminescence. This Acridinium-produced 
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chemiluminescence was measured as relative light units on the ARCHITECT 
immunoassay optical system. The relative light units are directly proportional to the 
insulin concentration in the serum sample. In our lab, the imprecision in CV% was 
3.65, 3.22 and 3.41% for low (107.6 pmol/L), medium (434.8 pmol/L) and high 
(1080.6 pmol/L) insulin levels respectively. All samples were tested in duplicate and 
the mean values have been reported. 
 
Insulin sensitivity (%S) and steady state beta-cell function (%B) were measured 
using the updated HOMA Calculator© as available for download from The 
University of Oxford Diabetes Trials Unit (https://www.dtu.ox.ac.uk/ 
homacalculator/). This updated model considers variations in hepatic and peripheral 
glucose resistance, increases in the insulin secretion curve for plasma glucose 
concentrations above 10 mmol/L (180 mg/dL) and the contribution of circulating 
proinsulin (575).  
 
Measurement of serum IGF-1 
Serum IGF-1 was measured using a 1-step sandwich chemiluminescense 
immunoassay kit. The kit was a LIAISON® IGF-1 kit (DiaSorin, Saluggia (VC), 
Italy) with the protocol published in the kit instructions and adhered to directly. A 
monoclonal antibody is used for coating magnetic particles (solid-phase) and another 
monoclonal antibody is liked to an isoluminol derivative (isoluminol-antibody 
conjugate). During the incubation period, any IGF-1 present in samples, calibrators 
or controls binds to the solid phase and to the conjugate. After the incubation, the 
unbound material is removed with a wash cycle. Following this, started reagents are 
added to induce a chemiluminescence reaction. The light signal, and the amount of 
isoluminol conjugate is measured as relative light units on a LIAISON® Analyser. 
The relative light units measured indicate the concentration of IGF-1 present in 
calibrators, samples and controls. In our lab, the imprecision in CV% was 4.60, 4.00 
and 3.50% for low (8.26 nmol/L), medium (26.05 nmol/L) and high (33.54 nmol/L) 
IGF-1 levels respectively. All samples were tested in duplicate and the mean values 
have been reported. 
 
Chapter 4 
Page | 160 
	
Measurement of Serum 25(OH)D 
Serum 25(OH)D was analysed at Monash Health, Melbourne, Australia. This 
laboratory is National Association of Testing Authorities, Australia (NATA) certified 
and subscribes to the Vitamin D External Quality Assessment Scheme. Samples were 
measured on the AbSciex Q Trap 5500 MS by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). This system used a Phenomenex Kinetex 
Pentafluorophenyl (PFP) column that achieves baseline separation of 25(OH)D. The 
assay was calibrated with the Chromsystems, 3 Plus1 Multilevel Calibrator for 25-
OH-Vitamin D3 (part number: 62029). The inter-assay CVs for the quality control 
analysed in each assay was 6.5-9.0% for 25(OH)D. 
 
Measurement of Serum Inflammatory Markers 
The measurement of the inflammatory parameters, IL-6, IL-8, IL-10, TNF- ɑ and 
Adiponectin was conducted by Cardinal Bio-research Pty Ltd (Australia). Serum 
concentrations of IL-6, IL-10, IL-8 and TNF-ɑ were measured in duplicate using a 
Millipore high sensitive cytokine immunoassay assay kit (Millipore Corp, Billerica, 
Massachusetts, USA) as per the manufacturer’s instructions. Plates were read on the 
Bioplex (V.5.0, Bio-Rad Laboratories, Hercules, CA). Adiponectin was assayed 
using an in-house multiplex immunoassay with capture and detection antibodies 
obtained from R&D Systems (Minneapolis, MN USA). Antibodies were coupled to 
Luminex xMAP beads using standard Luminex protocols and as previously 
described (541). The mean intra and inter-assay CVs for IL-6, IL-10, IL-8, TNF-ɑ 
and Adiponectin was <12%. Samples with results below the detectable limits of the 
assay were allocated the minimum detectable concentration for each assay: IL-6= 
0.19 pg/mL; IL-10= 0.03 pg/mL; IL-8= 0.08 pg/mL; TNF-ɑ = 0.03 pg/m; 
Adiponectin = 0.01 µg/mL.  
 
4.3.11.4  Blood Pressure 
Following a 5-minute rest period where all participants were seated in a quiet room, 
SBP and DBP was measured using an automated blood pressure monitor (AND Vital 
Sensor, Model number TM-2551P, Abingdon, Oxford). Four measurements were 
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taken on the left arm with a 2-minute interval between readings; the mean of the final 
three readings were used in the analysis. 
 
4.3.11.5  Muscle Strength 
Knee Extensor Strength 
Isometric knee extensor strength (force in kg) was measured on the participant’s 
dominant leg using Lord's strap assembly incorporating a strain gauge (Neuroscience 
Research Australia, Sydney, Australia). Participants were stabilised in a seated 
position with one Velcro strap wrapped around the dominant leg and connected to 
the spring-loaded strain gauge ensuring the hip and knee joint were both supported at 
90°. The Velcro strap was positioned approximately 5cm above the ankle joint 
allowing dorsiflexion of the ankle (Figure 4.5). Participants were instructed to leave 
the contralateral leg free of pressing against a chair leg or supporting arm on the 
chair, however, participants could hold on to the chair with their hands for support. 
Participants executed 3-4 submaximal concentric contractions with a 10 second rest 
between each sub-maximal contraction. Following a 60 second rest participants then 
performed one maximal concentric effort, holding this maximal force for 3-seconds 
followed by another 60 second rest. Following a second rest another maximal 
contraction was repeated. The two readings from the two maximal contractions were 
recorded with the peak force used in the analysis. This test has been shown to have 
excellent test-retest reliability ICC=0.97 (576).  
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Figure 4.5: Participant positioning for the knee extensor strength test. 
 
3-Repetition Maximum Assessment  
Maximal muscle strength of the lower limbs and back was estimated by employing 
three-repetition maximum strength (3-RM) tests for the bilateral leg press (Synergy 
Omni Leg Press S-31 OPD, QLD, AUS) and the seated row (Nautilus F3 Adjustable 
Tower Pulley System F3ATFS, Nautilus, Vancouver, WA). A 3-RM is the greatest 
weight that can be lifted for three complete repetitions of an exercise whilst 
maintaining correct form and technique. A 3-RM test corresponds to ~85% of an 
individual’s 1-RM (577). The 3-RM rather than the 1-RM test was chosen for use in 
this trial as previously it has been found that 1-RM testing can lead to injuries (578). 
The protocol employed is presented below but follows what has previously been 
published (578). Prior to 3-RM testing beginning participants completed a 5-minute 
warm-up on an exercise bike. To determine 3-RM, each participant initially 
performed a warm-up set of 8-10 repetitions with a light load. After the successful 
completion of a further 6-8 repetitions at an incrementally heavier weight selected by 
the instructing researcher and following a brief rest (~2 to 3 minutes), the workload 
was increased incrementally until only three repetitions with correct technique could 
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be completed. For each participant, the below formula, as employed by Wathen et al. 
(579) and used previously in older adults (580), was used to calculate participants leg 
and back strength 1-RM: 
 
1-RM = 100 x (3-RM load) / (48.8 + 53.8 x e (0:075x3)) 
 
The short-term CV for repeated measurements of strength testing in our laboratory 
was 2.04% for leg and 1.1% for back strength.  
 
4.3.11.6  Dietary Assessment  
Dietary data was collected through 24-hour dietary recalls at all time-points. 
Participants were provided two blank food diaries a minimum of one week prior to 
their testing appointment. Participants were asked to record all food and drink 
consumed on a regular weekday and one weekend day. At the 12- and 24-week 
assessments participants were instructed to complete the two dietary recalls on non-
training days. At the respective testing appointments completed food diaries were 
reviewed using the ‘triple pass’ method to maximise the respondents recall of all 
food and drink consumed. This procedure was based on that used by the Australian 
Bureau of Statistics in the 1995 National Nutrition Survey, and is designed to 
maximise the ability of respondents to recall everything consumed, ensuring an 
adequate food diary was completed. Staff conducting these recalls had all completed 
appropriate training in dietary assessment methods. Household measures (measuring 
cups, plates, bowls and glasses) were used to help estimate food portion sizes. The 
data collected from the 24-hour recalls was entered into FoodWorks Professional 
(Version 8, Xyris Software, Queensland, Australia) to calculate total dietary energy 
intake and dietary macronutrient composition using the AUSNUT 2011-13 database 
including AusBrands and AusFoods. 
 
Total energy intake (EI) was examined for under/over-reporting following collection. 
Several equations exist in order to calculate an estimated basal metabolic rate 
(BMRest), however, validation studies in overweight/obese populations have 
previously found the Mifflin-St Jeor equation to give the most precise calculation of 
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BMR in population groups with a BMI over 30 as opposed to other equations such as 
the Schofield, Owen or Harris-Benedict equation (581). A physical activity level 
(PAL) of 1.4 reflecting low activity and appropriately age-matched was selected 
based on that published (582). This PAL was held constant over the intervention 
period and used in the equations at all subsequent time points. To identify over- and 
under-reporters at the group level, the modified Goldberg equation (583) was used to 
calculate the specific lower and upper cut-offs for all participants as used by others 
(584-586). Individuals greater or less than two standard deviations outside of these 
upper and lower cut offs were classified as under and over-reporters respectively. 
Participants within this range were classified as plausible reporters. Participants were 
coded as over, plausible or under reporters at each assessment. A total of 91 and 95 
participants from the PRT+ProD and PRT groups respectively returned the 24-hour 
food recalls at baseline. Underreporting of energy intake at baseline was similar in 
the PRT+ProD and PRT groups (PRT+ProD, 12.0%, n=11 vs PRT, 9.5%, n=9). Over 
reporting of energy intake at baseline was also similar among both the PRT+ProD 
(1%, n=1) and PRT (2%, n=2) groups with no differences between the groups. The 
prevalence of under and over reporting remained consistent in both groups at 12- and 
24-weeks (data not shown). Removing individuals who were classified as over- and 
under-reporters did not change the results of the analysis and therefore all 
participants were included in subsequent analysis. 
 
Mean daily alcohol consumption was estimated from self-reported intakes over the 
previous seven days. Previous research has shown that the seven-day alcohol recall 
method is an accurate method to assess alcohol intake as it reduces the random 
variability found in methods which estimate typical consumption over a longer 
period of time (587). Participants were asked about their alcohol intake during the 
previous seven days and were required to recall both the amount (using the 
household measure they were familiar with e.g. wine glass, stubby, shot glass) and 
the type of alcohol consumed (e.g. beer, wine, spirits). Average daily alcohol 
consumption (g/day) was calculated using the summed volume of all alcoholic 
beverages consumed over the preceding week divided by seven. 
 
Chapter 4 
Page | 165 
	
Habitual Protein plus Protein from Whey Protein Supplements 
The additional protein consumed from the whey protein supplements was calculated 
for both training days and non-training days given the differing number of 
supplements prescribed (one on non-training days and two on PRT days). Individual 
compliance as a percentage at both 12-weeks and 24-weeks with the whey protein 
supplements was multiplied by the dose of protein (either 20 or 40 g) with this 
amount subsequently added to the habitual protein intake reported from the 24-hour 
food diaries to calculate the g/day of protein consumed. The same method was used 
to calculate g/kg/day at both 12- and 24-weeks with weight at both these respective 
time points used in these calculations to determine the g/kg/day of protein intake 
inclusive of the whey protein supplement at both 12- and 24-weeks.   
 
4.3.11.7  Habitual Physical Activity 
The Community Healthy Activities Model Program for Seniors (CHAMPS) physical 
activity questionnaire was specifically designed to evaluate total leisure and 
recreational physical activity time (hours per week) in older adults and found to be 
reliable, valid and sensitive to change (588). Participants documented the frequency 
and duration of their participation in a ‘typical week’ of a range of low, moderate, 
and vigorous physical activities at baseline, 12- and 24-weeks of the study. These 
results are reported as estimated kilojoules per week spent in aforementioned 
activities.  
 
4.3.11.8  Medical History, Health Status, Medication Use  
All participants completed a lifestyle questionnaire to obtain information on 
education background, current and previous employment details, history of diseases 
or illnesses, family history of diabetes, smoking history, current medication and 
dietary supplement use. Information on any alterations to or new medication 
prescribed by the participants’ doctors was collected by research staff via the 
monthly phone calls. Information recorded included medication name, dose 
prescribed and daily quantity taken. Medications were categorised into diabetic, 
hypolipidemic, anti-hypertensives, other cardiac agents such as anti-arrhythmic 
drugs, osteoporotic, thyroid, anti-depressant/psychiatric, diuretics, thiazide diuretics, 
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hormone replacement therapy, steroids, tamoxifen, and other (e.g. anti-inflammatory) 
medications. 
 
4.3.11.9  Compliance Assessment  
Lift for Life® Exercise Training Cards 
Compliance with the Lift for Life® PRT program was evaluated via self-completed 
exercise cards. These cards were returned to researchers at the completion of the first 
four weeks of training allowing the PRT programs to be reviewed. Training cards were 
reviewed to confirm training programs were of adequate intensity, volume and that 
appropriate progression could be applied. Following the collection of the first exercise 
card, participants were asked to post subsequent exercise cards back at the completion 
of one full card or every eight weeks. 
 
Supplement Calendars 
Compliance in taking the prescribed protein and vitamin D supplements was 
evaluated via self-completed compliance calendars. These calendars were cross-
referenced by counting the remaining sachets of protein and vitamin D capsules 
returned at the final testing appointment. The date supplements were commenced and 
ceased along with the date returned were all recorded. The exact number of 
supplements that should have been taken was able to be precisely calculated.  
 
Compliance was calculated on a percentage basis as what was consumed divided by 
what should have been consumed over the duration of the trial period for each 
participant.  
 
4.3.11.10  Adverse Events  
Any adverse events associated with the exercise program or supplements were 
recorded by research staff during the monthly phone calls to participants.  
For this trial, an adverse event was defined as any health-related untoward or 
unfavourable medical occurrence (sign, symptom, syndrome or illness) that 
developed or worsened during the 24-week trial. All adverse events were assessed 
for seriousness, causality and expectedness by the research staff and reported adverse 
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events were categorised into adverse event, serious adverse event or unanticipated 
problem based upon the National Institute of Ageing guidelines (589). Information 
on any alterations to or new medication prescribed for any event by a treating 
physician was collected by research staff with information including medication 
name, dose prescribed, and daily quantity taken recorded. 
 
4.3.12  Statistical Analysis 
Detailed information related to the statistical analysis for this study will be provided 
in Chapter 6. 
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Chapter 5 
 
Lessons Learned Recruiting Older Adults with Type 2 Diabetes  
to a Community-based Exercise and Nutrition  
Randomised Controlled Trial  
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5.1  Student Declaration 
The PhD student was responsible for the 21-month recruitment campaign outlined in 
the forthcoming Chapter. The student oversaw the implementation of each 
recruitment strategy used and assessed its success or determined when a strategy 
should be altered. The student was largely responsible for screening all expressions 
of interest received and subsequent baseline appointment scheduling. The student 
was responsible for the development, analysis and reporting contained within this 
Chapter and for the development and subsequent publication of this Chapter as a 
peer-reviewed journal article.   
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5.2  Abstract 
Recruiting participants into long-term community-based lifestyle intervention trials, 
particularly adults with a chronic disease, is often slow and challenging. There is 
limited data on successful recruitment strategies suitable for older adults with type 2 
diabetes mellitus (T2DM) into community-based lifestyle programs, and no 
information on cost estimates associated with recruitment. Herein we describe the 
recruitment strategies used, the success of each approach and the costs associated 
with the recruitment methods used in recruiting older adults with T2DM into a 6-
month community-based exercise and nutritional supplementation randomised 
controlled trial (RCT). The Resistance Exercise, Vitamin D and Muscle Protein 
Intervention Trial (REVAMP-IT) is a 24-week RCT targeting 200 adults with T2DM 
designed to evaluate whether ingestion of a whey-protein drink plus vitamin D can 
enhance the effects of progressive resistance training (PRT) on glycaemic control, 
insulin sensitivity, body composition and cardiovascular health. Participants in this 
RCT were randomly allocated to either: 1) a community-based PRT program 
combined with whey protein and vitamin D supplements, or 2) solely the PRT 
program. Recruitment strategies included state and local newspaper and radio 
advertisements, targeted mail-outs, doctor and allied health referrals, community 
presentations, web-based media and word of mouth. The number of expressions of 
interest (EOI) received, participants screened and randomised in the trial, and how 
they first heard of the study were recorded during the screening process. Reasons for 
ineligibility or non-participation were also recorded plus the cost of each recruitment 
method used. A total of 1,157 EOI were received over a 21-month period. Overall 
959 (83%) individuals were screened and found to be ineligible for the trial or chose 
not to participate. As a result, 198 participants were randomised to the 24-week 
intervention. The most effective recruitment strategies were targeted mass mail-outs 
(39% of the total participant sample), state (27%) and local (15%) print media. 
Recruitment expenditure totalled AUD$40,421, AUD$35 per enquiry and AUD$204 
per eligible participant. Targeted mail-outs and state print media were the most 
expensive strategies, accounting for 38% of total expenditure. To recruit around 200 
older adults with T2DM into a community-based lifestyle trial in a timely manner, 
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ensuring an adequate budget is allocated to recruitment is paramount as targeted 
mail-outs and state/local print media were the costliest yet most effective strategies. 
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5.3  Introduction 
The success of RCTs is dependent on effective recruitment of the target population. 
One of the key challenges associated with conducting intervention trials that target 
populations with specific medical conditions such as people with T2DM, is the 
successful recruitment of an adequate number of participants within budget and 
established timelines. Failing to recruit the required number of participants impacts 
the statistical power and adversely impacts on the internal and external validity of the 
trial. Delays in recruitment can also extend the trial duration and result in an increase 
in trial and recruitment costs. 
 
Recruitment of people with T2DM into a lifestyle modification trial involving an 
exercise and/or a nutritional intervention can be particularly challenging because it 
often involves identifying participants that must first meet certain inclusion criteria 
(e.g. currently inactive) and who are also motivated to change their behaviour (e.g. 
engage in regular exercise). Despite the clear evidence that physical activity (PA) 
and diet are key elements in the management (and prevention) of T2DM, individuals 
with this condition are typically inactive and have poor dietary habits (590, 591). 
Therefore, it is difficult for the target population to make a commitment to make the 
behavioural changes required in these types of studies. Exercise and dietary 
intervention trials can be long and demanding, requiring significant change to an 
individual’s daily routine. Common barriers and reasons for not participating in 
exercise trials reported by individuals include inconvenience, a lack of time to 
dedicate when managing work/family commitments and a lack of understanding of 
the potential health benefits of participating in such trials (592, 593). A review of 
recruitment strategies for participants into RCTs revealed that methods which do not 
directly target the population of interest (e.g. T2DM patients), advertisements which 
are not effective in conveying the key objectives of the research or which fail to 
accurately inform of the potential personal health benefits to participation, can all 
negatively impact on recruitment (594). Therefore, identifying the most effective 
recruitment strategies which overcome the aforementioned barriers to participation 
and which appeal to potential participants as well as convey an appropriate level of 
information is crucial to successfully achieving recruitment goals. 
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At present, there is limited literature on successful recruitment strategies suitable for 
older adults with T2DM into community-based exercise and nutrition programs with 
no information on cost estimates. There has only been one paper recently published 
describing the experiences and strategies used to recruit type 2 diabetic patients into 
an RCT to assess the efficacy of an automated, interactive voice-response telephone 
intervention to promote physical activity behaviour (593). Therefore, the aim of this 
chapter is to describe recruitment strategies used to recruit older adults with T2DM 
into a 6-month community-based exercise and nutrition research intervention. 
Strategies were defined as successful if they were effective in generating a greater 
number of enquiries to the trial and a higher proportion of eligible participants 
compared to other strategies. A secondary aim is to assess the costs associated with 
the recruitment methods used. By providing a detailed report of this trials recruitment 
experiences it is hoped this information will help to inform future intervention 
studies wishing to recruit older adults with T2DM to community-based exercise 
and/or nutrition programs.  
 
5.4  Methods 
5.4.1  Study Overview 
A detailed description of the protocol for this trial is provided in Chapter 4 and has 
previously been published (595). Briefly, this study was a 24-week RCT in which 
participants were randomly allocated to either: 1) the Lift for Life® community-based 
progressive resistance training (PRT) program combined with additional whey 
protein and vitamin D, or 2) the Lift for Life® PRT program alone. The primary 
outcomes were glycated haemoglobin (HbA1c) and homeostasis model assessment 2 
(HOMA-2) of insulin sensitivity and beta-cell function. Secondary outcome 
measures included changes in body composition, muscle strength, blood pressure, 
blood lipids, adipokines and inflammatory markers, growth factors, health related 
quality of life and cognitive function.  
 
All participants enrolled in the trial were asked to complete the Lift for Life® PRT 
program in local community health and fitness centres which involved training twice 
a week for the first eight weeks and three times a week thereafter. Training sessions 
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were supervised by qualified trainers, lasting approximately 45 to 60-minutes and 
consisted of moderate- to high-intensity resistance training (3 sets of 8-10 
repetitions) targeting all major muscle groups and with an emphasis on progressive 
overload (increments in weight of 2 to 10%). All participants were charged a fee by 
their local health and fitness provider to undertake the program, but were eligible for 
reimbursement up to the value of AUD$240 at the completion of the study based on 
their level of compliance (595).  
 
In addition to the above training commitment, those randomised to the Lift for Life® 
plus supplement group were provided with a supply of a whey-protein enriched 
powder and vitamin D supplements with the instruction to consume two vitamin D 
capsules (1,000 IU of vitamin D per capsule) each day, plus prepare and consume a 
whey protein drink (20 grams of protein once per day on non-training days plus 20 
grams after each Lift for Life® training session). The PRT alone group received no 
additional powder or supplements.  
 
Throughout the trial, participants were required to attend Deakin University for 
approximately 2 hours on two occasions (baseline and 24-weeks). Research staff 
conducted on-site testing at each health and fitness centre after 12-weeks. A rested 
morning (8-10am) venous blood sample was additionally collected from each 
participant’s antecubital vein at an accredited pathology laboratory following an 
overnight fast on three occasions over the 24-week period (baseline, 12- and 24-
weeks).  
 
5.4.2  Ethics 
This trial was managed by staff within the Institute for Physical Activity and 
Nutrition (IPAN) Research at Deakin University Burwood, Melbourne, Victoria, 
Australia. The study was approved by the Deakin University Human Research Ethics 
Committee (HREC 2013-050) (Appendix 4), and is registered with the Australian 
and New Zealand Clinical Trials Registry (ACTRN12613000592741). All 
participants provided written informed consent prior to their commencement in the 
study. 
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5.4.3  Funding 
This project was funded by a grant from the National Health and Medical Research 
Council Project (APP1046269). The whey-protein powder was provided by 
OmniBlend (Campbellfield, Victoria, Australia) and the vitamin D supplements 
(Ostelin) by Sanofi-Aventis Australia Pty Ltd (Macquarie Park, New South Wales, 
Australia). 
 
5.4.4  Sample Size Calculations 
As reported in Chapter 4, it was estimated that a sample size of 168 participants 
would provide the study with 90% power (P<0.05 two-tailed test) to detect a 0.5% 
absolute difference for the change in HbA1c levels between the groups, assuming a 
conservative standard deviation of 1.1%. For insulin sensitivity, a sample size of 140 
would be required to detect a 0.7 difference for the change in HOMA-2 insulin 
resistance between the groups at a power of 90%, assuming a conservative standard 
deviation of 1.2. To compensate for an estimated 20% drop-out rate, it was 
calculated that 202 participants would be recruited to the study and randomised 1:1 
to either of the two groups (101 participants per group).  
 
5.4.5  Screening Procedure and Inclusion/Exclusion Criteria  
As reported previously (595) and detailed extensively in Chapter 4, eligibility for this 
study was assessed using a two-step screening process. Briefly,  participants were 
screened via a telephone questionnaire and ineligibility was based on the following 
criteria: 1) aged <50 or >75 years of age; 2) HbA1c >10%; 3) current or prior 
participation in a structured resistance training programme >once per week or 
moderate-intensity physical activity ≥150 min/week in the previous 3-months; 4) 
vitamin D or calcium supplement use >500 IU/day and >600 mg/day, respectively, in 
the previous 3-months; 5) severe orthopaedic, cardiovascular or respiratory 
conditions that would preclude participation in an exercise programme, or those with 
absolute contraindications to exercise, according to American College of Sports 
Medicine guidelines (596); 6) renal impairment (estimated glomerular filtration rate 
(eGFR) <45 ml/(min 1.73 m2)) or disease; 7) regular use of protein supplements; 8) 
conditions that may affect vitamin D or calcium metabolism; 9) current smoker, or 
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10) body mass index (BMI) >40 kg/m2. Participants who passed the initial telephone 
screening were then required to obtain approval from their doctor to clear them of 
any medical conditions contraindicated to exercise, based on ACSM guidelines 
(Appendix 6). Participants were also required to provide a fasted, morning blood 
sample to confirm that their HbA1c level was <10%.  
 
5.4.6  Recruitment Strategies 
During the trial establishment period and prior to beginning the recruitment 
campaign, chief investigators and lead trial staff met repeatedly to discuss which 
strategies should be used to recruit participants into this trial. These meetings were 
used to brainstorm and plan the various recruitment strategies to be used. Those 
adopted first were ones which had been used previously by trial staff.  These 
included local newspaper advertisements, flyers/posters and GP presentations. 
Within the first 2 to 3-months, recruitment of participants was modest with very few 
expressions of interest received from these strategies alone and necessitated a change 
in the recruitment plan. At this point, lead trial staff consulted with the Deakin 
University public relations and communications team to discuss the re-development 
of trial advertisements and trial communications to a clear, informative and 
appealing style. Following these meetings, lead trial staff again devised additional 
recruitment strategies and a range of approaches, in addition to those already in use, 
were implemented to recruit participants from both metropolitan Melbourne and 
surrounding regions in Victoria, Australia such as the Werribee, Geelong and 
Mornington areas. Such strategies included state and local newspaper and radio 
advertisements, targeted mail-outs through the National Diabetes Support Scheme 
(NDSS) member database, GP and allied health referrals, community presentations, 
web-based media and word of mouth. A brief overview of each of the recruitment 
approaches used is below. Specific information relating to the method of recruitment 
for each participant was obtained during the participant’s first enquiry to the study.   
 
State Print Media   
A total of six paid advertisements were placed in key state-wide newspapers with the 
advertisements ranging in size, colour and placement within each paper. The content 
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of these advertisements included an eye-catching headline, a brief and simple 
description of the trial, including the potential health benefits to participants 
associated with participation, and relevant contact details as shown below in Figure 
5.1. The cost for each of the advertisements ranged from AUD$1,700 to AUD$3,000.  
 
 
 
Figure 5.1: Example of the study advertisement in state print media (newspaper). 
 
Local Print Media 
Twelve paid advertisements, similar in format to the state-based advertisements as 
shown below in Figure 5.2, were also placed in a range of local municipality 
newspapers throughout the recruitment period. These newspapers are delivered 
weekly to each household within a given area (municipality). In general, these 
advertisements were placed in the same paper fortnightly over a 6-week period, 
however, occasionally single advertisements were used to trial and target one locality 
to gauge the level of interest. Local paper advertisements cost AUD$400 to 
AUD$500 each, depending on the size and placement of the advert within the paper. 
Several free advertisements were also placed in local newspapers in the community 
‘What’s On’ section (limited to 40 words). These free advertisements were used as a 
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buffer to continue the recruitment campaign between paid state and local media 
advertisements.   
 
 
 
Figure 5.2: Example of the study advertisement for local print media (newspaper). 
 
Radio Advertising 
The study was also advertised on a state-wide radio station. Forty-five 15-second 
advertisements, which were drafted by study researchers and developed by the radio 
station, were played over a five-day period (Monday to Friday). The radio station 
was selected based upon the demographics of the majority of their audience (e.g. 
middle aged and older adults). The advertisements were initially played during the 
‘Seniors Spotlight on Trials and Studies’ segment and following this were spread 
sporadically over the course of the day ranging from 6am through to 10pm. 
Advertising this trial on Magic radio costs AUD$990 for the forty-five 15 second 
advertisements. 
 
Targeted Mail-outs 
The research team gained approval from Diabetes Australia, a non-government 
organisation, to access the NDSS database, which is a federally-funded register of 
Australians with diabetes that was initiated in 1987. Briefly, the aim of NDSS is to 
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enhance the capacity of people with diabetes to understand and self-manage their 
condition, and to provide relevant information, support and access to essential 
products at subsidised prices. In Victoria, the NDSS register contains the contact 
detail of more than 85% of all clinically confirmed cases of diabetes, which includes 
type 1, type 2 and gestational diabetes (597). Since 2001, individuals joining the 
NDSS have been asked whether they would be willing to be informed of any 
opportunities to participate in research. Only those who consented to be contacted 
were eligible to be invited to participate in this study. Because of the extensive nature 
of the database, the research staff first used the online Australian Diabetes Map 
(http://www.diabetesmap.com.au/), which is an interactive national diabetes 
prevalence map established and regularly updated by NDSS and the Australian 
Bureau of Statistics (ABS), to identify local government areas and the postcodes 
within these areas with a reported high prevalence of individuals with T2DM. 
Thereafter, the research team contacted NDSS who were responsible for identifying 
the number of individuals within each of the identified postcodes that had T2DM, 
who were aged 50-75 years and reported that they were not currently taking insulin 
to manage their condition. A letter of invitation to participate in the study, that was 
prepared by the research staff but sent by NDSS, was then forwarded to all 
individuals that fulfilled the necessary inclusion criteria (Appendix 8). Nine mail-
outs were conducted in total and the number of letters sent per mail-out ranged from 
80 to 5,000 depending upon the number of registrants within a target area. The cost 
of a direct mail-out was approximately AUD$1.80 per letter. This cost increased or 
decreased marginally depending on the number of individuals contacted (the greater 
the number of letters sent the cheaper the cost). 
 
Referrals from GPs and Allied Health Professionals  
General practitioners, endocrinologists and other relevant health professionals (e.g. 
diabetes educators, dietitians and pharmacists) identified from relevant directories 
(e.g. Yellow Pages), hospitals and profession specific association websites who were 
based in a 45km radius of Melbourne were sent information packs via the mail that 
provided details about the trial. Included in these packs was a one page study 
summary, which outlined the aims, commitment required and the potential benefits 
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to participants, and the key eligibility criteria. They also received trial flyers and 
posters (discussed below) and were asked to place these on notice boards and/or 
distribute them directly to relevant patients. Connections with several Medicare 
Local groups (regional organisations who co-ordinate improvements in healthcare for 
designated populations groups and oversee front line primary healthcare services) 
were also made during the establishment of this trial. Specifically, the Diabetes 
Australia map, mentioned previously, was used to identify areas with high 
prevalence of T2DM. The respective Medicare Local groups were subsequently 
contacted to inform them of the trial and were provided trial information and 
advertisements and requested to include these in any communications with GPs or 
allied health providers.  
 
Flyers and Presentations 
Flyers and posters (Figure 5.3) were placed in prominent public and relevant 
locations such as fitness clubs, libraries, senior citizen centres, pharmacies, 
community houses and retirement villages. In addition, three presentations were 
made to a range of audiences; one to a diabetes support group where the attendees 
were a mix of accredited Diabetes Educators, patients and carers, one to GPs at a 
Medicare Local meeting and another at the Northern Accredited Diabetes Educators 
annual general meeting. 
 
 
 
Figure 5.3: An example of the study recruitment flyer. 
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Website Advertisement 
Information about the study was posted on the Lift for Life®, Diabetes Victoria, 
Diabetes Australia, Fitness Australia, Deakin University’s Centre for Physical 
Activity and Nutrition and the Australian Centre for Behavioural Research in 
Diabetes websites. These listings were placed on respective websites at the beginning 
of the recruitment campaign and requested to be removed from the website at the 
completion of recruitment. There was no cost associated with posting information on 
these websites.  
 
Social Media 
A pay-per-click advertisement (AUD$0.03 per click at a capped limit of AUD$500) 
was placed on the social media domain Facebook five months into the recruitment 
campaign. This advertisement was 20 words long and used key words to capture 
potential participant’s attention. The adverts appeared on an individual’s Facebook 
page whose age fell into the eligible age range for the trial and a postcode pre-
identified to be within a 15km radius of Deakin University. An individual who 
clicked on an advertisement was directed to the Lift for Life® website for further 
information about the trial. The cap of AUD$500 was not reached during the 
recruitment period but did allow for ~16,600 clicks to the advert.  
 
Word of Mouth 
Participants enrolled in the trial were actively encouraged to refer family, friends or 
colleagues with T2DM into the study. In addition, participants with T2DM who 
enquired but were ineligible for other research studies being conducted within IPAN 
and who had consented to be contacted for any other research studies, were contacted 
by research staff via telephone to determine their interest and eligibility in regards to 
participating in this trial.  
 
5.4.7  Data Collection and Analysis  
The number of expressions of interest (EOIs), participants screened and included in 
the trial, and how they heard about the study was recorded by the research staff 
throughout the recruitment process. Reasons for ineligibility or non-participation in 
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the trial were also recorded. These were categorised into one of five categories; 
health-related, physical activity status, medication/supplement use, travel or age. 
Response rates were reported as the number and percentage of participants both 
interested in and recruited into the trial. Recruitment yield was calculated as the total 
number of participants recruited divided by the number of EOIs. The success of each 
recruitment strategy was determined from the number of participants recruited 
divided by the number of EOIs from each strategy expressed as a percentage. 
Recruitment rates were also calculated as the average number of participants 
recruited and randomised per month throughout the recruitment phase. Results were 
also split by gender. The cost of each recruitment method used was calculated by 
dividing the total amount spent on a given strategy by: 1) the number of EOIs 
generated for each strategy, and 2) the total number of eligible participants the 
strategy was responsible for recruiting (e.g. cost per participant recruited).   
 
5.5  Results 
5.5.1  Recruitment 
Recruitment for this trial was intended to be completed within 12-months. This was 
extended to a period of 21-months (February 2014 to October 2015) due to a lower 
than expected recruitment rate. In total, 1,157 EOI were received from which 198 
older adults with T2DM were deemed eligible for the trial and subsequently 
randomised. This represents 98% of the original specified target sample size of 202 
participants. The results of the recruitment campaign are presented below and 
include the number of EOIs whom were determined ineligible or chose not to 
participate in the trial, the recruitment yield for each strategy used, the recruitment 
timeline and a cost analysis of each of the strategies employed.  
 
5.5.2  Response Rates and Reasons for Ineligibility or Non-participation 
In total, 516 of 1,157 (45%) EOIs were found to be ineligible for this trial following 
the initial screening. As shown in Table 5.1 the most common reasons for 
ineligibility included being too physically active (26%), taking vitamin D 
supplements at a dose of >500 IU/day (25%) and management of T2DM by way of 
insulin therapy (11%).  
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Table 5.1: Reasons participants were deemed ineligible for the trial. 
Reason for Ineligibility Total Ineligible, n (%) 
Health-related 115 (22%) 
  Not diagnosed with T2DM 28 (5%) 
  Any medical condition contraindicated to PRT  18 (3%) 
  BMI >40kg/m2 30 (6%) 
  HbA1c >10% 14 (3%) 
  Presence or indication of kidney disease 8 (2%) 
  Current smoker 17 (3%) 
Physical Activity Status 135 (26%) 
  Meeting/exceeding Physical Activity Guidelines 135 (26%) 
Medication or Supplement Use 192 (37%) 
  Prescribed insulin for management of T2DM 59 (11%) 
  Taking Vitamin D supplements >500 IU/day 128 (25%) 
  Taking dietary protein supplements 5 (1%) 
Travel 53 (10%) 
  Travel plans 53 (10%) 
Age 21 (4%) 
  Aged <50 or >75 years of age 21 (4%) 
Total 516 (100%) 
Presence or indication of kidney disease was considered if eGFR <45 mL/min. Potential 
participants were excluded if meeting or exceeding National Physical Activity Guidelines of 
150 minutes of moderate to vigorous physical activity or participating in greater than one 
strength training session per week. Participants were excluded if responded yes to taking 
dietary protein supplements at a protein content of <10g per serve, as specified on the 
products nutrition information panel.   
 
A total of 443 participants chose not to participate in the trial. As shown in Table 5.2, 
189 (43%) were unable to meet the requirements of the trial based on the 
inclusion/exclusion criteria and a further 127 (29%) were lost to follow-up following 
their initial enquiries into the program. In total 62 (14%) participant could not meet 
the financial obligations of committing to the PRT program and 61 (14%) did not 
live within travel distance to Deakin University or a have a training facility within 
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their immediate area. Only 4 (1%) participants chose not to participate as they did 
not wish to take supplements of any form.  
 
Table 5.2: Number and proportion (percentage) of expressions of interest who chose 
not to participate in this trial and the reasons provided for non-participation. 
Reason for non-participation Total, n (%) 
  Unable to meet requirements of the trial 189 (42.7%) 
  Unable to afford the Lift for Life® PRT program 62 (14%) 
  Not willing to consume supplements  4 (0.9%) 
  Lost to follow-up following initial enquiry 127 (28.7%) 
  Not living within a reasonable travel distance to trial sites 61 (13.8%) 
Total 443 (100%) 
 
5.5.3  Recruitment Return by Recruitment Strategy 
As presented in Table 5.3, targeted mail-outs were the most successful approach for 
recruitment, generating 479 (42%) of the 1,157 EOIs, from which 78 participants 
were eligible for the trial (39% of those randomised). State-wide free and paid 
advertisements generated the second greatest number of enquiries (n=326, 28% of 
total), from which 54 participants were eligible and subsequently randomised. 
Advertising in local newspapers (both paid and unpaid) generated 173 enquires 
(15%), with 27 of these enquiries deemed eligible, whilst website advertisements 
produced 96 enquires (8%) that led to 19 participants randomised. All other forms of 
recruitment generated a low number of enquires and resulted in only 20 eligible 
participants in total: word of mouth (n=6, 3%); referral from health professionals 
(n=10, 5%); flyers/presentations (n=4, 2%), with zero eligible participants from radio 
advertising and social media.  
 
  
Chapter 5 
Page | 185 
	
Table 5.3: Number and proportion (percentage) of expressions of interest and 
participants deemed eligible for the trial based on the various recruitment strategies. 
 
Eligibility Status 
Eligible Expressions of Interest 
Recruitment Strategy n % n % 
  State Print Media 54 27 326 28 
  Local Print Media 27 14 173 15 
  Radio Advertising 0 - 6 0.5 
  Targeted Mail-outs 78 39 479 41 
  Allied Health Referrals 10 5 19 2 
  Website Advertising 19 10 96 8 
  Social Media 0 - 5 0.4 
  Flyers/Community Presentations 4 2 11 1 
  Word of Mouth  6 3 37 3 
  No Record  0 - 5 0.4 
Total 198 100 1157 100 
 
5.5.4  Recruitment Return by Gender and Age 
The total number of male participants recruited for the trial exceeded female (n=128 
and n=70, respectively) resulting in a gender distribution among the trial population 
of 65% male and 35% female, respectively. This male versus female distribution was 
similar overall when examining expressions of interest received and those deemed 
ineligible and eligible (Table 5.4). Interestingly, the only recruitment strategy that 
resulted in a higher number of females (n=9) than males (n=1) was allied health 
referrals, but the total number of referrals from this method was very low (Figure 
5.4). In terms of the age distribution, 39% of all eligible participants were aged 50-59 
years, 53% were aged 60-69 years with the remaining 11% aged over 70 years.   
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Table 5.4: Number and proportion of men and women screened and deemed eligible 
or ineligible for the trial. 
 Eligibility Status 
 
Eligible 
n=198 
Ineligible 
n=959 
Total Screened 
n=1157 
 n % n % n % 
Male 128 65 541 56 669 58 
Female 70 35 418 44 488 42 
Males and females who chose not to participate were included in the ineligible 
figures for this analysis only. 
 
 
 
Figure 5.4: The number of male and female participants eligible for this trial and the 
recruitment strategies they responded from.  
 
5.5.5  Recruitment Timeline 
As previously mentioned, recruitment for this trial spanned a 21-month period. 
Figure 5.5 illustrates the number of participants randomised per month over this 
period. On average, nine participants were randomised per month. The peaks on the 
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graph correspond with the implementation of State based newspaper advertisements 
(April, May, August, June, November 2014 and February 2015) and targeted mail-
outs through the NDSS (September, October and December 2014 and May, July, 
September and October 2015). Figure 5.6 clarifies the timing of each recruitment 
strategy. As shown, not all strategies were implemented continuously throughout the 
campaign, however, several methods of recruitment were often in place at the same 
time. This may have meant a participant was exposed to more than one recruitment 
strategy such as an advertisement, recruitment flyer or mail-out however, only the 
first recruitment strategy reported was recorded on the screening form.    
 
 
 
Figure 5.5: Number of participants randomised to this trial each month for the 
duration of the recruitment period. 
 
Chapter 5 
Page | 188 
	
 
 
Figure 5.6: Timeline and timing of recruitment strategies implemented during A) 
2014 and B) 2015.  
Black square represents active recruitment strategies. P, presentation; WOM, word 
of mouth. 
 
5.5.6  Recruitment Cost 
Table 5.5 provides recruitment yield by cost for each recruitment method used in this 
trial. Table 5.5 is presented from most to least expensive per eligible participant 
recruited. Expenses included in the cost analysis do not include staff costs. Staff 
costs were not included in the analysis as they were not tracked by each method and 
were not able to be differentiable from other tasks performed in the administration of 
the trial. The costliest recruitment methods were both state print media and NDSS 
mass mailing which both accounted for 38% of the total recruitment budget. Overall, 
the total costs attached to these two recruitment strategies were AUD$15,360 and 
AUD$15,327 respectively. Cost per eligible participant was greatest for state print 
media at AUD$284 with 54 participants recruited. By comparison the higher yield of 
eligible participants from the NDSS mass mailing meant the cost per eligible 
participant was lower at AUD$196. Costs per eligible participant for local print 
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media were similarly high to state print media at $AUD239 however, due to the 
small number of adverts placed the overall cost of AUD$6,445 was only 16% of the 
recruitment budget. Printed (paid) trial flyers and posters which were used at 
community presentations and provided to allied health professionals was the 
cheapest form of paid recruitment, however, of paid methods it also generated the 
least number of eligible participants. Radio advertising and social media, whilst 
generating enquires into the study, were found not to be effective methods of 
recruitment for this trial as no eligible participants were recruited from these 
approaches. Free methods of recruitment including focused website advertising and 
word of mouth were responsible for generating 25 eligible participants for the trial, 
and as such formed an important part of trial advertising and recruitment in their own 
right as there was no expense to the trial other than staff costs. The overall 
recruitment costs for this trial were AUD$40,421, which equated to AUD$35 per 
enquiry and AUD$204 per eligible participant. 
 
Table 5.5: The total costs, proportion of total recruitment costs, the number of 
eligible participants plus cost per participant for each recruitment strategy in this 
trial. 
 
Eligible 
Participants 
(n) 
Cost per 
Eligible 
Participanta 
Total 
Costa 
% of Total 
Recruitment 
Costs 
State Print Media 54 $284 $15,360 38 
Local Print Media 27 $239 $6,445 16 
Radio Advertising 0 - $990 2.5 
Targeted Mail-outs 78 $196 $15,327 38 
Allied Health & Flyers/ 
Presentations 
14 $128 $1,799 4.5 
Website Advertisement 19 $0 $0 0 
Social Media 0 - $500 1 
Word of Mouth 6 $0 $0 0 
Total 198  $40,421 100 
aStaff costs are not included in this analysis. All costs of recruitment are in Australian 
Dollars. Costs per eligible participant was calculated by dividing the total cost by the 
number of eligible participants. 
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5.6  Discussion 
In this 6-month community-based exercise and dietary supplementation trial in older 
adults with T2DM, a total of 1,157 EOI were received over a 21-month recruitment 
period from which 198 participants (17%) were deemed eligible and subsequently 
randomised. These figures reflect an average randomisation rate of nine participants 
per month. The most effective recruitment strategies for this trial were targeted mail-
outs to registered members of the NDSS database (39% of the total sample) and State 
print media (27%). Overall, recruitment expenditure totalled AUD$40,421, with the 
aforementioned two most effective recruitment strategies each costing approximately 
AUD$15,000, the combination of which corresponded to 76% of all expenditure. In 
total, recruitment costs equated to AUD$35 per enquiry and AUD$204 per eligible 
participant. Collectively, these findings highlight the significant challenges 
accompanying recruitment of T2DM patients into a community-based lifestyle 
modification trial involving exercise and a nutritional supplement.  
 
5.6.1  Eligibility Rate  
Of all the 1,157 EOIs for this trial, only 198 participants were found to be eligible, 
equating to a 17.1% success rate. This rate of recruitment is similar to a 17.9% 
recruitment rate that was reported in the Look AHEAD (Action for Health in 
Diabetes) trial. The aim of this large multi-centre RCT was to investigate the effects 
of a lifestyle intervention aimed at reducing bodyweight by 7% through increased 
physical activity (PA) and a reduction in calorie intake on a range of health 
outcomes, including incidence of heart attacks, stroke and cardiovascular-related 
death in overweight or obese adults with T2DM (598). Comparing the recruitment 
success rates of different trials can be problematic, as factors such as differences in 
the inclusion/exclusion criteria will influence recruitment rates.  Nevertheless, other 
exercise intervention trials recruiting sedentary overweight and obese post-
menopausal females have reported recruitment rates ranging from 2% to 20% (599-
602). Thus, the recruitment rate in this trial appears to be consistent with previous 
intervention trials in older adults and provides a realistic target for future exercise 
based RCTs designed to target older adults with T2DM, particularly where the 
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design of the trial has similar eligibility criteria and involves a comparable level of 
commitment.  
 
5.6.2  Success of Recruitment Strategies 
The recruitment strategies used in this study were diverse and varied depending on 
their success as the recruitment phase evolved. Mass mail-outs through the NDSS 
was the most successful strategy for recruiting participants with T2DM into this trial. 
These letters were responsible for recruiting 39% of all eligible participants. While it 
is difficult to compare the success rate of our mass mail-out campaign to other trials 
given the varying eligibility criteria, our rate is slightly above that reported by the 
Diabetes Prevention Program (DPP) conducted in the United States. In the DPP 29% 
of its randomised participants were recruited via direct mass mail-outs into their 
multi-centre RCT aimed at discovering whether modest weight loss through dietary 
changes and increased physical activity or treatment with the oral diabetes 
medication could prevent or delay the onset of T2DM in those at high risk for the 
condition (603). The ability of mass mail-outs to target a large number of participants 
at relatively low cost, combined with the reported success of this strategy to yield a 
high number of eligible participants in both healthy and clinical populations, has in 
recent years led to mass mail-out becoming an integral part of many RCTs 
recruitment plans (593, 604-606). From our experience, when implementing mass 
mail-outs as a recruitment strategy it is the choice of the mail-out lists which is likely 
to contribute to its effectiveness. For instance, in our trial we were able to selectively 
request the NDSS target members of the registry who met three of our inclusion 
criteria (T2DM diagnosis, current management of condition (prescribed only oral 
hypoglycaemic medication if any) and age). The NDSS database also allowed letters 
to be sent only to local government areas and postcodes which trial staff had 
identified as areas with a high prevalence of T2DM. We believe that this selective 
communication to a tailored list of potential participants in specific areas greatly 
assisted in the efficient identification of eligible participants.  
 
State and local print media were the second and third most prolific methods of 
recruitment, yielding 27% and 14% of participants, respectively. Other RCTs using 
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state and local print media have reported similar recruitment rates from such 
advertisements (603, 607, 608). It has previously been reported that the most 
efficient and comprehensive recruitment campaigns employ several overlapping 
strategies simultaneously, with constant assessment of the strategies employed to 
ensure appropriate allocation of resources to the most successful strategies (609). 
Trial staff remained diligent tracking and assessing the effectiveness of each 
recruitment strategy with only those with the greatest yield of eligible participants 
persisted with. This may have resulted in the success rate of the mass mail-outs and 
state media being over reported as these strategies were employed repeatedly 
compared to those that resulted in a smaller and slower yield of eligible participants 
(e.g. web advertising, allied health, word of mouth, flyers and community 
presentations). Previously, it had been reported that print media including direct 
mail-outs plus newspaper advertisements are two strategies which are more effective 
at capturing the attention of an older adult demographic (603). A finding which was 
also experienced in this trial with each of the alternate strategies employed; web 
advertising, allied health, word of mouth, flyers and community presentations, radio 
and social media, each recruiting less than 10% of participants. 
 
Interestingly, medical and allied health referrals were not successful in recruiting 
older adults with T2DM into the trial, a result which has also been noted previously 
as a less effective recruitment strategy in a previous large community-based 
Australian trial in older adults and the elderly (604). In our trial, it cannot be 
determined whether this was due to medical/allied health professional’s lack of 
communication about the trial, poor distribution of trial advertising material and/or if 
there was a general lack of interest in participating in an exercise program from 
individuals attending these appointments. Based on our experiences, it is a 
recommendation for future trials to consider practice-wide presentations which 
eliminates the burden on health professionals to convey trial information and may 
result in a greater percentage of trial participants recruited from this approach.  
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5.6.3  Recruitment Cost 
In total, AUD$40,421 was spent on all recruitment strategies combined, which 
equates to an average of AUD$204 per eligible participant. Very few detailed cost 
analyses of other large-scale RCTs recruitment campaigns exist making it difficult to 
comparatively assess the methods and associated costs of recruiting eligible 
participants. However, a trial investigating weight gain prevention in young adults 
reported the average cost of recruiting one participant was US$233 in 2014 (605). 
Similarly, a study investigating the recruitment of minority women into the Women’s 
Health Trial which also utilised targeted mass mail-outs reported per participant 
recruitment costs ranging from US$100 to $144 in 1998 (610). In contrast, the DPP 
trial which randomised 3,819 participants spent on average US$1,075 per 
randomised participant (191). The recruitment strategies employed by the DPP trial 
make comparing costs to our trial difficult as the DPP employed a public relations 
agency to help direct recruitment who worked alongside a recruitment committee 
with their recruitment phasing spanning a total of 3-years and costing $US4,105,000 
(611). 
 
Despite State print media acquiring the second highest number of eligible 
participants for our trial, it was the most expensive method, costing a total of 
AUD$15,360 or AUD$204 per eligible participant. Local print media advertising 
costs were considerably lower than State media however, the small yield in eligible 
participants (14%) resulted in this method being the second most expensive 
recruitment strategy. Mass mail-outs through the NDSS, a strategy employed within 
the first eight months of our recruitment campaign, produced a high eligibility to 
response ratio resulting in this approach being implemented multiple times over the 
recruitment period. Whilst this approach was the second most expensive strategy 
used (AUD$15,326) and accounted for 38% of the total dollars spent on recruitment, 
as indicated the large yield of eligible participants resulted in this approach costing 
AUD$196 per participant. A greater comparison of recruitment methods and 
associated costs will be able to be made when other investigators publish such data.   
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5.6.4  Reasons for Ineligibility  
Of all the EOIs received for our trial, 45% (n=516 participants) were deemed 
ineligible. Of these, 26% was due to the participants being classified as too 
physically active (e.g. meeting or exceeding the Australian National Physical 
Activity Guidelines). This result is not unexpected as there is recent evidence that 
approximately 30% of adults with T2DM were found to meet physical activity 
guidelines (590). Further, our findings are comparative to the 26% exclusion for 
physical activity reported by another recent RCT recruiting T2DM patients to an 
automated, interactive voice-response telephone intervention to promote physical 
activity behaviours in adults with T2DM (593). 
 
5.6.5  Reasons for Choosing Not to Participate 
Reasons for non-participation in RCTs for people that initially enquire are frequently 
missing from recruitment publications, but are important to consider as these factors 
may offer valuable insight into areas of trial design that may be improved upon to 
enhance recruitment to future trials. In our trial, 443 potential participants chose not 
to participate following a description of the trial and requirements of participating 
from trial staff over the telephone, or after reading the plain language statement; 43% 
felt the requirements of the 24-week PRT program was too much of a commitment. 
A further 14% cited not being able to bear the financial costs (approximately 
AUD$300-700 depending on training site) associated with joining the Lift for Life® 
resistance training program, despite the incentive of a monetary reimbursement at the 
completion of the trial based upon each participant’s level of compliance to the 
exercise program (AUD$240 if exercise compliance was 80% or above). 
Unfortunately, no information was collected on the potential effects of the monetary 
reimbursement acting as an incentive to participate in the trial. Similarly, the effect 
that having to pay for the Lift for Life® training program had on people’s reluctance 
to participate in the trial was also not assessed. 
 
5.7  Limitations 
There are a number of limitations that should be considered when interpreting the 
findings from this chapter. Our study specifically targeted older adults with T2DM 
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for an exercise and dietary supplementation trial and so the results and experiences 
reported should be tempered when applying to other trials recruiting alternate clinical 
populations. The effects of the monetary reimbursement on incentive to participate in 
the trial were not assessed and future studies need to ask these types of questions to 
assess the effects of such incentives on willingness to participate in research. The 
recruitment strategies found to be most successful in sourcing eligible participants 
for this trial were also the ones which were extensively repeated multiple times, 
potentially biasing the findings. Similar messages were used for all of the 
advertisements and as such no data is available for what type of message may be 
most salient to older adults with T2DM. Additionally, only one recruitment strategy 
was recorded per expression of interest leaving open the potential for cross-
contamination from different recruitment methods. For example, some participants 
who received a mail-out may also have been exposed to a trial advertisement in web 
or print media format, however, with only one form of recruitment noted for each 
expression of interest the effects of exposure to two recruitment strategies remains 
unknown. In the future, it would be useful for other trials to include such a question 
in order to determine the benefits of multiple exposures to recruitment methods. 
 
5.8  Conclusion  
This chapter aimed to address the practical considerations surrounding recruitment of 
older adults with T2DM into a RCT involving lifestyle modification. Recruitment 
required continual sustained efforts and necessitated flexibility within the recruitment 
strategies used to ensure the recruitment targets were being achieved. Of the vast 
array of recruitment approaches employed, strategies which were found to be 
ineffective at recruiting participants to this trial were radio advertising and social 
media. Successful recruitment approaches were found to be those which directly 
targeted the patient population of interest. The most successful strategy was targeted 
mail-outs to members of the NDSS database, with state print media the second most 
effective strategy. Overall, AUD$40,421 in total was spent on recruiting participants 
to this trial, costs per randomised participant were AUD$204. The reporting of this 
trials recruitment experiences offers several lessons about strategies and costs for 
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future trials looking to recruit T2DM patients for trials involving lifestyle 
modification.  
 
Future Recommendations  
An understanding of the specific population being recruited is key to identifying the 
optimal strategies to reach trial demographics. It is important to design an 
appropriately budgeted recruitment plan that is effective in sourcing eligible 
participants and engaging interest from the target group to ensure subsequent 
enrolment into the research trial. Such planning is paramount to successfully 
remaining on target for the timely completion of RCTs within the allocated budget.  
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Chapter 6 
 
The Effects of Progressive Resistance Training Combined with a 
Whey-Protein Drink and Vitamin D Supplementation on Glycaemic 
Control, Insulin Sensitivity and Body Composition and 
Cardiovascular Risk Factors in Older Adults with Type 2 Diabetes 
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6.1  Declaration Statement 
This Chapter presents the analysis, results and discussion of the 6-month community 
based PRT program titled REVAMP-IT. Under the guidance of my primary 
supervisor my role was to analyse the data arising from this trial as presented in this 
Chapter, draft and write the results, prepare all tables and figures along with 
preparing the discussion with assistance from my supervisory team.  
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6.2  Abstract 
Supervised and structured high-intensity progressive resistance training (PRT) has 
been shown to improve glycaemic control and lean mass in older adults with type 2 
diabetes mellitus (T2DM), but whether similar benefits are achieved with 
community-based moderate to high-intensity PRT remains uncertain. Emerging 
evidence suggests that high protein diets, whey protein and/or vitamin D 
supplementation may have beneficial effects on glycaemic control, body 
composition, and cardiovascular health in those with T2DM, but whether combining 
protein and vitamin D with PRT can provide additive or synergistic health benefits 
remains unknown. The aim of this 24-week RCT was to investigate whether 
combining PRT with whey protein and vitamin D supplements could enhance the 
effects of PRT alone on glycaemic control, body composition and cardiovascular 
health outcomes in older adults with T2DM. A total of 198 older adults (mean ± SD 
age 61.5 ± 6.2 years) with T2DM participated in a community-based PRT program 
(2-3 times per week) for 24-weeks with participants randomised to whey protein 
supplementation (20 g per day plus 20g following PRT) with vitamin D treatment 
(2,000 IU/day) (PRT+ProD, n=98) or PRT alone (PRT, n=100). Body composition 
(total body, regional lean and fat mass plus thigh muscle cross-sectional area (25% 
femur)) was measured at 0 and 24-weeks by DXA and pQCT. Glycaemic and 
insulinaemic parameters along with lipids and inflammatory markers were assessed 
at 0, 12- and 24-weeks using standard techniques. A total of 168 participants (85%) 
completed the 24-week intervention (PRT+ProD=88 and PRT=80). Mean exercise 
compliance was significantly higher in PRT+ProD compared to PRT (67% vs 58%, 
P<0.05) and compliance with the whey protein and vitamin D supplements was 79% 
and 92%, respectively. Overall serum 25(OH)D levels were ~72nmol/L at baseline 
and 24-weeks of supplementation led to a mean increase of 28 nmol/L in the 
PRT+ProD group (P=0.001); there was no change in PRT. Intention-to-treat analysis 
showed PRT led to significant improvements in glycaemic control, total body and 
regional (arm and leg) lean mass, thigh muscle size, upper and lower body muscle 
strength, waist circumference, fat mass and DBP, but there was no added benefits of 
the whey protein drink and vitamin D supplements, with the exception that there was 
a significantly greater reduction in serum insulin concentrations after 12- and 24-
weeks in the PRT+ProD compared to PRT group. Similarly, there was significant 
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beneficial effect of PRT combined with whey protein and vitamin D relative to PRT 
alone on the anti-inflammatory marker IL-10, yet no between-group differences for 
the change in any other inflammatory cytokines. Secondary pre-planned analysis 
examining those who achieved ³66% exercise and ³80% whey protein and vitamin 
D supplement adherence revealed a greater improvement in upper body muscle 
strength and serum IL-6 in the PRT+ProD group plus a greater reduction in total and 
low density lipoprotein (LDL) cholesterol. In summary, a community-based PRT 
program was found to be safe and effective for improving glycaemic control and 
body composition, but the addition of whey protein and vitamin D supplementation 
did not enhance these health benefits in older overweight and obese adults with 
T2DM. 
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6.3  Introduction 
Type 2 diabetes is largely considered a lifestyle-related disorder, and thus regular 
exercise and adequate nutrition are widely considered the key pillars for the 
management of glycaemic control and reducing body weight and fat mass in those 
who are overweight/obese (5, 6). Traditionally, aerobic exercise training and caloric 
restriction have been advocated for the management of weight and fat mass, but such 
an approach has typically been associated with a loss in lean mass (7, 8). This is 
important because lean mass is the primary site of glucose disposal under insulin 
stimulated conditions (9). Indeed, reductions in lean mass have been shown to 
negatively affect glycaemic control and metabolic rate, and further compound the 
problems of insulin resistance (10, 11).  
 
Progressive resistance training (PRT) is one mode of exercise that has been shown to 
be safe and effective for improving or maintaining lean mass, size and strength in 
older adults with T2DM (8, 12, 14, 204, 212, 225, 250, 612). Indeed, current national 
and international physical activity guidelines for the management of this condition 
recommended that moderate to high-intensity PRT be performed at least twice a 
week due to it beneficial effects on lean mass, glycaemic control and insulin 
sensitivity (6, 185, 211, 231). There is also some evidence supporting a beneficial 
effect of PRT on markers of systemic inflammation in older adults with T2DM (217, 
230, 238), which is important as increased inflammation has been implicated in the 
pathophysiology of insulin resistance, endothelial dysfunction and cardiovascular 
disease (22). To date however, the majority of randomised controlled trials (RCTs) 
examining the effects of PRT in older adults with T2DM have been conducted under 
tightly controlled and structured clinical laboratory settings. While there is some 
evidence that community-based programs can improve glycaemic control and body 
composition in adults with T2DM (204, 255), the benefits appear to be less 
impressive which may relate to a number of factors including training intensity, 
exercise compliance and/or inter-individual differences in dietary habits.  
 
Nutrition or nutritional modification, like exercise, is an integral component to the 
management of T2DM and influences many metabolic pathways that affect the 
progression of this disease. Enhancing the health benefits of PRT through nutritional 
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management may offer a synergistic effect on glycaemic control, body composition 
and cardiovascular risk factors. In recent years, there has been considerable interest 
into the role of dietary protein, including whey protein supplements, due to its 
positive effects on stimulating insulin secretion and improving glycaemic control 
(52, 329, 330, 379). Furthermore, in non-diabetic adults, post-exercise ingestion of a 
protein-rich supplement such as whey protein has also been found to maximise the 
anabolic effects of PRT on lean mass (305, 519, 572, 613, 614). Long-term 
consumption of whey protein supplements has been reported to reduce weight and fat 
mass through its effects on increasing satiety and subsequently reducing total energy 
intake (353, 403). There is also mounting evidence that vitamin D deficiency is 
associated with impaired beta-cell function, glucose intolerance, insulin resistance 
and increased systemic inflammation, all of which may be improved with 
supplementation, although the findings from RCTs are mixed (22, 59, 615). Whether 
there are additive health and metabolic benefits of combining vitamin D and whey 
protein with a community-based PRT program in older adults with T2DM is not 
known. However, in a recent 13-week double-blinded, randomised placebo 
controlled trial in 130 sarcopenic elderly adults without T2DM (mean age 80.3 years) 
it was reported that the combination of 22g of whey protein and 100 IU vitamin D 
twice/day with exercise improved total body lean mass, reduced android fat mass, 
and improved strength and reduced inflammation in comparison to the placebo plus 
exercise group (513).  
 
The primary aim of this community-based Resistance Exercise, Vitamin D and 
Muscle Protein Intervention Trial (REVAMP-IT) was to investigate if a community-
based PRT program combined with a whey protein and vitamin D enriched 
supplement could synergistically interact to concomitantly enhance the effects of 
PRT alone on glycaemic control and insulin sensitivity in older adults with T2DM. 
Secondary aims were to examine the effects of the intervention on body composition 
(total body and regional lean and fat mass and percent body fat), cardiovascular risk 
factors (lipid and lipoprotein levels, blood pressure) and various markers of systemic 
inflammation.  
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6.4  Methods 
As a detailed description of the methods for this study has been provided in Chapter 
4, a brief summary of the methods for REVAMP-IT is provided below. 
 
6.4.1  Study Design 
This study was a 24-week two-arm parallel, RCT. Participants with established 
(diagnosed by a GP or endocrinologist) T2DM who were suitable for the current 
community-based Lift for Life® PRT program and met the trial inclusion criteria 
(refer to Chapter 4 section 4.2.6 Screening and Eligibility) were randomised to one of 
two groups: 1) the Lift for Life® program combined with a whey-protein drink and 
vitamin D supplements or 2) the Lift for Life® program alone.  
 
6.4.2  Participants  
Men and women aged 50 to 75 years with established T2DM, treated with diet alone 
or any oral hypoglycaemic agents (except insulin), were invited to participate in this 
study. A two-step screening process was employed in this study. In the first instance, 
a telephone screening questionnaire (Appendix 5) was used to assess an individual’s 
eligibility. Participants were eligible if aged 50-75 years, had been diagnosed with 
T2DM and were treating/managing their condition through dietary change or oral 
hypoglycaemic medication only. Those who passed the telephone screening were 
then required to gain GP approval prior to randomisation and participation in the Lift 
for Life® program (second screening step) (Appendix 6). 
 
6.4.3  Ethics  
Ethics was approved by the Deakin University Human Research Ethics Committee: 
Project number EC2013-050 (Appendix 4). This study is also registered with the 
Australian New Zealand Clinical Trials Registry, registration number 
ACTRN12613000592741. 
 
6.4.4  Funding 
This project was funded by a grant from the National Health and Medical Research 
Council Project (APP1046269). The whey-protein powder was provided by 
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OmniBlend (Campbellfield, Victoria, Australia) and the vitamin D supplements 
(Ostelin) by Sanofi-Aventis Australia Pty Ltd (Macquarie Park, New South Wales, 
Australia). 
 
6.4.5  Randomisation 
Randomisation occurred at the level of the individual participant, stratified by gender 
and diabetes treatment (diet or oral hypoglycaemic medication), in blocks of 4-8 
using a computer-generated random number sequence (Microsoft Excel) by an 
independent researcher. All research staff responsible for the collection of 
anthropometric, blood pressure, and body composition data were blinded to the 
intervention groups. The project manager was solely responsible for the distribution 
of supplements to participants randomised to the Lift for Life® program plus whey-
protein and vitamin D supplements. A limitation of our study was that the project 
manager was involved in some of the strength assessments which may have 
introduced some observational bias.  
 
6.4.6  Intervention 
Lift for Life® PRT Program 
All participants were required to follow a training program modelled off the structure 
of the Lift for Life® PRT program (www.liftforlife.com.au). The Lift for Life® 
program comprises moderate-intensity PRT (2-3 sets of 8-12 repetitions at 60-75% 
of maximum strength of 8-10 exercises) involving dynamic concentric and eccentric 
contractions, focusing on the major muscle groups of the body. Training was made 
incrementally more challenging at a rate of 2-10% per week to meet the principles of 
progressive overload with the Borg RPE scale also used to validate training intensity. 
An appropriate training intensity level for this trial was established as 12-15 
(moderate- to high-intensity).  
 
Due to the limited number of accredited Lift for Life® program providers in 
Melbourne Australia, the trial was expanded to include training locations such as 
commercial gymnasiums that were not accredited as a Lift for Life® program 
provider but which did allow participants to safely perform a PRT program under the 
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guidance of qualified Certificate IV personal trainers (minimum qualification). In 
such instances, the structure of the training programs for these participants imitated 
that of the Lift for Life® program as depicted below in Figure 6.1.  
 
 
Figure 6.1: Flow diagram of the progress through the 24-week PRT program used in 
this trial modelled off the Lift for Life® program. 
 
Whey-Protein and Vitamin D Supplementation 
Participants randomised to the Lift for Life® plus whey-protein and vitamin D 
supplementation group received a 12-week supply of a whey-protein enriched 
powder and vitamin D supplements at the completion of baseline testing and again 
after 12-weeks of training. Whey-protein supplements were provided in single use 
sachet form (OmniBlend, Campbellfield, Victoria, Australia). Participants were 
instructed to mix one sachet containing 20g of WPC (80%) with 150ml of water 
every morning of the trial and consume an additional supplement within two hours of 
each Lift for Life® PRT session on the respective training days. Participants received 
a marked shaker cup with instructions on how to reconstitute the whey-protein 
powder in water (1 sachet per ~150ml of cold water) along with appropriate storage 
instructions for the supplements. Participants were offered two flavours to select 
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from (vanilla or mocha coffee). A detailed description of the preparation of these 
supplements is provided in Chapter 4. 
 
In addition to the whey-protein supplements, participants randomised to this 
treatment group were also asked to take two 1,000 IU capsules of vitamin D3 
(Ostelin, Melbourne, Victoria, Australia) each day for the duration of the study. The 
goal of vitamin D3 treatment was to raise serum 25(OH)D concentrations to at least 
75 nmol/L.  
 
6.5  Outcome Measures 
Participants attended Deakin University on three occasions throughout the duration 
of the study for assessment (baseline, 12- and 24-weeks). All outcome measures 
were assessed within the School of Exercise and Nutrition Sciences at Deakin 
University, Burwood campus with the exception of fasted blood sample collections 
which occurred at local pathology clinics at baseline, 12- and 24-weeks. 
 
6.5.1  Anthropometry 
All participants’ height, weight and waist circumference were measured using 
standard techniques.  
 
6.5.2  Blood Pressure 
Following a 5-minute rest period where all participants were seated in a quiet room, 
systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured 
using an automated blood pressure monitor (AND Vital Sensor, Model number TM-
2551P, Abingdon, Oxford). Four measurements were taken on the left arm with a 2-
minute interval between readings; the mean of the final three readings were used in 
the analysis. 
 
6.5.3  Body Composition  
Total body and regional (arm and leg) lean mass, fat mass and percentage body fat 
was measured from total body scans performed using Dual X-ray Absorptiometry 
(DXA) (Lunar Prodigy, GE Lunar Corp., Madison WI), using software version 
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12.30.008. The short-term co-efficient of variation (CV) for repeated measurements 
of total body lean mass and fat mass within the laboratory ranges from 1.0% to 1.7%. 
A peripheral quantitative computed tomography (pQCT) scanner (XCT 3000, Stratec 
Medizintechnik GmbH, Pforzheim, Germany) was used to measure muscle cross-
sectional area (CSA), subcutaneous and intermuscular fat CSA and muscle density, 
as a surrogate measure of intermuscular adiposity, at the 25% femur site. The CV for 
femur muscle CSA within the laboratory is 1.3%. 
 
6.5.4  Muscle Strength 
Isometric knee extensor strength (force in kg) was measured on the participant’s 
dominant leg using Lord's strap assembly incorporating a strain gauge (Neuroscience 
Research Australia, Sydney, Australia). Maximal muscle strength of the lower limbs 
and back was estimated by employing three-repetition maximum strength (3-RM) 
tests for the bilateral leg press (Synergy Omni Leg Press S-31 OPD, QLD, AUS) and 
the seated row (Nautilus F3 Adjustable Tower Pulley System F3ATFS, Nautilus, 
Vancouver, WA). One-repetition maximum (1-RM) muscle strength was determined 
using the formula by Wathen et al. (579): 1-RM = 100 x (3-RM load)/(48.8 + 53.8 x 
e (0:075x3)). The short-term CV for repeated measurements of 1-RM testing in our 
laboratory was 2.0% for leg and 1.1% for back strength.  
 
6.5.5  Biochemical, Hormonal and Inflammatory Cytokine Measurements 
Extensive methodology for the measurement of biochemical, hormonal and 
inflammatory markers is provided in Chapter 4. Following an overnight fast, a rested 
morning (8-10am) venous blood sample was collected from each participant’s 
antecubital vein at a local pathology laboratory. The following series of parameters 
were all assessed by the pathology clinic using standardised techniques: HbA1c, 
plasma glucose, creatinine, calcium, C-peptide, estimated glomular filtration rate 
(eGFR), high-sensitive C-reactive protein (hs-CRP) and blood lipids (total 
cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein 
(LDL) cholesterol and triglycerides).  
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A range of hormonal and inflammatory markers were assessed in a single batch at 
the completion of the study from serum aliquot samples collected and stored 
throughout the study. Serum 25(OH)D were analysed at Monash Health, Melbourne, 
Australia. Samples were measured on the AbSciex Q Trap 5500 MS by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). Serum IGF-1 was 
measured using a 1-step sandwich chemiluminescense immunoassay LIAISON® 
IGF-1 kit (DiaSorin, Saluggia (VC), Italy) with samples read on a LIAISON® 
Analyser. Insulin sensitivity was assessed from fasting plasma insulin and fasting 
plasma glucose (FPG) concentrations using the HOMA-2 calculator available from 
the Diabetes Trials Unit www.OCDEM.ox.ac.uk (616).  
 
A detailed description of the methods for inflammatory marker measurement is 
provided in Chapter 4. The mean intra and inter-assay CVs for IL-6, IL-10, IL-8, 
TNF-ɑ and Adiponectin was <12%. Samples with results below the detectable limits 
of the assay were allocated the minimum detectable concentration for each assay: IL-
6= 0.16 pg/mL; IL-10= 0.40 pg/mL; IL-8= 0.06 pg/mL; TNF-ɑ = 0.07 pg/m; 
Adiponectin = 0.20 µg/mL.  
 
6.5.6  Dietary Assessment  
Briefly, dietary data was collected with two 24-hour dietary recalls at baseline of 
which the second one was used in the analysis and one 24-hour dietary recall at 12- 
and 24-weeks. The data collected from the 24-hour recalls was entered into 
FoodWorks Professional (Version 8, Xyris Software, Queensland, Australia) to 
calculate total dietary energy intake and dietary macronutrient composition using the 
AUSNUT 2011-13 database including AusBrands and AusFoods. Mean daily 
alcohol consumption was estimated from self-reported intakes over the previous 
seven days.  
 
Habitual Protein plus Protein from Whey Protein Supplements 
The additional protein consumed from the whey protein supplements was calculated 
for both training days and non-training days given the differing number of 
supplements prescribed (one on non-training days and two on PRT days). Individual 
compliance as a percentage with the whey protein supplements was multiplied by the 
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dose of protein (either 20 or 40 g) with this amount subsequently added to the 
habitual protein intake reported from the 24-hour food diaries to calculate the grams 
per day of protein consumed. The same method was used to calculate g/kg/day at 
both 12- and 24-weeks with weight at both these respective time points used in the 
calculations to determine the g/kg/day of protein intake inclusive of the whey protein 
supplement.   
 
6.5.7  Habitual Physical Activity 
Total leisure and recreational physical activity time (hours per week) was assessed 
using the Community Healthy Activities Model Program for Seniors (CHAMPS) 
physical activity questionnaire. These results are reported as estimated kilojoules per 
week spent in moderate- to high-intensity activities.  
 
6.5.8  Medical History, Health Status and Medication Use  
All participants completed a lifestyle questionnaire to obtain information on 
education background, history of diseases or illnesses, current medial conditions, 
family history of diabetes, smoking history, current medication and dietary 
supplement use, average weekly alcohol consumption. Information on any alterations 
to or new medication prescribed by the participants’ doctors was collected by 
research staff via the monthly telephone calls.  
 
6.5.9  Compliance Assessment 
Lift for Life® Exercise Training Cards 
Compliance with the Lift for Life® PRT program was evaluated via self-completed 
exercise cards. These cards were returned to researchers at the completion of the first 
four weeks of training either by post or trial staff collection from respective training 
locations. This allowed the PRT programs to be reviewed and additional exercises 
prescribed or modified if not challenging enough.  
 
Supplement Calendars 
Compliance with the prescribed protein and vitamin D supplements were evaluated 
via self-completed compliance calendars and a capsule count of remaining vitamin D 
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supplements, respectively. The compliance calendars for the protein supplements 
were cross-referenced by counting the remaining sachets of protein returned at the 
final testing appointment.  
 
6.5.10  Adverse Events 
Any adverse events associated with the exercise program or supplements were 
recorded by research staff during the monthly phone calls to participants. For this 
trial, an adverse event was defined as any health-related untoward or unfavourable 
medical occurrence that developed or worsened during the 24-week trial as a direct 
result of either the exercise program or supplements. All adverse events were 
assessed for seriousness, causality and expectedness by the research staff and 
reported adverse events were categorised into adverse event, serious adverse event or 
unanticipated problem based upon the National Institute of Ageing guidelines (589).  
 
6.5.11  Statistical Analysis  
For the statistical analysis of this 24-week intervention we used the Statistical 
Package for the Social Sciences (SPSS, version 24) and Stata statistical software 
release 14.0 (College Station, TX: StataCorp LP.). Prior to all analyses, the data was 
checked for normality with natural log transformations used to achieve normality 
when required. This included: serum IL-10, IL-6, IL-8, TNF-a, adiponectin, hs-CRP, 
insulin sensitivity (HOMA2%S) and all strength measures (knee-extensor strength, 
1-RM leg press and 1-RM seated row). Independent t-tests were used for between-
group comparisons at baseline for continuous variables and Chi-square tests for 
categorical variables. The McNemar test was used to check for any differences 
between the groups for the change in the proportion of participants taking diabetes 
medication, anti-hypertensive, lipid-lowering, diuretic and nonsteroidal anti-
inflammatory drug (NSAIDs) therapies.  
 
All the data was analysed on a modified intention-to-treat basis, including all 
randomly assigned participants, regardless of exercise or supplement compliance, 
with at least one follow-up observation. To assess whether the whey protein drink 
and vitamin D supplements enhanced the effects of PRT after 12- and 24-weeks, 
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generalised linear mixed models were used with random intercepts fitted for each 
outcome, including fixed effects for time (baseline, 12- and 24-weeks), group 
(PRT+ProD, PRT), and an interaction between group and time. Several models were 
run: 1) unadjusted, 2) adjusted for the baseline value of the outcome variable, and 3) 
adjusted for various covariates (see below). Adjusting for baseline for each outcome 
variable made no difference to the results, with the exception of fasting insulin where 
a significant between-group interaction was seen at both 12- and 24-weeks (P=0.028 
and P=0.038) and for serum TNF-a where there were no longer any between-group 
differences after 12-weeks (P=0.620) and 24-weeks (P=0.241). For all outcome 
measures where there were only two time points, specifically body composition as 
assessed from DXA and pQCT along with 1-RM strength outcomes, analysis of 
covariance (ANCOVA) was performed with baseline values included as a covariate 
and the change as the outcome measure. Model 3 included the following covariates: 
age, gender, ethnicity, BMI, moderate-vigorous physical activity and diabetes 
management. Anti-hypertensive or lipid-lowering medication were also included as 
covariates for blood pressure and lipid measures, respectively. The P-values are 
presented from unadjusted analysis and model 3.  
 
To calculate the net between group differences for the changes over time, we first 
calculated the within-group changes from baseline in each group at each time point 
and then subtracted the within-group changes in the PRT+ProD group from those in 
the PRT group at 12- and 24-weeks. Percentage changes in the previously listed 
variables which were log-transformed prior to analysis represent the absolute 
differences from baseline multiplied by 100. All data is presented as means ± SD or 
95% CI, unless stated otherwise and P<0.05 was considered statistically significant. 
Whilst we acknowledge reporting of within-group changes at multiple time points 
increases the risk of type I error and could have performed Bonferroni corrections we 
set our significance level at P<0.05, as stated above, along with our hypotheses being 
established a priori and like others (617) considered such a method to be overly 
conservative in this instance as previously reported (618). 
 
In addition to the above, tests of interactions by gender, BMI (< 30 vs ≥ 30 kg/m2), 
diabetes management (use of oral hypoglycaemic medication or lifestyle 
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management) and anti-hypertensive or lipid-lowering medication use (yes or no) 
were also tested for all relevant measured outcomes variables. For glycaemic 
outcomes, we also conducted tests of interactions for baseline HbA1c (< 7 vs ≥ 7%) 
and FPG (< 7 vs ≥ 7 mmol/L). Of all these interactions tested for each outcome 
variable none were found to be significant and thus the results are not presented.  
 
All these same statistical tests and tests of interactions as stated above were run in the 
same manner for the per protocol analysis using only those participants who met the 
per protocol requirements. For the per protocol analysis, the cut point was set at 66% 
compliance or approximately two PRT sessions per week along with 80% of the 
whey protein and vitamin D supplements. 
   
6.6  Results 
6.6.1  Participant Characteristics 
A total of 198 adults (126 men and 72 women) with established T2DM aged 50-75 
years (mean ± SD: 61.5 ± 6.2 years) were randomised to participate in this 24-week 
intervention trial. The mean ± SD age at diagnosis for T2DM was 54.9 ± 7.7 years 
and the mean disease duration was 7.0 ± 5.2 years (range 21 days to 21.7 years). An 
equal proportion of participants in each group at baseline were classified as 
overweight (PRT+ProD, 41.8%; PRT, 36.0%, Chi-square P=0.40) or obese 
(PRT+ProD, 44.9%; PRT, 58.0%, Chi-square P=0.065). An equal proportion of men 
and women were allocated to each group and of similar ethnic backgrounds (Table 
6.1). Approximately 70% of participants managed their diabetes with medication but 
there were no differences in the proportion of participants in each group with regard 
to how they managed their diabetes (e.g. lifestyle alone or medication) (Table 6.1). 
There were also no differences at baseline between the two groups for any of the 
additional characteristics listed in Table 6.1, including the number and proportion of 
participants who reported previous diagnosis with hypertension, 
hypercholesterolaemia or CVD as diagnosed by a doctor. The only exception to this 
was the PRT+ProD group were found to have a significantly larger number and 
proportion (n=65, 66%) of participants who had a family history of T2DM compared 
to those in the PRT group (n=46, 46%, P<0.01). 
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Table 6.1: Baseline characteristics of participants in the PRT+ProD and PRT groups. 
 PRT+ProD PRT 
n 98 100 
Male / Female, n 62 / 36 64 / 36 
Age (years) 61.1 ± 6.2 62.0 ± 6.2 
Height (cm) 170.2 ± 10.3 170.5 ± 9.2 
Ethnicity   
   Caucasian, n (%) 84 (86) 89 (89) 
   Asian, n (%) 11 (11) 8 (8) 
   Other, n (%) 3 (3) 3 (3) 
Age at diagnosis (years) 54.1 ± 7.2 55.1 ± 7.9 
Duration of diabetes (years) 6.9 ± 5.4 6.9 ± 5.3 
Family history of diabetes, n (%) 65 (66)** 46 (46) 
Diabetes management (lifestyle / medication), n 27 / 71 32 / 68 
Overweight/Obese   
   Normal weight, n (%) 13 (13) 6 (6) 
   Overweight, n (%) 41 (42) 36 (36) 
   Obese, n (%) 44 (45) 58 (58) 
Ex-smoker, n (%) 36 (37) 41 (41) 
Self-reported co-morbid condition   
   Hypertension, n (%) 56 (60) 62 (62) 
   Hypercholesterolaemia, n (%) 27 (29) 25 (25) 
   CVD1, n (%) 7 (7) 12 (12) 
Employment status   
   Working full-time, n (%) 42 (43) 35 (35) 
   Working part-time/Semi-retired, n (%) 16 (16) 26 (26) 
   Not-working/Retired, n (%) 40 (41) 39 (39) 
Values presented are mean ± SD unless stated. The classification of overweight and obese 
was completed using the following BMI cut-offs, overweight BMI ≥ 25.0- ≤ 29.9 and obese 
BMI ≥ 30.0. 1 Cardiovascular disease encompassed previous diagnosis heart disease or 
previously having suffered a heart attack. 1 Cardiovascular disease encompassed previous 
heart attack, angina, heart disease and/or stroke. **P<0.01 vs PRT. CVD, Cardiovascular 
disease. PRT+ProD, progressive resistance training plus protein and vitamin D supplements; 
PRT, progressive resistance training. 
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6.6.2  Study Attrition 
Study Attrition 
A CONSORT flow-chart of the study design including information for all 
withdrawals and participants lost to follow-up is presented in Figure 6.2. Following 
randomisation and prior to the 12-week assessment, an equal proportion of 
participants from both the PRT+ProD (n=3) and PRT (n=5) groups were lost to 
follow-up (e.g. could not be contacted or did not reply to phone, email or postal 
requests) (Chi-square, P=0.721). In addition, a further 13 participants withdrew from 
the study during the initial 12-weeks, the number of withdrawals was significantly 
greater in the PRT than the PRT+ProD group (PRT+ProD n=2; PRT n=11; Chi-
square, P=0.011). The main reasons for withdrawal are discussed below. Following 
the 12-week assessment, a further five participants in the PRT+ProD group were lost 
to follow-up compared to only one participant in the PRT group (Chi-square, 
P=0.084). An additional three participants in the PRT group withdrew from the trial 
during this period, with no withdrawals in the PRT+ProD group. Thus, a total of 14 
participants were lost to follow-up throughout the study with an equal proportion 
from each group (PRT+ProD, n=8; PRT, n=6, Chi-square, P=0.553) and 16 
participants withdrew from the trial, with a greater proportion in the PRT group 
(14%, n=14) compared to the PRT + ProD group (2%, n=2) (Chi-square, P=0.002). 
Three participants in the PRT+ProD and 11 in PRT group never commenced the 
exercise program following randomisation. One participant in each of these groups 
who never commenced the training program returned for follow-up testing 
appointments at 12- and 24-weeks. These participants were not excluded from final 
analysis. Overall, a total of 168 (85%) participants completed the trial and had data 
available for final analysis, with slightly fewer drop-outs (withdrawals or lost to 
follow-up) in the PRT+ProD group (n=88 included in final analysis) compared to the 
PRT group (n=80 included in final analysis) (Chi-square, P=0.055).  
 
Reasons for Withdrawal 
During the first 12-weeks, the reasons for withdrawal in the PRT+ProD group were 
health-related (n=1) and dislike of the training program (n=1). For the PRT group, 
the reasons were health-related (n=5), carer/work commitments (n=4) and dislike of 
the training program (n=2). Following the 12-week assessment, another three 
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participants in the PRT group withdrew for either health-related reasons (n=2) or a 
dislike of the training program (n=1). Overall, there were no significant differences 
between the groups for the various reasons for withdrawing from the trial, with the 
exception that a greater proportion of participants in the PRT group (n=4) withdrew 
for health-related reasons compared to the PRT+ProD group (n=0) (Chi-square, 
P=0.045).  
 
When comparing those who either were lost to follow-up or withdrew from the 
intervention to those who remained in the study, there were no differences observed in 
any of the baseline outcome measures with the following exceptions; those who were 
lost to follow-up/withdrew had a higher mean (± SD) baseline HbA1c (7.46 ± 1.30 vs 
6.92 ± 1.10, P=0.01), FPG (9.36 ± 2.99 vs 8.04 ± 2.10, P=0.003), fasting insulin levels 
(125.1 ± 163.4 vs 89.8 ± 51.7, P=0.03) and lower serum adiponectin levels (1.86 ± 
0.91 vs 2.93 ± 0.12, P=0.001) compared to those who remained in the study.  
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Figure 6.2: CONSORT flow diagram of participants through the trial.  
Progressive resistance training (PRT); protein and vitamin D supplements (ProD). 
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6.6.3  Compliance 
Lift for Life® Exercise Program Compliance 
Compliance (the percentage of PRT sessions attended out of the total 64 prescribed 
over the 24-week intervention) with the PRT program was significantly greater for 
the PRT+ProD [mean (95% CI): 67.5% (62.0, 72.9)] compared to the PRT group 
[57.9% (51.7, 64.2)] (P=0.023 for the between-group difference). Figure 6.3 shows 
the histogram for the compliance (as a percentage) with the PRT program by group. 
For the per protocol analysis, the cut point was set at 66% compliance or 
approximately two PRT sessions per week. In the PRT group, 50% (n=50) of 
participants achieved this level of compliance compared to 57% (n=56) in the 
PRT+ProD groups. As the cost of training differed slightly across all the training 
locations, we assessed whether there was any associated between the cost of training 
and compliance with the PRT program yet found no significant association. 
 
 
 
Figure 6.3: Histogram of the percentage exercise compliance by participants in the 
progressive resistance training plus protein and vitamin D supplementation 
(PRT+ProD, panel A) and PRT (panel B) group. 
 
Whey Protein and Vitamin D Supplement Compliance 
Mean (95% CI) compliance with both the whey protein drink and vitamin D 
supplements in the PRT+ProD group, which was calculated as the percentage of the 
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protein sachets and vitamin D capsules consumed over the 24-week period, was 
78.6% (72.3, 84.9) and 91.5% (87.9, 95.1), respectively. Figure 6.4 shows the 
histograms of the percentage compliance with the whey-protein drink and vitamin D 
supplements. For the per protocol analysis, the cut-point was set at ≥80% 
compliance. Overall 79% (n=78) of participants in the PRT+ProD group achieved a 
mean compliance of ≥ 80% with the supplements. However, only 42% (n=41) of the 
participants in the PRT+ProD group attained a mean compliance of ≥ 66% with the 
PRT program and a mean compliance of ≥ 80% with the whey and vitamin D 
supplements, thus only 41 participants in the PRT+ProD group were included in the 
per-protocol analysis. 
 
 
 
Figure 6.4: Histogram of the percentage compliance with the whey protein drink 
(panel A) and vitamin D supplements (panel B) in the progressive resistance training 
plus protein and vitamin D supplementation (PRT+ProD) group. 
 
6.6.4  Adverse Events 
Lift for Life® Exercise Program  
In total, 42 musculoskeletal complaints or injuries were reported by 37 participants 
with no significant differences between the groups (PRT+ProD, n=20, PRT, n=17; 
P=0.538). One participant in each group reported two adverse events and an 
additional participant in the PRT group reported three adverse events. As shown in 
Table 6.2 the most common complaints were for the shoulder/neck and elbow/wrist 
in both groups. The most common reason provided for reporting a neck/shoulder 
complaint was neck tension/pain which led to a headache following a training 
session. For elbow/wrist and back complaints, these were most commonly associated 
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with aggravation of previously diagnosed tennis or golfers elbow or aggravation of 
previous pain or injury in the back. 
 
In the PRT+ProD group, 12 of the 20 participants continued their training with slight 
modification to the program, six ceased training for a short period (1- to 2-weeks), 
one participant reduced their training to two sessions per week for 6-weeks and one 
individual withdrew from the exercise program but agreed to return for follow-up 
testing. In the PRT group, nine of the 17 participants could continue with their 
training by making small modifications or removing the specific exercise responsible 
for the complaint/injury until recovery, six participants ceased training for a short 
duration (1- to 3-weeks) and two discontinued the exercise program but returned for 
follow-up testing. Of all the musculoskeletal complaints or injuries, eight participants 
in the PRT+ProD and six participants in the PRT groups reported their complaints 
were aggravations of a pre-existing injury.  
 
Table 6.2: Number and proportion of musculoskeletal complaints reported by 
participants in the PRT+ProD and PRT groups that were deemed to be associated 
with the PRT program. Categorised by skeletal/muscular site. 
 Study Group 
Adverse Event Location PRT+ProD PRT 
Shoulder/Neck, n (%) 5 (24) 8 (38) 
Elbow/wrist, n (%) 6 (29) 6 (28) 
Gluteal, n (%)  - 1 (5) 
Knee, n (%) 4 (19) 2 (10) 
Back, n (%) 5 (24) 2 (9) 
Hamstring, n (%) 1 (4) - 
Groin, n (%) - 1 (5) 
Achilles, n (%) - 1 (5) 
Total Number 21 21 
 
Whey Protein and/or Vitamin D Supplements 
No adverse events were reported with the ingestion of vitamin D supplements. A 
total of 44 gastrointestinal (GI) related adverse events in 27 (28%) participants were 
reported in relation to the whey protein drink in the PRT+ProD group over the 24-
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week period (Table 6.3). Of the participants reporting an adverse event, twelve 
(44%) discontinued consuming the whey protein drink (n=10 prior to week 8) and 
eight (30%) reduced or modified their supplement intake. Participants who modified 
or reduced their supplement intake were instructed to reduce the dose to half a sachet 
and gradually increase to the full sachet again over time if tolerated. A further seven 
(26%) participants continued to consume the whey protein drink as prescribed 
despite experiencing GI discomfort.  
 
Table 6.3: Physical symptom(s) and number of adverse events related to the whey 
protein supplement in the PRT+ProD supplement group. 
Physical Symptom(s) Number of Adverse Events 
Bloating 6 
Diarrhoea/Loose bowel movement 23 
Nausea 4 
Flatulence 4 
Constipation 2 
Abdominal Pain 5 
Total Number 44 
 
6.6.5  Physical Activity and Diet 
At baseline, the mean moderate-vigorous physical activity habits of participants in 
the PRT+ProD group was significantly less than those in the PRT group (mean 
difference 3,559 kJ per week, P<0.01) (Table 6.4). There were no differences 
between the groups for average daily energy intake (kJ), protein (g/day or g/kg/day), 
fat and carbohydrates (g/day) or the percentage of energy intake from protein, 
carbohydrates or fat at baseline (Table 6.5 and Table 6.6) 
 
After 24-weeks, a significant increase in energy expenditure from moderate-vigorous 
physical activity exclusive of the PRT program was observed in the PRT+ProD 
group [mean change 4,556 kJ per week (95% CI, 2,396, 6,717), P=0.001] with no 
change in the PRT group, which led to a significant between-group difference for the 
change over time (interaction P=0.007) (Table 6.4).  
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For all habitual dietary measures (total energy, fat, carbohydrates and alcohol), there 
were no differences between the groups for the change over time after 12- or 24-
weeks except for dietary protein intake (Table 6.5). There were also no between 
group differences for the change in dietary saturated fat, cholesterol, sodium, 
potassium, magnesium and calcium (Appendix 9). For total energy intake, there was 
a similar reduction in both groups after 24-weeks (PRT+ProD 437 kJ/day, P>0.05; 
PRT 647 kJ/day, P<0.05). At baseline, an equal number and proportion of 
participants in both groups reported consuming alcohol [(PRT+ProD, n=63 (64%) 
and PRT, n=61 (61%)], with no differences between the groups (Chi-square analysis, 
P=0.619). 
 
Habitual Protein Intake plus Whey Protein Supplementation 
The mean habitual dietary protein intake at baseline was 1.21 and 1.13 g/kg and 103 
and 100 g/day in the PRT+ProD and PRT group, respectively (Table 6.6). There was 
a small but significant 8 g reduction in habitual protein intake in the PRT+ProD 
group at 24-weeks (there was no change in protein intake expressed as g/kg/day) but 
no differences for the change over time between the group (Table 6.6 and Figure 
6.5). Based on compliance with the whey protein supplement, at 12-weeks an 
additional 11.2 g/day [(95% CI, 3.6, 18.9) P=0.014] or 0.13 g/kg ([95% CI, 0.09, 
0.19) P=0. 011] of protein was consumed on non-training days (single supplement 
day) and an additional 27.3 g/day [(95% CI, 19.3, 35.3) P=0.001] or 0.33 g/kg/day 
[(95% CI, 0.27, 0.38) P=0.001] on training days (two supplements per day) relative 
to baseline. As a result, protein intakes (at 12-weeks) were significantly greater in the 
PRT+ProD compared to PRT group (between-group difference P<0.01 on both 
training and non-training days). By 24-weeks the whey protein supplement provided 
an additional 7.3 g/day [(95% CI, -2.6, 17.1) P=0.237] or 0.11 g/kg/day [(95% CI, 
0.04, 0.18) P=0.061] on non-training days and 22.6 g per day [(95% CI, 12.5, 32.6) 
P=0.001] or 0.29 g/kg of protein/day [(95% CI, 0.22, 0.36) P=0.001] relative to 
baseline on top of habitual intakes (Table 6.6 and Figure 6.5). At 24-weeks, only the 
increase in protein intake on training days was significantly higher relative to 
baseline (P=0.001) in the PRT+ProD group. Similarly, there was a significant group-
by-time interaction for the change in protein intake on the training days only 
(P=0.001) with intakes higher in the PRT+ProD compared to the PRT group. 
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Table 6.4: Baseline values and absolute within-group changes in the PRT+ProD and PRT group and the net between-group differences for the change 
at 12- and 24-weeks relative to baseline for moderate-vigorous physical activity. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P- values 
Model 1  |  Model 3 
Moderate-vigorous Physical Activity (kJ/week)     
   Baseline  8,194 ± 8,067b  11,753 ± 10,885    
   ∆ 12-weeks 1,670 (-58, 3,399) 0.067 -314 (-2,101, 1,472) 0.986 1,985 (-484, 4,453) 0.248  |  0.223 
   ∆ 24-weeks 4,556 (2,396, 6,717) 0.001 -73 (-3,080, 2,933) 0.772 4,630 (991, 8,268) 0.007  |  0.006 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from model 1 – unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 
represents the P-value after adjusting for baseline values, age, gender, ethnicity and BMI. b P<0.01 vs PRT at baseline. PRT+ProD, progressive resistance training 
plus protein and vitamin D supplements; PRT, progressive resistance training. 
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Table 6.5: Baseline values and absolute within-group changes in the PRT+ProD and PRT groups and the net between-group differences for the change 
at 12- and 24-weeks relative to baseline for all macronutrients, excluding protein intake and the protein-vitamin D supplements. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P- values 
Model 1  |  Model 3 
Energy Intake (kJ/day)      
   Baseline  8,514 ± 2,584  8,687 ± 2,202    
   ∆ 12-weeks -357 (-898, -184) 0.158 -155 (-711, 401) 0.550 -201 (-972, 568) 0.640  |  0.835 
   ∆ 24-weeks -437 (-994, -120) 0.059 -647 (-1,347, 52) 0.042 210 (-670, 1,091) 0.763  |  0.845 
Carbohydrate (g/day)      
    Baseline  202.3 ± 82.7  200.3 ± 60.4    
    Δ 12-weeks -12.1 (-29, 4.8) 0.198 9.7 (-9.2, 28.6) 0.378 -21.8 (-46.9, 3.2) 0.124  |  0.144 
    Δ 24-weeks  -12.2 (-31.0, 6.7) 0.097 -12.0 (-31.4, 7.4) 0.167 -0.18 (-27.0, 26.7) 0.935  |  0.856 
Fat (g/day)       
    Baseline  76.6 ± 34.4  83.5 ± 37.5    
    Δ 12-weeks -1.8 (-9.6, 6.0) 0.334 -4.6 (-12.6, 3.4) 0.298 2.8 (-8.3, 13.8)  0.856  |  0.623 
    Δ 24-weeks  -2.3 (-10.0, 5.4) 0.447 -8.2 (-18.2, 1.8) 0.080 5.9 (-6.5, 18.2) 0.393  |  0.420 
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% Energy Protein       
    Baseline 20.7 ± 5.4  19.6 ± 5.4    
    Δ 12-weeks 0.1 (-1.4, 1.2) 0.881 -0.7 (-2.1, 0.6) 0.608 0.6 (-1.3, 2.4) 0.780  |  0.731 
    Δ 24-weeks  -0.9 (-2.6, 0.7) 0.374 -0.6 (-2.5, 1.3) 0.077 -0.3 (-2.9, 2.2) 0.059  |  0.060 
% Energy Fat       
    Baseline 33.2 ± 9.8  34.9 ± 9.9    
    Δ 12-weeks 0.6 (-1.7, 2.9) 0.984 -1.0 (-3.1, 1.2) 0.295 1.6 (-1.6, 4.8) 0.467  |  0.394 
    Δ 24-weeks  1.1 (-4.0, 1.7) 0.686 -3.2 (-6.3, 0.0) 0.440 2.0 (-2.2, 6.2) 0.403  |  0.387 
% Energy Carbohydrates      
    Baseline  39.6 ± 9.2  39.3 ± 9.7    
    Δ 12-weeks -0.4 (-2.6, 1.8) 0.925 2.0 (-0.4, 4.4) 0.116 -2.4 (-5.6, 0.8) 0.204  |  0.147 
    Δ 24-weeks  -1.7 (-4.5, 1.0) 0.858 -2.5 (-5.9, 0.9) 0.983 -0.8 (-3.5, 5.1) 0.936  |  0.860 
Alcohol§ (g/day)                                         
    Baseline  10.2 ± 12.8  12.7 ±15.3    
    Δ 12-weeks -0.4 (-2.3, 1.6) 0.567 -2.7 (-5.1, -0.2) 0.094 2.3 (-0.7, 5.4) 0.180  |  0.158 
    Δ 24-weeks  0.6 (-1.5, 2.7) 0.155 -1.2 (-3.1, 0.7) 0.477 1.8 (-1.0, 4.6) 0.515  |  0.486 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to the within group change from 
baseline in the intervention group minus the within group change from baseline in the control group. All change values and net differences were derived from unadjusted values. Significant differences 
are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-value after adjusting for age, gender, ethnicity, BMI and moderate-vigorous physical activity § Baseline 
alcohol intake and the change in alcohol intake was calculated only on the number of participants in each group who reported being a consumer of alcohol at respective time points. PRT+ProD, 
progressive resistance training plus protein and vitamin D supplements; PRT, progressive resistance training.
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Table 6.6: Baseline values and absolute within-group changes in the PRT+ProD and PRT groups and the net between-group differences for the change 
at 12- and 24-weeks relative to baseline for habitual protein intake and protein intake inclusive of supplemental protein on non-training and training 
days in g/day and g/kg/day. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  |  Model 3 
Protein (g/day)       
Habitual Protein (Excluding Whey Supplement)     
   Baseline 103.4 ± 33.8  99.9 ± 30.7    
   ∆ 12-weeks -4.8 (-12.3, 2.6) 0.229 -5.8 (-13.1, 1.5) 0.200 1.0 (-9.5, 11.4) 0.966  |  0.824 
   ∆ 24-weeks -8.0 (-17.9, 1.9) 0.025 -3.2 (-12.1, 5.7) 0.330 -4.8 (-18.0, 8.5) 0.321  |  0.263 
Habitual Protein plus Whey Supplement (Non-Training Day)    
    Baseline  103.4 ± 33.8  99.9 ± 30.8    
    Δ 12-weeks 11.2 (3.6, 18.9) 0.014 -5.8 (-13.1, 1.6) 0.200 17.1 (6.5, 27.6) 0.008  |  0.003 
    Δ 24-weeks  7.3 (-2.6, 17.1) 0.237 -0.5 (-8.7, 7.7) 0.330 7.8 (-5.1, 20.6) 0.125  |  0.167 
Habitual Protein plus Whey Supplement (Training Day)    
    Baseline  103.4 ± 33.8  99.9 ± 30.8    
    Δ 12-weeks 27.3 (19.3, 35.3) 0.001 -5.8 (-13.1, 1.6) 0.200 33.1 (22.3, 43.9) 0.001  |  0.001 
    Δ 24-weeks  22.6 (12.5, 32.6) 0.001 -0.5 (-8.7, 7.7) 0.330 23.0 (10.1, 36.0) 0.001  |  0.001 
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Protein (g/kg/day)      
Habitual Protein (Excluding Whey Supplement)     
    Baseline         1.21 ± 0.37  1.13 ± 0.39    
    Δ 12-weeks -0.05 (-0.14, 0.03) 0.263 -0.06 (-0.14, 0.02) 0.224 0.01 (-0.11, 0.12) 0.985  |  0.808 
    Δ 24-weeks  -0.08 (-0.20, 0.04) 0.102 -0.03 (-0.13, 0.08) 0.370 -0.02 (-0.20, 0.11) 0.576  |  0.513 
Habitual Protein plus Whey Supplement (Non-Training Day)    
    Baseline 1.21 ± 0.37  1.13 ± 0.39    
    Δ 12-weeks 0.13 (0.09, 0.19) 0.011 -0.06 (-0.10, -0.01) 0.224 0.20 (0.13, 0.27) 0.007  |  0.003 
    Δ 24-weeks  0.11 (0.04, 0.18) 0.061 -0.03 (-0.09, 0.03) 0.370 0.14 (0.05, 0.23) 0.044  |  0.062 
Habitual Protein plus Whey Supplement (Training Day)    
    Baseline 1.21 ± 0.37  1.13 ± 0.39    
    Δ 12-weeks 0.33 (0.27, 0.38) 0.001 -0.06 (-0.10, -0.01) 0.224 0.4 (0.3, 0.5) 0.001  |  0.001 
    Δ 24-weeks  0.29 (0.22, 0.36) 0.001 -0.03 (-0.09, 0.03) 0.370 0.32 (0.23, 0.42) 0.001  |  0.001 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-
value after adjusting for age, gender, ethnicity, BMI and moderate-vigorous physical activity PRT+ProD, progressive resistance training plus protein and vitamin D 
supplements; PRT, progressive resistance training
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Figure 6.5: Total dietary protein intakes (habitual plus supplemental) in older adults 
with type 2 diabetes at baseline, 12- and 24-weeks. The x-axis represents the two 
intervention groups (PRT (black bars) and PRT+ProD (white bars)) with the protein 
intake in the PRT+ProD presented on both non-training (NT) days and training (T) 
days. Data presented as mean ± SD. * P<0.05 vs baseline (within-group change). a 
P<0.05, b P<0.01, c P<0.001 between-group interaction. 
 
6.6.6  Glycaemic and Insulinaemic Outcomes  
Oral Hypoglycaemic Medication Use and Change 
Table 6.7 shows the number of participants in each group at each time point who 
were prescribed oral hypoglycaemic medication for the management of their T2DM. 
At baseline, there were no differences between the groups, however at 12- and 24-
weeks a slightly higher proportion of participants in the PRT+ProD group were 
taking prescribed oral hypoglycaemic medication compared to the PRT group (both 
P<0.001). Throughout the study period there were no significant within-group 
changes or differences between the groups for the number of participants that 
increased or decreased their number of prescribed oral hypoglycaemic medication 
(Table 6.7). Similarly, only a small number of participants changed (increased or 
decreased) their oral hypoglycaemic medication dose, with no differences between 
the groups with the exception that a greater proportion of participants in the PRT 
group increased their doses after 24-weeks (PRT+ProD 3% vs PRT 11%, P<0.05). 
 
Type of Oral Hypoglycaemic Medication  
As shown in Table 6.8, the majority of participants prescribed oral hypoglycaemic 
medication were taking biguanides (PRT+ProD 67%; PRT 58%) and/or 
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sulphonylureas (PRT+ProD 27%; PRT 23%). There were no within-group changes 
or between-group differences for the type of oral hypoglycaemic medication 
prescribed to participants, with the exception of the following; 1) at 12- and 24-
weeks significantly more participants in the PRT+ProD group were prescribed 
biguanides (P<0.001 and P<0.05, respectively) compared to the PRT group; 2) at all 
time periods the PRT+ProD participants were more likely to be prescribed a 
dipeptidyl peptidase 4 (DPP-4) (all P<0.001), and 3) participants in the PRT group 
were more likely to be on combination therapy for their diabetes (all P<0.001).   
 
Table 6.7: Total number and proportion of participants taking oral hypoglycaemic 
medications and the changes at baseline, 12- and 24-weeks in the PRT+ProD and 
PRT groups. 
 Baseline 12-weeks 24-weeks 
Prescribed Medication, n (%)    
    PRT+ProD 71 (72) 69 (75)*** 65 (74)*** 
    PRT 68 (68) 53 (63) 52 (65) 
Increased | Decreased Number, n (%)   
    PRT+ProD - 3 (3) | 4 (4) 6 (7) | 7 (8) 
    PRT - 0 (0) | 2 (2) 2 (3)  | 2 (3) 
Increased | Decreased Dose, n (%)    
    PRT+ProD - 2 (2) | 3 (3) 3 (3)* | 5 (6) 
    PRT - 5 (6) | 1 (1) 9 (11) | 4 (5) 
Commenced | Ceased Medication, n (%)   
    PRT+ProD - 1 (1) | 2 (2) 2 (2) | 2 (2) 
    PRT - 0 (0) | 0 (0) 0 (0) | 0 (0) 
The percentages of participants on a type of oral hypoglycaemic agent was calculated from 
the total participants on a type of agent divided by the total number of participants multiplied 
by 100. *P<0.05, ***P<0.001 between-group difference. PRT+ProD, Progressive resistance 
training plus whey protein and vitamin D supplements; PRT, progressive resistance training. 
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Table 6.8: Total number and proportion of participants taking oral hypoglycaemic 
medications at baseline, 12- and 24-weeks in the PRT+ProD and PRT groups. 
 Baseline 12-weeks 24-weeks 
Biguanides, n (%)    
    PRT+ProD 66 (67) 65 (71)***  61 (69)* 
    PRT 58 (58)  44 (52) 43 (54)  
Sulphonylureas, n (%)    
    PRT+ProD 26 (27) 24 (26)  23 (26) 
    PRT 23 (23) 16 (19) 16 (20) 
Thiazolidinediones, n (%)    
    PRT+ProD 0 (0) 0 (0) 0 (0)  
    PRT 3 (3) 2 (2) 2 (3) 
Alpha Glucosidase Inhibitors, n 
(%) 
   
    PRT+ProD 0 (0)  0 (0) 0 (0) 
    PRT 2 (2) 2 (3) 2 (3) 
DPP-4 Inhibitors, n (%)    
    PRT+ProD 24 (24)*** 21 (23)*** 20 (23)*** 
    PRT 9 (9) 6 (7) 5 (6) 
Incretin Mimetics, n (%)     
    PRT+ProD 3 (3) 2 (2) 2 (2) 
    PRT 6 (6) 6 (7) 7 (9) 
Sodium-glucose Co-transporter 2 Inhibitors, n (%) 
    PRT+ProD 4 (4) 5 (5) 5 (4) 
    PRT 1 (2) 2 (5) 2 (2)  
 Insulin, n (%)    
    PRT+ProD 0 (0) 0 (0) 1 (1) 
    PRT 0 (0) 0 (0) 0 (0) 
Combination therapy1, n (%)    
    PRT+ProD    0 (0)***     0 (0)***       0 (0)*** 
    PRT 11 (11) 8 (10) 8 (10)  
The percentages of participants on a type of oral hypoglycaemic agent was calculated from 
the total participants on a type of agent divided by the total number of participants multiplied 
by 100.  *P<0.05, ***P<0.001 between-group difference. 1 Combination therapy included 
poly-pills such as Janumet, Glucovance, Avandamet, Metaglip or Avandaryl. PRT+ProD, 
Progressive resistance training plus whey protein and vitamin D supplements; PRT, 
progressive resistance training. 
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Baseline Glycaemic Control and Insulin Sensitivity  
There were no differences between the groups at baseline for HbA1c, insulin, insulin 
sensitivity (HOMA2%S) or C-peptide levels (Table 6.9), with the exception that the 
PRT+ProD group had slightly lower FPG levels (P<0.05) and higher insulin 
sensitivity (HOMA2%S, P<0.01).  
 
HbA1c and Fasting Plasma Glucose  
At 12-weeks, both groups experienced a similar significant absolute 0.13 to 0.15% 
(P=0.039 and P=0.060) reduction in HbA1c. While this modest improvement in 
HbA1c persisted only in the PRT group after 24-weeks, there were no between-group 
differences for the changes over time after 12- or 24-weeks (Table 6.9 and Figure 
6.6). Levels of FPG improved by 4.3% and 6.6% after 12- and 24-weeks in the PRT 
group (P<0.01 and P<0.001, respectively), with no changes observed in the 
PRT+ProD group, which resulted in significant group-by-time interaction at 24-
weeks. However, after adjusting for the covariates in model 3 this result was no 
longer significant (Table 6.9). 
 
Fasting Insulin, C-peptide and Insulin Sensitivity  
The PRT+ProD group experienced a significant reduction in fasting insulin after 12- 
and 24-weeks relative to baseline [mean -9.89 pmol/L (95% CI, -16.99, -2.79) 
P=0.003 and -6.2 pmol/L (95% CI, -13.6, 1.1) P=0.045]. There were no within-group 
changes in fasting insulin in the PRT group. A trend (P=0.060) towards a significant 
between-group difference at 12-weeks was noted following adjustment for covariates 
(model 3). After adjusting for baseline fasting insulin a significant between-group 
interaction was seen at both 12- and 24-weeks (P=0.028 and P=0.038). C-peptide 
levels did not change at any time in either group and there were no group-by-time 
interactions. For insulin sensitivity (HOMA2%S), there were no within-group 
changes or between-group differences for the changes over time (Table 6.9 and 
Figure 6.6). All results were similar whether adjusted for covariates included in 
model 3. 
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Table 6.9: Baseline values and absolute within-group changes in the PRT+ProD and PRT groups and the net between-group differences for the change 
relative to baseline for HbA1c, fasting plasma glucose, insulin, insulin sensitivity and C-peptide. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
(95% CI) P-value 
Mean ± SD or  
(95% CI) P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  |  Model 3 
HbA1c %       
   Baseline 6.86 ± 1.11  7.14 ± 1.17    
   Δ 12-weeks -0.13 (-0.24, -0.02) 0.039 -0.15 (-0.28, -0.03) 0.006 0.02 (-0.14, 0.19) 0.627  |  0.668 
   Δ 24-weeks  -0.10 (-0.24, 0.05)  0.072 -0.17 (-0.32, -0.03) 0.002 0.08 (-0.13, 0.28) 0.325  |  0.595 
HbA1c (IFCC mmol/mol)      
   Baseline  51.48 ± 12.11  54.46 ± 12.86    
   Δ 12-weeks -1.63 (-2.80, -0.45) 0.016 -1.64 (-3.05, -0.22) 0.008 0.01 (-1.80, 1.83) 0.827  |  0.845 
   Δ 24-weeks  -1.08 (-2.68, 0.52) 0.064 -1.88 (-3.46, -0.31) 0.002 -0.80 (-1.43, 3.04) 0.328  |  0.573 
Fasting Glucose (mmol/L)      
   Baseline  7.88 ± 2.21a  8.60 ± 2.33    
   Δ 12-weeks -0.12 (-0.39, 0.16) 0.493 -0.37 (-0.64, -0.10) 0.004 0.25 (-0.13, 0.63) 0.143  |  0.072 
   Δ 24-weeks  0.00 (-0.32, 0.32) 0.586 -0.57 (-0.90, -0.24)  0.001 0.57 (0.11, 1.02) 0.018  |  0.087 
Continued over page      
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Fasting Insulin (pmol/L)      
    Baseline  94.9 ± 102.8  95.2 ± 46.7    
    Δ 12-weeks -9.9 (-17.0, -2.8)  0.003 -2.5 (-10.3, 5.3)  0.515 -7.4 (-17.9, 3.1) 0.093*  |  0.060 
    Δ 24-weeks  -6.2 (-13.6, 1.1) 0.045 0.8 (-5.1, 6.7) 0.995 -7.0 (-16.5, 2.5) 0.151*  |  0.271 
Insulin sensitivity (HOMA2%S)      
    Baseline  78.1 ± 46.8b  60.4 ± 24.5    
    Δ 12-weeks 6.6 (-1.5, 14.6) 0.092 3.6 (-3.2, 10.3) 0.247 3.0 (-7.5, 13.5) 0.603  |  0.594 
    Δ 24-weeks  2.7 (-5.2, 10.6) 0.389 2.5 (-3.8, 8.8) 0.341 0.2 (-10.0, 10.5) 0.986  |  0.967 
C-peptide (nmol/L)       
    Baseline  1.13 ± 0.58  1.20 ± 0.36    
    Δ 12-weeks -0.06 (-0.11, 0.00) 0.027 -0.03 (-0.09, 0.03) 0.291 -0.02 (-0.10, 0.06) 0.451  |  0.530 
    Δ 24-weeks  -0.03 (-0.08, 0.03) 0.084 -0.02 (-0.09, 0.05) 0.371 -0.02 (-0.10, 0.06) 0.595  |  0.588 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-
value after adjustments for age, gender, ethnicity, BMI, oral hypoglycaemic use and moderate-vigorous physical activity. a P<0.05, b P<0.01 vs PRT at baseline. * 
P<0.05 significant between-group difference when adjusted for baseline. PRT+ProD, progressive resistance training plus protein and vitamin D supplements; PRT, 
progressive resistance training.
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Figure 6.6: Mean absolute changes from baseline (95% CI) in HbA1c (%) (A), fasting glucose (mmol/L) (B), fasting insulin (pmol/L) (C) and 
HOMA2%S (D) in the PRT+ProD (●) and PRT (○) groups. * P<0.05, † P<0.01 and ‡ P<0.001 within-group difference from baseline. # P<0.05 
between-group differences for the changes over time (group-by-time interaction) in the unadjusted model (Model 1). 
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6.6.7  Body Composition and Muscle Strength 
As shown in Tables 6.10 to 6.13, no significant differences were observed between 
the groups at baseline for any anthropometric, DXA-derived or pQCT (25% femur 
site) assessed body composition or muscle strength parameters with the exception of 
the following; (1) BMI was on average 1.5 kg/m2 higher in the PRT group (P<0.05) 
and (2) the PRT+ProD group had a lower mean total body fat mass compared to the 
PRT group (P<0.05). The proportion of participants categorised as normal weight, 
overweight and obese is described above in Table 6.1. For waist circumference, there 
were no differences between the groups at baseline for those classified as having a 
normal (<94 cm men; <80 cm women) (PRT+ProD 12.4% and PRT 10.1%; Chi-
square P=0.615), or at risk waist circumference (≥ 94 cm men; ≥ 80 cm women) 
(PRT+ProD 87.6% and PRT 89.9%; Chi-square P=0.123).  
 
Anthropometry 
Over the 24-week intervention, there were no significant between-group differences 
for the change over time for weight, BMI or waist circumference (Table 6.10). 
However, there was a significant mean 0.65 kg reduction in weight in the PRT group 
after 24-weeks compared to baseline (P<0.05). Both groups experienced a similar 
significant 1 to 2 cm reductions in waist circumference after 12- and 24-weeks when 
compared to baseline (both P<0.05).  
 
DXA Body Composition  
In both the PRT+ProD and PRT groups, there were similar significant within-group 
improvements over time in total body fat mass, percentage fat and total body lean 
mass (P ranging <0.001 to 0.05), with no between group differences (group-by-time 
interactions) for the changes over 24-weeks whether the results were unadjusted or 
adjusted for covariates (model 3). For arm and leg lean mass, the PRT+ProD group 
experienced a significant 0.15 kg [(95% CI, 0.09, 0.22) P=0.001] and 0.19 kg [(95% 
CI, 0.07, 0.31) P=0.002] gain relative to baseline, but there were no significant 
changes in the PRT group. While there was a trend towards a significant between 
group difference for the change over time (group-by-time interaction, P=0.056) in 
arm lean mass in the unadjusted model, this was not significant after adjustments 
were made for covariates in model 3. There were no within-group changes or 
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between-group differences for the change over time in arm or leg fat mass, with the 
exception that the PRT group had a 0.18 kg (95% CI, -0.34, -0.03) P=0.017] 
reduction in leg fat mass relative to baseline. For appendicular lean mass (ALM), 
there was a trend for a significantly greater gain in the PRT+ProD relative to PRT 
group after 24-weeks (group-by-time interaction) in model 1 (P=0.075) and model 3 
(P=0.064), which was driven by a 0.34 kg [(95% CI, 0.19, 0.49) P=0.001] gain in the 
PRT+ProD group relative to a 0.14 kg [(95% CI, -0.02, 0.30) P=0.081] gain in the 
PRT group (Table 6.11). 
 
pQCT Body Composition 
After 24-weeks, 25% femur muscle CSA increased significantly by 3.5% in the 
PRT+ProD (P=0.001) and 1.8% in the PRT groups (P=0.086), but there was no 
difference between the groups (group-by-time interaction, P=0.087) for these 
changes over time (Table 6.12). A significant 0.9% [(95% CI, 0.3, 1.5) P=0.016] 
increase in muscle density was observed in the PRT group compared to baseline, 
indicating a reduction in intramuscular fat infiltration with a significant between-
group difference (P=0.047) observed only after adjusting for covariates in model 3. 
For thigh (25% femur) intermuscular fat and subcutaneous CSA, there were no 
significant within-group changes or between-group differences throughout the study.  
 
Muscle Strength 
Over time, both groups experienced similar significant mean 7 to 19% (all P=0.001) 
increases in both upper and lower body strength measures with no between-group 
differences (group-by-time interactions) for the changes over time (all P>0.05) 
(Table 6.13).  
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Table 6.10: Baseline values and absolute within-group changes in the PRT+ProD and PRT groups for weight, body mass index (BMI) and waist 
circumference and the net between-group differences for the change relative to baseline. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or  
(95% CI) P-value 
Mean ± SD or  
(95% CI) P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  |  Model 3 
Body Weight (kg)      
   Baseline 86.1 ± 16.6  90.4 ± 15.2    
   Δ 12-weeks -0.05 (-0.45, 0.35) 0.865 -0.05 (-0.39, 0.30) 0.852 0.00 (-0.53, 0.53) 0.972  |  0.980 
   Δ 24-weeks  -0.26 (-0.75, 0.24) 0.185 -0.65 (-1.30, -0.01)  0.010 0.39 (-0.41, 1.19) 0.271  |  0.229 
BMI (kg/m2)      
   Baseline  29.6 ± 4.7a  31.1 ± 4.6    
   Δ 12-weeks 0.01 (-0.14, 0.13) 0.972 -0.05 (-0.19, 0.08) 0.568 0.05 (-0.14, 0.25) 0.625  |  0.629 
   Δ 24-weeks  -0.09 ( -0.26, 0.09) 0.211 -0.24 (-0.50, 0.01) 0.019 0.16 (-0.14, 0.46) 0.231  |  0.213 
Waist Circumference (cm)      
   Baseline  101.1 ± 12.6a  104.7 ± 12.0    
   Δ 12-weeks -1.0 (-1.5, -0.40) 0.005 -1.4 (-1.8, -0.9) 0.001 0.4 (-0.4, 1.1) 0.395  |  0.423 
   Δ 24-weeks  -1.3 (-2.1, -0.64) 0.001 -1.9(-2.5, -1.3) 0.001 0.7 (-0.3, 1.6) 0.328  |  0.189 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to the within group change from 
baseline in the intervention group minus the within group change from baseline in the control group. All change values and net differences were derived from unadjusted values. Significant differences 
are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-value after adjustments for age, gender, ethnicity and moderate-vigorous physical activity. a P<0.05 vs PRT at 
baseline. PRT+ProD, progressive resistance training plus protein and vitamin D supplements; PRT, progressive resistance training. 
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Table 6.11: Baseline values and absolute within-group changes in the PRT+ProD and PRT groups and the net between-group differences for the 
change at 24-weeks from baseline for total body and regional (arms and legs) lean mass, fat mass and appendicular lean mass. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  |  Model 3 
Total Body      
Fat Mass (kg)      
   Baseline 30.5 ± 9.5a  33.4 ± 10.0    
   Δ 24-weeks  -0.57 (-1.02, -0.12)  0.010 -0.92 (-1.42, -0.41)  0.001 0.35 (-0.32, 1.02) 0.301  |  0.320 
Lean Mass (kg)      
   Baseline  51.6 ± 10.7  53.2 ± 10.2    
   Δ 24-weeks  0.50 (0.18, 0.82) 0.002 0.37 (0.04, 0.70) 0.001 0.13 (-0.33, 0.58) 0.616  |  0.381 
Percentage Fat Mass (%)      
   Baseline  36.8 ± 8.1  38.2 ± 8.4    
   Δ 24-weeks  -0.63 (-1.04, -0.21)  0.003 -0.88 (-1.29, -0.46)  0.001 0.25 (-0.33, 0.84) 0.367  |  0.486 
Appendicular Lean Mass (kg)      
   Baseline  23.2 ± 5.4  24.1 ± 5.2    
   Δ 24-weeks  0.34 (0.19, 0.49)   0.001 0.14 (-0.02, 0.30) 0.081 0.20 (-0.02, 0.42) 0.075  |  0.064 
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Arm       
Fat Mass (kg)       
   Baseline  3.1 ± 1.3  3.5 ± 1.5    
   Δ 24-weeks  -0.03 (-0.09, 0.02) 0.240 -0.05 (-0.13, 0.04) 0.225 0.02 (-0.08, 0.12) 0.723  |  0.952 
Lean Mass (kg)       
   Baseline  6.1 ± 1.6  6.2 ± 1.4    
   Δ 24-weeks  0.15 (0.09, 0.22)  0.001 0.05 (-0.02, 0.20) 0.129 0.10 (0.03, 0.20) 0.056  |  0.111 
Leg       
Fat Mass (kg)       
   Baseline  8.3 ± 3.6  9.3 ± 4.1    
   Δ 24-weeks  -0.04 (-0.18, 0.09) 0.475 -0.18 (-0.34, -0.03) 0.017 0.14 (-0.06, 0.3) 0.168  |  0.195 
Lean Mass (kg)       
   Baseline  17.1 ± 3.9  17.9 ± 3.9    
   Δ 24-weeks  0.19 (0.07, 0.31)  0.002 0.08 (-0.04, 0.21) 0.168 0.10 (-0.07, 0.28) 0.259  |  0.189 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-
value after adjustments for age, gender, ethnicity and moderate-vigorous physical activity. a P<0.05 vs PRT at baseline. PRT+ProD, progressive resistance training 
plus protein and vitamin D supplements; PRT, progressive resistance training. 
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Table 6.12: Baseline values and absolute within-group changes in the PRT+ProD and PRT groups and the net between-group differences for the 
change at 24-weeks from baseline for 25% femur muscle cross-sectional area (CSA), muscle density, intermuscular and subcutaneous fat CSA. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or  
(95% CI) P-value 
Mean ± SD or  
(95% CI) P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  | Model 3 
Muscle CSA      
    Baseline (cm2) 62.4 ± 14.6  64.8 ±16.0    
    % Δ 24-weeks 3.5 (1.7, 5.3) 0.001 1.8 (0.3, 3.4) 0.086 1.7 (-0.7, 4.1) 0.087  |  0.137 
Muscle Density      
    Baseline (mg/cm3) 73.6 ± 11.0  73.5 ± 11.9    
    % Δ 24-weeks -0.1 (-0.9, 0.8) 0.655 0.9 (0.3, 1.5) 0.016 -1.0 (-2.0, 0.2) 0.127  |  0.047 
Intermuscular Fat Area      
   Baseline (cm2) 21.7 ± 7.7  23.1 ± 8.2    
   % Δ 24-weeks  1.7 (-1.5, 4.8) 0.623 -0.7 (-3.6, 2.2) 0.290 2.4 (-1.9, 6.6) 0.267  |  0.247 
Subcutaneous Fat Area      
   Baseline (cm2) 38.7 ± 24.9  44.6 ± 29.3    
   % Δ 24-weeks  -0.8 (-3.7, 2.1) 0.745 -1.4 (-4.1, 1.4) 0.602 0.6 (-3.4, 4.6) 0.807  |  0.738 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to the within group change from 
baseline in the intervention group minus the within group change from baseline in the control group. All change values and net differences were derived from unadjusted values. Significant differences 
are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-value after adjustments for age, gender, ethnicity and moderate-vigorous physical activity. CSA, Cross 
sectional area; PRT+ProD, progressive resistance training plus protein and vitamin D supplements; PRT, progressive resistance training. 
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Table 6.13: Baseline values and within-group changes in the PRT+ProD and PRT groups and the net between-group differences for the change 
relative to baseline in leg press and seated row one-repetition maximum muscle strength and knee extensor isometric muscle strength. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or  
(95% CI) P-value 
Mean ± SD or  
(95% CI) P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  |  Model 3 
1-RM Leg Press      
   Baseline (kg) 186.9 ± 74.4  195.5 ± 79.2    
   % Δ 24-weeks 15.7 (9.7, 21.6) 0.001 14.7 (7.2, 22.2) 0.001 0.9 (-8.4, 10.4) 0.889  |  0.736 
1-RM Seated Row      
   Baseline (kg) 53.4 ± 17.3  55.9 ± 17.1    
   % Δ 24-weeks 11.3 (5.7, 16.9) 0.001 7.3 (2.9, 11.6) 0.001 4.0 (-3.0, 11.1) 0.299  |  0.330 
Knee Extensor Strength       
   Baseline (kg) 39.5 ± 14.1  40.9 ± 13.0    
   % Δ 12-weeks 12.1 (6.4, 17.8) 0.001 12.7 (7.3, 18.1) 0.001 -0.6 (-8.4, 7.2) 0.646  |  0.703 
   % Δ 24-weeks  18.9 (12.3, 25.5) 0.001 18.2 (12.2, 24.1) 0.001 0.8 (-8.1, 9.6) 0.954  |  0.953 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to the within group 
change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net differences were derived from 
unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-value after adjustments for age, gender, 
ethnicity and moderate-vigorous physical activity. PRT+ProD, progressive resistance training plus protein and vitamin D supplements; PRT, progressive resistance training.
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6.6.8  Cardiovascular Health  
Anti-Hypertensive and Lipid-Lowering Medications 
At baseline, 55% and 58% of participants in the PRT+ProD and PRT group were 
taking anti-hypertensive medication. Similarly, just over 50% of participants in each 
group at baseline were taking lipid-lowering medication. There were no significant 
within-group changes or differences between-groups for the proportion of 
participants taking anti-hypertensive or lipid-lowering medications at any point 
during the intervention (Table 6.14). Similarly, there was no significant within-group 
changes or between-group differences regarding a change in the number or dose of 
these medications or whether participants commenced or ceased these medications 
over the duration of the intervention (Table 6.14).  
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Table 6.14: Total number and proportion of participants prescribed anti-hypertensive 
and/or lipid-lowering medications at baseline, 12- and 24-weeks in the PRT+ProD 
and PRT groups. 
 Baseline 12-weeks 24-weeks 
Anti-Hypertensive Medications, n (%)   
     PRT+ProD 54 (55) 52 (56) 49 (56) 
     PRT 58 (58) 45 (54) 43 (54) 
  Increased | Decreased Number, n (%)   
     PRT+ProD - 0 (0)  |  0 (0) 0 (0)  |  1 (1) 
     PRT - 0 (0)  |  0 (0) 1 (1)  |  0 (0) 
  Increased | Decreased Dose, n (%)   
     PRT+ProD - 2 (2)  |  1(1) 3 (3)  |  3 (3) 
     PRT - 1 (1)  |  0(0) 2 (3)  |  0 (0) 
  Commenced | Ceased Medication, n (%)   
     PRT+ProD - 1 (1)  |  0 (0) 1 (1)  |  2 (2) 
     PRT - 0 (0)  |  0 (0) 1 (1)  |  1 (1) 
Lipid-lowering Agents, n (%)   
     PRT+ProD 53 (54) 48 (52) 45 (51) 
     PRT 56 (56) 47 (55) 44 (54) 
  Increased | Decreased Number, n (%)   
     PRT+ProD - 0 (0)  |  0 (0) 0 (0)  |  0 (0) 
     PRT - 0 (0)  |  0 (0) 0 (0)  |  0 (0) 
  Increased | Decreased Dose, n (%)   
     PRT+ProD - 0 (0)  |  3 (7) 1 (2)  |  3 (7) 
     PRT - 2 (4)  |  1 (2) 2 (4)  |  2 (4) 
  Commenced | Ceased Medication, n (%)   
     PRT+ProD - 2 (2)  |  1 (1) 1 (1)  |  4 (5) 
     PRT - 1 (1)  |  0 (0) 1 (1)  |  1 (1) 
The proportion of participants on anti-hypertensive or lipid-lowering medications was 
calculated based on the total number of participants in each group at each time point. 
PRT+ProD, Progressive resistance training plus whey protein and vitamin D supplements; 
PRT, progressive resistance training. The percentages were calculated from the total 
participants prescribed anti-hypertensive or lipid-lowering medication or had a change in 
either of these medications divided by the total number of participants multiplied by 100. 
PRT+ProD, Progressive resistance training plus whey protein and vitamin D supplements; 
PRT, progressive resistance training. 
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Type of Anti-Hypertensive Medication 
There were no between-group differences at any time point for the proportion of 
participants prescribed different types of anti-hypertensive medications (Table 6.15). 
 
Table 6.15: Types of anti-hypertensive medications participants were prescribed at 
baseline, 12- and 24-weeks in the PRT+ProD and PRT groups. 
 Baseline 12-weeks 24-weeks 
ACE Inhibitors, n (%)   
    PRT+ProD  11 (11)  11 (12) 8 (9) 
    PRT 20 (20) 16 (19)  15 (19) 
Calcium-Channel Blocker, n (%)    
    PRT+ProD 5 (5) 4 (4) 3 (3) 
    PRT 7 (7) 4 (5) 2 (3) 
β-Blocker, n (%)     
    PRT+ProD 10 (10) 8 (9) 7 (8) 
    PRT 10 (10) 7 (8) 6 (8) 
AT1-Receptor Blocker, n (%)   
    PRT+ProD 3 (3) 3 (3) 3 (3) 
    PRT  2 (2)  1 (1) 1 (1) 
Angiotensin II Receptor Antagonists, n (%)    
    PRT+ProD 13 (13)  12 (13) 11 (13) 
    PRT 16 (16) 12 (14)  12 (15) 
Combination Therapy1, n (%)    
    PRT+ProD  31 (32) 30 (32) 30 (34) 
    PRT 23 (23) 19 (23)  20 (25) 
The percentages were calculated from the total number of anti-hypertensive drugs prescribed 
divided by the total number of participants on a type of anti-hypertensive medication 
multiplied by 100. 1 Combination therapy reflected those on combined anti-hypertensive 
drugs, an anti-hypertensive combined with a thiazide diuretic and hypertensive medication 
not otherwise classified. PRT+ProD, Progressive resistance training plus whey protein and 
vitamin D supplements; PRT, progressive resistance training. 
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Baseline Hypertensive Status and Lipid Profile 
At baseline, there were 50% and 39% of participants in the PRT+ProD and PRT 
groups respectively, with measured blood pressure levels indicative of hypertension 
with no differences between the groups. Including those prescribed anti-hypertensive 
medications, this prevalence increased to 70% and 65% in the PRT+ProD and PRT 
groups respectively, with no difference between the groups (data not shown). At 
baseline, a similar number and proportion of participants in both groups presented 
with high serum total cholesterol, triglyceride and LDL cholesterol and low HDL 
cholesterol levels (Table 6.16). 
 
Table 6.16: Number and proportion of participants in the PRT+ProD and PRT 
groups presenting with hyperlipidaemia. 
 PRT+ProD PRT 
Cholesterol and Lipoprotein Status   
  Total cholesterol >5.5 mmol/L, n (%) 15 (15) 18 (18) 
  LDL cholesterol <2.0 mmol/L, n (%) 38 (39) 36 (36) 
  HDL cholesterol ≥1.0 mmol/L, n (%) 14 (14) 21 (21) 
  Triglycerides >1.7 nmol/L, n (%) 36 (37) 49 (49) 
Elevated lipid(s) + lipid-lowering medication,3 n (%) 67 (68) 57 (57) 
The percentage of participants suffering from any of the above conditions was calculated 
based on the total number of participants in that group divided by those who reported a 
comorbid condition multiplied by 100. 1 SBP ≥140 and/or DBP ≥90 mmHg; 2 SBP ≥140 
and/or DBP ≥90 mmHg and/or taking anti-hypertensive medication; 3 Elevated triglycerides 
and/or taking lipid-lowering medication. PRT+ProD, progressive resistance training plus 
protein and vitamin D supplements; PRT, progressive resistance training; SBP, systolic 
blood pressure; DBP, diastolic blood pressure.  
 
Baseline Blood Pressure, Serum Lipids and Cholesterol 
There were no differences between the groups at baseline for SBP or DBP or any 
serum lipid and lipoprotein concentrations (Table 6.17 and 6.18).  
 
Blood Pressure 
Throughout the intervention no significant changes in SBP were observed in either 
group. However, a significant 2.5 and 2.6 mmHg reduction in DBP at both 12- and 
24-weeks compared to baseline was observed in the PRT+ProD group (P=0.004 and 
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P=0.010), with the PRT group also experiencing a 2.5 mmHg reduction in DBP only 
after 24-weeks (P=0.010). However, there were no between-group differences for the 
change over time in either SBP or DBP whether the results were unadjusted, adjusted 
for covariates in model 3 as shown in Table 6.17.    
 
Serum Lipid and Lipoprotein Levels 
After 12-weeks the PRT+ProD group experienced a mean reduction in total and LDL 
cholesterol of 0.20 mmol/L and 0.19 mmol/L, respectively (P=0.011 and P=0.005), 
but these changes were not maintained after 24-weeks. There were no other within 
group changes in any other measure in either group, and there were no between 
group differences (group-by-time interactions) for the changes over 24-weeks 
whether the results were unadjusted or adjusted for covariates (age, gender, ethnicity, 
BMI, lipid-lowering medication and moderate-vigorous habitual physical activity) 
(Table 6.18).  
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Table 6.17: Baseline values and absolute within-group changes in PRT+ProD and PRT groups and the net between-group differences for the 
change at 12- and 24-weeks relative to baseline for systolic and diastolic blood pressure. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or  
(95% CI) P-value 
Mean ± SD or  
(95% CI) P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  |  Model 3 
Systolic Blood Pressure (mmHg)      
   Baseline  136.0 ± 15.7  134.9 ± 15.2    
   Δ 12-weeks -2.5 (-5.5, 0.4) 0.144 0.4 (-3.6, 4.4) 0.965 -2.9 (-7.8, 1.9) 0.267  |  0.397 
   Δ 24-weeks  -4.3 (-8.8, 0.2) 0.023 -2.4 (-6.2, 1.4) 0.093 -1.9 (-7.9, 4.0) 0.825 |  0.811 
Diastolic Blood Pressure (mmHg)      
   Baseline  85.2 ± 9.0  83.1 ± 8.3    
   Δ 12-weeks -2.8 (-4.6, -1.0) 0.004 -0.9 (-3.1, 1.4) 0.392 -2.0 (-4.8, 0.8) 0.175  |  0.219 
   Δ 24-weeks  -2.6 (-4.7, -0.5) 0.010 -2.5 (-4.6, -0.3) 0.010 -0.1 (-3.1, 2.8) 0.933  |  0.854 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers 
to the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the 
P-value after adjustments for age, gender, ethnicity, BMI, anti-hypertensive use and moderate-vigorous physical activity. PRT+ProD, progressive resistance 
training plus protein and vitamin D supplements; PRT, progressive resistance training. 
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Table 6.18: Baseline values and absolute within-group changes in the PRT+ProD and PRT groups and the net between-group differences for the 
change at 12- and 24-weeks relative to baseline for serum total, HDL and LDL cholesterol and triglycerides. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or  
(95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  |  Model 3 
Total Cholesterol (mmol/L)      
   Baseline  4.40 ± 1.06  4.51 ± 1.08    
   Δ 12-weeks -0.20 (-0.35, -0.05) 0.011 -0.03 (-0.18, 0.13) 0.689 -0.18 (-0.39, 0.03) 0.131  |  0.197 
   Δ 24-weeks  -0.11 (-0.27, 0.06) 0.171 0.00 (-0.16, 0.15) 0.889 -0.10 (-0.33, 0.12) 0.390  |  0.538 
HDL Cholesterol (mmol/L)      
   Baseline  1.30 ± 0.34  1.24 ± 0.30    
   Δ 12-weeks -0.02 (-0.05, 0.02) 0.355 0.00 (-0.03, 0.04) 0.955 -2.0 (-4.8, 0.8) 0.488  |  0.436 
   Δ 24-weeks  0.00 (-0.04, 0.03) 0.934 0.00 (-0.03, 0.04) 0.997 -0.1 (-3.1, 2.8) 0.946  |  0.507 
LDL Cholesterol (mmol/L)      
   Baseline  2.37 ± 0.92  2.44 ± 0.93    
   Δ 12-weeks -0.19 (-0.31, -0.07) 0.005 -0.09 (-0.20, 0.03) 0.233 -0.10 (-0.27, 0.06) 0.275  |  0.652 
   Δ 24-weeks  -0.12 (-0.25, 0.02) 0.113 0.02 (-0.12, 0.16) 0.712 -0.13 (-0.33, 0.06) 0.175  |  0.245 
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Triglycerides (mmol/L)      
   Baseline  1.62 ± 1.03  1.82 ± 0.86    
   Δ 12-weeks 0.00 (-0.22, 0.23) 0.963 0.10 (-0.15, 0.36) 0.431 -0.10 (-0.44, 0.24) 0.546  |  0.275 
   Δ 24-weeks  0.03 (-0.10, 0.16) 0.907 0.03 (-0.15, 0.22) 0.993 0.00 (-0.23, 0.21) 0.920  |  0.761 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-
value after adjustments for age, gender, ethnicity, BMI, lipid-lowering medication and moderate habitual physical activity. PRT+ProD, progressive resistance 
training plus protein and vitamin D supplements; PRT, progressive resistance training. 
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6.6.9  Other Medication Use and Change 
The number and proportion of participants prescribed diuretics and NSAIDs are 
presented in Table 6.19. There were no significant within-group changes or between-
group differences for any of the above medications, with the exception that a lower 
number (and proportion) of participants in the PRT+ProD group were prescribed 
diuretics in comparison to the PRT group at baseline (Chi-square; P<0.01) 
 
Table 6.19: Total number and type of other medications prescribed to participants at 
baseline, 12- and 24-weeks in the PRT+ProD and PRT groups. 
 Baseline 12-weeks 24-weeks 
Diuretics, n (%)    
    PRT+ProD 4 (4)* 5 (5) 4 (5) 
    PRT 14 (14) 8 (9)  8 (10) 
NSAIDs, n (%)     
    PRT+ProD 8 (8) 6 (6)  8 (9) 
    PRT 5 (5) 4 (5)  4 (5) 
The proportion of participants on any of the above medications was calculated based on the 
total number of participants in each group at each time point. NSAIDs, nonsteroidal anti-
inflammatory drugs. PRT+ProD, Progressive resistance training plus whey protein and 
vitamin D supplements; PRT, progressive resistance training. * P<0.01 versus PRT. 
 
6.6.10  Inflammatory Cytokines, Hormonal and Biochemical Factors 
There were no differences between the groups in any of the inflammatory markers at 
baseline with the exception that serum levels of IL-8 (P<0.05), TNF-a (P<0.01) and 
hs-CRP (P<0.01) were all significantly lower in the PRT+ProD group (Table 6.20). 
As shown in Table 6.20, there were no differences between the groups at baseline for 
serum creatinine, eGFR, serum 25(OH)D or IGF-1 levels. 
 
Inflammatory Cytokines 
After 12- and 24-weeks, the PRT+ProD group experienced significant gains (48.8% 
and 40.0%, respectively, both P=0.001) in the anti-inflammatory marker IL-10 
compared to baseline. This increase combined with a 14% non-significant and 22% 
significant (P=0.023) reduction in the PRT group resulted in a significant between-
group difference for the change over time (P=0.001). A significant between-group 
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difference (group-by-time interaction) was also observed for the change in IL-8 
(P=0.010) at 12-weeks. This was driven by a 6% (P=0.174) increase in the 
PRT+ProD group and a 7% (P=0.103) reduction in the PRT group. Further, a 
significant 7% reduction in TNF-α levels after 12-weeks in the PRT group relative to 
baseline drove a significant between-group interaction (P=0.047) in the unadjusted 
model. This was no longer significant following adjustment for covariates (model 3) 
(P=0.057). At 24-weeks again a significant between-group difference (group-by-time 
interaction) was observed for TNF-α, yet at this time-point the significant interaction 
was driven by an 11% [(95% CI, 0.10, 20.6) P=0.033] significant increase in the 
PRT+ProD group (Table 6.20 and Figure 6.7). This result was retained when 
adjusting for covariates. However, after adjusting for the baseline values there were 
no significant between-group differences at 12-weeks (P=0.620) or 24-weeks 
(P=0.241). In addition to the results above, there was a non-significant within-group 
reduction in serum adiponectin in the PRT+ProD group [mean change -4.0% (95% 
CI, (-7.9, -0.1) P=0.115] after 24-weeks which resulted in a trend towards a 
significant between-group difference (P=0.069) for the change over time when 
adjusting for covariates in model 3. For all other inflammatory cytokines, there were 
no within-group changes or between-group differences for the change over time 
(Table 6.20 and Figure 6.7). 
 
Hormonal and Biochemical Measures 
After 12- and 24-weeks, the PRT+ProD group experienced a mean significant 25 
nmol/L and 28 nmol/L increase in serum 25(OH)D (both P=0.001), with no change 
observed in the PRT group (Table 6.21). This led to significant between-group 
differences at both 12- and 24-weeks (both P=0.001). No within-group changes or 
between-group differences were observed for serum IGF-1 following the 24-week 
intervention (Table 6.21). Both groups experienced similar significant reductions in 
serum creatinine and eGFR by 24-weeks (both P=0.001) with no group-by-time 
interactions observed. 
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Table 6.20: Baseline values and percent changes in the PRT+ProD and PRT groups and the net between-group differences for the change at 12- and 
24-weeks relative to baseline for serum levels of interleukin (IL)-10, IL-6, IL-8, tumor necrosis factor-alpha (TNF-α), adiponectin and high-sensitive 
C-reactive protein (hs-CRP). 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  |  Model 3 
IL-10       
    Baseline (pg/ml) 8.1 ± 13.7  11.6 ± 18.9    
    %Δ 12-weeks 48.8 (27.7, 70.0) 0.001 -13.8 (-33.3, 5.6) 0.109 62.7 (34.1, 91.3) 0.001  |  0.001 
    %Δ 24-weeks  40.0 (18.1, 61.8) 0.001 -21.5 (-42.6, -0.3) 0.023 61.4 (31.0, 91.9) 0.001  |  0.001 
IL-6       
    Baseline (pg/ml) 2.8 ± 2.5  3.2 ± 3.7    
    %Δ 12-weeks 10.5 (-7.4, 28.4) 0.211 -11.9 (-28.5, 4.7) 0.196 22.4 (-1.9, 46.7) 0.072  |  0.165 
    %Δ 24-weeks  13.7 (-2.2, 29.6) 0.139 -9.9 (-26.9, 7.1) 0.415 23.5 (0.4, 46.6) 0.105  |  0.160 
IL-8       
    Baseline (pg/ml) 15.1 ± 7.1a  20.9 ± 25.3    
    %Δ 12-weeks 5.7 (-3.8, 15.3) 0.174 -7.0 (-18.1, 4.2) 0.103 12.7 (-1.8, 27.2) 0.033  |  0.010 
    %Δ 24-weeks  2.0 (-4.1, 8.4) 0.493 -3.7 (-16.1, 8.6) 0.377 5.9 (-7.2, 19.0) 0.262  |  0.158 
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TNF-α       
    Baseline (pg/ml) 7.6 ± 2.5b  9.2 ± 5.3    
    %Δ 12-weeks 6.3 (-4.5, 17.2) 0.355 -6.7 (-13.8, 0.0) 0.046 13.0 (0.0, 26.0) 0.047c  |  0.057 
    %Δ 24-weeks  10.6 (0.10, 20.6) 0.033 -4.8 (-12.9, 3.2) 0.141 15.5 (2.5, 28.5) 0.009c  |  0.009c 
Adiponectin       
    Baseline (µg/mL) 2.9 ± 1.8  2.6 ± 1.3    
    %Δ 12-weeks -1.6 (-6.5, 3.3) 0.839 -2.9 (-6.5, 0.1) 0.201 1.3 (-4.7, 7.3) 0.582  |  0.716 
    %Δ 24-weeks  -4.0 (-7.9, -0.1) 0.115 -0.5 (-4.8, 3.7) 0.985 -3.5 (-9.2, 2.3) 0.195  |  0.069 
High sensitive-CRP       
    Baseline (mg/mL) 1.7 ± 1.5b  3.3 ± 5.7    
    %Δ 12-weeks -10.3 (-26.3, 5.8) 0.204 -4.1 (-23.4, 15.2) 0.606 -6.2 (-31.0, 18.7) 0.514  |  0.528 
    %Δ 24-weeks  -2.0 (-16.2, 12.1) 0.854 0.0 (-20.0, 20.2) 0.910 -2.1 (-26.2, 21.9) 0.719  |  0.922 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-
value after adjustments for age, gender, ethnicity, BMI and moderate habitual physical activity. a P<0.05 b P<0.01 vs PRT at baseline. * Group-by-time interaction 
lost when model was adjusted for baseline serum levels. PRT+ProD, progressive resistance training plus protein and vitamin D supplements; PRT, progressive 
resistance training. 
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Figure 6.7: Mean percentage change from baseline (95% CI) in log transformed 
serum interleukin (IL)-6 (A), IL-10 (B), IL-8 (C), TNF-α (D), adiponectin (E) and 
high sensitive hs-CRP (F) in the PRT+ProD (●) and PRT (○) groups. * P<0.01 ‡ 
P<0.001 within-group change from baseline # P<0.05, ^ P<0.001 between-group 
difference for the changes over time (group-by-time interaction). All p-values are 
based upon results adjusted for covariates. Please note the different scales for 
different graphs. 
 
 
 Page | 254 
	
Table 6.21: Baseline values and absolute within-group changes in the PRT+ProD and PRT groups and the net between-group differences for the 
change at 12- and 24-weeks relative to baseline for serum creatinine, estimated glomular filtration (eGFR), 25-hydroxyvitamin D (25(OH)D) and 
insulin-like growth factor-1 (IGF-1). 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P-values 
Model 1  |  Model 3 
Creatinine (mol/L)      
   Baseline  75.5 ± 15.8  79.7 ± 17.5    
   Δ 12-weeks 0.6 (-1.2, 2.4) 0.499 0.3 (-1.8, 2.3) 0.679 -0.4 (-2.3, 3.1) 0.876  |  0.994 
   Δ 24-weeks 3.1 (1.2, 5.0) 0.001 3.2 (1.2, 5.3) 0.001 -0.2 (-3.0, 2.6) 0.783  |  0.988 
eGFR (ml/min/1.73m2)       
   Baseline  84.8 ± 8.3b  81.2 ± 12.2    
   Δ 12-weeks -0.1 (-1.1, 1.0) 0.843 -0.3 (-2.1, 1.4) 0.661 0.3 (-1.7, 2.2) 0.822  |  0.640 
   Δ 24-weeks -2.6 (-4.0, -1.2) 0.001 -2.4 (-4.1, -0.7) 0.001 0.2 (-2.3, 2.0) 0.880  |  0.964 
25(OH)D (nmol/L)      
   Baseline  75.5 ± 22.1a  68.7 ± 22.4    
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   Δ 12-weeks 25.2 (20.7, 29.6) 0.001 0.2 (-3.9, 4.3) 0.754 24.9 (18.9, 31.0) 0.001  |  0.001 
   Δ 24-weeks 28.0 (22.8, 33.2) 0.001 3.3 (-2.0, 8.5) 0.155 24.7 (17.4, 32.0) 0.001  |  0.001 
IGF-1 (nmol/L)      
   Baseline  20.0 ± 7.4  18.9 ± 6.2    
   Δ 12-weeks 0.0 (-0.6, 0.7) 0.813 -0.1 (-0.8, 0.6) 0.970 0.1 (-0.9, 1.0) 0.834  |  0.699 
   Δ 24-weeks 0.5 (-0.2, 1.1) 0.169 0.1 (-0.8, 1.1) 0.508 0.3 (-0.8, 1.4) 0.663  |  0.409 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-
value after adjustments for age, gender, ethnicity, BMI and moderate habitual physical activity. a P<0.05, b P<0.01 vs PRT at baseline. PRT+ProD, progressive 
resistance training plus protein and vitamin D supplements; PRT, progressive resistance training. 
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6.6.11  Per Protocol Analysis 
The per protocol analysis was limited to participants who achieved ≥ 66% 
compliance with the PRT program and those in the PRT+ProD group who also 
achieved ≥ 80% compliance with the whey protein and vitamin D supplements. 
This sensitivity analysis was limited to a total of 41 participants in the PRT+ProD 
group and 50 participants in the PRT group. Baseline characteristics for 
participants included in the per protocol analysis are presented below in Table 
6.22 with the remaining results tables found in Appendix 10 at the end of this 
thesis.  
 
Baseline Characteristics  
The baseline characteristics were not different between the groups with the 
exception that the PRT+ProD group were found to have a significantly higher 
number (proportion) of individuals with a family history of diabetes (PRT+ProD, 
n=30 (73%) vs PRT, n=20 (41%), P<0.05) and participants classified as normal 
weight (BMI 18.5-24.9 kg/m2) (PRT+ProD, n=8 (19%) vs PRT, n=1 (2%), 
P<0.05). As a result, the number and proportion of participants classified as 
overweight (BMI 25.0-29.9 kg/m2) and obese (BMI >30 kg/m2) was lower in the 
PRT+ProD compared to the PRT group (overweight, PRT+ProD, n=13 (32%) vs 
PRT, n=18 (19%) and obese, PRT+ProD, n=20 (49%) vs PRT, n=31 (62%), both 
P<0.05).  
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Table 6.22: Baseline characteristics of participants included in the per protocol 
analysis of the PRT+ProD and PRT groups. 
 PRT+ProD PRT 
n 41 50 
Male / Female, n 23/18 33/17 
Age (years) 70.0 ± 6.2 61.8 ± 5.5 
Height (cm) 168.8 ± 10.3 170.5 ± 9.7 
Ethnicity   
   Caucasian, n (%) 36 (88) 46 (92) 
   Asian, n (%) 4 (10) 1 (2) 
   Other, n (%) 1 (2) 3 (6) 
Age at diagnosis (years) 53.2 ± 7.2 54.4 ± 7.4 
Duration of diabetes (years) 7.8 ± 5.7 7.5 ± 5.0 
Family history of diabetes, n (%) 30 (73)* 20 (41) 
Diabetes management (lifestyle / medication), n 12/29 18/32 
Overweight/Obese   
   Normal weight, n (%) 8 (19)* 1 (2) 
   Overweight, n (%) 13 (32)* 18 (36) 
   Obese, n (%) 20 (49)* 31 (62) 
Ex-smoker, n (%) 17 (42) 21 (43) 
Self-reported co-morbid condition   
   Hypertension, n (%) 26 (63) 26 (53) 
   Hypercholesterolaemia, n (%) 12 (29) 13 (27) 
   CVD1, n (%) 5 (12) 5 (10) 
Employment status   
   Working full-time, n (%) 20 (49) 16 (33) 
   Working part-time/Semi-retired, n (%) 3 (7)** 15 (31) 
   Not-working/Retired, n (%) 18 (44) 18 (36) 
Values presented are mean ± SD unless stated. The classification of overweight and 
obese was completed using the following BMI cut-offs, overweight BMI ≥ 25.0- ≤ 29.9 
and obese BMI ≥ 30.0. 1 Cardiovascular disease encompassed previous diagnosis heart 
disease or previously having suffered a heart attack. 1 Cardiovascular disease 
encompassed previous heart attack, angina, heart disease and/or stroke. *P<0.05, 
**P<0.01 vs PRT. CVD, Cardiovascular disease. PRT+ProD, progressive resistance 
training plus protein and vitamin D supplements; PRT, progressive resistance training. 
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Intervention Results 
The findings from the per protocol analysis were similar to those from the 
intention-to-treat analysis apart from the following results. Refer to Appendix 10 
for all the per protocol results tables. 
 
Diet 
A significant between-group difference at 24-weeks was observed in all measures 
of habitual protein intake (g, g/kg and percent energy per day, respectively), 
which was due to a significant reduction in dietary protein intake (excluding the 
supplement) of 12 g/day in the PRT+ProD group along with a non-significant 6 g 
increase in the PRT group. A significant between-group difference was also 
observed for the change in potassium intake at 24-weeks (P=0.019) only after 
adjusting for covariates including age, gender, ethnicity, BMI and moderate-
vigorous physical activity. This between-group difference was driven by a non-
significant 254 mg reduction in the PRT+ProD group and the 338 mg non-
significant increase in the PRT group. 
 
Anthropometry and pQCT 
Significant between-group differences at 24-weeks were observed for weight and 
BMI (P=0.030 and P=0.046) after adjusting for age, gender, ethnicity and 
moderate-vigorous physical-activity, which was driven by significant reductions 
(-1.02 kg and -0.42 kg/m2, both P<0.001) in the PRT group along with no change 
in the PRT+ProD group. A significant 1.3 cm reduction in waist circumference 
(P<0.001) in the PRT group was observed at 12-weeks although this difference 
was not different to the PRT+ProD group. A similar significant reduction in waist 
circumference in both the PRT+ProD and PRT groups was observed at 24-weeks, 
although the magnitude of reduction was slightly greater in the PRT group (mean 
change, PRT -2.6 cm and PRT+ProD -1.3 cm). In addition to the above results, 
there was a 4.9% increase in 25% femur muscle CSA in the PRT+ProD group 
(P=0001) with no change in the PRT group. This led to a trend towards a 
significant between-group difference in both the unadjusted model (P=0.056) and 
model 3 (P=0.078). Additionally, there was a significant 0.53 kg [(95% CI, 0.31, 
0.74) P=0.001] increase in ALM in the PRT+ProD group which greater that the 
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gain in the PRT group [0.21 kg (95% CI, 0.01, 0.40) P=0.031] (group-by-time 
interaction, P=0.027), but this was not significant after adjustment for the 
covariates in model 3 (P=0.184). 
 
Muscle Strength 
For the PRT+ProD group, there was a significantly greater gain in upper body 
strength compared to the PRT group [net difference for change 16.8% (95% CI, 
7.8, 25.8), group-by-time interaction, P=0.033], which remained following 
adjustment for covariates in model 3 (P=0.041). 
 
Serum Lipids  
The PRT+ProD group experienced a significantly greater reduction in total 
cholesterol and LDL cholesterol after 24-weeks compared to the PRT group [net 
differences for change: cholesterol -0.24 mmol/L (95% CI, -0.49, 0.01) P=0.049; 
LDL -0.20 mmol/L (95% CI, -0.49, -0.05), P=0.011], which remained after 
adjusting for covariates (model 3). 
 
Inflammatory Markers  
For IL-6, there was a significant between-group difference (group-by-time 
interaction) observed at 12- and 24-weeks only in the unadjusted model (P=0.037 
and P=0.036). The interaction was driven by a non-significant 23% (P=0.073) 
increase in the PRT+ProD group at 12-weeks and a significant 31% (P=0.016) 
increase in the PRT+ProD group at 24-weeks with no change in the PRT group at 
either 12- or 24-weeks. However, these results were attenuated following 
adjustment for covariates in model 3. 
 
6.7  Discussion 
The main findings from this 24-week two-arm parallel, RCT in older adults with 
T2DM was that the provision of a whey-protein drink (20 g daily and 20 g after 
each of the three weekly PRT sessions) and 2,000 IU/day vitamin D did not 
enhance the effects of the community-based Lift for Life® PRT program on 
glycaemic control, body composition, muscle strength, blood pressure or blood 
lipids. However, there was a significantly greater reduction in serum insulin 
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concentrations after 12- and 24-weeks in the PRT+ProD compared to PRT group. 
Further, there was a significant beneficial effect of PRT combined with whey 
protein and vitamin D relative to PRT alone on the anti-inflammatory marker IL-
10, but there were no between-group differences for the change in hs-CRP, TNF-
α, adiponectin, IL-8 or IL-6 after 24-weeks. However, we did find that the PRT 
program was safe and effective for improving glycaemic control, total body and 
regional (arm and leg) lean mass, thigh muscle size, upper and lower body muscle 
strength and lowering waist circumference, fat mass, percentage body fat and 
DBP.  
 
Secondary pre-planned analysis examining those who achieved ³66% exercise 
adherence combined with ³80% adherence with the whey protein and vitamin D 
supplements revealed that there were significant net gains in the PRT+ProD group 
for upper body muscle strength and serum IL-6, and a greater reduction in total 
cholesterol and LDL cholesterol with a trend for a greater gain in thigh (25% 
femur) muscle CSA and arm lean mass. Importantly, there were no serious 
adverse events associated with the intervention, and kidney function (eGFR) 
improved significantly in both groups. The following sections will provide a 
critical discussion of the above findings.  
 
6.7.1  Effects of PRT, Whey Protein and Vitamin D on Lean Mass, Muscle 
Size and Strength  
Previous research has shown that older adults with T2DM typically experience an 
accelerated loss in lean mass and/or strength compared to age-matched, non-
glycaemic controls (146-148). Given the importance of skeletal muscle for 
glucose uptake from the circulation, there has been considerable interest in 
identifying strategies to optimise lean mass in this group. In this 6-month 
community-based RCT, we showed, for the first time, that a daily whey-protein, 
leucine enriched, drink combined with vitamin D supplementation, both of which 
have shown promise to influence muscle outcomes, did not significantly enhance 
the effects of PRT on total body and regional lean mass and thigh muscle size in 
older adults with T2DM. However, there was a trend for a modest 0.2 kg (95% 
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CI, -0.02, 0.42) greater gain in ALM in the PRT+ProD compared to the PRT 
group (P=0.075), which may be due in part, to the significantly higher adherence 
to the exercise program in the PRT+ProD group (68% vs 58%). Similarly, the 
PRT-related gains in arm and leg lean mass and thigh muscle CSA were 0.5 to 
1.8% greater in the PRT+ProD group, but none of these gains were significantly 
different from those observed in PRT alone. There are several factors which are 
likely to have contributed to the lack of a significant additive effect of the protein-
vitamin D supplement on PRT on muscle outcomes in our study. This includes, 
but is not limited to, the baseline habitual protein intakes of participants, the dose 
of protein consumed and the subsequent spread in protein intake between the 
groups and/or change (increase) over time and the initial vitamin D status of the 
participants. 
 
For healthy older adults and the elderly, current guidelines and expert committee 
statements recommend PRT be combined with a dietary protein intake level of at 
least 1.2 g/kg/day with at least 25–30 g of high-quality protein ingested post-
exercise in order to overcome the anabolic resistance associated with ageing 
muscle (495, 619). However, several recent systematic reviews and meta-analyses 
have reported that protein/essential amino acid supplementation does not 
significantly augment the effects of PRT on muscle mass and/or strength in older 
adults (486, 487) or only provides small additional benefits to lean mass (485). In 
our study, the lack of any marked additive muscular benefits may be related to the 
already high baseline habitual protein intakes of the participants, which averaged 
1.21 g/kg/day in the PRT+ProD group and 1.13 g/kg/day in the PRT group. In 
support of this notion, a number of other intervention trials in healthy older adults 
which found that greater protein intake did not enhance the effects of PRT on 
muscle mass or strength also had participants that had initial habitual protein 
intakes of ~1.0 to 1.2 g/kg/day (283, 284, 493, 620). However, it is possible that 
the type, dose and distribution of protein intake in these studies also contributed 
to the lack of any added skeletal muscle benefits to PRT.  
 
Previous research has shown that consuming a bolus of protein (amino acid) can 
act as a strong stimuli for endogenous insulin release by the beta–cells of the 
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pancreas, particularly when combined with PRT (52, 621). This is important 
because insulin stimulates an increase in MPS and suppresses breakdown (622), 
and thus insulin resistance in T2DM may contribute further to age-related 
anabolic resistance. In our study, long-term supplementation with whey protein 
combined with PRT was associated with significantly greater reductions in insulin 
levels relative to PRT alone after adjusting for baseline values. This finding is 
supported by several acute studies which have shown that whey protein ingestion 
post-PRT can increase plasma insulin levels and assist in enhancing the MPS 
response in older adults and those with T2DM (276, 281, 379, 623). Conversely, 
several other longer-term (≥12-week) trials in healthy or overweight/obese elderly 
adults (282-285) and those with T2DM (286) have reported no additive effect of 
increased protein consumption with PRT on serum insulin levels. Nevertheless, 
the finding that serum insulin levels decreased in the PRT+ProD group in our trial 
is consistent with the findings from a previous RCT examining the effects of PRT 
plus whey protein supplementation in overweight/obese adults which reported a 
significant reduction in plasma insulin area under the curve (AUC) (285). The 
reason(s) for this reduction in circulating insulin levels with a combination of 
PRT and protein supplementation remains uncertain, and requires further 
investigation, but will be discussed in further detail below.  
 
The lack of a significant additive effect of the whey protein supplement with PRT 
on muscle outcomes may also be related to the lack of any increases in serum 
IGF-1 levels, which is a key growth factor important for muscle hypertrophy 
(624, 625). Several previous studies have shown that PRT, particularly high-
intensity PRT, increased protein intake (or supplementation), and the combination 
of these factors, can stimulate an increase in IGF-1 in older adults (42, 513, 620). 
While the precise reason(s) for the lack of any changes in serum IGF-1 levels in 
either group in our study is unclear, it may be related to the modest adherence 
with the exercise program, which averaged two session out of the prescribed three 
per week, issues related to adhering to the prescribed training intensity (since the 
program was implemented within a community-setting), the high level of protein 
intake at baseline and/or the relatively modest increase in overall dietary protein 
throughout the study.  
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Another important factor that has been shown to influence whether protein can 
augment the effects of PRT on muscle outcomes in older adults is the type and 
dose of protein prescribed. It is well established that whey protein (with an 
adequate dose of leucine) can elicit greater increases in postprandial MPS than 
other sources of protein (e.g. casein, soy) (39). Acute studies in the elderly have 
reported that at least 20 g of whey protein is required to stimulate an increase in 
MPS above exercise alone (10 g was ineffective), but 40 g elicited the greatest 
response (51). Moreover, there is evidence that 20 g of high-quality protein 
containing 2-3 g of leucine maximally stimulates MPS (626-628). In our study, 
participants were prescribed a daily dose of 20 g of whey protein providing ~2.4 g 
leucine to be consumed prior to breakfast and an additional 20 g after each of the 
three weekly PRT sessions. Mean adherence to the supplement was 79%, which 
indicates that participants consumed on average, an additional 15.8 g of protein 
per day on the non-training days and 31.6 g in a divided dose on the training days. 
It is possible that the lack of a significant additive effect on muscle outcomes in 
our study relates to the fact that participants were not provided with a single 40 g 
dose of whey protein post-exercise. In part support of this notion, the results from 
a 6-month trial in 80 mobility limited adults aged 70-85 years found that 40 g of 
whey protein divided into 20 g after breakfast and 20 g after the evening meal 
combined with PRT led to a non-significant 0.26 kg net gain in total body lean 
mass compared to PRT alone (377). Furthermore, in this study by Chale and 
colleagues the average increase in protein intake in the whey protein group was 
only 18 g when both supplement adherence (mean 72%) and dietary protein 
intake was considered, a level similar to that observed in our trial. In the study by 
Chale and colleagues this was due to a reduction in habitual total energy and 
protein intake, which suggests that the supplement may have been a partial meal 
replacements or that there was possibly a satiety effect of the supplement leading 
to a reduction in total food intake. Indeed, an acute study in 15 young resistance 
training males found that whey protein consumption after PRT reduced 
subsequent energy intake by a mean of 437 kJ (348). Consistent with these 
results, we also observed a significant reduction in both total energy (mean 437 
kJ/day) and protein intake (mean 8 g/day) in the PRT+ProD group.  
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The lack of a significant interaction of PRT and whey protein on PRT-related 
gains in muscle outcomes in our study may also be explained by an insufficient 
spread (difference) in protein intake between the groups (373). After taking into 
consideration the changes in habitual protein intake over the course of the 
intervention and the adherence to whey protein supplements, we found that there 
was an 18% and 36% spread between the groups or a 0.2 g/kg/day and 0.4 
g/kg/day between-group spread on the non-training and training days, 
respectively.  In a previous review of 17 intervention trials examining the effects 
of additional protein combined with PRT in both younger and older adults, Bosse 
and colleagues (373) found that in studies which detected an additive or 
synergistic benefit on muscle outcomes, there was an average 66% g/kg/day 
between group spread (difference) in protein intake; a spread of protein intake of 
10.2% g/kg/day was found to be ineffective (373). When we performed the pre-
planned per-protocol analysis in participants with ≥66% exercise adherence 
(equivalent to two sessions per week) and ≥80% adherence to the whey-protein 
and vitamin D supplements the spread in protein intake between-groups on 
training and non-training days was around 50% (0.5 g/kg/day) and 20% (0.2 
g/kg/day), respectively. This may help to explain the trend towards significantly 
greater gains in ALM and thigh muscle CSA in the PRT+ProD compared to PRT 
group with this secondary analysis. However, the findings from a 9-month trial in 
middle-aged overweight and obese adults found that exercise (PRT 2 days and 
aerobic training 1 day per week) combined with an additional 20, 40 or 60 g of 
whey protein (divided into two doses and consumed with breakfast and lunch) 
and which increased habitual intakes from around 1.0 g/kg/day to 1.15, 1.44 and 
1.68 g/kg/day yet compared to control (0.94 g/kg/day) did not increase exercise-
induced responses to total body lean body mass (285). This was despite a 78% 
spread in protein intake between the control group and those receiving the highest 
dose (60 g/day) of whey protein. However, these findings must be interpreted 
with caution given that 43% of participants withdrew from the study, and thus the 
study may have been underpowered to detect any differences.  
 
The timing of protein intake when performing PRT and the distribution of protein 
intake throughout the day may also influence the skeletal muscle responses to 
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exercise (49). Although data on the optimal timing of protein to maximise PRT-
related gains in older adults is limited, a study in elderly men found that ingestion 
of 10 g of protein immediately following exercise resulted in greater gains in 
muscle size and strength compared to delaying intake by 2 hours after PRT (496). 
In addition, the results from a 24-week trial in frail elderly found that providing 
additional protein (2 x 15 g) at breakfast and lunch to ensure a more even 
distribution of protein throughout the day enhanced the effects of PRT on lean 
mass (283). In our study, participants were instructed to consume the whey 
protein enriched drink prior to breakfast and as soon as possible following each 
PRT session. Unfortunately, no information was collected on the actual times that 
the protein supplements were consumed, and data on the dietary protein intakes of 
the participants at each meal was not examined. While there is some evidence that 
muscles remain sensitive to protein ingestion for up to 24-hours following 
training (629), the findings from our study are consistent with several previous 
trials in healthy older adults which found that consumption of protein in close 
proximity to exercise (282, 497) or through a divided dose (148) did not 
significantly augment the effects of PRT on muscle hypertrophy. However, it is 
clear that further research is still needed to determine whether a divided dose of 
protein when combined with exercise is necessary to enhance the skeletal muscle 
responses to training in older adults or those with chronic conditions like T2DM. 
 
A unique aspect of our trial is that it included the combination of PRT with whey 
protein and the provision of 2,000 IU vitamin D per day. Vitamin D deficiency 
has been associated with reduced muscle mass, strength and function (630-
632)and insulin resistance (633, 634). There is also some evidence that vitamin D 
treatment can have a positive effect on muscle protein metabolism (635, 636) and 
may act synergistically with leucine and insulin to stimulate MPS (637). 
However, the findings from our intention-to-treat analysis indicate that 
supplementing with vitamin D and whey protein does not enhance the effects of 
PRT on the mass, size or strength of muscle in older adults with T2DM. 
Furthermore, pre-planned per protocol analysis in participants with ≥66% 
exercise adherence and ≥80% adherence to the whey-protein drink and vitamin D 
supplements revealed that there was a significantly greater gain upper body 
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muscle strength, ALM (unadjusted only) plus a strong trend towards a greater 
gain in thigh (25% femur) muscle CSA and arm lean mass. Several previous 
human intervention trials which have investigated the effects of exercise 
combined with vitamin D (including fortified milk) or multi-nutrient supplements 
with additional vitamin D and protein (503, 512-514, 638-640) on muscle mass 
and strength have reported mixed findings. This is likely due to differences in the 
dose of vitamin D and protein prescribed (and subsequent changes over time), the 
baseline serum 25(OH)D level and habitual protein intake of the participant, and 
the health status of cohorts (healthy, elderly/frail or sarcopenic). In our trial, both 
groups presented with a sufficient serum 25(OH)D levels at baseline (pooled 
mean 72 nmol/L), but as expected, the provision of 2,000 IU of vitamin D daily in 
the PRT+ProD group resulted in a significant increase in 25(OH)D levels (mean 
change 28 nmol/L) with no change in the PRT group. While there is some 
evidence (and expert opinion) that serum 25(OH)D levels of 50 to 75 nmol/L are 
required for optimal muscle health and function (641), a recent meta-analysis 
found that the greatest benefits of vitamin D treatment on muscle strength were 
evident in those with 25(OH)D levels <30 nmol/L and when levels increased by at 
least 25 nmol/L; there was no effect of vitamin D on lean mass (462). While it is 
difficult to differentiate between the potential effects of protein and vitamin D on 
the outcomes in our trial, it is likely that any potential beneficial effects of the 
vitamin D on muscle outcomes in our study were blunted by the already high 
serum 25(OH)D levels of the participants at baseline.  
 
6.7.2  Effects of PRT, Whey Protein and Vitamin D on Fat Mass and Body 
Weight  
Along with PRT, long-term whey-protein supplementation or greater protein 
intake in older overweight/obese adults has been associated with reductions in fat 
mass and total body weight compared to control, (12, 352, 354, 642-644). Whey 
protein is believed to improve satiety with the action of satiety hormones 
contributing to this effect (348). Vitamin D is another dietary supplement shown 
that has been shown to have a positive influence on fat mass and fat distribution, 
although the data is very limited (451, 452). Whilst the exact mechanistic 
pathways by which vitamin D can achieve this are not known, it has been 
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speculated that high intakes of vitamin D can repress fatty acid synthase enzyme 
by decreasing intracellular calcium in adipocytes (645). In our trial, no additive 
effect of protein and vitamin D was seen on fat mass or total body weight 
reductions, but there was a small but non-significant 0.5 kg reduction in fat mass. 
The lack of a more pronounced effect on fat mass may have related to several 
factors including the dose of protein, the change in total energy intake over the 
course of the trial or metabolic adaptations to the intervention. There is also the 
possibility that the already sufficient serum 25(OH)D levels of our participants at 
baseline influenced the effect supplementary vitamin D had on such outcomes. 
 
Due to whey proteins thermic effect of feeding, high satiety value and ability to 
alter hunger hormones such as ghrelin, the regular addition of whey protein 
supplements to adults with T2DM diet could plausibly limit total energy intake, 
promote weight loss and have a positive effect on fat mass whilst preserving lean 
mass (520). When supplementing whey protein with the aim of enhancing 
PRT/exercise induced reductions in fat mass the quantity of whey protein has 
been suggested to be an important factor influencing such a response (285). In our 
trial, we provided 20 g of whey protein on the non-training days or two 20 g doses 
on the training days. Whilst these doses of whey protein significantly increased 
total protein intake from 1.2 to ~1.5 g/kg/day, there was not a concomitant 
reduction in total energy intake. We speculate that the dose of protein on non-
training days (20 g) and the divided dose on training days (one 20 g serving in the 
morning and another following training) was inadequate to attenuate energy 
intake. Previously studies have shown that whey protein effects subsequent 
energy intake in a dose-dependent manner (646) with some studies reporting 
significant reductions in body weight, fat mass and even visceral adipose tissue 
following the consumption of a~60 g bolus dose of whey protein in older 
overweight adults performing exercise or PRT (355, 520). Coinciding with these 
body composition improvements in one of the studies, significant reduction in 
appetite and energy intake was also observed (355). In contrast to these findings, 
a 36-week study providing whey protein in doses ranging from 20 g, as in our 
trial, up to 60 g per day observed no significant between group differences for the 
change in fat mass or total body weight between the group or controls receiving 
Chapter 6 
Page | 268 
	
no additional protein (285). The lack of a difference between the groups in fat 
mass reduction in that study was proposed to be due to the participants already 
consuming an adequate level of protein intake at baseline (>0.9 g/kg/day) which 
may have blunted the satiety effect of additional whey protein (285). Participants 
in our trial also had high intakes of protein at baseline which may explain the 
absence of a significant reduction in energy intake and/or differences for the 
change in body composition. 
 
In our study changes in fat mass and body weight were small and similar in both 
groups. These results are consistent with another trial which found that the 
combination of exercise, whey protein and vitamin D was no different to exercise 
alone in reducing fat mass or total body weight in older sarcopenic adults (513). 
Indeed, the magnitude of change in fat mass and weight loss in this study by 
Rondanelli et al (513) was similar to that observed in our trial. Similarly, another 
trial also observed no added benefit of a high-whey protein and vitamin D 
enriched supplement plus PRT on fat mass or total body weight in obese adults, 
although this trial also included a caloric restricted diet making comparisons 
difficult. (512). Nevertheless, the small improvements in fat mass and total body 
weight in our trial are similar to some other PRT trials in older overweight/obese 
adults with T2DM in the absence of caloric restriction (203, 216, 250), yet others 
have reported much greater losses in weight and fat mass (7, 8, 202, 208, 217). 
These differences could be related to the fact that we conducted a ‘real-world’ 
community-based program which contrasts with many others which were 
performed in clinically controlled exercise laboratories.  
 
6.7.3  Effects of PRT, Whey Protein and Vitamin D on Glycaemic and 
Insulinaemic Outcomes 
Previous research has shown that whey protein (and a high protein diet) can have 
an insulinotropic effect, and thus stimulate insulin secretion to enhance glucose 
clearance from the blood (333, 403, 647). Moderate- to high-intensity PRT has 
also been shown to improve glycaemic control and insulin sensitivity, but whether 
whey protein supplementation can enhance the effects of PRT on these outcomes 
in older adults with T2DM remains uncertain. In this 6-month RCT in 198 
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overweight and obese older adults with T2DM there was a 0.56 mmol/L (6.8%) 
greater reduction in FPG in the PRT compared to PRT+ProD group after 24-
weeks, but this was not significant after adjusting for covariates. Conversely, 
there was a significant reduction in serum insulin concentrations in the 
PRT+ProD after 12- and 24-weeks, that differed from the PRT group after 
adjusting for baseline values, which would indicate an improvement in insulin 
sensitivity. However, there was no evidence to support an additive effect of PRT 
with 20 g of whey protein consumed daily prior to breakfast and an additional 20 
g within two hours of each of the two to three weekly PRT sessions, on the 
clinically relevant outcome measures of HbA1c or insulin sensitivity as assessed 
via the HOMA model.  
 
Consistent with the results from our 6-month RCT in older adults with T2DM, a 
number of previous intervention trials in healthy older adults and those with 
metabolic syndrome or T2DM have also failed to detect any additive effect of 
increased dietary protein, whey protein or a milk-based protein supplementation 
with PRT on glycaemic and insulinaemic outcomes when compared to exercise 
/PRT (283-285, 305, 519-521, 648). For instance, a 16-week intervention 
involving an energy-restricted diet with either a standard or high protein intake 
(19% vs 33%), with or without PRT performed three days per week, in 
overweight and obese adults with T2DM resulted in similar significant reductions 
in HbA1c, FPG and serum insulin, despite greater weight and fat loss in the high 
protein plus PRT group (286). Similarly, the findings from a 36-week RCT in 
middle-aged overweight and obese adults with FPG levels within the ‘normal’ 
range (<6.1 mmol/L) revealed that whey protein supplementation at 0, 20, 40 or 
60 g per day combined with twice weekly PRT and aerobic training had no effect 
on glucose levels [OGTT glucose area under the curve (AUC)] or insulin 
resistance (HOMA-IR) yet insulin AUC decreased significantly by 2.6% across 
the groups (285). There are a number of factors which may explain the lack of an 
added benefit of increased protein combined with PRT on glycaemic outcomes in 
both our study and previous trials. This could include the baseline HbA1c or FPG 
status of the participants, the use of oral hypoglycaemic medications, the habitual 
protein intake of participants, the type, timing and dose of protein prescribed and 
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subsequent spread (difference) in protein intake between groups, and differences 
in duration of the intervention period.  
 
For people with T2DM it is generally recommended that they maintain a HbA1c 
level ≤ 7% and FPG between 6-8 mmol/L as this has been associated with a 
reduced risk of long term T2DM-related complications (649, 650). In our study, 
the mean baseline HbA1c level of participants in the PRT+ProD and PRT group 
was 6.9 and 7.1%, respectively (mean FPG levels were 7.9 and 8.6 mmol/L, 
respectively). Overall less than half of the participants (44%) had an initial HbA1c 
>7%, and there was a significantly higher proportion of participants with a level 
above this cut-point in the PRT compared to PRT+ProD group (51% vs 37%). 
This may explain, in part, our finding that the combination of PRT with whey 
protein supplementation did not lead to greater benefits on glycaemic control and 
insulin sensitivity compared to PRT alone. However, secondary analysis revealed 
that there was no significant interaction by baseline HbA1c status (≤7 vs >7%). 
Consistent with our findings, nearly all previous studies which reported no added 
benefit of increased dietary or supplemental protein with PRT on HbA1c, insulin 
sensitivity or insulin resistance included participants with adequate glycaemic 
control (148, 283, 285, 520, 521, 648). Given that there are some reported 
benefits of whey protein supplementation or a higher protein intake (without 
PRT) on HbA1c or FPG levels in participants with poor glycaemic control (HbA1c 
>7.5%) (38, 263, 272, 396), further research is warranted to investigate whether 
the combination of exercise with increased dietary protein or protein 
supplementation can improve glycaemic measures in older adults with poorly 
controlled T2DM.  
 
One of the challenges when conducting lifestyle-related intervention trials in 
individuals with T2DM is that many participants are taking oral hypoglycaemic 
medications to maintain their blood glucose levels. Given the marked effect that 
these agents have on measures of glycaemic control, it is possible that they may 
mask or attenuate any potential beneficial effects of lifestyle-related approaches. 
In our study, 70% of the participants were taking a prescribed oral hypoglycaemic 
agent at baseline, with an equal proportion within each group. Although the 
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number of participants taking such medication did not change significantly in 
either group throughout the study (and there was no marked change in dosage), 
there was a higher proportion (~10% difference) of participants in the PRT+ProD 
group taking oral hypoglycaemic medications at 12- and 24-weeks. However, this 
is unlikely to have influenced the findings as all results remained unchanged after 
adjusting for the use of oral hypoglycaemic medications, and secondary analysis 
revealed that there was no interaction by diabetes management (lifestyle alone 
versus medication) for any of the glycaemic outcome measures. However, given 
the small number of participants that were managing their diabetes through 
lifestyle approaches alone, it is likely that we were underpowered to detect any 
potential added benefits of the whey protein supplement on PRT related changes 
in glycaemic outcomes in this subgroup.  
 
As already indicated, there is considerable evidence supporting an insulinotropic 
effect of protein, but whether there is an optimal level of intake (intake at 
g/kg/day) or dose of protein necessary to cause this effect and improve glycaemic 
control or enhance the glycaemic improvements of PRT over the long-term 
remains uncertain. Yet the findings from various acute studies indicate that there 
are positive effects on postprandial glucose levels and insulin secretion with 10 to 
55 g of whey protein provided with a meal or pre-meal (52, 342, 621, 651, 652). 
Based on these findings one would anticipate that a 20 g daily dose of whey 
protein consumed prior to breakfast and an additional 20 g taken after each PRT 
session would be sufficient to elicit a positive response when combined with PRT. 
It is possible that the lack of any exercise-protein interaction in our study may 
relate to the habitual protein intake of the participants which exceeded 1.1 
g/kg/day at baseline (~20% protein). However, the results from a 5-week 
randomised, calorie-controlled crossover study in 12 adults with T2DM (mean 
HbA1c 8.0%) revealed that a high-protein diet (30% protein) led to a 40% 
reduction in the 24-hour glucose area response and a 0.5% absolute greater 
reduction in HbA1c (-0.8 vs -0.3%) compared to an isocaloric conventional low-
fat diet (15% protein) (263). A possible reason for the positive effect in this study 
by Gannon and colleagues is the large between-group difference in protein intake 
(30% vs 15%). However, in our study similar between-group differences were 
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observed. The average protein intake (diet plus supplement) differed by 
approximately 10-18% and 26-35% on the non-training and training days, 
respectively. Another potential explanation may be that older adults with T2DM 
require a higher dose of protein to experience a similar response. Indeed, several 
acute studies have shown that 50 to 55 g of whey protein consumed prior to a 
meal significantly improved postprandial glycaemia in adults with T2DM (342, 
379), although others have reported that a dose of ~20-25g is also effective (341, 
653). Further research is needed in adults with T2DM to evaluate the effects of 
whey protein alone and combined with PRT on long-term glycaemic control. 
 
Contrary to the findings from many acute studies examining the effects of whey 
protein on insulin responses, we found that there was a significant reduction in 
serum insulin concentrations in the PRT+ProD group after 12- and 24-weeks, 
which differed from the changes in the PRT group after adjusting for baseline 
values. In line with these findings, a 12-week study in overweight and obese 
adults found that daily consumption of 55 g of whey protein resulted in a 
significant 10-11% reduction in plasma insulin concentrations (351). However, 
unlike the findings from our trial this study by Pal and colleagues also detected a 
significant decrease in HOMA assessed insulin resistance, suggesting that there 
was an improvement in long-term insulin sensitivity. While a number of previous 
intervention trials ranging from 12- to 36-weeks in healthy older adults and those 
with metabolic syndrome or T2DM have reported a significant reduction in serum 
insulin levels following increased dietary protein or whey protein 
supplementation with and without exercise, none of these studies observed an 
added benefit of protein combined with exercise or between-group differences 
when different doses of protein were combined with exercise (285, 286, 520, 
648). Furthermore, secondary analysis of a 36-week trial in overweight and obese 
adults who performed resistance and aerobic exercise twice weekly and were 
supplemented with either 0, 20, 40 or 60 g per day of whey protein found that 
neither total protein intake nor the change in protein intake expressed as g/kg/day 
throughout the study was associated with changes in insulin, HOMA-IR or insulin 
sensitivity (494). The finding that there was a greater reduction in insulin levels in 
the PRT+ProD group in our study may be explained, in part, by the higher level 
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of adherence to the training as there is some evidence that training volume is 
related to the magnitude of decrease in serum insulin concentrations (654). 
Furthermore, since there was a decrease in C-peptide levels in the PRT+ProD 
group, which provides a measure of insulin secretion, this suggests that the 
decrease in insulin was driven by a reduction in insulin secretion. However, the 
clinical significance of these changes remains uncertain given that there were no 
significant long-term benefits on insulin sensitivity.  
 
Increased levels of pro-inflammatory markers (e.g. hs-CRP, IL-6 and TNF-α) 
have also been associated with poor glycaemic control in adults with T2DM 
(525). While there is some data showing that PRT-related improvements in 
inflammatory markers in older overweight adults coincide with improvements in 
insulin resistance and/or glycaemic control (236, 237, 555), from the limited data 
available (most studies have only measured hs-CRP) there appears to be no 
evidence that increasing protein intake or protein supplementation can enhance 
this response (285, 286). However, in our study there was a significant increase in 
the level of the anti-inflammatory marker IL-10 in the PRT+ProD compared to 
PRT group, but this was also associated with a greater increase in the pro-
inflammatory marker IL-8 at week 12. It is difficult to explain these findings, 
particularly as there was little shift in the remaining pro- and anti- inflammatory 
markers (adiponectin, IL-6, hs-CRP) in either group, which may be related to the 
modest reductions in fat mass, a well-known contributor to increased 
inflammation. Given these mixed findings, it is possible that the lack of a more 
systemic between-group difference or improvement in the various inflammatory 
markers in our study may have contributed to the lack of any between-group 
differences in the glycaemic outcome measures, but this requires further study. 
 
Evidence exists to support a direct relationship between serum 25(OH)D 
concentrations and insulin sensitivity and HbA1c (634, 655, 656). Further, 
correcting vitamin D deficiency with supplementation has been shown to improve 
insulin sensitivity in some studies (657, 658),  However, as reviewed by others, 
the evidence from intervention trials assessing the effects of vitamin D 
supplementation on glycaemic outcomes in adults with normal glucose tolerance 
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and people with T2DM remained mixed (659) with any potential benefits likely to 
be most prominent in people with prediabetes and insufficient/deficient baseline 
serum 25(OH)D levels (571). In our study, the mean baseline serum 25(OH)D 
level of the participants in the PRT+ProD and PRT group was well within the 
normal range (mean 75 and 69 nmol/L, respectively); only 19% of participants 
had a level below 50 nmol/L which some consider insufficient. Although 
treatment with 2,000 IU daily increased serum 25(OH)D levels by an average of 
28 nmol/L after 6-months, given that adequate basal serum 25(OH)D levels (and 
HbA1c status) it is unlikely that such an increase provided any added benefits. If 
vitamin D treatment does influence glycaemic measures in adults T2DM, further 
research is still needed to determine if there is an optimal dose and serum 
25(OH)D concentration that is likely to provide any benefits, and whether it is 
restricted to those with poorly controlled diabetes.  
 
Despite the lack of any significant exercise-protein-vitamin D interaction on the 
glycaemic outcome measures, there was a significant 0.13% to 0.15% absolute 
reduction in HbA1c in both the PRT+ProD and PRT group after 12-weeks, which 
tended to persist in both groups after 24-weeks. Over the past two decades, there 
have been many intervention trials and subsequent meta-analyses which have 
reported that PRT, particularly supervised and structured in well controlled 
laboratory, clinic or gymnasium settings, can improve glycaemic control and/or 
insulin sensitivity in people with T2DM (12, 157, 203, 212, 228, 612, 660). In the 
most recent meta-analysis of PRT trials of at least 8-weeks duration in older 
adults aged at least 60 years with T2DM (n=8), Lee et al. (660) found that PRT 
significantly lowered (absolute reduction) HbA1c by 0.50%. Other meta-analyses 
have reported similar absolute mean 0.34% to 0.57% improvements in HbA1c 
following PRT (227, 228), although it was noted that there was considerable 
heterogeneity among the studies. Nevertheless, these changes are considerably 
greater than the mean changes observed in our study, which may be explained by 
a number of factors, including the baseline HbA1c status of our participants. 
Subgroup analysis from several previous meta-analyses have shown that 
participants with higher baseline HbA1c levels (>7.0 or 7.5%) experience greater 
PRT-related improvements when compared with those with baseline levels below 
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these cut-points (8, 228, 661). Thus, the modest reductions observed in our study 
are likely related to the fact that the mean basal HbA1c levels of the participants in 
the PRT+ProD and PRT group was 6.9 and 7.1%, respectively. However, it is 
worth noting that no significant interaction by baseline HbA1c status (≤7 vs >7%) 
was observed in our study, but less than half of all participants had a baseline 
HbA1c level >7%.  
 
Another likely explanation for the modest improvements in our study was that the 
PRT program was conducted across 80 different local health and fitness and not 
within a controlled clinical setting. Although all participants were enrolled within 
the community-based Lift for Life® program, which is a structured PRT program 
based on evidence from clinical trials that is implemented and supervised by 
exercise trainers who have received specialised training as part of the Lift for 
Life® accreditation process, it was not possible to control or standardise the 
prescription of exercise across all facilities. A previous cluster RCT examining 
the effectiveness of the standard compared to an enhanced behaviourally focused 
Lift for Life® program in overweight adults and those with T2DM reported no 
changes in HbA1c following the standard program and a modest net 0.13% 
absolute improvement after 24-weeks in those who received the enhanced 
program; when the analysis was restricted to those participants with T2DM the 
net benefit was 0.3% (662). On this basis, it is difficult to explain why such 
modest improvements were observed in HbA1c in our cohort of overweight and 
obese adults with T2DM.  
 
A previous meta-analysis of community-based physical activity interventions for 
adults with T2DM reported a trend toward a lowering of HbA1c (mean -0.32%, 
P<0.06) (23), but another meta-analysis found that structured exercise training of 
>150 minutes per week was associated with greater reductions in HbA1c in adults 
with T2DM than that of ≤150 minutes per week (227). While neither of these 
studies focused specifically on PRT, the findings from several meta-analyses have 
indicated that the characteristics of PRT programs (volume, intensity, frequency 
or duration) appear to have little influence on the changes in HbA1c or other 
related measures (227, 228, 660). While this may be due to the similarity in the 
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design of many of the previous PRT programs, a potential explanation for the 
small improvements in glycaemic control in our study may relate to the adherence 
to the training (PRT+ProD 68%; PRT 58%). However, this still equates to 
approximately two out of three PRT sessions per week, which is in line with most 
current exercise guidelines for people with T2DM. An alternative reason for the 
small improvements in HbA1c in our study may relate to the relatively modest 
gains in lean mass (mean 0.4 to 0.5 kg), which was lower than that observed in 
another laboratory clinical trials which observed greater benefits on glycaemic 
control (12). However, as indicated earlier there is some evidence that PRT-
related reductions in HbA1c can occur without any marked changes in lean mass 
(660, 663).  
 
The cessation of a single bout of PRT/exercise causes improvements in both 
glucose disposal and metabolism which may last for several hours or possibly 
days (664). Due to this it is unknown whether the improvements typically 
observed in insulin sensitivity following exercise training in those with T2DM is 
due to the accumulative effects of the individual exercise sessions or an 
adaptation induced from long-term training (665). To avoid any residual effect of 
the final PRT session on FPG and insulin levels, participants in our trial were 
instructed to provide a fasted blood sample at least 48-hours following their last 
PRT session. It is possible that this timing may explain the lack of a significant 
difference between the PRT+ProD and PRT groups in FPG and insulin sensitivity 
as assessed by the HOMA model. It is also possible that the major effect of the 
PRT program was on postprandial glucose and insulin sensitivity which were not 
assessed but are dependent on muscle insulin sensitivity.  
 
In summary, this study indicates that a community-based PRT intervention in 
older adults with T2DM was associated with modest improvements HbA1c, but 
there no evidence of any added benefits of whey protein and vitamin D treatment 
on either glycaemic control or insulin sensitivity.   
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6.7.4  Effects of PRT, Whey Protein and Vitamin D on Blood Pressure and 
Lipids 
Despite reports from some reviews and meta-analyses that PRT, high protein diets 
and supplementation with whey/dairy proteins or vitamin D can improve various 
cardiovascular outcomes (38, 212, 333, 659, 666-670), few intervention trials 
have investigated whether such nutritional approaches can provide additive 
benefits to exercise in people with T2DM. In our 6-month RCT in older 
overweight and obese adults with T2DM, we found that there was no additive 
benefits of daily whey protein and vitamin D supplementation to a community-
based PRT program on any cardiovascular outcomes. After 24-weeks there were 
similar significant reductions in DBP in both groups along with a small reduction 
in total cholesterol and LDL cholesterol in the PRT+ProD group at 12-weeks, but 
these benefits were not maintained to 24-weeks. The reason(s) why we did not 
observe more meaningful improvements in these outcomes following either PRT 
alone or PRT in combination with whey protein and vitamin D supplements may 
be due to a number of factors, including the small changes in weight and fat mass, 
the relatively high proportion of participants taking anti-hypertensive and lipid-
lowering medication, the basal blood pressure and lipid levels of the participants, 
the adequate basal dietary protein and serum 25(OH)D status of participants 
and/or differences in the adherence to the intervention. Indeed, per-protocol 
analysis of participants who achieved ≥66% compliance with the PRT program 
and ≥80% compliance with the whey protein and vitamin D supplements revealed 
that the PRT+ProD group experienced a significantly greater reduction in both 
total cholesterol and LDL cholesterol after 24-weeks compared to the PRT alone. 
 
In line with the findings from the intention-to-treat analysis of our 6-month trial, 
several previous intervention trials in older overweight adults and those with 
metabolic syndrome or T2DM have failed to detect any added benefits of whey 
protein supplementation or increased dietary protein in combination with PRT on 
change in cholesterol or lipid profiles and blood pressure compared to PRT alone 
(42, 284-286, 513, 648, 671). The lack of an interactive effect in our study and 
many of these previous trials is likely related to the fact that most participants had 
baseline lipid and/or blood pressure profiles within the normal healthy range. In 
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addition, more than 50% of participants in our study were taking anti-
hypertensive or lipid-lowering medication, which may attenuate any potential 
benefits. We detected no interaction by use of lipid-lowering or anti-hypertensive 
medication in our study for any blood pressure or lipid profile measure and like 
our findings one 12-week trial in 28 overweight men with hyperlipidaemia also 
failed to detect any added benefit of 26.6 g per day of whey protein combined 
with PRT on blood lipids levels compared to PRT alone (671). While this may be 
related to the small sample size in the previous study, an alternative explanation is 
that a higher dose of whey protein may be needed to elicit a positive response.  
 
Subgroup analysis of a previous meta-analysis of 13 RCTs found that the effects 
of whey protein (without exercise) on serum triglyceride levels were greatest at 
doses of ≥30 g (670). Moreover, a 12-week non-exercise trial in overweight and 
obese adults (not taking lipid-lowering or anti-hypertensive medication) 
demonstrated that supplementation with 27 g of whey protein isolate twice daily 
(total 54 g per day) decreased total cholesterol and LDL cholesterol compared to 
either casein and a control group (351). In part support of these findings, the per 
protocol analysis in our study revealed that participants who were ≥80% 
compliant with the whey protein and vitamin D supplements (and ≥66% 
compliant with PRT) experienced a significantly greater reduction in total 
cholesterol and LDL cholesterol compared to the non-supplemented group. 
Interestingly however, the mean daily protein intakes after 12- and 24-weeks in 
the PRT+ProD group increased by only 15 and 7 g and 34 and 26 g relative to 
baseline on the non-training and training days, respectively. While further 
research is still needed to determine if there is an optimal dose of protein to 
enhance cardiovascular health outcomes, secondary analysis of a previous 36-
week exercise-whey protein supplementation trial in middle-aged overweight and 
obese adults revealed that neither total protein intake (mean 1.18 g/kg/day) or 
change in protein intake (mean 0.15 g/kg/day) throughout the study combined 
with exercise were associated with changes in any cardiovascular index (blood 
pressure or lipid measures) (494). 
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We hypothesised that combining a whey protein drink with vitamin D 
supplements would provide added benefits to PRT on cardiovascular risk factors. 
To our knowledge, no previous studies have examined the effects of additional 
protein plus vitamin D treatment with PRT with both protein and vitamin D on 
blood pressure or lipids levels in older adults or those with T2DM. However, data 
from a 12-week trial in vitamin D deficient elderly women discussed already in 
section 2.11.1 was more effective at lowering blood lipids than either exercise or 
vitamin D alone or even controls (502). Thus, in our study the lack of any additive 
benefits of the vitamin D (plus protein) supplementation with PRT on blood 
pressure or serum lipid measures may be related to the fact that a large proportion 
of the participants had serum 25(OH)D levels that would be considered sufficient 
(>50 nmol/L). Interestingly, a 20-week RCT in 130 hypertensive patients found 
that 3,000 IU cholecalciferol per day had no effect on blood pressure, but 
subgroup analysis revealed that participants with 25(OH)D levels <80 nmol/L did 
experience a decrease in blood pressure (672). Whether there is an optimal serum 
25(OH)D concentration to improve cardiovascular health outcomes remains 
uncertain, but other long-term trials where participants had insufficient/deficient 
levels of serum 25(OH)D levels (<30 nmol/L) have more consistently 
demonstrated improvements in cardiovascular health following vitamin D 
supplementation, including SBP and/or lipid measures (177, 502) 
 
In older adults with T2DM the findings from two meta-analyses of RCTs have 
reported a positive effect of PRT on blood pressure (212, 673). In our study, there 
was a similar significant mean 2.4 to 2.6 mmHg reduction in DBP in both groups 
after 24-weeks; SBP also decreased by an average of 2.4 mmHg in the PRT and 
2.6 mmHg in the PRT+ProD group, but these within-group changes were not 
statistically significant (P=0.08 and P=0.10, respectively). Nevertheless, a 
previous meta-analysis of RCTs of blood pressure lowering regimens reported 
that a reduction in SBP and DBP of 2.1 and 0.9 mmHg was associated with a 10% 
reduced risk of major cardiovascular events (674). While this suggests that the 
changes in our study are clinically meaningful, the magnitude of the changes were 
slightly lower than these weighted mean differences of -4.44 mmHg for SBP and 
-2.84 mmHg for DBP between PRT and controls from a meta-analysis of 10 
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interventions in adults with T2DM (247). The reason(s) for these differences, 
particularly regarding SBP, may relate to the modest mean 0.6 to 0.9 kg 
reductions in total body fat mass in both groups in our study. Indeed, the findings 
from a meta-analysis of 6,754 participants in 11 studies examining the effects of 
weight loss from lifestyle interventions (diet and/or physical activity) over 12-
months on blood pressure in overweight and obese adults with T2DM found that 
less than 5% weight loss was not associated with any marked improvements 
(675). Other potential reasons for the modest improvements in blood pressure in 
our study may relate to the implementation of the PRT within community-based 
facilities which may have contributed to marked inter-individual variability in the 
training intensity, the finding that only 44% of participants in the study were 
classified as hypertensive based on SBP (≥140 mmHg) and/or DBP (≥90 mmHg) 
and/or that more than 50% of the participants were taking anti-hypertensive 
medication. However, subgroup analysis of several meta-analysis has found that 
any between group differences for the change in blood pressure following PRT 
were not related to either baseline blood pressure level or training intensity (228, 
247), but there is some evidence that structured and longer duration programs 
(>40-weeks) are most effective for improving blood pressure (676). 
 
With regard to the effects of our PRT program on blood lipid levels, we found 
that there were no marked benefits in either group after 24-weeks, despite some 
initial benefits in the PRT+ProD group after 12-weeks. This appears to be in 
contrast with the findings from a 2014 meta-analysis comparing aerobic and PRT 
interventions in adults with T2DM which reported significant improvements in 
total cholesterol, LDL cholesterol and triglycerides following PRT; there was no 
effect of PRT on HDL cholesterol (212). There are likely to be a number of 
factors that contributed to the lack of any improvements in blood lipids levels 
following our 24-week PRT intervention. First, the baseline blood lipid profiles of 
the participants in our study were generally within the healthy range; for each 
lipid measure 60 to 83% of participants were classified as ‘normal’. In a previous 
6-month RCT in older overweight and obese adults with T2DM with mean basal 
lipid levels generally within the healthy range, Dunstan et al. (12) found that high-
intensity PRT combined with moderate weight loss had no effect on any blood 
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lipid measure. Second, more than 50% of the participants in our study were taking 
lipid-lowering medication, although no interaction by lipid-lowering medication 
use was detected for any measure which may again be related to the basal lipid 
profiles of our participants. Finally, the magnitude of the change (loss) in weight 
and fat mass in our study was small. Previous research has shown that reductions 
in weight of less than 5% following PRT or a multi-modal exercise program 
failed to alter blood lipid levels in older adults with T2DM in interventions lasting 
from 22-weeks to 24-months (8, 677).  
 
6.7.5  Effects of PRT, Whey Protein and Vitamin D on Markers of 
Inflammation 
Since T2DM has been associated with chronic low grade systemic inflammation 
which has been linked to poor glycaemic control and an increased risk of 
diabetes-related complications, there has been considerable interest in identifying 
strategies to improve the inflammatory profile of people with this condition. 
There is emerging evidence that PRT (230, 244), vitamin D supplementation 
(678) and dairy or whey protein supplementation (325, 326) may improve various 
circulating pro- and/or anti- inflammatory markers in older adults and those with 
T2DM, but whether the combination of vitamin D and whey protein 
supplementation interact to enhance the effects of exercise on inflammatory 
markers remains uncertain. In our 24-week RCT in overweight and obese adults 
with T2DM, we observed mixed effects for the combination of PRT with whey 
protein and vitamin D supplementation compared to PRT alone on various 
circulating inflammatory markers. There was a significantly greater increase in 
the anti-inflammatory marker IL-10 in the PRT+ProD compared to PRT group 
after 12- and 24-weeks. While there were no significant between group 
differences for the change in hs-CRP, TNF-α, adiponectin, IL-8 or IL-6 after 24-
weeks, an interesting observation was that all inflammatory markers tended to 
increase relative to baseline in the PRT plus supplemented group and decrease in 
the PRT group. 
 
While it is difficult to explain the contrasting findings from our study and the 
clinical relevance of the results, the most profound changes and between-group 
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differences were for the anti-inflammatory marker IL-10 which increased in the 
PRT+ProD group and decreased in the PRT group. A previous 16-week 
intervention in free living overweight/obese adults found that whey protein 
supplementation (20 g three times per day) combined with either PRT or a 
multimodal exercise program (4 times per week) increased serum adiponectin 
levels, another anti-inflammatory cytokine, by 18 to 23% compared to protein 
supplementation alone (-6% change) (520). However, since there was no exercise 
alone group in this study it is difficult to compare these findings with our results. 
The reason(s) why some circulating inflammatory cytokines appear to improve 
and others do not change in response to a given intervention remains uncertain, 
particularly given that many cytokines (e.g., IL-6, TNF-α, adiponectin) are 
produced at the same site (e.g. adipose tissue) and the pro-inflammatory markers 
IL-6 and TNF-α are known to induce hepatic production of hs-CRP. Nevertheless, 
this mixed response is a consistent observation from many previous exercise 
and/or nutrition interventions (679-681).  
 
One of the most common inflammatory markers that has been measured in many 
previous exercise and nutrition interventions is the pro-inflammatory cytokine hs-
CRP. The inflammatory marker hs-CRP is a substance produced by the liver that 
increases in the presence of inflammation in the body, and has been linked to 
cardiovascular disease (682-684). In our study, hs-CRP levels did not change or 
differ between the groups at any time throughout the 24-week intervention. 
Consistent with these results, several previous intervention trials in 
overweight/obese adults or those with T2DM reported that increased dietary 
protein (286), whey protein supplementation (285) or vitamin D supplementation 
(685) did not augment the effects of PRT on serum hs-CRP levels. This may be 
due in part, to the fact that baseline hs-CRP levels were not elevated (only 19% of 
participants in our study had an hs-CRP level >3 mg/L which is considered high). 
Indeed, subgroup analysis of a 2015 meta-analysis reported that there was a small, 
but significant effect of whey protein on lowering serum hs-CRP levels in those 
with baseline values ≥3 mg/L (326). However, a 12-week study in 130 sarcopenic 
elderly people with apparently normal hs-CRP levels found that there was still a 
significant net benefit on hs-CRP levels following supplementation with a multi-
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nutrient drink containing whey protein (22 g), essential amino acids (10.9 g, 
including 4 g leucine) and vitamin D (100 IU/day) in combination with a 
moderate-intensity strength and balance exercise program (5 days per week) 
compared to exercise plus placebo (513). This was due to a non-significant 
reduction in the supplement group (P=0.329) and a non-significant increase 
(P=0.061) in the placebo group. Unfortunately, nearly all the above trials did not 
measure other pro- or anti-inflammatory cytokines, and thus it is not possible to 
determine whether exercise combined with increased protein and/or vitamin D 
has an effect on improving systemic inflammatory markers. However, the 
findings from a 3-month intervention in 36 patients with chronic obstructive 
pulmonary disease found that circulating levels of TNF-α, IL-6 and IL-8 all 
decreased significantly after daily consumption of a whey protein enriched drink 
combined with a low-intensity exercise program compared with those in the 
control group, which may be related in part, to the elevated levels of inflammation 
at baseline (386).  
 
In overweight/obese adults previous research has consistently shown that diet 
induced weight loss has a positive effect on lowering circulating pro-
inflammatory markers and increasing anti-inflammatory cytokines (549, 686, 
687). Given that there was a significant, albeit modest, similar reduction in 
weight, fat mass and waist circumference in both groups in our study, it is 
somewhat surprising that we did not see consistent reductions in the measured 
pro-inflammatory cytokines after 24-weeks, particularly in the PRT+ProD group 
as exercise adherence was significantly higher in this group. Indeed, a 4-month 
RCT in elderly women found that PRT combined with a protein enriched diet 
achieved through the consumption of lean red meat (daily protein intake of ~1.3 
g/kg/day) was associated with a 16% significantly greater reduction in the pro-
inflammatory marker IL-6 compared to PRT alone (42). Consistent with our 
findings however, was the observation that there was no effect on any other pro- 
or anti-inflammatory markers including TNF-α (42). Peake et al. (569) reported a 
trend for an increase in serum IL-6 concentrations in older men following 
supplementation with calcium-vitamin D fortified milk for 18-months, but this 
was attenuated after adjusting for changes in fat mass. In our study, all results 
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remained unchanged after including total body fat mass in the model. Based on 
these mixed findings, further research is warranted to evaluate if there are any 
potential additive or synergistic effects of exercise with various nutritional factors 
on a range of circulating systemic markers of inflammation. 
 
6.8  Strengths and Limitations 
The strengths of this study lie in its randomised controlled design, the 24-week 
intervention period, the large sample size of older adults with T2DM, the high 
retention rate (85%), the low number of adverse events associated with the 
intervention, and the successful implementation of the intervention within the 
community. However, there are a number of limitations which may help to 
explain some of the findings from this trial.  
 
First, the older men and women with T2DM recruited to this trial had an average 
HbA1c level of 7.0% which is indicative of good glycaemic control. Further, 
around 70% of the participants were prescribed oral anti-hyperglycaemic 
medication to manage their T2DM. Similarly, many had blood pressure and lipid 
levels within the normal range which may also be explained by the high 
proportion of participants taking anti-hypertensive and lipid-lowering medication. 
In addition, mean dietary protein intakes and vitamin D status were adequate at 
baseline based upon current recommendations. Collectively, these factors may 
have limited the ability to detect potential improvements or between group 
differences with the intervention. 
 
Second, the PRT program was implemented across 80 different health and fitness 
centres throughout Melbourne and surrounding regions. This was more sites than 
originally we had planned but it was a necessity that we expand to this many 
training sites when recruitment slowed. Mean adherence to the exercise program 
averaged 63% which is equivalent to approximately two sessions out of the 
prescribed three per week. This level of adherence is comparable or slightly lower 
to that reported in many other PRT interventions over a similar period in older 
adults and those with T2DM, even when training was performed under a 
supervised laboratory based setting (42, 514). However, the fact that participants 
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exercised at 80 different health and fitness centres across Melbourne and 
surrounding regions with each location having their own exercise trainers made it 
difficult to ensure consistency with regard to the prescription of exercise across 
all programs. However, we did attempt to control for this variability by having all 
trainers attend a two-day training workshop prior to any participants being 
allocated to their respective training location. Similarly, the intensity of training 
(or each exercise) was recorded using the RPE scale, but since this is a subjective 
rather than a quantifiable measure it is possible that the intensity of training 
between individuals varied considerably. However, the collection of the exercise 
cards monthly for review by trial staff meant any drop in self-reported intensity 
was readily observed and promptly rectified. In addition, the PRT program 
consisted of equal parts upper and lower body exercises, however, given the 
lower body has some of the largest muscle groups it is possible that the training 
program underemphasised major muscle groups of the hips and legs. This 
limitation in the design of the PRT program inadvertently may have had an 
impact on the change in strength, body composition and even glycaemic control. 
 
Third, a placebo or energy matched control drink was not used in this trial as it 
became evident during the initial establishment phase of the study that the 
ingredients used to develop such a placebo product had the potential to alter blood 
glucose levels or influence muscle mass which were the two key outcomes of this 
trial. The absence of a placebo or energy matched drink meant participants were 
not blinded to which treatment group they were in which could have created a 
certain bias towards performing the PRT program in the study or that the non-
supplemented group may have increased their protein and/or vitamin D intake. 
However, the findings from the dietary analysis indicate that this did not occur. In 
addition, the supplement may have also acted as an incentive to perform the PRT 
program, which may possibly explain the significantly higher adherence to the 
training in the PRT+ProD group. Also, the glycaemic effects of meals adjacent to 
the consumption of the protein supplement was not considered and is a limitation 
of our analysis. For instance, a 25 g bolus of protein consumed prior to a high 
carbohydrate meal has been associated with marked reductions in postprandial 
glycaemia in both acute and long-term settings (688). Fourth, we were not able to 
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assess the distinct effects of the vitamin D supplements from the whey protein 
drink, as we did not have a whey protein plus PRT or vitamin D plus PRT group 
which would have allowed such a comparison. However, the inclusion of a 
protein-vitamin D supplement group would have further increased the sample 
size, and this study was designed to specifically evaluate whether whey protein 
plus vitamin D could enhance the health benefits of PRT.  
 
Fifth, there were also some limitations related to the outcomes measured and the 
procedures used during our data collection. To assess insulin sensitivity, we relied 
on the commonly used HOMA2%S formula which requires only FPG and insulin 
concentrations to be measured. We acknowledge that this method is more variable 
compared to the euglycaemic hyperinsulinaemic clamp method (689, 690) and is 
more reflective of hepatic as opposed to muscular insulin sensitivity (691, 692). 
However, performing euglycaemic hyperinsulinaemic clamps on all participants 
on three occasions over the 24-week intervention period would not have been 
feasible. Furthermore, previous studies have confirmed that the HOMA-2 method 
for assessing insulin sensitivity/resistance is precise, reproducible and strongly 
correlated to the results achieved by the glucose clamp technique (690). Another 
potential limitation is the use of a 24-hour dietary recall to assess habitual dietary 
intakes. Assessment of dietary intake is typically difficult with several 
opportunities for misreporting of energy intake; typically, these include conscious 
underreporting, undereating if the food recall is planned, respondent memory 
lapses and misrepresentation of portion sizes (693). Further, misreporting (either 
over- or under-reporting) has been found to occur more commonly in those with a 
BMI >25 kg/m2, females compared to males and those of older age are also more 
likely to misreport their energy intake (typically under-reporting as opposed to 
over-reporting) (693). Despite these limitations, this dietary assessment technique 
was the most appropriate for our trial given the large sample size and length of the 
intervention. Further, when completing the 24-hour food recalls, we consistently 
used a food model booklet with a clear description of portion-size measurements 
and many household items (glasses, mugs etc.) to accurately estimate food, 
energy and nutrient intake. Further, all trial staff conducting the food recalls and 
subsequently entering this information into FoodWorks Professional (Version 8, 
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Xyris Software, Queensland, Australia) to calculate total dietary energy intake 
and dietary macronutrient composition were all highly trained and experienced in 
performing such assessments. 
 
Finally, not all research staff involved in the testing were blinded to the group 
allocation, which may have introduced some observational bias. However, staff 
who were not blinded were not involved in outcome assessments which could 
have been altered based on this knowledge. Further, staff performing the 
statistical analysis in this trial were blinded to treatment allocation. 
 
6.9  Conclusion 
In conclusion, this study has demonstrated that PRT improved glycaemic control, 
total body and regional (arm and leg) lean mass, thigh muscle size, upper and 
lower body muscle strength, waist circumference, fat mass, percentage body fat 
and DBP. However the addition of 20 g of daily whey protein supplementation 
with a further 20 g consumed following each PRT session (2 to 3 times per week) 
with 2,000 IU of daily vitamin D did not enhance the effects of PRT on total body 
or regional lean mass, fat mass, glycaemic control, insulin sensitivity or 
cardiovascular risk factors in older overweight and obese adults with type 2 
diabetes. While there was a greater beneficial effect of PRT combined with whey 
protein and vitamin D relative to PRT alone on the anti-inflammatory marker IL-
10, there were no between group differences in any other pro- or anti-
inflammatory markers, and thus the clinical relevance of these findings are 
unclear. Despite the lack of any consistent additive benefits following the 
intention-to-treat analysis, secondary pre-planned analysis revealed that those 
who achieved (≥66% exercise adherence) in upper body muscle strength and 
serum IL-6, and a greater reduction in total cholesterol and LDL cholesterol. 
While these findings must be interpreted with caution, they provide some 
evidence that supplementation with whey-protein and vitamin D may provide 
some added benefits to PRT in older overweight and obese adults with T2DM. 
Another key finding from our intervention was that the community-based Lift for 
Life® PRT program used in this study was safe and succesfully improved 
glycaemic control, total body and regional (arm and leg) lean mass, thigh muscle 
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size, upper and lower body muscle strength, waist circumference, fat mass, 
percentage body fat and DBP. Importantly, there were no serious adverse events 
associated with the intervention, and kidney function (eGFR) improved 
significantly in both groups. Collectively, these findings add to the growing body 
of literature to support the role of exercise, particularly PRT, as a safe, feasible, 
and effective approach to improve multiple clinical risk factors associated with 
T2DM in older overweight and obese adults with this condition. 
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7.1  Summary 
Lifestyle management focusing on regular exercise and nutrition is the first line in 
the treatment of older adults with type 2 diabetes mellitus (T2DM) (5, 6). Optimising 
lean mass is critical for those with this condition, particularly older adults with 
T2DM, as this is the largest mass of insulin-sensitive tissue and the predominant 
reservoir for glucose disposal (9). Supervised and structured high-intensity PRT 
programs in controlled laboratory settings have been found to be safe, well-tolerated 
and effective for improving glycaemic control as well as lean mass, size and strength 
in older adults with T2DM (8, 12, 14, 204, 212, 225, 250, 612). There is also some 
evidence that exercise alone, including PRT, or combined with weight loss can 
improve various cardiovascular risk factors, including blood pressure, lipids and 
various circulating inflammatory markers. This is important because increased 
inflammation has been implicated in the pathophysiology of insulin resistance and 
several comorbidities associated with this condition including CVD (22). Whether 
these same benefits can be achieved by participating in ‘real-world’ community 
based PRT interventions has received less attention.  
 
Dietary or nutritional modification in addition to physical activity is also an integral 
component in the management of T2DM. Yet the most appropriate diet or 
macronutrient distribution for the management of T2DM remains a continued topic 
of debate among peak health authorities. Traditionally, caloric restriction is 
recommended for those with T2DM due to the beneficial effects on body weight and 
fat mass, however such an approach has been associated with poor long-term 
adherence and weight re-gain. Further, whether caloric restriction plus PRT can 
influence markers of systemic inflammation in older adults with T2DM remains 
uncertain. In recent years, novel dietary approaches focusing on alternate macro- and 
micronutrients including protein and vitamin D, alone or in combination with 
exercise/PRT have been proposed as potential nutritional strategies to improve 
several health outcomes in those with T2DM. This is largely driven by the findings 
from acute studies demonstrating that these dietary factors alone, particularly protein, 
or combined with exercise, can have a positive effect on MPS and stimulate beta-
cells of the pancreas to secrete insulin. However, few long-term human intervention 
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trials in adults with T2DM have investigated whether such a combination transcribe 
into measurable health outcomes. Thus, the aim of this thesis was to investigate if 
lifestyle strategies such as caloric restriction, to promote weight loss, or nutritional 
supplementation with protein and vitamin D, in combination with exercise/PRT 
could promote greater improvements in glycaemic control, body composition, 
cardiovascular related risk factors and systemic inflammation compared to PRT 
alone in older overweight and obese adults with T2DM. 
 
The specific aims are:  
1. To compare the effect of PRT plus a moderate weight loss program versus 
weight loss alone on systemic and endothelial markers of inflammation in 
older overweight adults with T2DM (Chapter 3). 
2. To report on the challenges of recruiting older adults with T2DM into a 6-
month community-based PRT and nutrition program along with reporting on 
strategies which successfully resulted in participants randomised to the 
intervention (Chapter 5). 
3. To investigate whether ingestion of a daily whey-protein drink in 
combination with vitamin D supplementation can enhance the effects of a 
community-based PRT program on glycaemic control and insulin sensitivity 
in older adults with T2DM (Chapter 6). 
4. To examine whether a community-based PRT program combined with a 
whey-protein drink and vitamin D supplementation is more effective for 
enhancing total body and regional lean mass, muscle cross-sectional area 
(CSA), muscle strength and reducing inter-/intra-muscular fat infiltration, 
than PRT alone in older adults with T2DM (Chapter 6). 
5. To compare the effects of a community-based PRT program combined with 
whey-protein and vitamin D supplementation versus PRT alone, on 
cardiovascular risk factors, including blood pressure and blood lipid levels, 
and pro-inflammatory and anti-inflammatory cytokines. (Chapter 6). 
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While the discussion sections within each previous chapter (3-6) consider the 
limitations and methodological issues specific to these studies, section 7.2 below will 
focus on the key research findings, limitations and corresponding directions for 
future research arising from the studies in this thesis. This chapter closes with the 
overarching clinical and public health implications of this research and a final 
summary and conclusion for this thesis (section 7.3)  
 
7.2  Key Research Findings, Limitations and Directions for Future Research  
Below is a brief summary of the key findings from this thesis 
1. Recruitment of older adults with T2DM into a community-based exercise and 
nutrition intervention trial took longer than anticipated, was costly, required 
continual sustained efforts and necessitated flexibility within the recruitment 
strategies used to ensure the final target was achieved. Overall, 1,157 
expressions of interest (EOI) were received over a 21-month period from which 
959 (83%) individuals were screened and found to be ineligible for the trial or 
chose not to participate. A total of 198 participants were deemed to be eligible 
and randomised to the 24-week intervention. The most effective recruitment 
strategies were targeted mass mail-outs (39% of the total participant sample) and 
state (27%) print media. These strategies were also the most expensive each 
accounting for 38% of total expenditure. Recruitment expenditure totalled 
AUD$40,421, which equated to AUD$35 per enquiry and AUD$204 per eligible 
participant. 
2. Resistance training performed under supervised, clinically controlled and 
structured settings or within local community-based facilities can improve 
several clinically relevant outcomes important for adults with T2DM, including 
lean mass, glycaemic control and muscular strength whilst also reducing fat 
mass, DBP and some systemic markers of inflammation. However, the greatest 
benefits were associated within the highly-controlled settings. Home-based PRT 
program was largely ineffective at maintaining body composition and glycaemic 
improvements gained under a supervised-laboratory controlled environment with 
only slight improvements in some systemic markers of inflammation observed.  
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3. Six-months of weight loss combined with high-intensity PRT did not have any 
marked effects on any marker of systemic inflammation or endothelial function 
in older adults with poorly controlled T2DM, despite reduction in weight and fat 
mass and an improvement in lean mass. However, continued participation in 
PRT over 12-months, independent of change in weight, was associated with 
some improvements in certain inflammatory markers in older overweight adults 
with type 2 diabetes. 
4. PRT was associated with improved glycaemic control, total body and regional 
(arm and leg) lean mass, thigh muscle size, upper and lower body muscle 
strength, waist circumference, fat mass, percentage body fat and DBP. The 
addition of once to twice daily 20 g of whey protein and 2,000 IU of vitamin D 
per day did not further enhance these outcomes. there was a greater reduction in 
serum insulin levels and a beneficial effect on the anti-inflammatory marker IL-
10 in the those supplemented with whey protein and vitamin D, the clinical 
relevance of these findings remains uncertain given that lack of any additional 
benefits on the clinically important outcome measures of glycaemic control and 
insulin sensitivity. 
5. In older overweight and obese adults who had greater adherence to the 
community-based PRT and whey protein-vitamin D supplements there was some 
evidence for additive benefits to upper body muscle strength, serum IL-6 and 
total cholesterol and LDL cholesterol and to a lesser extent thigh muscle size 
(CSA) and arm lean mass compared to those undertaking PRT alone. 
 
This next section discusses these key findings, including their strengths and 
limitations, and the corresponding future research directions.  
 
7.2.1  Recruiting ‘at risk’ older adults with T2DM into exercise and nutrition 
intervention trials is challenging and expensive 
Ineffective or slow recruitment of participants into RCTs can lead to extended study 
duration, greater resource usage and findings that are not as statistically precise as 
intended if the required sample size is not obtained. A detailed and thorough 
description of the recruitment strategies used for the 24-week community-based 
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exercise-nutrition trial, the strategies which were successful (and not successful) and 
the costs associated with recruiting older adults with T2DM into this trial is reported 
in Chapter 5 of this thesis. At present, there is limited available data on successful 
recruitment strategies which are suitable for recruiting older adults with a chronic 
disease such as T2DM into community-based exercise and nutrition programs.  
 
Further, no information is available on estimated costs associated with such 
recruitment, which has important budget implications when planning such trials.  
A wide range of recruitment strategies were implemented which included state and 
local newspaper and radio advertisements, targeted mail-outs, doctor and allied 
health referrals, community presentations, web-based media and word of mouth. Our 
consistent monitoring of the effectiveness of strategies implemented and the vast 
array of recruitment methods used meant we identified successful methods of 
recruitment early and could focus our efforts and funds on such strategies. We found 
the most successful and proliferative strategies (e.g. those which resulted in a high 
number of expressions of interest and eligible participants and were subsequently 
performed multiple times) were targeted mass mail-outs (39% of the total participant 
sample), state (27%) and local (15%) print media. A total of 1,157 EOI over a 21-
month period were received for this intervention. Overall 83% of these participants 
were deemed to be ineligible or chose not to participate. Physical activity status (e.g. 
exceeding the national physical activity guidelines) and medication/supplement use 
(e.g. taking vitamin D supplements >500 IU/day or being prescribed insulin for 
diabetes management) were the two key reasons why individuals were not eligible 
for the trial. A total of 198 participants (21% of all those screened) were found to be 
eligible and were randomised to the 24-week intervention.  
 
At present, there is limited literature on successful recruitment strategies suitable for 
older adults with T2DM into community based exercise and nutrition programs and 
no information on cost estimates. There were several key lessons from our study. We 
had originally allocated 12-months for the recruitment for this trial, but this was 
extended to 21-months due to the lower than expected success rate from those 
screened. The strategies which were successful (targeted mail-outs and state print 
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media) were the most expensive. Overall a total AUD$40,421 was spent, which 
equated to AUD$35 per enquiry and AUD$204 per eligible participant.  
 
In reporting the challenges, successes, failures and costs associated with recruiting 
older adults with T2DM into our trial it is hoped studies in the future can learn from 
these experiences and formulate an appropriate timeline of strategies to remain 
within budget and trial timelines whilst expediently recruiting the target number of 
participants. Whilst our reporting in Chapter 5 of our recruitment strategies and 
experiences for our 24-week exercise and nutrition intervention was comprehensive 
and methodical, limitations are still present. 
 
Limitations 
A limitation of our reporting of the success of recruitment strategies was that only 
one recruitment strategy was recorded per EOI received. It is possible given the 
numerous strategies we used for this intervention that individuals were exposed to 
more than one recruitment strategy. Further, for each EOI received individuals were 
informed about the opportunity for monetary re-imbursement equivalent to the Lift 
for Life® training costs. Offering payment to clinical research participants, in an 
effort to enhance recruitment by providing an incentive to take part or enabling 
participants to participate without financial sacrifice, is common. Whether the 
opportunity to receive the monetary reward offered in our intervention unduly 
influenced participation of some participants or population groups was not addressed 
nor recorded and thus cannot be commented on.  
 
Future Recommendations 
Other RCTs should report on the success or limitations of their chosen methods of 
recruitment on a range of population groups and not just in those with T2DM. Cost-
benefit analysis of all recruitment strategies used should also be reported to help 
guide future RCTs recruitment efforts. Further, knowing more about the effect 
monetary reimbursement has on decisions to participate in such RCTS among 
different age and population groups is required. Whilst we acknowledge that 
payment may not be necessary for recruiting participants, particularly those with a 
chronic condition such as T2DM who may be motivated to participate by the 
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opportunity for therapeutic benefit, if the goal of payment is to reduce the financial 
sacrifice that research participants must make and/or to compensate people for their 
time, the influence this has on willingness to participate and bias on those who do 
participate should be investigated.  
 
7.2.2  Structured and supervised as well as community-based PRT results in 
relevant cardiometabolic health improvements important to those with T2DM. 
In Chapter 3 of this thesis, secondary analysis was performed on existing data from a 
12-month RCT to investigate the effects of supervised high-intensity PRT plus 
weight loss (caloric restriction) compared to a weight loss intervention alone had on 
systemic and endothelial markers of inflammation in older overweight adults with 
poorly controlled T2DM. After the first 6-month supervised phase of training, similar 
significant reductions in body weight and fat mass were observed in both groups. 
However, the PRT plus weight loss group experienced a net gain in total body lean 
mass in comparison to weight loss alone, and a greater absolute improvement in 
glycated haemoglobin. Despite these greater net benefits, there were no significant 
changes in any markers of systemic inflammation or endothelial function in either 
group. Interestingly, 6-months of continued home-based PRT (without weight loss) 
was associated with some modest but significant improvements in various 
inflammatory markers, suggesting that long-term training may lead to some 
beneficial effects on markers of systemic inflammation. 
 
Many previous studies have demonstrated the independent benefits that regular 
exercise, including PRT, can have on several health outcomes in people with T2DM, 
yet most of these studies to date have been conducted under clinically controlled 
supervised gymnasium-based settings with little understanding of the clinical 
relevance of a community-based program (8, 12, 154, 203, 207, 215, 216, 220, 224, 
227, 566, 694). In Chapter 6, we reported the findings following our 24-week 
nutrition and exercise intervention which incorporated whey protein and vitamin D 
supplementation plus participation in a community-based PRT program. We 
observed significant PRT-related improvements in a number of cardiometabolic 
outcomes following this community-based intervention, including HbA1c, fasting 
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glucose and insulin levels, waist circumference, upper and lower body muscular 
strength, fat mass, lean mass and DBP. Although the magnitude of these health 
improvements was considerably less than those achieved in Chapter 3 from the 
supervised, clinically controlled PRT gymnasium-based program, it is important to 
remember the intervention in Chapter 6 was more representative of a ‘real-world’ 
PRT program. Community-based programs have the potential to be far wider 
reaching and accessed by a greater proportion of the population than those performed 
in clinically controlled environments. Thus, the results found in Chapter 6 remain 
important as they provide high-level scientific evidence to support a translational 
research-to-practice community-based PRT program as a safe, feasible and effective 
strategy to improve multiple cardiometabolic health outcomes in older overweight 
and obese adults with T2DM.  
 
Despite the strengths of both trials, such as the well-designed and independently 
tailored PRT programs, the relatively high level of exercise adherence, the small 
number of drop-outs and adverse events related to the PRT program plus the 
significant improvements in a range of outcomes measured, these studies were not 
without limitations. 
 
Limitations 
A limitation of our investigations in both these studies was the potential recruitment 
bias. As mentioned in Chapters 3 and 5 of this thesis, individuals were required to 
meet a number of eligibility requirements and were recruited to participate in long-
term exercise interventions, demonstrating a willingness and ability to exercise that 
might be misrepresentative of the overall Australian population with T2DM or other 
chronic diseases. Further, anyone with an HbA1c above 10%, a BMI greater than 40 
kg/m2 or prescribed insulin for the management of their condition was ineligible for 
the study. Such a selection bias may limit the relevance and applicability of our 
findings in this thesis to those individuals with T2DM who are in a more advanced 
stage of this disease.  
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Future Recommendations 
Given that the secondary per protocol analysis for the study in Chapter 6 
demonstrated that whey-protein and vitamin D supplementation enhanced the effects 
of PRT on a number of important health outcomes in older overweight and obese 
adults with T2DM, further trials are needed to evaluate whether various nutritional 
factors can provide additive health benefits to exercise in this group. There is also a 
need to further evaluate the efficacy and effectiveness (and cost-effectiveness) of 
community-based PRT (or related exercise) programs like the current Lift for Life® 
program for people with T2DM. This should include an investigation into what 
aspects of a community-based PRT (or exercise) program are most appealing to 
those with T2DM and which may enhance long-term adherence. Future studies 
should also recruit participants in more advanced stages of this disease to be more 
representative of the broader T2DM population as such groups have not been 
investigated sufficiently, in this thesis or the broader population.  
 
7.2.3 The most effective diet or nutritional approach for the management of 
T2DM remains unclear.  
This section details the findings from both Chapter 3 and 6 of this thesis regarding 
the two dietary related approaches which were prescribed in combination with PRT 
for the improvement in glycaemic, insulinaemic, cardiovascular, inflammatory and 
body composition outcomes in older adults with T2DM. These studies prescribed 
two very different nutritional approaches. Weight loss from caloric restriction is 
typically advised in those with T2DM yet the effects of combining PRT with weight 
loss on markers of systemic inflammation had not been examined. Promising 
evidence exists for the independent effects of high protein diets, whey protein and 
vitamin D supplementation on several metabolic and body composition health 
outcomes in healthy older adults and those with T2DM. Whether the combination of 
these nutritional factors can enhance PRT associated health outcomes in older adults 
with T2DM remains uncertain. 
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Limited benefits of weight loss and/or PRT on markers of systemic inflammation 
The secondary analysis performed in Chapter 3 revealed that 6-months of caloric 
restriction alone or performed alongside high-intensity PRT, both of which resulted 
in similar significant reductions in body weight and fat mass and an improvement in 
HbA1c levels, was not associated with any significant improvement in markers of 
systemic inflammation in older adults with poorly controlled T2DM. Given that 
strong link between obesity and inflammation, the lack of any marked changes 
during the initial 6-months may be related to the relative modest reductions in weight 
and fat mass in our trial. However, other studies have also found that participation in 
exercise or PRT alone is beneficial for improving markers of inflammation, 
independent of changes in weight or fat mass. In partial support of such studies, we 
observed 6-months of continued home-based training following the supervised 
gymnasium-based program, despite weight and fat mass regain, was associated with 
some modest improvements in various inflammation markers compared to sham-
exercise (stretching). However, in Chapter 6 we found that there were no 
improvements in any pro- or anti-inflammatory marker following our 24-week 
community-based PRT program. While this may be related in part to differences in 
the intensity of the training, collectively these findings suggest that long-term 
participation (>6-months) in PRT may be required to provide some benefits on 
circulating inflammatory markers in older overweight and obese adults with T2DM. 
Furthermore, given that there were significant improvements in HbA1c following 
both PRT-related interventions, the findings from this thesis also suggest that 
changes in circulating inflammatory markers may not play a key role in mediating 
exercise-induced changes in glycaemic control, although this hypothesis requires 
further investigation.  
 
Whey protein plus vitamin D supplementation provided little or no additive benefits 
to PRT in older overweight and obese adults with T2DM 
Chapter 6 builds upon the findings in Chapter 3 by examining the potential additive 
effects of a novel nutritional approach incorporating whey protein and vitamin D 
with PRT in older adults with T2DM. The main findings from this chapter were that 
the addition of a daily whey-protein drink and vitamin D supplements did not 
enhance the effects of a community-based ‘real-world’ PRT program on measures of 
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body composition, glycaemic control or cardiovascular risk factors in older 
community-dwelling sedentary adults with T2DM. Although there was a trend for a 
greater improvement in appendicular lean mass (ALM), the lack of any marked 
additive effect on glycaemic or insulinaemic measures may be due to the adequate 
baseline dietary protein intake (mean ~1.1 g/kg/day) and sufficient serum 25(OH)D 
levels (mean 72 nmol/L) in this cohort of older adults with T2DM at the 
commencement of this trial. The effects of combined whey protein and vitamin D 
supplementation with PRT has not previously been examined in those with T2DM, 
but of the few studies conducted in non-diabetic older adults the greatest benefits 
have typically been observed in high risk groups (e.g., elderly and those with 
sarcopenia) and/or those with inadequate protein intakes at baseline (512, 513, 515). 
Indeed, in studies examining the independent effects of whey protein or vitamin D 
supplementation on glycaemic control, body composition and/or cardiovascular risk 
factors there is also some evidence that these nutritional factors provide greater 
benefits in individuals with low baseline intakes and serum 25(OH)D levels (41, 452, 
483). Collectively, these findings suggest that the greatest benefits of exercise 
combined with nutritional supplement(s) are likely to occur in high risk groups that 
are inactive and have insufficient intakes at baseline for the targeted nutritional 
approach. However, it is evident that further research is need to help define the most 
appropriate nutritional approach to be used in combination with PRT for the 
management of T2DM.  
 
Limitations 
Chapter 3 in this thesis was a secondary analysis that was limited by a relatively 
small sample size. Given the known variability in circulating inflammatory 
cytokines, it is likely that this study was underpowered to detect any potential 
between group differences. Additionally, whilst the caloric restriction imposed 
during the supervised-gymnasium based phase of the trial (the first 6-months) was 
sufficient to significantly reduce body weight and fat mass, these reductions were not 
of the same magnitude observed in other trials which reported significant 
improvements in a range of inflammatory markers concomitant to the weight loss. 
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The independent contributions whey protein and vitamin D had on the measured 
outcomes were not able to be assessed in this trial as there was no group in our trial 
who were prescribed whey protein or vitamin D only with or without PRT. Further, 
whilst this trial had a large sample size (in comparison to many previous exercise 
RCTs in adults with T2DM) and examined the long-term effects, the participants 
recruited were found to have intakes of protein and serum 25(OH)D levels at 
baseline that are considered adequate (sufficient), and the vast majority were 
prescribed some form of oral hypoglycaemic medication, which possibly blunted any 
potential effects of the supplements on the measured outcomes in our trial.  
 
Future Recommendations 
Further RCTs are needed to investigate whether whey protein and vitamin D can 
enhance the effect of community-based or supervised controlled PRT on body 
composition, glycaemic and insulinaemic outcomes as well as CVD risk factors in 
older adults with T2DM with inadequate dietary protein intakes and/or 
deficient/insufficient serum 25(OH)D status. Further, almost 70% of our participants 
were taking oral hypoglycaemic medication to management there T2DM. Thus, 
future trials should consider recruiting and randomising a weighted proportion of 
participants not on any oral hypoglycaemic medication to assess the effects of such 
an intervention on those taking and not taking oral hypoglycaemic medication. 
 
7.3  Conclusions and Public Health Implications 
In this thesis, a number of different lifestyle approaches including PRT, PRT plus 
weight loss and PRT plus whey protein and vitamin D supplementation were 
prescribed with the aim of increasing lean mass, improving glycaemic control and 
insulin sensitivity plus various cardiovascular risk factors and markers of systemic 
inflammation in older adults with T2DM. Several different PRT settings were also 
examined including a supervised clinically controlled gym-based setting, home-
based training and community-based health and leisure facilities. The main findings 
from the studies in this thesis were that weight and fat mass reductions resultant from 
supervised high-intensity PRT plus caloric restriction or caloric restriction alone did 
not result in immediate improvement in systemic or endothelial markers of 
inflammation. In contrast, there was some evidence that continued long-term 
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exercise training was associated with modest improvements in some inflammatory 
markers, but the clinical significance of these findings remains to be determined. 
Second, participation in a long-term community-based PRT program improved 
glycaemic control and lean mass, reduced fat mass and improved some CVD risk 
factors, but the addition of a novel dietary approach incorporating increased protein 
intake and vitamin D supplementation provided little or no added benefits. 
 
The challenge remains following the completion of long-term exercise and nutrition 
intervention studies, such as those in this thesis, of how to foster long-term 
compliance and promote ongoing participation in community-based lifestyle 
programs for continued health benefits. In addition, despite the large subject numbers 
and long follow-up periods required, further studies are needed in older adults to 
identify whether ongoing participation in PRT along with nutritional factors which 
may enhance improvements in lean mass, translate to long-term improvements in 
glycaemic control, insulin sensitivity and improve CVD risk factors in those with 
T2DM and potentially lead to co-morbidity and mortality risk reduction benefits.   
Below are a series of key messages and public health implications which can be 
taken from this thesis and which could be used to guide clinical practice guidelines 
or community care programmes and future health recommendations for those with 
T2DM. It is important these implications are interpreted in the context of the 
limitations outlined previously.  
 
1. Weight loss in the absence of PRT may not be the most effective recommendation 
for improving markers of inflammation in those with T2DM. 
2. In older overweight and obese adults with T2DM who have adequate dietary 
protein intakes and sufficient serum 25(OH)D levels there appears to be little 
benefit to be gained in certain health outcomes by supplementing the diet with 
daily whey protein and vitamin D. However, given that there was evidence for 
some additional health benefits in those who were most compliant with the 
exercise and supplements, further research is still needed to address whether such 
a nutritional approach can provide added health benefits.   
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3. Community-based PRT interventions for older overweight and obese adults with 
T2DM are safe and effective for improving various health outcomes, but the 
greatest benefits appear apparent when training is supervised and performed at a 
high-intensity PRT. Thus, an approach moving forward for people with T2DM 
regarding exercise may be to ensure they receive a high level of supervision and 
attention during the initial few months of commencing a PRT program.   
4. Policies and funding at both local government and national level should be 
developed and made available to implement sustainable and accessible health-
oriented community-based PRT or physical activity programs for older adults 
with T2DM. 
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Appendix 1 
Mean baseline and the absolute change from baseline and the net differences for the 
change for HbA1c and body composition measurements in the PRT+WL and WL 
groups at 3, 6, 9 and 12-months. 
 PRT+WL WL Net Difference (95% CI) 
HbA1c  
  Baseline (%) 8.1 ± 1.0 7.5 ± 1.1  
  ∆ 3-months -0.6 (-1.0, -0.3)* -0.1 (-0.5, 0.4) 0.6 (0.0, 1.1)# 
  ∆ 6-months -1.2 (-1.7, -0.7)† -0.4 (-0.9, -0.1)* 0.8 (0.1, 1.5)# 
  ∆ 9-months -0.5 (-1.2, 0.2) 0.0 (-0.4, 0.4) 0.5 (-0.3, 1.4) 
  ∆ 12-months -0.3 (-1.0, 0.4) 0.2 (-0.4, 0.7) 0.5 (-0.4, 1.4) 
Body Weight   
  Baseline (kg) 88.7 ± 10.9 89.5 ± 12.1  
  ∆ 3-months -1.8 (-2.8, -0.7)† -2.0 (-2.9, -1.1) † -0.2 (-1.6, 1.2) 
  ∆ 6-months -2.5 (-4.0, -0.9)† -3.1 (-4.3, 1.8) † -0.6 (-2.6, 1.3) 
  ∆ 9-months -2.3 (-3.8, -0.8)† -3.2 (-4.8, -1.6) † -0.9 (-2.9, 1.2) 
  ∆ 12-months -1.7 (-2.6, -0.6)* -1.6 (-2.9, -0.3)* 0.0 (-1.6,1.6) 
Fat Mass   
  Baseline (kg) 33.1 ± 7.4 35.6 ± 6.8   
  ∆ 6-months -2.4 (-3.8, -0.9)† -2.1 (-3.6, -0.5)† 0.3 (-1.8, 2.3) 
  ∆ 12-months -1.2 (-2.0, -0.3) 0.0 (-1.2, 0.8) 1.0 (-0.2, 2.2) 
Lean Mass  
  Baseline (kg) 51.8 ± 8.1 49.7 ± 9.5  
  ∆ 6-months 0.5 (-0.1, 1.1) -0.4 (-1.1, 0.3) -0.9 (-1.8, 0.0) 
  ∆ 12-months 0.1 (-0.6, 0.8) -0.7 (-1.2, -0.1)* -0.7 (-1.6, 0.2) 
Percent Fat Mass  
  Baseline (%) 37.7 ± 6.8 40.6 ± 7.4  
  %∆ 6-months -2.0 (-3.1, -0.8)† -1.5 (-2.7, -0.2) 0.5 (-1.1, 2.1) 
  %∆ 12-months -0.7 (-1.5, 0.0) -0.9 (-3.6, 1.7) -0.2 (-2.6, 2.2) 
DXA measurements for fat mass, lean mass and percent fat mass were only 
performed at 0-, 6- and 12-months. Baseline values represent mean ± SD; change 
represents mean (95% CI). * P < 0.05, † P <0.01 vs baseline; # P < 0.05 between-
group difference from baseline. 
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Appendix 2 
Mean values ± SD in various inflammatory markers for the PRT+WL and WL 
groups at 3-, 6-, 9- and 12-months. 
 PRT + WL WL 
IL-10 (pg/ml) 
   Baseline 14.1 ± 19.2 4.2 ± 5.7 
   3-months 11.0 ± 17.8 5.2 ± 12.6 
   6-months 10.7 ± 19.0 4.4 ± 3.4 
   9-months 10.0 ± 18.7 6.5 ± 8.2 
   12-months 14.1 ± 23.0 7.4 ± 13.5 
IL-6 (pg/ml) 
   Baseline 3.7 ± 3.1 1.6 ± 1.8 
   3-months 3.9 ± 4.0 1.3 ± 1.1 
   6-months 4.4 ± 4.7 3.9 ± 7.9 
   9-months 6.1 ± 10.5 1.8 ± 1.7 
   12-months 5.9 ± 7.3 4.3 ± 6.4 
TNF-α (pg/ml) 
   Baseline 8.2 ± 3.6 7.1 ± 5.0 
   3-months 7.3 ± 2.9 6.9 ± 6.2 
   6-months 9.1 ± 5.9 13.4 ± 20.2 
   9-months 7.1 ± 2.9 7.8 ± 4.5 
   12-months 6.2 ± 2.3 8.9 ± 6.6 
Adiponectin (µg/ml) 
   Baseline 1.7 ± 0.7 2.7 ± 0.9 
   3-months 1.8 ± 0.5 2.9 ± 0.9 
   6-months 2.0 ± 0.8 2.9 ± 1.3 
   9-months 2.2 ± 1.3  3.0 ± 1.1 
   12-months 2.2 ± 1.5 2.5 ± 0.9 
Values are raw means ± SD 
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Appendix 3 
Mean value ± SD in endothelial markers for the PRT+WL and WL groups at 3-, 6-, 
9- and 12-months. 
    PRT+WL PRT 
 
ICAM-1 (ng/ml) 
   Baseline 134.9 ± 59.6 142.4 ± 69.4 
   3-months 135.7 ± 51.3 143.0 ± 75.2 
   6-months 134.3 ± 49.3 121.7 ± 47.5 
   9-months 113.9 ± 22.6 122.2 ± 54.7 
   12-months 120.0 ± 32.6 113.8 ± 41.3 
Resistin (ng/ml) 
   Baseline 10.5 ± 5.6 11.0 ± 3.9 
   3-months 12.2 ± 4.2 10.8 ± 3.7 
   6-months 11.7 ± 4.6  10.5 ± 4.5 
   9-months 10.4 ± 4.6 11.5 ± 5.6 
   12-months 10.6 ± 5.3 10.4 ± 4.2 
Values are raw means ± SD 
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Appendix 7 
 
PLAIN LANGUAGE STATEMENT AND CONSENT FORM                               
 
TO:  Participants  
Plain Language Statement  
Date:   3rd April, 2014 
Full Project Title:  Does a High Protein Enriched Drink and Vitamin D 
Enhance the Health Benefits of the Lift for Life® 
Resistance Training Program in Older Adults with Type 2 
Diabetes? 
Principal Researcher:  Professor Robin Daly 
Student Researcher: Ms Eliza Miller 
Associate Researcher(s): Professor David Dunstan, Professor Caryl Nowson, 
Associate Professor Deborah Kerr, Associate Professor 
Vicky Solah, Mr David Menzies, Dr Helen Macpherson, Dr 
Matthew Hughes  
 
This Plain Language Statement and Consent Form is 9 pages long. Please make sure 
you have all the pages.  
1. Your Consent 
You are invited to take part in this research project which will investigate the effects 
of resistance training (lifting weights) alone or resistance training in combination 
with a protein enriched drink with additional vitamin D on blood glucose levels, 
body composition and cardiovascular risk factors in people with type 2 diabetes. 
This Plain Language Statement contains detailed information about the research 
project. Its purpose is to explain to you as openly and clearly as possible all the 
procedures involved in this project before you decide whether or not to take part in it.  
Please read this Plain Language Statement carefully. Feel free to ask questions about 
any information in the document.  You may also wish to discuss the project with a 
relative or friend or your local health worker. Feel free to do this. 
Once you understand what the project is about and if you agree to take part in it, you 
will be asked to sign the Consent Form. By signing the Consent Form, you indicate 
that you understand the information and that you give your consent to participate in 
the research project. 
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You will be given a copy of the Plain Language Statement and Consent Form to keep 
as a record. 
Participation in this study is voluntary. If you do not wish to take part you are not 
obliged to. If you decide to take part and later change your mind, you are free to 
withdraw from the project at any stage. Your decision whether or not to participate 
will not affect your relationship with Deakin University.    
2. Purpose and Background 
Regular exercise is important for maintaining blood glucose levels in people with, or 
at risk of developing, type 2 diabetes because it helps to make the muscles use 
glucose more effectively. Resistance training (lifting weights) is particularly 
effective for improving blood glucose levels as well as increasing muscle mass, 
strength and physical function. To optimise the health benefits of resistance training, 
it has been suggested that it should be combined with adequate nutrition, particularly 
an adequate intake of dietary protein. Maintaining adequate vitamin D levels has also 
been shown to be important for both optimal blood glucose levels and muscle 
function. Thus, this 6-month study is designed to investigate whether daily 
consumption of a protein enriched drink and vitamin D can enhance the benefits of 
participation in the Lift for Life® resistance training program on glycaemic control, 
body composition and cardiovascular risk factors in people with type 2 diabetes. Lift 
for Life® is a community-based resistance training program for people with or at risk 
of developing type 2 diabetes that is being coordinated by Fitness Australia and 
Baker IDI Heart and Diabetes Institute.   
A total of 202 men and women with type 2 diabetes who have agreed to participate 
in the commercial Lift for Life® resistance training program will participate in this 
project. 
You are invited to participate in this research project because you have type 2 
diabetes and are aged between 50 and 75 years and free of any serious health 
conditions that might limit your participation in the Lift for Life® resistance training 
program. If you are not eligible for this study, you may still be able to participate in 
the standard Lift for Life® program. 
This study is being sponsored by the National Health and Medical Research Council 
(NHMRC).  
This trial has been initiated by the investigator, Professor Robin Daly.  
3. Procedures – what you will be asked to do  
If you decide to participate in this study you will be asked to sign this Participant 
Information and Consent Form. 
To participate in this study, you must have passed the initial telephone screening test 
conducted by one of the research staff. Before you commence the study, you will be 
required to visit your local doctor who will be required to complete the Lift for Life® 
recommendation to participate health and medical screening form to make sure that 
you don’t have any medical conditions that could affect your participation in this 
study (e.g. unstable heart disease).  
Upon entry into the study, you will undergo initial baseline testing and then you will 
be randomly allocated (like the flip of a coin) to one of two groups. You will have a 
one in two chance of being in either group. This is called randomisation. This is a 
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standard research method used to ensure that the results of a study are true and 
correct.  
Group 1: Lift for Life® resistance training with increased dietary protein and 
vitamin D.   
If you are allocated to this group you will be prescribed an individually tailored and 
progressive resistance training program which will be conducted at an accredited Lift 
for Life® health and fitness centre. You will be required to attend 2 supervised 
exercise sessions and another non-supervised exercise session each week for 6-
months. The supervised sessions will be conducted by qualified Lift for Life® 
exercise trainers. Each session will last approximately 45-60 minutes, and include a 
warm-up and cool-down and moderate intensity resistance training. Therefore, the 
total time commitment for the 6-months of training will be approximately 150 
minutes per week, which is the current recommended level of physical activity. To 
monitor your progress, you will be asked to complete a diary of your participation in 
the exercise program. You will also be asked to take vitamin D supplements (2000 
IU) and consume one protein enriched drink (about 150 ml providing 20g of protein) 
each morning before breakfast and the same drink after each Lift for Life® training 
session. You will be supplied with all drinks and supplements at no charge for the 
duration of the study. To monitor your intake, you will be asked to complete a daily 
calendar/checklist throughout the study.  
Group 2: Lift for Life® resistance training. 
If you are allocated to this group you will be prescribed the same exercise program as 
outlined for Group 1, but you will not be asked to consume either the protein drinks 
or vitamin D supplements. As per group 1, you will also be asked to record your 
participation in the exercise program in a diary.  
For all people involved in the study, we will collect the following information and 
conduct a number of tests throughout the 6-month study. This testing will be 
conducted at both the Lift for Life® health and fitness centres and at Deakin 
University in Burwood.  
• You will be asked to complete a general lifestyle and health questionnaire to 
obtain information on past employment history, education history, marital status, 
cultural background, menopausal history (women only), dieting and weight 
history, alcohol intake, smoking history, medical history, use of prescription and 
non-prescription medications and diabetes history and perceived barriers and 
obstacles to participating in exercise. We will also measure your weight, height 
and waist circumference at the beginning of the study and after 3 and 6 months. 
• Total body composition (amount of muscle and fat) and bone density of the total 
body, hip and spine will be measured using a non-invasive method referred to as 
dual energy X-ray absorptiometry (DXA) at the beginning and end of the study.  
The assessment of body composition and bone density by DXA involves lying 
on a bed for approximately 20 minutes whilst a scanning arm moves along the 
length of your body above you. This test will be conducted at Deakin University 
and we will arrange transport for you to Deakin from your home if needed.   
• Peripheral computed tomography (pQCT) is a non-invasive method that will be 
used to assess muscle and fat size and density in your thigh at the beginning and 
end of the study.  Your leg will be inserted into the opening of a gantry (ring 
with x-ray source and detectors) for scanning.  This test will involve remaining 
still for three to five minutes during the measurement. The pQCT scans will 
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cause no pain or discomfort other than having to remain still. This test will be 
conducted at Deakin University at the same time as your DXA scan. 
• We will take a small blood sample to assess the effects of the program on a 
number of important markers in your blood, including blood glucose, glycated 
haemoglobin (HbA1c), insulin, cholesterol and lipids, vitamin D and other 
markers of muscle and bone metabolism and inflammation.  A blood sample of 
30 mls (1.5 tablespoon) will be taken from a vein in your arm using a needle at 
baseline, 3 and 6 months.  The blood sample will collected by a trained research 
nurse in the morning when you have had nothing to eat or drink since the night 
before.  
• We would also like to assess your blood pressure at baseline, 3 and 6 months.  
• You will be required to undergo some simple balance and walking tests to 
measure your muscle function at baseline, 3 and 6 months. We will assess your 
maximal muscle strength on specific resistance (strength) training equipment. 
This involves lifting weights until you can only lift a weight three times.  
• We would also like to ask you a few questions about your exercise/physical 
activity and TV/computer habits three times over the study.  In addition, we 
would also like to assess your dietary habits using a food frequency 
questionnaire at baseline, 3 and 6 months and a 24-hour food recall each month, 
which will be completed over the telephone with one of the researchers. 
• You will be asked to complete a questionnaire which will assess your health-
related quality of life at the beginning and end of the study. You will also be 
asked to complete a simple computer test and questionnaire to assess you 
cognitive function at baseline, 3 and 6 months.  
There will be continual review and monitoring during your participation in this 
research to enable the early detection of any problems that you may experience. 
THIS NEXT ASSESSMENT TASK IS OPTIONAL  
You will also be invited to have a brain scan using MRI (Magnetic Resonance 
Imaging) at Swinburne University in Hawthorn (at no cost to you). MRI scanning 
involves brain imaging techniques that are non-invasive and provide the ability to 
image the brain whilst completing a simply task. Before the MRI session begins, you 
will be required to complete a safety questionnaire administered by the 
neuroimaging technologist regarding any metal you have on or in your body, such as 
that from any surgery involving metal plates and pace makers. A copy of the MRI 
safety questionnaire is attached to this document. Due to the nature of MRI that 
involves magnets, no metal may be taken into the room.  The scanner is also quite 
noisy so you will be provided with some headphones to reduce this noise. Once in 
the scanner, you will undergo a structural brain scan, a resting state scan, where you 
will have your eyes closed, and a functional scan where you will perform a simple 
memory task. The entire time spent in the MRI scanner should not exceed 45 
minutes. 
4. Collection of Tissue Samples for Research Purposes 
By consenting to take part in this study, you also consent to the collection, storage 
and use of tissue samples as specified below. 
A blood sample of 30 mls (1.5 tablespoon) will be taken from a vein in your arm 
using a needle at the beginning of the study, 3 and 6 months by a qualified research 
nurse.  The samples will not be labelled with information that directly identifies you. 
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The samples will be “coded”, which means that it will be labelled with a number that 
can be linked to you. All samples will be stored securely at Deakin University and 
only the research staff involved in this study will have access to the samples. Some 
of the samples will be tested immediately at the end of the study and some will be 
frozen and stored for 10-years following the publication of study findings.  We wish 
to store these samples to conduct further testing to look for other muscle, bone, 
inflammatory or cardiometabolic biomarkers when and if funding for this becomes 
available in the future. This future testing may be conducted by researchers from the 
present study or by other researchers employed by Deakin University. If any changes 
to the study are made which affect how these samples will be used, your samples will 
not be used, without your further consent. These samples will be disposed of 
according to standard laboratory practice, immediately after testing. 
5. Possible Benefits 
We cannot guarantee or promise that you will receive any benefits from this project.   
By participating in this project, you will receive information on ways to improve 
your health.  For some people the possible benefits may include an improvement in 
blood glucose levels and blood lipids and an increase in muscle mass, strength and 
function (e.g. balance), and a reduction of circulating (blood) markers of 
inflammation which are linked to common chronic diseases.  We also expect that the 
findings from this study will make an important contribution to the development of 
exercise and dietary guidelines to improve health outcomes for people with type 2 
diabetes.   
6. Possible Risks 
Possible risks, side effects and discomforts include the following: 
• The exercise program will involve resistance (strength) training and you may 
experience some minor and transient muscle soreness initially following the 
training sessions or the muscle strength testing. However, this form of training has 
been shown to be safe and acceptable, and the Lift for Life® program is designed 
in such a way to help minimise risks for participants through (1) supervised and 
graduated exercise programs; (2) specialised training for Lift for Life® Trainers; 
(3) requirement for Doctor’s approval prior to commencing the program; (4) pre-
exercise assessment; and (5) regular assessments during the program.   
• This research study involves exposure to a very small amount of radiation from 
DXA and pQCT scans of your body. As part of everyday living, everyone is 
exposed to naturally occurring background radiation and receives a dose of about 
2 millisieverts (mSv) each year. The effective dose you will receive from all the 
DXA and pQCT scans of your body will be approximately 0.065 mSv. At these 
dose levels, no harmful effects of radiation have been demonstrated, as any effect 
is too small to measure. The risk is believed to be very low. 
• If you have been involved in any other research studies that involve radiation, 
please inform us. Please keep this Patient Information and Consent Form that 
includes information about your exposure to radiation in this study for at least five 
years. You will be required to provide this information to researchers of any 
future research studies 
• When you have blood samples taken for this study, you might feel pain or be 
light-headed and there is a chance you might get a small bruise on your arm.  
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• Participants randomised to the protein and vitamin D fortified group (Group 1) 
will be asked to consume an additional 20-40g of protein and 2000 IU of vitamin 
D each day for 6 months. The amount of protein is within the recommended range 
for a healthy diet. We will measure your kidney function from the blood sample 
that you provide. If we detect any problems we will refer you to your doctor and 
ask you to withdraw from the study. Treatment with vitamin D is also very safe. 
There is a very small risk of hypercalcemia (high calcium levels in the blood) and 
hypercalciuria (high calcium levels in the urine) with vitamin D therapy. If you 
know you have high levels of blood calcium, then you will not be asked to take 
part in this study.  The amount of vitamin D in the supplement is at the level 
recommended for health benefits. Thus, normal health will not be adversely 
affected by consumption of the test product to be used in this study. 
• MRI uses radio waves and magnetism to make diagnostic images of the body. 
There are no known harmful effects. This test involves no radiation. Some people 
may find the MRI scan unpleasant, and feel claustrophobic, because you have to 
lie in a chamber while the scan is performed. Certain medical devices must be 
excluded from the MRI facilities. Such as cardiac pacemakers, cochlear implants, 
neuro-stimulators, certain metallic dental work, body jewellery and other metallic 
foreign objects implanted in the body. A complete list is outlined on MRI Pre-
Scan Safety Questionnaires. You will be asked to indicate on this questionnaire 
any previous surgery regarding implanted metal in your body and any surgical 
operation performed on your head/arm. Some people may find the MRI scan 
unpleasant, and feel claustrophobic, because you have to lie in a chamber while 
the scan is performed. In the event that anxiety, claustrophobia or panic attacks 
are experienced during the scan and you wish to stop the scan, then the scan shall 
be terminated. After the MRI scans, a Swinburne University’s radiologist will 
examine the brain scans. There is a rare possibility that an abnormality may be 
found that is significant and which should be investigated further. Although a 
significant abnormality is extremely unlikely, if one is detected you will be 
informed by the radiologist or your nominated health practitioner. If you would 
prefer not to be exposed to this unlikely (yet possible) experience, then you are 
advised not to participate in the MRI scan. 
There may be additional unforeseen or unknown risks. 
7. Other Treatments Whilst on Study 
It is important to tell your doctor and the research staff about any treatments or 
medications you may be taking, including non-prescription medications, vitamins or 
herbal remedies and any changes to these during your participation in the study. 
9. Privacy, Confidentiality and Disclosure of Information 
Any information obtained in connection with this research project that can identify 
you will remain confidential and will only be used for the purpose of this research 
project.  All collected information will be labelled with a unique study code, and not 
with your name or any other identifying information, which be kept separate from 
the information collected. All paper copies of this information will be kept in a 
locked filing cabinet in the researcher’s office at Deakin University or in a password 
protected computer. Only researchers involved in this project will have access to this 
information. The information collected from this study will be kept until the end of 
the project and then placed in archives for 6 years from the publication of findings. 
All data will also be kept in a database stored on a computer which will be password 
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protected and only accessible to the research staff involved in this study, and may be 
used in future research which is closely related to this project.  
We wish to store blood samples to conduct further testing to look for other muscle, 
bone or inflammatory biomarkers when and if funding for this becomes available in 
the future. This future testing may be conducted by researchers from the present 
study or by other researchers employed by Deakin University.   
In any publication, information will be provided in such a way that you cannot be 
identified; only group findings will be published.   
In accordance with the Freedom of Information Act 1982 (Vic), you have the right to 
access and to request correction of information held about you by Deakin University. 
10. New Information Arising During the Project 
During the research project, new information about the risks and benefits of the 
project may become known to the researchers. If this occurs, you will be told about 
this new information. This new information may mean that you can no longer 
participate in this research. If this occurs, the person(s) supervising the research will 
stop your participation. In all cases, you will be offered all available care to suit your 
needs and medical condition. 
11. Results of Project 
At the completion of the study, you will be provided with an individual report of 
your results. You will also receive access to the main findings from the study. 
12. Further Information or Any Problems 
If you require further information or if you have any problems concerning this 
project (for example, any side effects) you can contact the principal researcher or 
associate researcher.   
Contact Person Telephone Number 
Professor Robin Daly 03 9244 6040 
Ms Eliza Miller 03 9244 6739 
13. Other Issues 
If you have any complaints about any aspect of the project, the way it is being 
conducted or any questions about your rights as a research participant, then you may 
contact:   
The Manager, Research Integrity, Deakin University, 221 Burwood Highway, 
Burwood Victoria 3125, Telephone: 9251-7129, research-ethics@deakin.edu.au 
Please quote project number [2013-050]. 
14. Participation is Voluntary 
Participation in any research project is voluntary. If you do not wish to take part you 
are not obliged to. If you decide to take part and later change your mind, you are free 
to withdraw from the project at any stage.   
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Your decision whether to take part or not to take part, or to take part and then 
withdraw, will not affect your routine treatment, your relationship with those treating 
you or your relationship with Deakin University. 
You will also have the option to withdraw your data and tissues from the research 
project if you wish to do so. 
Before you make your decision, a member of the research team will be available so 
that you can ask any questions you have about the research project. You can ask for 
any information you want. Sign the Consent Form only after you have had a chance 
to ask your questions and have received satisfactory answers. 
If you decide to withdraw from this project, please notify a member of the research 
team before you withdraw. This notice will allow that person or the research 
supervisor to inform you if there are any health risks or special requirements linked 
to withdrawing. 
15. Reimbursement for your costs 
As reimbursement for some of the expenses incurred by you for participating in the 
Lift for Life® resistance training program, you will be eligible to receive up to $240 
in vouchers or cash at the completion of the study. The amount you will be 
reimbursed will be determined each month based on your continued involvement in 
the study. All protein-based drinks and supplements will be provided to you free of 
charge if you are randomly allocated to this group. No costs will be incurred by you 
for the blood collection or any of the other tests.   
16. Ethical Guidelines 
This project will be carried out according to the National Statement on Ethical 
Conduct in Research Involving Humans (June 1999) produced by the National 
Health and Medical Research Council of Australia. This statement has been 
developed to protect the interests of people who agree to participate in human 
research studies. 
The ethical aspects of this research project have been approved by the Deakin 
University Human Research Ethics Committee (project number [2013-050].   
17. Termination of the Study 
This research project may be stopped for a variety of reasons. These may include 
reasons such as: unacceptable side effects. 
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 PLAIN LANGUAGE STATEMENT AND CONSENT FORM 
TO:  Participants 
 
Consent Form 
Date:  3rd April 2014 
Full Project Title: Does a High Protein Enriched Drink and Vitamin D Enhance the 
Health Benefits of the Lift for Life® Resistance Training Program in Older Adults 
with Type 2 Diabetes? 
Reference Number: [2013-050] 
I have read, and I understand the attached Plain Language Statement. 
I freely agree to participate in this project according to the conditions in the Plain 
Language Statement.  
As indicated in the plain language statement there is an OPTIONAL component of 
this study involving the use of Magnetic Resonance Imaging (MRI) to assess the 
effects of the intervention on brain structure and function. Please indicate below (tick 
box) whether you are willing to participate in this aspect of the study.   
o I AGREE to participate in the MRI sub study to assess brain structure and 
function.  
o I DO NOT wish to participate in the MRI sub study to assess brain structure and 
function.  
I have been given a copy of the Plain Language Statement and Consent Form to 
keep.  
The researcher has agreed not to reveal my identity and personal details, including 
where information about this project is published, or presented in any public form.   
Participant’s Name (printed) 
………………………………………………………………………………………… 
Signature ……………………………………………….. Date…………………......... 
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Appendix 9 
Baseline values and absolute within-group changes in the progressive resistance training (PRT) plus protein and vitamin D supplementation 
(PRT+ProD) and PRT groups and the net between-group differences for the change at 12- and 24-weeks relative to baseline for saturated fat, dietary 
cholesterol and select micronutrients excluding the protein-vitamin D supplements.  
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) P-value 
Mean ± SD or  
(95% CI) P-value 
Net Difference  
(95% CI) 
P- values 
Model 1  |  Model 3 
Saturated Fat (g/day)      
    Baseline  26.1 ± 13.0  30.0 ± 17.6    
    Δ 12-weeks 0.4 (-2.8, 3.6) 0.890 -2.5 (-6.7, 1.7) 0.284 2.9 (-2.3, 8.1) 0.430  |  0.273 
    Δ 24-weeks  -0.6 (-3.5, 2.4) 0.622 -5.0 (-9.1, -1.0) 0.018 4.5 (-0.4, 9.4) 0.105  |  0.087 
Cholesterol (mg)      
    Baseline  279.7 ± 164.3  329.6 ± 278.0    
    Δ 12-weeks 20.6 (-31.9, 80.0) 0.805 -11.4 (-77.1, 54.2) 0.740 32.0 (-50.7, 114.7) 0.663  | 0.570 
    Δ 24-weeks  32.5 (-26.7, 91.7) 0.302 -29.0 (-96.3, 38.3) 0.225 61.5 (-27.1, 150.1) 0.101  |  0.092 
Sodium (mg)      
   Baseline  2648 ± 1504  2602 ± 1438    
Continued over page       
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   Δ 12-weeks -185 (-536, 166) 0.173 -146 (-494, 202) 0.242 -39 (-530, 452) 0.809  |  0.814 
   Δ 24-weeks 146 (-275, 567) 0.989 -171.1 (-544, 202) 0.165 317 (-245, 878) 0.337  |  0.241 
Potassium (mg)      
    Baseline  3493 ± 1161  3620 ± 1138    
    Δ 12-weeks 75 (-233, 383) 0.502 -114 (-414, 186) 0.451 189 (-239, 617) 0.313  |  0.268 
    Δ 24-weeks  -100 (-383, 183) 0.359 -18 (-352, 317) 0.969 -82 (-515, 350) 0.541  |  0.381 
Calcium (mg)       
    Baseline  899 ± 414  945 ± 414    
    Δ 12-weeks -67 (-156, 21) 0.219 3 (-100, 106) 0.944 -70 (-204, 64) 0.444  |  0.438 
    Δ 24-weeks  27 (-79, 133) 0.796 -69 (-178, 40) 0.136 96 (-54, 247) 0.205  |  0.216 
Magnesium (mg)       
    Baseline  399 ± 149  421 ± 142    
    Δ 12-weeks -14 (-50, 23) 0.496 -10 (-44, 24) 0.442 -4 (-53, 46) 0.917  |  0.844 
    Δ 24-weeks  -14 (-51, 23) 0.325 -2 (-41, 38) 0.937 -12 (-65, 41) 0.547  |  0.465 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-
value after adjustments for age, gender, ethnicity, BMI and moderate-vigorous physical activity. PRT+ProD, progressive resistance training plus protein and vitamin 
D supplements; PRT, progressive resistance training. 
  
 Page | 383 
	
 
Appendix 10 
Per Protocol Results Tables 
Table 1: Baseline values and absolute within-group changes in the PRT+ProD and PRT group and the net between-group differences for the change at 
12- and 24-weeks relative to baseline for moderate habitual physical activity. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P- values 
Model 1  |  Model 3 
Moderate-vigorous Physical Activity (kJ/Week)     
   Baseline  7,475 ± 8,418a  10,908 ± 8,342    
   ∆ 12-weeks 1,004 (-1,129, 3,137) 0.343 890 (-1,018, 2,797) 0.390 114 (-2,699, 2,928) 0.970  |  0.985 
   ∆ 24-weeks 3,874 (1,401, 6,347) 0.001 44 (-2,570, 2,658) 0.985 3,830 (212, 7,449) 0.009  |  0.012 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from model 1 – unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 
represents the P-value after adjusting for baseline values, age, gender, ethnicity and BMI. a P<0.05 vs PRT at baseline. PRT+ProD, progressive resistance training 
plus protein and vitamin D supplements; PRT, progressive resistance training. 
 
  
 Page | 384 
	
Table 2: Baseline values and absolute within-group changes in the PRT+ProD and PRT groups and the net between-group differences for the change at 
12- and 24-weeks relative to baseline for all macronutrients, excluding protein intake and the protein-vitamin D supplements. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P- values 
Model 1  |  Model 3 
Energy Intake (kJ/day)                
   Baseline  8498 ± 2618  8382 ± 2305    
   ∆ 12-weeks -186 (-1059, 687) 0.623 -28 (-676, 618) 0.829 -158 (-1210, 893) 0.847  |  0.900 
   ∆ 24-weeks -532 (-1343, 279) 0.205 -302 (-1266, 662) 0.392 -230 (-1513, 1053) 0.771  |  0.705 
Carbohydrate (g/day) 
    Baseline  213.3 ± 94.7  193.7 ± 54.4    
    Δ 12-weeks -8.5 (-35.3, 18.3) 0.531 20.1 (-2.4, 42.7) 0.160 -28.6 (-62.9, 5.6) 0.148  |  0.153 
    Δ 24-weeks  -16.9 (-46.9, 13.0) 0.195 -3.8 (-29.2, 21.6) 0.667 -13.1 (-51.6, 25.4) 0.503  | 0.548   
Fat (g/day) 
    Baseline  72.8 ± 30.3  78.8 ± 33.2    
    Δ 12-weeks -2.2 (-14.4, 10.1) 0.661 -5.7 (-14.8, 3.4) 0.254 3.6 (-11.2, 18.3) 0.600  |  0.542 
    Δ 24-weeks  -0.9 (-12.1, 10.3) 0.932 -5.6 (-18.5, 7.2) 0.297 4.7 (-12.5, 22.0) 0.497  |  0.602 
% Energy Protein  
    Baseline 21.0 ± 6.0  19.2 ± 5.4    
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    Δ 12-weeks -0.5 (-2.3, 1.3) 0.512 -0.6 (-2.3, 1.0) 0.739 0.1 (-2.2, 2.5) 0.824  |  0.838 
    Δ 24-weeks  -0.4 (-2.4, 1.6) 0.279 2.0 (0.1, 3.8) 0.005 -2.3 (-5.0, 0.4) 0.007  |  0.006 
% Energy Fat 
    Baseline 31.9 ± 10.1  34.1 ± 8.5    
    Δ 12-weeks -0.3 (-3.2, 2.6) 0.819 -2.0 (-5.0, 0.9) 0.154 1.7 (-2.4, 5.8) 0.397  |  0.350 
    Δ 24-weeks  1.1 (-2.3, 4.5) 0.324 -0.4 (-3.2, 2.4) 0.444 1.5 (-2.8, 5.8) 0.213  |  0.274 
% Energy Carbohydrates 
    Baseline  41.5 ± 9.8  39.5 ± 8.5    
    Δ 12-weeks 0.2 (-2.7, 3.1) 0.849 3.6 (0.7, 6.5) 0.036 -3.4 (-7.5, 0.7) 0.180  |  0.146 
    Δ 24-weeks  -0.7 (-4.7, 3.3) 0.714 -0.2 (-3.2, 2.8) 0.833 -0.4 (-5.2, 4.3) 0.902  |  0.937 
Alcohol§ (g/day) 
    Baseline                                5.8 ± 8.8  10.2 ± 15.7    
    Δ 12-weeks 0.3 (-1.6, 2.3) 0.670 -2.5 (-4.7, -0.4) 0.010 2.8 (0.0, 5.8) 0.044  |  0.048 
    Δ 24-weeks  0.77 (-1.1, 2.6) 0.372 -1.1 (-2.3, 0.2)  0.383 1.8 (-0.3, 3.9) 0.221  |  0.268 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-
value after adjusting for age, gender, ethnicity, BMI and moderate-vigorous physical activity § Baseline alcohol intake and the change in alcohol intake was 
calculated based only on the number of participants in each group who reported being a consumer of alcohol at respective time points. PRT+ProD, progressive 
resistance training plus protein and vitamin D supplements; PRT, progressive resistance training. 
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Table 3: Baseline values and absolute within-group changes in PRT+ProD and PRT groups and the net between-group differences for the change at 
12- and 24-weeks relative to baseline for saturated fat, cholesterol, sodium, potassium, calcium and magnesium. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) 
P-
value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P- values 
Model 1  |  Model 3 
Saturated Fat (g/day)      
    Baseline  26.2 ± 12.4   27.4 ± 14.8    
    Δ 12-weeks -0.1 (-5.5, 5.3) 0.958 -2.6 (-6.9, 1.7) 0.264 2.5 (-4.1, 9.2) 0.447  |  0.424 
    Δ 24-weeks  -0.1 (-4.6, 4.5) 0.969 -2.9 (-7.9, 2.1) 0.208 2.9 (-4.0, 9.7) 0.393  |  0.338 
Cholesterol (mg)      
    Baseline  258.6 ± 99.7  272.9 ± 181.9     
    Δ 12-weeks 44.8 (-25.5, 115.2) 0.261 18.5 (-48.0, 84.9) 0.532 26.4 (-69.2, 121.9) 0.754  |  0.723 
    Δ 24-weeks  17.7 (-53.8, 89.2) 0.630 15.7 (-56.4, 87.8) 0.640 -2.0 (-99.6, 103.5) 0.999  |  0.974 
Sodium (mg)      
   Baseline  2740 ± 1438  2378 ± 960    
   Δ 12-weeks -457 (-994, 80) 0.120 79 (-317, 475) 0.824 -536 (-1182, 109) 0.143  |  0.147 
   Δ 24-weeks 22 (-650, 693) 0.919 48 (-351, 448) 0.848 -26 (-762, 709) 0.865  |  0.982 
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Potassium (mg)      
    Baseline  3649 ± 1188  3504 ± 1124    
    Δ 12-weeks 231 (-241, 703) 0.336 -85 (-428, 259) 0.580 316 (-248, 880) 0.282  |  0.240 
    Δ 24-weeks  -254 (-616, 108) 0.260 338 (-92, 768) 0.128 -592 (-1165, -19) 0.062  |  0.019 
Calcium (mg)       
    Baseline  929 ± 377  897 ± 359    
    Δ 12-weeks -159 (-279, -38) 0.016 -11 (-127, 104) 0.857 -148 (-312, 17) 0.144  |  0.155 
    Δ 24-weeks  -18 (-139, 103) 0.373 -17 (-164, 130) 0.686 -1 (-193, 190) 0.748  |  0.763 
Magnesium (mg)       
    Baseline  402 ± 184  410 ± 143    
    Δ 12-weeks -18 (-79, 43) 0.434 -24 (-62, 14) 0.158 5 (-63, 73) 0.769  |  0.720 
    Δ 24-weeks  -44 (-97, 10) 0.116 10 (-37, 57) 0.790 -14 (-49, 22) 0.159  |  0.080 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-
value after adjustments for age, gender, ethnicity, BMI and moderate-vigorous physical activity. PRT+ProD, progressive resistance training plus protein and vitamin 
D supplements; PRT, progressive resistance training.  
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Table 4: Baseline values and absolute within-group changes in the PRT+ProD and PRT groups and the net between-group differences for the change 
at 12- and 24-weeks relative to baseline for habitual protein intake and protein intake inclusive of supplemental protein on non-training and training 
days in g/day and g/kg/day. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P- values 
Model 1  |  Model 2 
Protein (g/day)      
Habitual Protein (Excluding Whey Supplement)     
   Baseline  103.8 ± 32.4  93.5 ± 26.4    
   ∆ 12-weeks -3.5 (-12.7, 5.8) 0.471 -2.8 (-11.5, 5.9) 0.651 -0.65 (-13.2, 11.9) 0.777  |  0.836 
   ∆ 24-weeks -12.4 (-25.7, 0.8) 0.035 5.9 (-3.8, 15.5) 0.190 -18.3 (-34.1, -2.26) 0.012  |  0.006 
Habitual Protein plus Whey Supplement (Non-Training Day)    
    Baseline  103.8 ± 32.4  93.5 ± 26.4    
    Δ 12-weeks 15.5 (6.1, 24.8) 0.009 -2.8 (-11.5, 5.9) 0.651 18.2 (5.7, 30.9) 0.018  |  0.014 
    Δ 24-weeks  6.6 (-6.7, 19.9) 0.219 2.7 (-8.0, 13.3) 0.190 3.9 (-12.7, 20.5) 0.869  |  0.932 
Habitual Protein plus Whey Supplement (Training Day)   
    Baseline  103.8 ± 32.4  93.5 ± 26.4    
    Δ 12-weeks 34.4 (24.9, 43.8) 0.001 -2.8 (-11.5, 5.9) 0.651 37.2 (24.5, 49.9) 0.001  |  0.001 
    Δ 24-weeks  25.6 (12.3, 38.9) 0.001 2.7 (-8.0, 13.3) 0.190 22.9 (6.3, 39.5) 0.005  |  0.011 
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Protein (g/kg/day)      
Habitual Protein (Excluding Whey Supplement)     
    Baseline  1.23 ± 0.35 b  1.03 ± 0.28    
    Δ 12-weeks -0.03 (-0.14, 0.07) 0.561 -0.03 (-0.13, 0.07) 0.633 0.00 (-0.15, 0.14) 0.855  |  0.874 
    Δ 24-weeks  -0.13 (-0.28, 0.03) 0.090 0.08 (-0.02, 0.19) 0.086 -0.21 (-0.39, -0.03) 0.015  |  0.015 
Habitual Protein plus Whey Supplement (Non-Training Day)    
    Baseline  1.23 ± 0.35 b  1.03 ± 0.28    
    Δ 12-weeks 0.20 (0.09, 0.31) 0.005 -0.03 (-0.13, 0.07) 0.633 0.23 (0.08, 0.37) 0.009  | 0.009 
    Δ 24-weeks  0.11 (-0.05, 0.27) 0.079 0.08 (-0.02, 0.19) 0.086 0.02 (-0.16, 0.21) 0.656  |  0.688 
Habitual Protein plus Whey Supplement (Training Day)    
    Baseline 1.23 ± 0.35 b  1.03 ± 0.28    
    Δ 12-weeks 0.43 (0.31, 0.54) 0.001 -0.03 (-0.13, 0.07) 0.633 0.46 (0.31, 0.60) 0.001  |  0.001 
    Δ 24-weeks  0.34 (017, 0.51) 0.001 0.08 (-0.02, 0.19) 0.086 0.26 (0.07, 0.45) 0.001  |  0.002 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values, net differences 
and interaction effects were derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 
represents the P-value after adjustments for age, gender, ethnicity, BMI and moderate-vigorous physical activity. PRT+ProD, progressive resistance training plus 
protein and vitamin D supplements; PRT, progressive resistance training. 
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Table 5: Baseline values and absolute within-group changes in PRT+ProD and PRT groups and the net between-group differences for the change at 
12- and 24-weeks relative to baseline for HbA1c, fasting plasma glucose, C-peptide and measures of insulin resistance, sensitivity and beta-cell 
function.  
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P- values 
Model 1  |  Model 3 
HbA1c (%)       
   Baseline 6.76 ± 1.00  6.88 ± 1.08    
   Δ 12-weeks -0.27 (-0.45, -0.08) 0.006 -0.06 (-0.21, 0.09) 0.422 -0.20 (-0.43, 0.02) 0.095  |  0.111 
   Δ 24-weeks  -0.22 (-0.46, 0.02) 0.022 -0.09 (-0.27, 0.10) 0.265 -0.14 (-0.43, 0.16) 0.266  |  0.134 
HbA1c (IFCC mmol/mol)      
   Baseline  50.34 ± 10.96  51.64 ± 11.72    
   Δ 12-weeks -2.98 (-4.94, -1.02) 0.005 -0.54 (-2.16, 1.08) 0.524 -2.44 (-4.92, 0.05) 0.287  |  0.081 
   Δ 24-weeks  -2.44 (-5.05, -0.17) 0.021 -0.90 (-2.92, 1.12) 0.288 -1.54 (-4.74, 1.66) 0.344  |  0.119 
Fasting Glucose (mmol/L)      
   Baseline  7.52 ± 1.80a  8.47 ± 2.12    
   Δ 12-weeks -0.31 (-0.64, 0.02) 0.153 -0.38 (-0.74, -0.03) 0.036 0.07 (-0.41, 0.56) 0.304  |  0.631 
   Δ 24-weeks  -0.07 (-0.52, 0.38) 0.737 -0.57 (-0.98, -0.17) 0.002 0.50 (-0.10, 2.00) 0.451  |  0.311 
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Fasting Insulin (pmol/L) 
    Baseline  84.96 ± 51.08  102.82 ± 50.96    
    Δ 12-weeks -13.8 (-26.3, -1.4) 0.010 -2.9 (-14.7, 8.9) 0.594 -11.0 (-27.9, 6.0) 0.155  |  0.138 
    Δ 24-weeks  -9.5 (-20.8, 1.8) 0.078 -3.1 (-10.8, 4.6) 0.570 -6.0 (-10.8, 4.6) 0.404  |  0.689 
Insulin sensitivity (HOMA2%S)      
    Baseline  79.4 ± 48.8b  57.3 ± 25.4    
    Δ 12-weeks 8.3 (-3.7, 20.3) 0.095 5.2 (-4.0, 14.4) 0.314 3.1 (-11.5, 17.8) 0.911  |  0.454 
    Δ 24-weeks  5.5 (-6.1, 17.1) 0.282 7.3 (-0.7, 15.2) 0.088 -1.7 (-15.4, 11.9)  0.369  |  0.787 
C-peptide (nmol/L)       
    Baseline  1.10 ± 0.44a  1.26 ± 0.36    
    Δ 12-weeks -0.07 (-0.14, 0.01) 0.058 -0.03 (-0.10, 0.04) 0.453 -0.04 (-0.15, 0.06) 0.394  |  0.425 
    Δ 24-weeks  -0.04 (-0.11, 0.03) 0.254 -0.06 (-0.14, 0.02) 0.093 0.02 (-0.09, 0.12) 0.745  |  0.974 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-
value after adjustments for age, gender, ethnicity, BMI, oral hypoglycaemic use and moderate-vigorous physical activity. a P<0.05, b P<0.01 vs PRT at baseline. 
PRT+ProD, progressive resistance training plus protein and vitamin D supplements; PRT, progressive resistance training.
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Table 6: Baseline values and absolute within-group changes in the PRT+ProD and PRT groups for weight, body mass index (BMI) and waist 
circumference and the net between-group differences for the change relative to baseline at 12- and 24-weeks. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P- values 
Model 1  |  Model 3 
Body Weight (kg)      
   Baseline 84.4 ± 16.3a  91.6 ± 12.6    
   Δ 12-weeks 0.2 (-0.3, 0.7) 0.464 -0.1 (-0.5, 0.4) 0.811 0.3 (-0.4, 1.0) 0.499  |  0.487 
   Δ 24-weeks  -0.2 (-1.0, 0.6) 0.491 -1.0 (-1.8, -0.2) 0.001 0.8 (-0.3, 1.9) 0.064  |  0.030 
BMI (kg/m2)      
   Baseline  29.5 ± 4.4a  31.6 ±4.1    
   Δ 12-weeks 0.9 (-0.1, 0.3) 0.386 0.0 (-0.2, 0.1) 0.864 0.1 (-0.1, 0.3) 0.509  |  0.516 
   Δ 24-weeks  -0.1 (-0.4, 0.1) 0.268 -0.4 (-0.7, -0.1) 0.001 0.3 (-0.1, 0.7) 0.066  |  0.046 
Waist Circumference (cm)      
   Baseline  100.0 ± 12.3a  105.7 ± 10.5    
   Δ 12-weeks -0.6 (-1.4, 0.3) 0.179 -1.3 (-2.0, -0.7) 0.001 0.8 (-0.2, 1.8) 0.271  |  0.254 
   Δ 24-weeks  -1.3 (-2.4, -0.2) 0.001 -2.6 (-3.4, 1.8) 0.001 12.6 (-0.1, 2.6) 0.083  |   0.180 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to the 
within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net differences were 
derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-value after adjustments 
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for age, gender, ethnicity and moderate-vigorous physical activity. a P<0.05 vs PRT at baseline. PRT+ProD, progressive resistance training plus protein and vitamin D 
supplements; PRT, progressive resistance training. 
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Table 7: Baseline values and absolute within-group changes in PRT+ProD and PRT groups and the net between-group differences for the change at 
24-weeks from baseline for total body and regional (arms and legs) fat mass and lean mass and appendicular lean mass. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P- values 
Model 1  |  Model 3 
Total Body      
Fat Mass (kg)      
   Baseline 30.68 ± 8.55  34.14 ± 9.47    
   Δ 24-weeks  -0.73 (-1.41, -0.06) 0.029 -1.33 (-1.98, -0.67) 0.001 -0.60 (-0.34, 1.54) 0.206  |  0.169   
Lean Mass (kg)      
   Baseline  49.58 ± 10.97a  53.53 ± 9.33    
   Δ 24-weeks  0.85 (0.38, 1.31) 0.001 0.51 (0.12, 0.90) 0.008 0.19 (-0.38, 0.76) 0.270  |  0.213   
Percentage Fat Mass (%)      
   Baseline  38.05 ± 7.70  38.73 ± 8.35    
   % Δ 24-weeks  -0.89 (-1.48, -0.31) 0.002 -1.25 (-1.78, -0.72) 0.001 0.36 (-0.42, 1.14) 0.357  |  0.334 
Appendicular Lean Mass (kg)      
   Baseline  22.10 ± 5.37a  24.47 ± 4.73    
   Δ 24-weeks  0.53 (0.31, 0.74) 0.001 0.21 (0.01, 0.40) 0.031 0.32 (0.03, 0.60) 0.027  |  0.184 
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Arms       
Fat Mass (kg)       
   Baseline  3.11 ± 1.09  3.46 ± 1.48    
   Δ 24-weeks  -0.03 (-0.01, 0.06) 0.479 -0.07 (-0.16, 0.02) 0.136 0.04 (-0.10, 0.17) 0.584 |  0.441 
Lean Mass (kg)       
   Baseline  5.70 ± 1.56a  6.38 ± 1.28    
   Δ 24-weeks  0.25 (0.16, 0.34) 0.001 0.13 (0.04, 0.21) 0.003 0.09 (-0.03, 0.22) 0.054  |  0.066 
Legs       
Fat Mass (kg)       
   Baseline  8.36 ± 3.05  9.56 ± 4.26    
   Δ 24-weeks  -0.13 (-0.32, 0.00) 0.149 -0.26 (-0.46, -0.07) 0.007 0.01 (-0.01, 0.04) 0.334  |  0.357 
Lean Mass (kg)       
   Baseline  16.35 ± 3.89a  18.10 ± 3.54    
   Δ 24-weeks  0.28 (0.01, 0.05) 0.001 0.01 (-0.08, 0.02) 0.305 0.20 (-0.04, 0.43) 0.095  |  0.141 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-
value after adjustments for age, gender, ethnicity and moderate-vigorous physical activity. a P<0.05 vs PRT at baseline. PRT+ProD, progressive resistance training 
plus protein and vitamin D supplements; PRT, progressive resistance training. 
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Table 8: Baseline values and absolute within-group changes in PRT+ProD and PRT groups and the net between-group differences for the change at 
24-weeks from baseline for 25% femur muscle cross-sectional area (CSA), density and intermuscular plus subcutaneous fat CSA. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P- values 
Model 1  |  Model 3 
Muscle CSA      
    Baseline (cm2) 59.1 ± 12.8a  66.3 ± 14.6    
    % Δ 24-weeks 4.9 (2.2, 7.6) 0.001 2.3 (0.1, 4.4) 0.177 2.6 (-0.7, 6.0) 0.056  |  0.078 
Muscle Density      
    Baseline (mg/cm3) 73.4 ± 3.4  73.4 ± 2.8    
    % Δ 24-weeks 0.2 (-1.1, 1.5) 0.895 0.8 (0.1, 1.6) 0.041 -0.6 (-2.1, 0.8) 0.336  |  0.497 
Intermuscular Fat Area (cm2)      
   Baseline  21.3 ± 6.3  22.1 ± 4.9    
   % Δ 24-weeks  1.0 (-3.5, 5.5) 0.964 -1.5 (-5.5, 2.5) 0.244 2.5 (-3.5, 8.4) 0.419  |  0.469 
Subcutaneous Fat Area (cm2)      
   Baseline  40.2 ± 22.2  47.8 ± 32.2    
   % Δ 24-weeks  -3.2 (-7.4, 1.0) 0.362 -2.6 (-5.9, 0.8) 0.620 -0.6 (-5.8, 4.7) 0.906  | 0.616 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-
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value after adjustments for age, gender, ethnicity and moderate-vigorous physical activity. a P<0.05 vs PRT at baseline. CSA, Cross sectional area; PRT+ProD, 
progressive resistance training plus protein and vitamin D supplements; PRT, progressive resistance training. 
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Table 9: Baseline values and absolute within-group changes in PRT+ProD and PRT groups and the net between-group differences for the change at 
24-weeks relative to baseline in leg press and seated row one-repetition maximum muscle strength and knee extensor isometric muscle strength. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P- values 
Model 1  |  Model 3 
1-RM Leg Press       
   Baseline (kg) 177.6 ± 67.8   206.8 ± 90.5     
   % Δ 24-weeks 18.8 (10.7, 26.8) 0.001 13.5 (4.4, 22.7) 0.003 5.2 (-7.1, 17.5) 0.408  |  0.710 
1-RM Seated Row      
   Baseline (kg) 51.2 ± 17.2a  58.2 ± 16.7    
   % Δ 24-weeks 16.8 (7.8, 25.8) 0.001 4.2 (-1.2, 9.6) 0.120 12.7 (2.7, 22.6) 0.033  |  0.041 
Knee Extensor Strength       
   Baseline (kg) 36.9 ± 13.7  42.0 ± 14.5    
   % Δ 12-weeks 7.7 (4.4, 11.0) 0.001 9.4 (6.4, 12.4) 0.001 -1.7 (-6.1, 2.7) 0.391 |  0.227 
   % Δ 24-weeks  26.3 (14.6, 38.1) 0.001 29.1 (17.1, 41.0) 0.001 -4.8 (-21.1, 11.6) 0.313  |  0.229 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-
value after adjustments for age, gender, ethnicity and moderate-vigorous physical activity. PRT+ProD, progressive resistance training plus protein and vitamin D 
supplements; PRT, progressive resistance training. 
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Table 10: Baseline values and absolute within-group changes in PRT+ProD and PRT groups and the net between-group differences for the change at 
12- and 24-weeks relative to baseline for systolic and diastolic blood pressure. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P- values 
Model 1  |  Model 3 
Systolic Blood Pressure (mmHg)      
   Baseline  138.0 ± 16.52  135.1 ± 12.58    
   Δ 12-weeks -4.6 (-9.0, -0.17) 0.167 -0.1 (-5.2, 5.0) 0.965 -4.5 (-11.3, 2.3) 0.273  |  0.244 
   Δ 24-weeks  -3.9 (-8.9, 1.2) 0.017 -3.5 (-7.9, 1.0) 0.166 -0.4 (-7.0, 6.3) 0.273  |  0.181 
Diastolic Blood Pressure (mmHg)      
   Baseline  85.7 ± 9.9  83.8 ± 7.4    
   Δ 12-weeks -2.9 (-5.5, -0.4) 0.032 -1.1 (-3.5, 1.3) 0.378 -1.8 (-5.3, 1.6) 0.315  |  0.307 
   Δ 24-weeks  -8.0 (-15.9, 0.0) 0.040 -3.5 (-8.0, 1.0) 0.010 -4.50 (-13.1, 4.1) 0.789  |  0.999 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-
value after adjustments for age, gender, ethnicity, BMI, anti-hypertensive use and moderate-vigorous physical activity. PRT+ProD, progressive resistance training 
plus protein and vitamin D supplements; PRT, progressive resistance training. 
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Table 11: Baseline values and absolute within-group changes in PRT+ProD and PRT groups and the net between-group differences for the change at 
12- and 24-weeks relative to baseline for serum total cholesterol, HDL and LDL cholesterol and triglycerides. 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P- values 
Model 1  |  Model 3 
Total Cholesterol (mmol/L)      
   Baseline  4.39 ± 1.21  4.17 ± 0.95    
   Δ 12-weeks -0.21 (-0.45, 0.03) 0.041 -0.02 (-0.15, 0.10) 0.762 -0.19 (-0.44, 0.07) 0.128  |  0.079 
   Δ 24-weeks  -0.22 (-0.44, 0.00) 0.030 0.02 (-0.13, 0.17) 0.783 -0.24 (-0.49, 0.01) 0.049  |  0.014 
HDL Cholesterol (mmol/L)      
   Baseline  1.26 ± 0.35  1.23 ± 0.28    
   Δ 12-weeks -0.02 (-0.09, 0.04) 0.426 0.03 (-0.01, 0.08) 0.148 -0.05 (-0.12, 0.02) 0.118  |  0.081 
   Δ 24-weeks  0.00 (-0.06, 0.04) 0.708 0.00 (-0.05, 0.05) 0.973 0.00 (-0.08, 0.06) 0.766  |  0.560 
LDL Cholesterol (mmol/L)      
   Baseline  2.41 ± 1.00  2.11 ± 0.81    
   Δ 12-weeks -0.18 (-0.37, 0.02) 0.034 -0.04 (-0.14, 0.06) 0.537 -0.13 (-0.35, 0.07) 0.203  |  0.169 
   Δ 24-weeks  -0.20 (-0.38, -0.01) 0.018 0.07 (-0.06, 0.21) 0.271 -0.27 (-0.49, -0.05) 0.011  |  0.003 
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Triglycerides (mmol/L)      
   Baseline  1.59 ± 0.75  1.84 ± 0.95    
   Δ 12-weeks -0.02 (-0.21, 0.16) 0.786 -0.03 (-0.25, 0.19) 0.781 0.01 (-0.28, 0.30) 0.960  |  0.977 
   Δ 24-weeks  -0.03 (-0.19, 0.13) 0.724 0.01 (-0.35, 0.27) 0.931 -0.04 (-0.35, 0.28) 0.782  |  0.704 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-
value after adjustments for age, gender, ethnicity, BMI, lipid-lowering medication and moderate habitual physical activity. PRT+ProD, progressive resistance 
training plus protein and vitamin D supplements; PRT, progressive resistance training. 
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Table 12: Baseline values and percent changes in the PRT+ProD and PRT groups and the net between-group differences for the change at 12- and 24-
weeks relative to baseline for serum levels of interleukin (IL)-10, IL-6, IL-8, tumour necrosis factor-alpha (TNF-α), adiponectin and high-sensitive C-
reactive protein (CRP). 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P- values 
Model 1  |  Model 3 
IL-10      
    Baseline (pg/ml) 9.45 ± 11.12  11.16 ± 19.69    
    % Δ 12-weeks 55.9 (22.2, 89.7) 0.001 -12.7 (-28.5, 3.0) 0.061 68.7 (33.9, 103.5) 0.001  |  0.001 
    % Δ 24-weeks  57.4 (23.2, 91.6) 0.001 -14.8 (-30.9, 1.3) 0.030 72.2 (36.8, 107.5) 0.001  |  0.001 
IL-6       
    Baseline (pg/ml) 2.75 ± 2.31  2.59 ± 2.14    
    % Δ 12-weeks 22.8 (-4.9, 50.5) 0.073 -12.3 (-32.5, 8.0) 0.267 35.1 (19.4, 68.2) 0.037  |  0.047 
    % Δ 24-weeks  30.7 (9.3, 52.2) 0.016 -4.4 (-26.5, 17.7) 0.687 35.1 (4.4, 65.8) 0.036  |  0.051 
IL-8       
    Baseline (pg/ml) 15.18 ± 8.18  15.03 ± 7.25    
    % Δ 12-weeks 10.8 (-2.1, 23.8) 0.062 1.1 (-5.6, 7.8) 0.761 9.7 (-4.0, 23.4) 0.142  |  0.106 
    % Δ 24-weeks  5.2 (-2.8, 13.1) 0.379 7.4 (-0.3, 15.0) 0.043 -2.2 (-13.1, 8.8) 0.736  |  0.671 
      
 Page | 403 
	
TNF-a 
    Baseline (pg/ml) 7.69 ± 2.23  7.71 ± 2.48    
    % Δ 12-weeks 2.6 (-3.7, 9.0) 0.369 -3.2 (-9.2, 2.9) 0.343 5.8 (-2.9, 14.5) 0.198  |  0.202 
    % Δ 24-weeks  3.3 (-2.7, 9.3) 0.260 2.0 (-4.8, 8.9) 0.503 1.3 (-7.8, 10.4) 0.784  |  0.751 
Adiponectin       
    Baseline (µg/mL) 3.23 ± 2.25  2.93 ± 1.25    
    % Δ 12-weeks -1.0 (-8.2, 6.3) 0.343 -3.5 (-7.8, 0.9) 0.150 2.5 (-5.6, 10.5) 0.532  |  0.512 
    % Δ 24-weeks  -3.7 (-7.8, 0.3) 0.503 -2.2 (-7.5, 3.0) 0.349 -1.5 (-8.2, 5.2) 0.691  |  0.240 
High sensitive-CRP      
    Baseline (mg/mL) 1.59 ± 1.34  2.08 ± 2.36    
    % Δ 12-weeks -8.4 (-35.6, 18.9) 0.512 -1.4 (-23.5, 20.6) 0.893 -6.9 (-41.1, 27.2) 0.674  |  0.672 
    % Δ 24-weeks  -6.8 (-29.0, 15.3) 0.593 9.6 (-13.9, 33.1) 0.367 -16.4 (-48.8, 15.9) 0.319  |  0.431 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-
value after adjustments for age, gender, ethnicity, BMI and moderate habitual physical activity. a P<0.05 vs PRT at baseline. PRT+ProD, progressive resistance 
training plus protein and vitamin D supplements; PRT, progressive resistance training. 
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Table 13: Baseline values and absolute within-group changes in PRT+ProD and PRT groups and the net between-group differences for the change at 
12- and 24-weeks relative to baseline for serum creatinine, estimated glomular filtration (eGFR), 25-hydroxyvitamin D (25(OH)D) and insulin-like 
growth factor-1 (IGF-1). 
 Baseline Values and Within-Group Changes  
 PRT+ProD PRT Intervention Effects 
 
Mean ± SD or 
 (95% CI) P-value 
Mean ± SD or 
 (95% CI) P-value 
Net Difference  
(95% CI) 
P- values 
Model 1  |  Model 3 
Creatinine (mol/L)      
   Baseline  74.41 ± 13.27a  80.70 ± 15.83    
   Δ 12-weeks 2.27 (-0.47, 5.01) 0.097 -1.02 (-3.58, 1.54) 0.411 3.29 (-0.42, 6.99) 0.075  | 0.113 
   Δ 24-weeks 5.10 (2.39, 7.80) 0.001 4.24 (1.49, 6.99) 0.001 0.86 (-2.99, 4.70) 0.642  |  0.449 
eGFR (ml/min/1.73m2)       
   Baseline  85.00 ± 6.81a  80.38 ± 11.77    
   Δ 12-weeks -0.98 (-2.50, 0.53) 0.320 0.80 (-1.21, 2.81) 0.404 -1.78 (-4.35, 0.80) 0.199  |  0.258 
   Δ 24-weeks -3.83 (-6.00, -1.66) 0.001 -3.10 (-5.23, -0.97) 0.001 -0.73 (-3.75, 2.29) 0.598  |  0.510 
25(OH)D (nmol/L)      
   Baseline  78.77 ± 22.30  68.12 ± 22.21    
   Δ 12-weeks 26.74 (18.82, 34.66) 0.001 3.06 (-2.09, 8.20) 0.257 23.68 (14.68, 32.69) 0.001  |  0.001 
   Δ 24-weeks 33.88 (25.82, 41.95) 0.001 5.05 (-1.39, 11.49) 0.061 28.83 (-18.79, 38.88) 0.001  |  0.001 
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IGF-1 (nmol/L) 
   Baseline  20.62 ± 6.96  20.4 ± 7.50    
   Δ 12-weeks 0.48 (-0.56, 1.51) 0.365 -0.82 (-1.53, -0.12) 0.063 1.30 (0.10, 2.51) 0.057  |  0.068 
   Δ 24-weeks 0.80 (-0.32, 1.93) 0.127 -0.25 (-1.29, 0.79) 0.568 1.06 (-0.46, 2.57) 0.122  |  0.054 
Baseline values represent mean ± SD and within group changes and net differences represent means with 95% confidence intervals (CI). Intervention effect refers to 
the within group change from baseline in the intervention group minus the within group change from baseline in the control group. All change values and net 
differences were derived from unadjusted values. Significant differences are highlighted in bold. Model 1 represents unadjusted P-values. Model 3 represents the P-
value after adjustments for age, gender, ethnicity, BMI and moderate habitual physical activity. a P<0.05 vs PRT at baseline. PRT+ProD, progressive resistance 
training plus protein and vitamin D supplements; PRT, progressive resistance training. 
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